Glen Burnie East: Church Offers All Ages Game Night

By Susan Shillen for The Maryland Gazette

Singles, families with young children, senior citizens and anyone who would enjoy wholesome, brain-stimulating entertainment are invited to attend the game night that will be held at 7 p.m. Friday at Harundale Presbyterian Church, 1020 Eastway.

The church’s Men’s Fellowship and Ministries group hosts this free event on the third Friday of each month, providing a selection of games, refreshments and nursery services.

Participants may add to the fun by taking additional games and snacks.

Those attending in large groups or hoping to use the nursery should call Lee Wexel in advance at 410-768-9754.

Car wash

The Glen Burnie High School Music Boosters will wash cars for donations at Bruster’s Real Ice Cream, 80 Aquahart Road, from 8:30 a.m. to 2 p.m. Saturday.

The funds raised by the boosters are used by the school’s color guard and vocal and instrumental groups to help pay for such things as sheet music, instruments, cleaning and repair of uniforms and robes, competition fees and transportation to competitions, parades and other community events.

For more information, visit www.gbhsmusic.org or e-mail [email protected].

Christian coffeehouse

North Arundel Church’s Saturday Night Live coffeehouse will feature a musical performance by the group “Uprising” at around 7:30 p.m. Saturday.

The coffeehouse opens at 7 p.m. and admission, coffee and the concert are free. Other refreshments will be sold.

The church is located at 7610 Baltimore Annapolis Blvd.

For more information, call 410-787-9893.

Clubs and organizations in the 21060 ZIP code can call Maryland Gazette Glen Burnie East correspondent Susan Shillenn at 410-768- 9498 for publication of their news, or send e-mail to [email protected]. {Corrections:} {Status:}

(c) 2008 Maryland Gazette. Provided by ProQuest Information and Learning. All rights Reserved.

State Issues Another Air Pollution Watch for County

By Brad Kellar, Greenville Herald-Banner, Greenville, Texas

Jul. 16–The lazy, hazy days of summer are beginning to prove unhealthy for people with breathing difficulties.

Stagnant, humid atmospheric conditions have again led to yet another warning of potentially poor air quality in North Central Texas, including Hunt County.

It is the fourth time since the Memorial Day weekend the Texas Commission on Environmental Quality (TCEQ) has issued such an alert.

Area residents who may have difficulties breathing due to asthma or other conditions are again being urged to take extra precautions when venturing outside today.

Hunt County and areas to the west, including the Dallas/Fort Worth Metroplex, have been placed under a level orange “unhealthy for sensitive groups” air pollution watch by the TCEQ, which indicated atmospheric conditions are expected to be favorable during the day for producing high levels of ozone pollution.

Elevated levels of ozone can act as a lung irritant, according to the TCEQ. Individuals with chronic lung disease, such as asthma and emphysema, as well as the elderly and young children, are particularly sensitive to ozone and should attempt to avoid exposure, and to minimize exertion outdoors during the mid-day to early evening hours, or to stay indoors in an air-conditioned room during the time frame.

The air pollution watch also includes Collin, Kaufman and Rockwall counties.

The National Weather Service forecast called for mostly sunny skies today, with little or no wind and a high of 92 degrees and heat index values — what it feels like when the humidity is added in — of 97 degrees.

In late May, the same locations were placed under a level “orange” air pollution watch for one day and the counties were placed on a level “red” air pollution watch — the highest level under the alert system — on June 22.

On June 30, the same locations were placed under a two-day orange level pollution watch.

In March, the Environmental Protection Agency placed Hunt and 344 other counties across the United States into nonattainment zones for air pollution, ruling the areas did not meet federal standards for smog.

Additional information about ozone can be found at www.tceq.state.tx.us/nav/data/ozone_data.html.

—–

To see more of Greenville Herald-Banner, or to subscribe to the newspaper, go to http://www.heraldbanner.com/.

Copyright (c) 2008, Greenville Herald-Banner, Greenville, Texas

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Trackers for ‘Wanderers’ Not Popular

By RANKIN, Janine

Red Cross wants to know why people don’t seem to want to use them. ——————– Wander Risk trackers designed to help find people with dementia quickly if they go walkabout are gathering dust a year after their launch.

Just one of the devices has been out for a brief time with one patient, said Red Cross area manager Lee Welch.

The system was introduced after two high profile cases in 2006 when dementia patients wandered off and died despite extensive and costly search efforts.

“It’s a programme that could be very valuable, and we are going through an analysis at the moment to find out why it has not been taken up more,” said Ms Welch.

The newly-appointed area manager said the one patient who had been put on to the programme only kept the tracking device for a short time before becoming more dependent and needing to be moved to a higher level of care.

“And that may be an issue – that there is a fairly tight window between when someone is identified as a wander risk and when they need to be in permanent care.”

Ms Welch was working with another couple of people who had made inquiries about the scheme.

One caller had been under the impression it could be used for 24- hour monitoring, which is not part of the plan.

“We only turn the tracker on when we are alerted to the need to go looking for someone.”

The device has a 2km detection range, so the search has to start at the place the person was last seen before they have time to move beyond that range.

The system depends on someone raising the alert promptly.

It won’t help with patients who refuse to wear the tracker, or those with poor road sense or behaviour likely to place them in danger quickly.

Red Cross has teams trained in how to respond to a tracking situation, and on how to handle a lost wanderer when they are found.

Ms Welch hopes to give the system another round of promotion at a search and rescue conference in Palmerston North in November.

(c) 2008 Evening Standard; Palmerston North, New Zealand. Provided by ProQuest Information and Learning. All rights Reserved.

Hope Pageant to Benefit American Cancer Society

By Kandace McCoy, Mt. Vernon Register-News, Ill.

Jul. 16–MT. VERNON — The Southern Illinois Annual Mr./Miss Hope Benefit Pageant is returning again this year to help out the American Cancer Society.

According to information from event organizer Rhonda Moffit, the pageant will be held at the Times Square Mall Aug. 9 and is open to boys and girls of all ages.

Proceeds from the event will benefit the ACS and others affected by cancer. Since last year’s event, Moffit said groups have been formed to help patients, such as Wigs for Friends, which supply wigs for people who have hair loss due to chemotherapy.

Moffit organized the pageant last year after deciding she wanted to do something in support of a friend who is a cancer survivor.

“The pageant rewards contestants with something more than crowns, trophies and gifts,” Moffit stated. “It gives our youth a chance to provide moral support to worthy causes and recognition that they are trying to do something positive to make a difference.”

Categories in each age division at the pageant include queen and king, Most Photogenic, Most Beautiful/Handsome, Best Personality/Charming, Best Hair, Best Eyes and Best Smile, among others.

The top three winners, picked by a panel of judges, will be selected as the 2008 Little Mr./Miss Hope Ambassadors.

Moffit said individuals and businesses may contribute to the pageant, either by donation or by sponsoring a contestant.

For more information or to register as a contestant, contact Moffit at 315-4199 or 822-6836 or by e-mail at [email protected].

—–

To see more of Mt. Vernon Register-News or to subscribe to the newspaper, go to http://www.register-news.com/.

Copyright (c) 2008, Mt. Vernon Register-News, Ill.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Iraqi Kurdish Landmine Official Discusses Clearance Programme

Text of report by Muhammad Jamal headlined: “There are more than 2,407 landmine fields in Sulaymaniyah and only 972 of them have been cleared”, published by Iraqi Kurdistan Islamic Group weekly newspaper Komal on 5 July; subheadings as published

“Landmine Awareness Directorate communication officer”

Landmines are the hazard that has claimed the life of many Kurdish citizens and it is a theme that needs to be discussed. Therefore, Komal newspaper has arranged an interview with the landmine Awareness Directorate, communication officer, Mirwan Ahmad, moreover, publishing the edited information in this article. The establishment of the Central landmine works directorate took place after the uprising in 1991, following several organizations that use to take the responsibility for landmines in Kurdistan. It was established by three of the directorate for landmine awareness, which complemented the awareness of landmine and explosives KOMA [Kurdistan Organization for Mine Awareness] as well as the technical activities to support the landmine victims. Landmine martyrs are to be counted as conflict martyrs.

Consideration has been given to considering landmine and explosive martyrs as war martyrs. It is true to say that martyrs who lost their lives cannot be compensated by anything. We have managed with the assistance of KORD [Kurdistan Organization for Retraining the Disabled] to open several courses for the disabled and try to make them feel that they have not lost their entire capabilities. The courses are six-months long and the candidates are able to select a different workshop of their choosing, in the field that they think they have neither expertise nor knowledge. The workshops are there to train them as carpenters, ironmongers, tailors or traditional cobblers. Thereafter they would enter into new workshops of two to three people together, while we assist them for an additional year and at the same time, we would be meeting all their needs. The income from the workshop work would be divided into two halves. The victims keep one half and the other half would go back to the department to cover the cost of running the course. After the trial year, they are required to depend on themselves and gradually get used to working on their own. Furthermore, they will be encouraged to have the belief that they can do the job on their own. They usually forget their disability. The villagers that are not capable of work because they are incapacitated by 100 per cent disability would be given animals, as it might be easier for them to take advantage of the animal produce.

The effort of technical activates and the work methods

Landmine clearance is contracted out to different companies in Kurdistan and they would be bidding for the contracts. The companies involved are; Ararat, Khabat Zangana, Chami Rezan and Aras Baiz. There are two ways of carrying out landmine clearing operations, Manual, which is carried out by hands, and Mechanical. The manual method is not in use as much these days unless the area is very awkward and manoeuvring is not possible. Eighty per cent of all the areas used to be cleared by hand, which means a person was carrying out the clearing by using an instrument called Mine Lap [metal detector] which is an advance machine widely used in most countries.

A metre of dirt excavated for cigarette foil

The issue with mine lap was that it used to register all type of metals and sometimes it takes more than an hour to excavate a spot, where the mine lap has showed readings and its bells rang. However, one would not be able to tell whether the instrument is indicating the whereabouts of a landmine, explosives or a nail. This process is very slow, as the readings need to be looked at all times to check if there are any mines. It is possible to clear an area covering only two to five metres in a day, therefore, sometimes it is likely that you dig the ground a metre deep and find a cigarette foil or find a landmine within 10 cm. This manual device is still in use but not as much.

How to accelerate the work?

The companies are working with armoured bulldozers and landmine suppressor machine. The machine enters into the landmine fields and digs the field up to 30 cm, which is an international standard. Then the soil would be removed and a de-miner comes and spread the soil to search for landmines, if any landmines found during the search then they would be deactivated. This method is faster than the manual method; however, the manual clearance is repeated after the machine clearance.

Dogs have saved the government money

Using dogs to look for mines are very effective and they have been playing an active role. The dogs can detect mines and explosives as well as being used in security operations. In 2007, they had 24 dogs, 18 of them were explosive detectors and six were mine detectors. The dogs are usually based in the military bases because they can detect explosives. The difference between the dogs and the Mine lap machine is that the machine detects every metal; on the other hand, the dogs only detect TNT. By using dogs, it has been possible to clear an area of 12,050 sq metres. There were an area thought to be a landmine field but the dogs proved the contrary and there were not any landmines found. Therefore, the dogs have saved the government money. The dogs usually check the landmine field clearance operations after the machines to make sure that there are no landmines left in the area. The other advantage of the dogs is that they have contributed to the security in KRG [Kurdistan Regional Government] because they have been spread throughout the bases to detect intruders who have entered into our city with explosives.

There are 7m mines in KRG and Sulaymaniyah has the lion’s share

Previous Iraqi government have bought 20m landmines from four different companies in 10 different countries. From the 20m landmines Iraqi government bought, it used 7m in Kurdistan. The number of landmines has been reduced over the years and they were laid in an area of 388sq km divided between 3,150 landmine fields. Sulaymaniyah has the lion’s share of the landmines, also parts of Kirkuk and Khanaqin area near Sulaymaniyah borders. There are more than 2,407 landmine fields, which cover 222 sq km of which 927 minefields have been cleared and this covers an area of 35 to 36 sq km. Nevertheless, there are still 1,430 landmine fields which covers 186,710 sq m to be cleared.

Operations are not based on the number of the landmines cleared

We do not work on the bases of the number of landmines cleared, but we work on the bases of how many landmine fields have been cleared. Because it might take one year to clear one, field which contains only 30 landmines. Nevertheless, it would be classified as a minefield and it is also possible that some fields might contain 10000 mines.

There are 110m mines

Kurdistan and Iraq have faced many issues because of the different policies of successive powers in Iraq. They were all bad public officials and even the current one with respect for them; have not worked for the people. They entered into different wars, with Iran and Kuwait and earlier with the Kurds. Before September 11 there was a large-scale war with the Kurds as it was known as the largest struggle and lasted for a long time. During the war there have been extensive landmine laying in the border areas and the areas close to the Iraqi and Kurdish front. After the failure of 1975 landmine laying has been taking place until the eighties. Thereafter the Iraq-Iran war, which has seen the largest number of landmines laying. The issue of landmines have commenced in world war one and so far it is estimated that there are 110m landmines in different varieties in 64 countries.

Landmines were laid in the civil conflict

As a main observation which is in front of me, we do not have any evidence that landmines were laid in the conflict between PUK [Patriotic Union of Kurdistan] and KDP [Kurdistan Democratic Party]. However, it is possible that they could have been left in observation posts, but officially, it was not announced. Nevertheless, during the conflict between PUK and Jund Al-Islam [Islamist group], landmines were laid unscientifically and Jund Al- Islam has laid booby traps for example they laid landmines in the middle of the roads.

Mines have claimed the lives of 14,000 victims

The number of the victims according to the latest survey is 14,000 dead and injured. There have been many interpretations of the survey and everyone talks about it differently. However, the facts confirmed are that the numbers of victims have reached 14,000.

This year the drought has increased the number of landmine victims

This year the number of landmine victims has slightly increased in comparison with previous years. This is not due to the people who provide protection services being negligent. It is also not because they did not listen to the warning massages or those massages have aged and being forgotten but the main problem was drought. Most of the victims are shepherds in need of grazing grounds for their herds. Because of the drought, they have been forced to go to areas with good grazing grounds. However, other shepherds have not used those grazing ground in years because they are dangerous landmine fields. Therefore, this has resulted in a large number of victims and disabled as well as large lose of live stock which is a national loss.

So far Arbil and Sulaymaniyah landmine agencies have not been united.

When there were two administrations, Sulaymaniyah administration has thought about establishing the Central Landmine Directorate for Mine Works, at the same time Arbil wanted to follow suit. Arbil also had directorate of landmine clearance previously and they later converted to an agency. The problem in Sulaymaniyah is that we do not have a ministry to refer back to and ask for assistance. Therefore, we have relied on the ministry of treasury and economics that have been beneficial to us; however, Arbil landmine agency is directly linked to minsters council.

They are preparing to unite the landmine agency in Arbil and mine directorate in Sulaymaniyah. All the necessary steps have been organized but it has not been possible to merge this to administration as interior ministry and treasury ministry are not able to do so. In addition, our agency had its specifics in Sulaymaniyah and Arbil.

No one else has bonuses like ours

The money we receive does not go to waste because the funding is based on putting forward proposals and later a special unit will praise the work and investigate it. The members are working in two different ways, many of them are contractors that are paid better that those employed by the government, and we hope we benefit from plans to raise wages. It has been requested that those people who run the risk of landmine explosions 100 per-cent be awarded 100 per- cent bonuses. Furthermore, every employee in this directorate, working in administration, accounting or any other work would be entitled to bonuses. The bonuses are 100,000 Iraqi dinars for the head of departments and 75,000 Iraqi dinars for the rest of the employees. This is only for people working with landmines and nobody else gets this bonuses.

One metre used to cost 50 US dollars but now it costs one

Landmine clearance and other areas were criticized in the past for being slow and wasting a lot of money as well as the cost of rent for landmine clearance. Apart from the process, being slow one- metre clearance was costing around 50 US dollars. However, because of the local companies competing for the contract the prices have been driven down. The clearance companies still manage to make profits with the reduced cost of the contracts and the question remain to be asked is, how much they used to profit in the past. The price has been reduced now to 2 or 3 US dollars or even in some cases to less than a dollar per meter. There have been reports that the speedy clearance can have a consequence of leaving land mines behind. These cases have been very few because there are quality control unit visiting the fields and they make sure it is clear. There have been two cases so far which was not by a large margin, as it is possible that the land mine was fallen from the Bulldozer fork. This has been noted and money has been deducted from their contract.

We take out the landmines without damaging the ruins

The areas were we cannot work with machines like hills, which are not ruins; we would resort back to the manual clearance. The de- miners would be working manually to preserve the areas that have ruins. We are not allowed to use machines even if the area is flat and machines can be used.

What is Ottawa?

In 18 of September 1997, Ottawa treaty was agreed and was later implemented in 1999. The treaty was designed to try to put an end to the issues facing people and to stop those countries that have personal landmines using them. Few countries have not become a member of the treaty despite having landmines. The number of the members in December 2007 was standing at 106 and Iraq was the last country to join on 18/08/2007. The treaty requires the countries in possession of personal landmines or has landmines in use to be destroyed within 10 years and those have stored landmines to destroy their stock within 4 years.

Every Tuesday the cleared land is returned to the citizens

After making sure the land is clear from landmines, every Tuesday the land which have been cleared are returned to their owners.

The last request

We have few request for the citizens, do not come close to the areas where there are natural signs, manmade signs and military signs indicating the existing of landmines. And do not tamper with the landmine signs for some material gains because they would be more beneficial if they stay where they are.

Originally published by Komal, Sulaymaniyah, in Sorani Kurdish 5 Jul 08.

(c) 2008 BBC Monitoring Middle East. Provided by ProQuest Information and Learning. All rights Reserved.

Hundreds Travel to New Mexico to Celebrate International Peace Prayer Day

ESPANOLA, N.M., July 16 /PRNewswire/ — The 3HO Foundation and Yogi Tea recently sponsored the 23rd annual International Peace Prayer Day at Ram Das Puri near Espanola, New Mexico. Held every June, this interfaith celebration features guest speakers, live music, meditation circles, evening chanting and a Peace Prayer led by Rahmani.

International Peace Prayer Day is part of the Summer Solstice celebration; a yoga and meditation retreat founded by Kundalini Yoga master Yogi Bhajan. Yoga and meditation classes are held daily during the retreat and include three full days of courses in White Tantric Yoga. The retreat also features multiple classes taught by well-known yoga instructors from Los Angeles, California, Italy, South America and beyond.

During the Summer Solstice, guests camp at Ram Das Puri and enjoy a yogic diet consisting of nourishing foods prepared on-site. These meals aid in meditation and include fruit and soup in the morning as well as beans, rice, vegetables and a special hot sauce that makes it all tasty. This diet was developed by Yogi Bhajan and has been in use since the first Summer Solstice in 1971.

This year, a record-breaking 1,800 people traveled to New Mexico to practice yoga and share their collective passion for world peace as part of the week-long Summer Solstice event. Among these attendees were teachers and practitioners of Kundalini Yoga along with other guests from around the world.

“The event was founded by Yogi Bhajan to involve as many people from as many faiths and cultures as possible in uniting and praying for peace,” said Daya Singh Khalsa, president of Akal Security, Inc. “It has grown every year and it will continue to grow as we reach out to more and more people in the future.”

Each year, International Peace Prayer Day takes place on the sacred land of the Hopi Indians and other native tribes known as Ram Das Puri. This campsite was believed to have healing affects on those who walked the mile and a quarter circle around the area, and guests have an opportunity to participate in this ancient tradition as part of the Sacred Healing Walk that takes place on Peace Prayer Day.

Another tradition associated with International Peace Prayer Day is that of the Peace Flame runners, who carry a torch and embark on a 20-mile run from the El Santuario de Chimayo Shrine in Chimayo, New Mexico to Ram Das Puri.

Yet aside from these practices, International Peace Prayer Day now has its own tradition of inviting people from around the world to learn about other faiths and practice peace through personal growth and understanding.

“The road to peace is bringing people together and trying to change consciousness by raising awareness, healing wounds, and creating understanding through prayer,” said Khalsa. “It’s not a political approach, but rather it focuses on service, unity and prayer.”

3HO Foundation

CONTACT: Daya Singh Khalsa of Akal Security, Inc., +1-505-692-6622, for3HO Foundation

Gulf of Mexico ‘Dead Zone’ Reaches Unprecedented Size

Scientists expect the Gulf of Mexico’s so-called dead zone to increase to record levels this year due to ethanol use and massive Midwest flooding this season.

The strip, which is located off the Texas and Louisiana coasts, could stretch to an unprecedented 8,800 square miles this year, according to scientists from the U.S. National Oceanic and Atmospheric Administration, Louisiana Universities Marine Consortium and Louisiana State University.

That expectation would put the dead zone at almost the size of New Jersey and nearly double the annual average since 1990 of 4,800 square miles.

The dead zone earned its name from being a dense area of algae fed by farm use of fertilizers like nitrogen and phosphorous, which results in lowered levels of oxygen thus causing marine life to suffer.

This year’s strong increase has been linked to the high demand for biofuels in U.S. motor gasoline supplies. Midwestern farmers who raise corn use nitrogen fertilizer, which eventually make its way into the gulf through the Mississippi River.

“We’re planting an awful lot of corn and soybeans,” said Eugene Turner, a scientist at Louisiana State University. “It rinses off easily when there is a rain.”

These algae settle and decay in the bottom waters of the Gulf, and the bacteria that decompose them gobble up oxygen faster than it can be replenished from the surface, which means lower levels of dissolved oxygen in the water.

Fishermen who rely on the gulf as a source of income will be forced to venture further out into the gulf’s waters to find their catch.

One-third of this year’s U.S. corn crop, or 4 billion bushels, will go to make the alternate fuel ethanol, the U.S. government has projected, compared to 3 billion bushels of the 2007 crop.

U.S. scientists estimate that a record 83,000 tons of phosphorus seeped into the Gulf of Mexico from April through June, up to 85 percent above normal seasonal levels.

“Excess nutrients from the Mississippi River watershed during the spring are the primary human-influenced factor behind the expansion of the dead zone,” said Rob Magnien, director of the NOAA Center for Sponsored Coastal Ocean Research.

Turner said that it is imperative that U.S. farmers plant perennial crops in order to trap rainwater from running into the Gulf of Mexico. He added that new developments would be necessary to invent new breeds of perennial corn plants that can remain in the soil from one planting season to the next.

On the Net:

NASA: Chinese May Be Next To Reach Moon

NASA Administrator Michael Griffin said China might be the next nation to complete a manned mission to the moon. And while NASA has plans to use its new Orion spacecraft to follow up on its 1972 Apollo 17 manned lunar mission, it may very well be the case that Chinese astronauts will be the next to reach the moon.

“Certainly it is possible that if China wants to put people on the Moon, and if it wishes to do so before the United States, it certainly can. As a matter of technical capability, it absolutely can,”  Dr. Griffin told BBC News.

In 2003, China became the third country to launch a person into orbit. But authorities say the nation has no plan to send people to the moon, and have even expressed doubt that such a mission would be possible by 2020.

But China’s National Space Administration (CNSA) chief Sun Laiyan told journalists last year that a lunar mission was all but inevitable.

“I’m not a psychologist, so I can’t say if it matters or not. That would just be an opinion and I don’t want to air an opinion in an area that I’m not qualified to discuss,”  Dr. Griffin said, referring to the importance of which nation reached the Moon next.

However, some in the space industry believe that America’s long-held dominance in space exploration is slipping away.  A report by consulting firm Futron found other countries were expanding their space capabilities at a remarkable rate, “threatening US space leadership”.

Over the last five years China has completed two manned missions into space. The initial mission, in 2003, launched “yuhangyuan” (astronaut) Yang Liwei into orbit for 21 hours on board the Shenzhou 5 spacecraft.

On the second mission aboard the Shenzhou 6, two astronauts spent nearly five days in orbit.   Another future manned mission is planned for October, shortly after the Beijing Summer Olympic Games.

Dr Griffin said the China and the U.S. were taking preliminary steps towards collaborative efforts in space exploration.

“We do have some early co-operative initiatives that we are trying to put in place with China, mostly centered around scientific enterprises. I think that’s a great place to start,” he told BBC News.

“I think we’re always better off if we can find areas where we can collaborate rather than quarrel. I would remind your [audience] that the first US-Soviet human co-operation took place in 1975, virtually at the height of the Cold War.”

“And it led, 18 years later, to discussions about an International Space Station (ISS) program in which we’re now involved.”

Although India’s space program is not as large as China’s, it is nevertheless making significant progress. The country will launch its Chandrayaan unmanned Moon probe later this year, and has also announced plans for a manned mission.

Since becoming NASA’s administrator in 2005, Dr Griffin has led the implementation of President Bush’s Vision for Space Exploration, which has the goal of  returning Americans to the Moon by 2020, and then on to Mars.

Dr Griffin has led the agency’s efforts to complete construction of the ISS prior to the retirement of the space shuttle in 2010. However, the Orion spacecraft and Ares rockets, the shuttle’s replacements, will not be operational until 2015, leaving a five-year gap during which no spacecraft will be available to reach the space station.

Last year, Dr Griffin told Congress the gap could be shortened to three years with the injection $2 billion in funding, a request Congress rejected. 

“Even if a new president and a new Congress decided they wanted to shorten the gap between shuttle retirement and Ares and Orion deployment, at this point with water over the dam, even if they were substantially increasing our funding, we would be talking about 2014 as the earliest,” Dr. Griffin said.

NASA has provided seed money to some commercial ventures in hopes of spurring development of a manned spacecraft capable of re-supplying the ISS.   The agency also retains the option of purchasing some of the European Space Agency’s ATV (Automated Transfer Vehicle) resupply craft.

Image Caption: Michel D. Griffin, NASA administrator (NASA)

On the Net:

McKesson Acquisition of EN-Chart Enhances Emergency Care Solutions

McKesson today announced it has acquired EN-Chart Scanning Program, LLC, a market-leading provider of computer-assisted facility coding and compliance solutions for emergency department (ED) visits. Based in Dandridge, Tenn., EN-Chart provides advanced coding and charge capture capabilities that enhance emergency department information systems (EDIS) and help to optimize revenue. EN-Chart solutions can be used stand-alone or integrated with existing hospital EDIS, including McKesson’s comprehensive Horizon Emergency Care(TM) emergency department solution.

“The emergency department is the front door for more than 40 percent of clinical experiences in the hospital setting, but it’s also one of the greatest areas of lost revenue,” said Duncan James, group president of Health System Solutions for McKesson Provider Technologies. “For a department that operates with limited resources and razor-thin margins, EN-Chart helps EDs save both time and money. Combined with our industry-leading ED information system or an organization’s existing EDIS, McKesson enables hospitals to not only achieve clinical excellence but also improve the economics of delivering care.”

According to EN-Chart analysis, a health system with 50,000 ED visits may lose $84 per patient visit annually due to chart deficiencies and compliance issues. Using EN-Chart solutions to automate their coding and compliance processes, at least nine health systems have recovered between 30 percent and 50 percent of lost charges for an improvement of up to $4 million annually.

McKesson’s acquisition of EN-Chart is the culmination of a two-year business partnership in which McKesson has offered EN-Chart as Horizon Emergency Care Facility Coding(TM). “The ED is often a hospital’s first impression for patients, making it critical to provide the best possible experience, the highest-quality care, and to do it as efficiently as possible,” said Mark Bentley, vice president and general manager for McKesson’s emergency care solutions. “Our comprehensive solution supports that goal while helping customers preserve and improve their financial health.”

EN-Chart Founder and Chief Executive Officer Karen Marsh is a former registered nurse with more than 25 years’ experience in emergency medicine. “Capturing proper ED coding on the front end of care generates positive returns,” she said. “Our solution serves a vital need for hospitals by improving documentation, while simultaneously applying up-to-date coding guidelines and patient data analysis to create accurate and timely revenue cycles.”

Like McKesson’s recently announced Horizon Enterprise Revenue Management(TM) solution, the addition of EN-Chart reinforces McKesson’s commitment to help health systems improve the economics of care. “Reinventing processes to link revenue management with real-time care delivery is critical,” Bentley said.

About McKesson

McKesson Corporation, currently ranked 18th on the FORTUNE 500, is a healthcare services and information technology company dedicated to helping its customers deliver high-quality healthcare by reducing costs, streamlining processes, and improving the quality and safety of patient care. McKesson is the longest-operating company in healthcare today, marking its 175th anniversary this year. Over the course of its history, McKesson has grown by providing pharmaceutical and medical-surgical supply management across the spectrum of care; healthcare information technology for hospitals, physicians, homecare and payors; hospital and retail pharmacy automation; and services for manufacturers and payors designed to improve outcomes for patients. For more information, visit www.mckesson.com.

Doctors Make More House Calls to Meet Patient Demand

By Phil Galewitz, The Palm Beach Post, Fla.

Jul. 14–The house call is back. Just ask Tessie Lucas.

Last winter, when Lucas was too busy to go to her doctor’s office for a physical, the doctor came to her.

At an auto repair shop Lucas owns with her husband in West Palm Beach, Dr. Lorne Stitsky drew her blood and took her temperature and blood pressure.

“I loved it because I didn’t have to take off from work for half a day,” Lucas said.

Welcome to the next level of “concierge medical care,” which continues to grow here seven years after the concept began with one doctor in Boca Raton.

Today, at least 35 doctors in the region have VIP-style practices to give patients more perks — for a price.

In February, Stitsky opened a concierge medicine practice in Jupiter where his patients pay a $1,500 annual membership fee for same-day appointments, no wait and yes, house calls.

He has a posh Abacoa office, with a small waiting area that boasts plush couches, a fancy chess set and large plasma television.

But patients don’t wait.

Stitsky has only 100 patients and says he plans to have only 200 when his practice is full.

“People who sign up with me are fed up with waiting two hours in the waiting room or not being able to get a hold of their doctor when they are sick,” said Stitsky, a general practitioner.

Even patients without health insurance have joined, including Tessie Lucas and her husband, Bruce.

Both are uninsured, as health insurers consider them too high a risk because they have diabetes.

“Even if I did have insurance, I would pay for the convenience of not having to wait to get treated,” Bruce said.

Stitsky first tried the concierge medicine concept four years ago with an office near 45th Street in West Palm Beach, but he said couldn’t attract a large following because of the area’s lower-income population.

By offering to see patients where they live and work, Stitsky hopes to differentiate himself from other concierge practices — most notably Boca Raton-based MDVIP Inc., which has 22 doctors in Palm Beach County.

Stitsky still charges patients’ insurance if they have it, and he charges extra for lab tests.

The concierge medicine trend is not limited to Palm Beach County.

Dr. Cheryl Jordan, a former U.S. Army doctor who moved to the region last year, has opened the Treasure Coast’s first such practice on Ocean Boulevard in Stuart.

The Jupiter High School graduate, who said she plans to limit her practice to 300 patients, charges a $2,250 annual membership fee.

For that, patients get, among other things, Jordan’s cellphone number, same-day appointments and a comprehensive yearly physical.

Jordan also throws in a customized leather binder in which patients’ complete medical reports and records can be kept for speedy reference.

And she makes house calls, if necessary.

“I have always wanted to have my own practice,” she said, “and I like the concept of concierge medicine to help give patients longer appointments and easier access.”

—–

To see more of The Palm Beach Post — including its homes, jobs, cars and other classified listings — or to subscribe to the newspaper, go to http://www.palmbeachpost.com.

Copyright (c) 2008, The Palm Beach Post, Fla.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Former Day-Care Worker to Stand Trial

By Ed Treleven, The Wisconsin State Journal

Jul. 16–It ‘s been nine months since a former Sun Prairie day-care worker was charged with abusing a toddler, but on Tuesday she finally faced a preliminary hearing in the case and was ordered to stand trial.

Sara Kladehall, 20, of Portage, will stand trial on charges of first-degree reckless injury and three counts of child abuse for allegedly abusing an 18-month-old girl in December 2006 and January 2007 at the Rock-A-Bye Child Care Learning Center, where she worked as a lead day-care provider.

Some of the alleged abuse was caught on videotape by a system the center uses to monitor the performance of its employees. The last alleged incident was on Jan 24, 2007, when Kladehall allegedly swaddled the girl in a blanket, set her face-down on the floor and pressed herself onto the girl ‘s upper torso.

The girl ‘s heart stopped beating, she stopped breathing and turned blue. She was given CPR by former worker Lindsey Anderson, 21, of DeForest, who was assigned to the girl ‘s care at the center.

Anderson was ultimately charged with felony child abuse. Under a May plea agreement, Anderson pleaded guilty to three counts of child neglect and was placed in a first-offenders program.

In court Tuesday, Anderson testified that she witnessed Kladehall abuse the girl on several occasions, including instances where she swaddled the girl tightly in a blanket, placed weight on the girl ‘s torso and set a beanbag chair on top of the girl while she was swaddled.

Anderson admitted to having done some of those things, but testified that she never put any weight on the girl ‘s torso, only on her buttocks, to hold her down. She said the girl ‘s parents suggested swaddling her or placing some weight on her if she would not sleep during nap time.

On Jan. 24, 2007, Anderson said, she was on a lunch break and saw Kladehall with her arm over the girl ‘s torso while the girl rested on her stomach. After a time, she testified, Kladehall said, “Oh my God, Lindsey, she ‘s not breathing, ” and went to get help. Anderson said the girl ‘s face and lips were purple.

Sun Prairie police Officer Zach Bolling, who arrived before an EMS crew, said the girl was conscious and breathing by the time he got there, but said her response appeared slow. When she looked around, he said, “she looked through you and not at you. “

Assistant District Attorney Shelly Rusch has said the delay in the case involved a problem with the videotape, which had to be meticulously time-corrected to compensate for the camera not being set up to shoot continuous video. The video was not shown at Tuesday ‘s hearing.

—–

To see more of The Wisconsin State Journal, or to subscribe to the newspaper, go to http://www.wisconsinstatejournal.com.

Copyright (c) 2008, The Wisconsin State Journal

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Remedi SeniorCare Acquires HealthCare Pharmacy

Remedi SeniorCare, a provider of pharmacy services for senior healthcare facilities, has acquired HealthCare Pharmacy of Covington, Ohio.

Remedi SeniorCare, formerly Woodhaven Health Services, will now serve more than 20,000 residents in Maryland, Delaware, Washington DC, Virginia, Ohio, Kentucky, Indiana and Michigan.

All Remedi SeniorCare customers will gain access to My Remedi, which provides an integrated ‘e-pharmacy’ experience that simplifies drug dispensing and documentation, and offers real-time tracking of prescription drug usage and costs.

HealthCare Pharmacy CEO Jay Meyer will become president and COO of Midwest operations for Remedi SeniorCare.

Michael Mahon, president and CEO of Remedi, said: “We’re building on Remedi’s successful track record to help more senior healthcare facilities achieve healthier results for their residents. The acquisition is part of our controlled-growth strategy to be a multi-regional provider of institutional pharmacy solutions.”

Men Feel Yoga’s Pull

By Wendy Lemus, The Cary News, N.C.

Jul. 16–Rob Rose of Apex figured if yoga is good enough for football players, he’d give it a try.

Eric Aittala of Apex had a shoulder injury from his martial-arts practice that never quite healed “100 percent.” He began taking yoga five months ago.

And Thani Kumar Cheran, a retired Cary engineer, says that at the age of 70 he feels more energetic these days thanks to his yoga practice. Yes, men are doing yoga, too.

They’re gaining strength, flexibility and overall health benefits from doing those same downward dogs, triangles and plank poses that have brought women to gyms and yoga studios in record numbers the last couple of decades.

After all, men face many of the same challenges as women — they’re seeking ways to relieve stress, improve fitness or just work out the kinks from our culture’s largely sedentary, but often stressful, lifestyle.

Men sit at computers all day, too, causing neck and shoulder tightness.

They’ve got knee problems and back problems and other ailments that have long had women seeking remedy in yoga.

Aittala has a black belt in hapkido — he’s an instructor at Raleigh Institute of Martial Arts. He also works out daily at the gym at Cisco Systems Inc., where he works in tech support.

He had surgery on his shoulder two years ago and recently started yoga to “try something different to try to rehab it,” he said.

“It’s getting stronger,” he said. “It’s not 100 percent but [yoga has] definitely made a difference.”

Rose also sits at a computer, resulting in that chronic shoulder tightness that so many computer users feel.

So when Rose took a yoga class offered at his church several years ago, the practice seemed a good fit.

“I kind of knew I would like it,” he said.

He even talked his wife into signing up for classes.

In addition to the physical relief that yoga offers for his neck and shoulders, Rose enjoys other benefits as well.

“It’s a great way to get your mind off most everything,” he said.

It’s hard to let your mind drift when you’re concentrating on sun salutations or warrior sequences, or remembering just to breathe.

And it’s a great workout, Rose said.

“I like to sweat, so I work pretty hard when I’m there,” he said.

Yes, gentlemen, don’t let what you might have heard about yoga — the meditation, the calming relaxation — fool you, Aittala said. “Yoga’s hard if you do it right.”

(Disclaimer: Yoga teachers will tell you that yoga is as challenging as one wants it to be; let your body decide. And yoga should never cause pain.)

It can be a challenge even for those who consider themselves physically fit, said Donna Enichen, a group fitness coordinator at the Cary Family YMCA who also teaches yoga at Peak Fitness in MacGregor Village.

“Men who can bench 100-plus pounds and think they’ve got it all going on, they come in and do a plank or chaturanga. Their abs sag, it kicks their butts,” Enichen said. “Sometimes holding a pose is a challenge in itself.”

Well, yoga used to be more challenging for Cheran when he first started taking classes four or five years ago. He didn’t even like it at first, calling it “monotonous.”

The more he practiced, the more he caught on and the easier it became.

“The more I did it the more I started liking it,” he said.

Cheran said he does other things, too, such as a “body flex” class offered at Peak Fitness where he has been a member for 11 years. He also does Pilates occasionally.

Historically men were the main practitioners of the ancient practice that combines breath and movement. But Cheran said yoga wasn’t widely practiced at all when he lived in India, where yoga originated thousands of years ago.

“I lived [in India] until I was 29 years old and I had rarely seen anybody doing yoga,” Cheran said.

Like in the West, media have more recently popularized the modern-day practice there.

Men are doing yoga, but in America those seas of purple and blue mats are still largely navigated by women.

According to a Yoga Journal article, a 2005 study showed 77 percent of practitioners were women. And that same article said only one in 10 subscribers to the magazine are men.

Even with those numbers, Enichen said she has seen more men both taking yoga classes and learning to become instructors.

“I feel men are becoming more comfortable going into a yoga class,” Enichen said.

When Enichen first started taking yoga about eight years ago, “it used to be ‘Oh look, there’s a man in class,'” she said. “Now it’s not an exceptional class if I have four or five men.”

Enichen said men and women can enjoy the same benefits from yoga practice including more flexibility — men tend to be less flexible than women — strength and lower blood pressure as well as learning to live in the present, be nonjudgmental and quiet the mind.

The first hurdle for men, though, may be getting through the door that first time. Apprehension and not knowing what to expect may be holding some back, Enichen said.

But what many men who have made it past that threshhold realize is that yoga has become an integral part of their overall well being.

Even though Cheran says he is gradually taking more “body flex” classes, yoga will always be a part of his routine.

“When I started I did not even know how to breathe [properly],” he said. “[Now] I make it a point to come if I’m not out of town.”

All rights reserved. This copyrighted material may not be published, broadcast or redistributed in any manner.

—–

To see more of the Cary News or to subscribe to the newspaper, go to http://www.carynews.com/.

Copyright (c) 2008, The Cary News, N.C.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

NASDAQ-NMS:CSCO,

Nurse Accused of Drug Theft

By Suzanne Ulbrich, The Daily News, Jacksonville, N.C.

Jul. 16–The State Bureau of Investigation has charged a licensed practical nurse of stealing drugs from Onslow Memorial Hospital while employed there.

April Lenora Locklear, 35, of Newbold Road in Jacksonville, was arrested Monday by SBI Special Agent Cecil Cherry and charged with six felony counts of trafficking by possession, one count of possession of hydromorphone, a schedule II controlled substance, and one count of embezzlement of a controlled substance by employee of a registrant.

She was placed under a $100,000 secured bond in the Onslow County Jail.

According to warrants, Locklear is accused of embezzling 463 ampules of hydromorphone (opium) for her own use from the hospital’s Pyxis med station drug dispensing machine without legal authorization. She was also charged with possession of more than four dosage units of injectable hydromorphone.

Jenna Martin, chief nursing officer for Onslow Memorial Hospital, said the Pyxis machine is used as a safety system for dispensing all medications by front-line clinical providers, and the automated machine serves as a control of medication inventories. She said on the evening of June 4, a nurse was pulling medications from the machine and noticed seven ampules of hydromorphone were missing and reported it to hospital authorities.

“That’s the advantage of the Pyxis machine; it keeps tract of all the medications. Within an hour after (Locklear) left we were able to proceed with appropriate administration interventions,” Martin said. “I was notified and the hospital performed due diligence. We contacted all the external regulatory agencies according to policy and procedure including the board of nursing. Our medication administrator contacted SBI.”

Martin said the investigation by SBI and the hospital revealed the drugs were taken in moderation over a significant period of time, but the hospital does not know how long a period of time.

“We contacted Locklear — she came to the hospital of her own free will and returned the seven ampules. After discovering a discrepancy of that nature the person has to be relieved of duty,” Martin said. “Until that night we had no reason to suspect anything, she had nothing on her disciplinary record at all.”

Martin said Locklear was employed at the hospital as a certified nursing assistant in June 2005, then went to school and received her LPN. She has been an LPN at the hospital for about a year and a half.

Contact Topsail area reporter Suzanne Ulbrich at [email protected] or 910-219-8466. Visit www.jdnews.com to comment on this report.

—–

To see more of The Daily News, or to subscribe to the newspaper, go to http://www.jacksonvilledailynews.com.

Copyright (c) 2008, The Daily News, Jacksonville, N.C.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

PatientKeeper Continues Its Strong Growth in the Meditech Hospital Market

PatientKeeper(R), Inc., the leading provider of integrated physician information systems, announces that its MEDITECH customer base has grown to over 200 hospitals, representing a significant portion of the hospitals running MEDITECH in the United States. Across the nation, the market demand for PatientKeeper software is driven by a growing need among hospitals to improve the physician experience with access to data in MEDITECH and other ancillary systems, provide a cost-effective means of accessing clinical data outside the hospital, and to implement a robust business continuity solution to allow all clinicians to access data in MEDITECH when the MEDITECH system is not available.

PatientKeeper software has recently been implemented at a number of MEDITECH facilities including Ohio’s Berger Health System, St. Joseph Medical Center in Towson, Maryland (a member of Catholic Health Initiatives), and Provena St. Joseph Medical Center in Joliet, Illinois.

By adding the PatientKeeper Physician Information System as a layer on top of MEDITECH and other ancillary systems, hospitals deliver a unified view of patient information and provide their physicians with a tightly integrated suite of physician-centric applications. The Physician Information System gives physicians a modern browser-based view of patient data on tablets, laptops and PCs, and offers a mobile companion that runs on most major Smartphones and PDAs.

PatientKeeper’s proven integration technology connects disparate systems that physicians typically access throughout their workday into a single physician portal. With a single sign-on, the PatientKeeper Portal enables providers to review clinical data from multiple sources –including lab and test results, EKG, PACS, fetal monitoring, Ambulatory EMRs and medication histories; hand off patients to other physicians at the end of a shift; and electronically sign medical record documentation. This improves physician satisfaction with hospital IT, provides cost-effective remote access to information for the affiliated physician community and extends the value of MEDITECH and other hospital applications.

“What impressed us most about PatientKeeper’s portal solution is that not only does it provide a physician-friendly shell over MEDITECH, but it actually integrates clinical information into a physician-centric workflow,” said Andy Chileski, Berger Health System CIO. “Physicians rave about PatientKeeper’s Portal and its usability. Some of the physicians have commented that our system now outshines those offered by some of the bigger tertiary facilities in the area.”

Another benefit of the PatientKeeper Physician Information System is that it provides redundancy for clinical information — an effective and economical solution to ensure business continuity during both planned and unplanned MEDITECH system downtime. This capability ensures that physicians and other caregivers will always have the information they need for patient care while supporting the JCAHO guidelines for continuous access to clinical information.

“We are very excited to add these hospitals and their physicians to our growing customer base,” said Paul W. Brient, PatientKeeper president and CEO. “The breadth and depth of our physician applications give our customers the opportunity to expand the capabilities they can offer their physician community to improve patient care. We look forward to working with them as they continue on this bright path.”

About PatientKeeper

As an innovator, creator and leading supplier of integrated physician information systems, PatientKeeper’s applications provide a single point of anytime, anywhere access to clinical and financial data from multiple, disparate systems. PatientKeeper’s technology automates the provider’s day to transform their experience and improve satisfaction. The Company’s physician-centric portal and mobile applications improve user satisfaction and patient safety, increase revenue and simplify data access and interoperability for community health information exchange. For more information, visit http://www.patientkeeper.com.

Covidien Launches Optistar(TM) Elite(TM) Contrast Delivery System

Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, today announced that its Imaging Solutions business is launching the Optistar(TM) Elite(TM) contrast delivery system. The product, which recently received U.S. Food and Drug Administration clearance, is designed to inject contrast media-related drugs into a patient’s vascular system to aid in obtaining diagnostic images when used with magnetic resonance (MR) imaging equipment. The new Optistar Elite provides improved performance and ease of use, compared with the previous Optistar LE model.

The Optistar Elite carries the CE mark, a mandatory European marking for certain product groups to indicate conformity with the essential health and safety requirements set out in directives established by the European Union. Regulatory agencies in other regions are currently reviewing Optistar Elite for approval.

“Covidien’s Optistar Elite contrast delivery system is an evolution in design,” said Steve Hanley, President, Imaging Solutions, Covidien. “With its advancements in imaging technology, we expect this system to deliver greater reliability and improved performance, as well as bring enhanced clinical value to the patient and end user.”

Among the significant features on the Optistar Elite injector is Patency Check(TM), which aids in preventing extravasation, assists in reducing the potential of certain medical errors and helps enhance clinical and work flow efficiency. Aimed at improving patient comfort, care and safety, the patency check feature enables healthcare providers to confirm an unobstructed, or patent, fluid pathway to the patient prior to injection of contrast media-related drugs. A visual alert on the injector powerhead and on the control console also warns clinicians when the programmed pressure limit engages due to a blockage during the patency check.

The Optistar Elite, combined with the use of Covidien’s Ultraject(TM) prefilled syringes for contrast media-related drugs, can help decrease the risk of certain medication errors that may be caused by manually filling syringes. Designing the Optistar Elite to be compatible with the Ultraject prefilled syringes also eliminates syringe preparation and labeling steps, which helps meet certain regulatory requirements of the Joint Commission (formerly known as JCAHO). In addition, the powerhead buttons on the Optistar Elite injector are color-coordinated with the Ultraject prefilled syringes to help avoid medication errors resulting from the use of the wrong syringes and to help ensure proper procedural set up, while a status line banner guides technologists through each step of the set up process.

With the Optistar Elite injector, the powerhead can be enabled from either the control console or the injector, which may minimize delays. A multi-phase programming feature provides the ability to set as many as six phases for each exam protocol and to store up to 40 protocols in the system’s memory. A Timing Bolus(TM) feature allows specific amounts of contrast media to be injected during a test scan to determine optimum transit time of the imaging agent to the area being scanned, thus helping to maximize the diagnostic information obtained in the scan. The Optistar Elite injector’s 3T-compatible dual-syringe powerhead allows injection set up and control at the patient’s side.

The auto retract sequence on the Optistar Elite contrast delivery system may also save time by allowing clinicians to quickly remove both syringes from the dual powerhead without waiting for both rams to fully retract.

“The Optistar Elite encompasses a number of new, important features and software enhancements, improving the reliability and performance of the contrast delivery system,” Hanley added. “Our new delivery system underscores Covidien’s commitment to assist medical professionals in better caring for their patients while improving their ability to diagnose disease.”

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2007 revenue of nearly $9 billion, Covidien has more than 42,000 employees worldwide in 57 countries, and its products are sold in over 130 countries. Please visit www.covidien.com to learn more about our business.

Repair Stem Cell Institute Announces Science Advisory Board

DALLAS, July 16 /PRNewswire/ — The Repair Stem Cell Institute LLC (RSCI; http://www.repairstemcells.org/), a Dallas, Texas-based stem cell global public affairs organization, today announced the formation of a new Science Advisory Board (SAB) consisting of some of the world’s leading stem cell medical, science and research professionals. RSCI was founded in April 2008 and has offices located in Washington, D.C. and Bangkok.

According to Don Margolis, RSCI chairman and founder ([email protected]; 214-556-6377), “RSCI’s new Science Advisory Board has been created to provide the general public with the latest repair stem cell research and therapeutic innovations. Each of these five SAB members are active stem cell leaders who are not only researching, but successfully delivering cells to patients suffering from heart disease, diabetes, spinal cord injuries, neurological disorders, and 100+ other incapacitating conditions, all of which are covered at http://www.repairstemcells.org/ – click-on ‘Diseases Treated.'”

RSCI’s world-leading stem cell treatment experts are as follows:

SAB chairman Dr. Kitipan V. Arom, M.D., Ph.D., FACS, FACC, FACCP, FRCST, established an innovative stem cell treatment program at Bangkok Heart Hospital (BHH) and may be the only doctor in the world to successfully inject RSC directly into the heart muscles of more than 120 late-stage heart patients. Dr. Arom, associate professor of surgery and chief cardiothoracic surgeon at BHH, previously served in many capacities with several hospitals in the Minneapolis/St. Paul area, founded the Minneapolis Heart Institute & Minneapolis Heart Institution Foundation and is currently the President of the Society of Thoracic Surgeons of Thailand.

Dr. Roberto Jorge Fernandez – Vina, M.D. is known for his innumerable cardiology advances, is an authority on the utilization of RSC treatment of Type-2 diabetes and is the first and only known person with a successful clinical trial on helping Type-2 diabetes with repair stem cell treatment. He has treated hundreds of patients with RSC for heart disease, Type-2 diabetes and emphysema; both in his clinic in Argentina and in clinics in other Latin American countries. He is on the verge of another discovery for the most difficult to treat common disease of all, diabetes Type-1.

Professor Shimon Slavin, M.D., an expert bone marrow transplantation scientist and clinician, is world-famous for his innovative clinical application of cell-mediated immunotherapy for the treatment of hematological malignancies, solid tumors, immune disorders and a broad spectrum of non-malignant conditions treatable by stem cell transplantation. He and his team are the first known in the world to treat multiple sclerosis and amyotropic lateral sclerosis patients by injecting their spinal fluid with large numbers of repair stem cells (mesenchymal stromal stem cells) taken from their bone marrow and multiplied in culture. Dr. Slavin is the medical & scientific director of the newly established International Center for Cell Therapy & Cancer (ICTC) at the Tel Aviv (Sourasky) Medical Center in Israel.

Dr. Carlos Lima, M.D., one of the foremost neuropathologist experts in RSC treatments, rejected traditional bone marrow stem cells as a too limited source for the neurological stem cells required to repair injured spinal cords. Using olfactory stem cells harvested from the patients’ own nose, Dr. Lima transplants the cells at the spinal cord break utilizing the successful OMA transplant surgical procedure he developed. Dr. Lima is the only doctor in the world whose treatments have created the neurological redevelopment required to allow some paraplegics to engage in extensive rehabilitation therapy, rise from their wheelchairs and walk.

Dr. Zannos G. Grekos, M.D., Director of Cardiology & Vascular Disease at Metropolitan Hospital – Santiago, Dominican Republic, is a RSC innovator. In April 2008 he saved a young meningitis patient’s arms and legs from amputation and in May he saved a young cardiomyopathy patient with serious complications by developing a new multi-faceted comprehensive repair stem cell treatment procedure. He has collaborated with the major treatment centers in Asia, been active in both the development of research and treatment protocols and consults with patients throughout the world. Dr. Grekos utilizes RSC to treat pulmonary hypertension and fibrosis, heart and peripheral vascular diseases and diabetes.

Visit http://www.repairstemcells.org/ and click-on “Science Advisory Board” for more information about each of these five leaders, now treating over 100 different medical conditions.

The Repair Stem Cell Institute LLC

CONTACT: Jack Wynn of The Repair Stem Cell Institute LLC,+1-703-623-4288, [email protected]

Web site: http://www.repairstemcells.org/

Tony Snow’s Cancer: Is There a Lesson for Us?

As a two-time cancer survivor, I would love to see Tony Snow’s tragic death last week help raise awareness about colorectal cancer. The former White House press secretary was just three years younger than me and I know all too well how tough his battle was. Sadly, it’s one that 50,000 Americans lose each year.

When famous people like Snow or journalist Tim Russert pass away, their deaths often inspire news coverage about their particular disease. That’s good because it helps educate the public. Unfortunately, the articles often focus on early detection or the latest treatments.

As someone who detected her first cancer early and lives with many complications from various treatments, I know there’s an infinitely better approach. It’s cheaper, less painful, and comes with fewer side effects. It’s called prevention. I would be thrilled if Tony Snow’s death inspired a serious discussion about cancer prevention. That’s the best hope any of us have for a long, healthy life.

One way we can help prevent cancer _ in addition to not smoking, keeping slim, exercising and not drinking _ is to eat right. But what constitutes “eating right” is often up for debate.

Food manufacturers and their lobbyists like to pretend that even the most unhealthful foods _ like hot dogs, bacon and other processed meats _ are OK in moderation. And anyone with a pepperoni addiction likes to pretend that jogging three miles a day will keep them healthy. But late last year, the game was up.

That’s when two prestigious cancer research organizations _ the World Cancer Research Fund and the American Institute for Cancer Research _ released a landmark report on diet and cancer risk. The scientists announced that when it comes to colon cancer, there is absolutely no amount of processed meat that’s safe to eat.

In fact, according to researchers, just one 50-gram serving of bacon, sausage, deli meats, or other processed meat (think one hot dog) daily increases our risk of colorectal cancer, on average, by 21 percent. Do the math. If your spouse or your kids are eating ham slices or hot dogs just a couple of times a week, they are significantly increasing their risk of colon cancer.

What is it about processed meats that can cause cancer? Scientists actually aren’t certain. Processed meats contain plenty of fat, especially saturated fat, as well as cholesterol, salt and heme iron, which promotes the production of carcinogens. The nitrites used as preservatives, coloring or flavoring agents can also produce carcinogens _ as can food preparation such as grilling at high temperatures.

Meanwhile, Americans go on blindly eating processed meats. In 2006, we wolfed down 1.5 billion pounds of hot dogs. Sixty-two percent of all Americans eat some form of processed pork, the average person eating 32 pounds of it a year. Children are at particular risk as lifelong eating habits are established during childhood and school menus are packed with processed meats.

I wish I had known how I was risking my health by eating processed meats through so much of my life. When I finally stopped eating meat _ too late to help prevent the cancer _ it was because of concern over how animals are treated on factory farms. But I quickly learned that vegetarian diets could alleviate an enormous amount of human suffering as well. Now, when I see a teenage girl smoking a cigarette or a young boy eating a hot dog, I wish I had the nerve to tell them what I’ve learned the hard way.

Processed meats aren’t the only unsafe foods _ no animal products are good for us. They increase our risk of diabetes, heart disease, high blood pressure, and numerous other conditions. And no medicine can reduce the risk of these diseases the way a healthful diet rich in whole plant foods like beans, whole grains, fruits and vegetables can.

So, if there’s one thing you can do to help keep your family healthy, it’s to think about replacing meats with healthier choices. Then, the next time you see a headline about a favorite newscaster or politician who’s succumbed to cancer, you’ll know you’re doing the best you can do.

Death . . Margo’s Greatest Challenge in Life

By Stephen McGinty

THE scene is the epitome of suburbia. An elderly woman with the merest hint of a blue rinse stands at the kitchen table and rolls out a clear plastic bag which the casual viewer might assume is designed to hold a chicken or turkey but is, in fact, for the human head.

The short documentary, complete with background music more suitable for a 1970s public information film on road safety, was made in Australia and details a DIY death. “It’s like an outsized oven bag,” explains the octogenarian host about the home-made “suicide hood” designed to be used in conjunction with a drug overdose. “One size fits all heads. And if you want to look nice, make sure you visit the hairdressers as it can mess up your hair.”

Watching the footage on the internet and joking about its kitsch manner is Margo MacDonald, the independent MSP who suffers from the degenerative condition, Parkinson’s Disease, and who has filmed a documentary for BBC Scotland, to be broadcast tonight. My Right To Die explores the politician’s journey from support of assisted suicide, but opposition to legalised euthanasia, to finally embracing the option of doctors helping their patients to die. The arrival of a “suicide hood” in a plain padded envelope marked “Orchid accessory” at her office in the Scottish Parliament marks one step closer to her new position. Tearing it open on air, her humour is replaced by horror at the prospect of drawing one’s last breath under its clear plastic skin.

As Margo explains, euthanasia or an assisted suicide is not a path she expects to go down; what she wants is the option, the peace of mind that comes from knowing that if her condition and health becomes intolerable, there is a way out. “It’s the prescription on the mantelpiece,” she explains. “I don’t know if I would use it, I don’t want to have to use it, but I do want the reassurance that comes from knowing that it is there.”

The law, as it currently stands, is quite clear in offering no such option. Under the Suicide Act 1961, aiding or abetting a suicide is a crime punishable by up to 14 years’ imprisonment, although no-one has recently been prosecuted. Dr Michael Irwin, a GP, was struck off for admitting that he was prepared to help a friend die.

In Europe other options exist. The Dignitas clinic in Zurich offers facilities for the terminally ill to kill themselves but they must still have the motor control to raise a cup containing a fatal dose of drugs to their mouth then swallow. Over 100 people from Britain have already done so, paying GBP 3,000 to end their life, while hundreds more have made contact and plan to go in the future. Among those contemplating a visit to Dignitas is Valerie Mackay from Perth, who has a very aggressive form of MS. She tells MacDonald in the documentary how she may have to go while still not ready but able to lift a cup rather than wait until it is too late. As she said: “My son has to help me to the toilet. That just shouldn’t be. I have no privacy at all. I don’t want people to feel sorry for me. I’m not like a lot of people who were born disabled. I’ve had 40- odd years of a normal life. But that’s finished now. It’s over.”

Ms Mackay’s favoured option would be the system now in place in Holland. For the past eight years, euthanasia has been legal. The Dutch system involves a suffering patient being under the supervision of a doctor for at least 18 months before being allowed to end their own life. The rule is designed to ensure that no-one is allowed to end their life for no good medical reason. Since the law changed, an average of 2,000 people each year kill themselves, with a GP assisting a patient, on average, to die once every 18 months. The fact that the annual figure has not increased over the past eight years is taken by supporters as proof that the fears of opponents, of the old and ill being bullied into accepting euthanasia, are ungrounded.

Yet in Britain, there is a lack of support among the medical establishment. The BMA attracted controversy a few years ago when they moved their position from opposition to being neutral towards the idea. However, they quickly moved back to opposing euthanasia.

In the documentary, MacDonald meets Dr Sheila McGettrick at the Prince and Princess of Wales Hospice in Glasgow who argues against the idea. She said: “I deal with hundreds of dying people every year. They talk about being a burden to their families and wanting to end it all. But what they’re really looking for is an affirmation of their worth.”

It is a position supported by Cardinal Keith O’Brien, a friend of MacDonald’s distressed to hear her talking of wanting to be able to end her life. As the Archbishop of St Andrews and Edinburgh said: “I thought, ‘How can Margo think like that?’ I love and respect her so much. Life is a gift from Almighty God. If he can give it, he can take that gift from us. But we can’t say, ‘God, I am finished with it. I can’t cope with cancer or Parkinson’s’.”

Yet the politician believes the question of how our life ends will continue to be asked as our population ages.

During the investigation, she discovered that a growing number of people had tracked down and were storing the drug, Nembutal, used by vets to put down animals. While some people acquire it via the internet, the drug is also available over the counter in Mexico. Dr Michael Irwin, now a campaigner for the right to die, plans to purchase the drug and then declare the reason for its use when he arrives back in Britain.

The practice of assisted suicide has been touched upon at Holyrood, where Lib Dem MSP Jeremy Purvis failed in an attempt to bring forward a private member’s bill on the issue. A similar bid in England, with the Assisted Dying for the Terminally Ill Bill (ADTI), was blocked by the Lords in 2006. Both bills proposed legalising doctor-assisted death for the terminally ill – meaning a doctor writes a prescription at the patient’s request and the patient chooses whether or not to use it.

This autumn, MacDonald plans to revisit the issue in an attempt to introduce laws similar to Holland in Scotland. She explained: “The beginning of life is a reserved matter – the issue of abortion cannot be tackled by the Scottish Parliament but they left the other end of life open.” She adds with a chuckle: “Death is devolved.”

(c) 2008 Scotsman, The. Provided by ProQuest Information and Learning. All rights Reserved.

Valley Residents Participate in U.S. Transplant Games

By Celanie Polanick, The Valley News-Dispatch, Tarentum, Pa.

Jul. 16–Surgeons removed Rudy Molnar’s first bad heart in 1989, but they couldn’t remove his love of bowling.

The 70-year-old from Natrona Heights, Harrison, was among more than 100 people from the Pittsburgh area — and about a dozen from the Alle-Kiski Valley — to participate in the 2008 National Kidney Foundation U.S. Transplant Games at the Petersen Events Center in Oakland, Pittsburgh.

Also called the Transplant Olympics, it’s a nationwide athletic event designed to suit — and to honor — people who have had transplants, the organ donors and their loved ones.

The weeklong games ended with closing ceremonies Tuesday night and a final golf outing today.

Molnar used to bowl in a church league, but gave it up when he developed the virus that led to his first transplant, he said.

His second transplant came in 2005.

But last fall, he said, he started bowling again to prepare for his first Transplant Olympics — and found he still loves the game.

“I hadn’t bowled in 20 years,” Molnar said. “It was nice getting back out there. I was really sore after a while, but I guess I got used to it again, because I feel pretty good again.”

The games have been around in some form for more than 25 years, and have been held every two years since 1990.

Now, the games draw over 1,300 athletes from all over the United States, as well as several international teams.

This year’s Pittsburgh team was made up of 125 athletes from western Pennsylvania and northern West Virginia.

Not all the events are competitive — and not all the athletes are, either, said Maggie Pratt of the Dormont, who is one of the team’s managers.

To participate, would-be athletes must be at least six months from their last life-saving transplant, and that transplant must be functioning well, Pratt said.

The athletes have a wide range of skill levels, “but they all enjoy themselves,” Pratt said. “It’s a mix. Some are very, very competitive. Others are just excited to be able to have a life-saving organ transplant, and to show to their families that they’re survivors.”

Shane Carnahan, 19, of Washington Township had a liver transplant when he was not quite 4, because of his Byler’s syndrome. But that didn’t stop him from blossoming into a promising young athlete, according to his mother, Lisa.

“Really, we tried to treat him as a normal child his whole life,” she said. “Other people treated us as a different family, but we tried to have everything normal for him. Pretty much anything he wants to do, he does it.”

In this year’s Transplant Olympics, his second, Shane Carnahan won a gold medal in basketball and a bronze in track and field.

He is also studying graphic design at Pittsburgh Technical Institute, and loves to run “as a stress reliever,” he said.

He also loves talking to people who understand his experience in a way the average person doesn’t.

“The (Transplant) Olympics themselves, it’s pretty much a break from normal life,” he said. “It’s just seeing other people who don’t care about having transplants, like it doesn’t really affect them that much.”

Kim Krebs, 46, of East Deer said she enjoys talking to others who understand the impact of undergoing an organ transplant. She also likes meeting with donors and donor families.

“You get to meet people from across the U.S. and share your experience,” Krebs said.

Krebs suffered from juvenile diabetes and needed a kidney, bone marrow and islet cell transplant 14 years ago. In 2000, she needed a new pancreas.

“I was very fortunate,” Krebs said of the availability of organs after 15 months on dialysis. She said her mother wasn’t as fortunate and died while waiting for a kidney-pancreas transplant in 2001.

Krebs said raising awareness for the need for donor organs is another reason she’s active in the Transplant Games.

Krebs participated in singles and team bowling. When asked how she did, she simply noted, “We had fun.”

Successful heart transplant patient John Polczynski, 73, of Lower Burrell said he didn’t do too well in his bowling events due to performance anxiety. But he said the most important part to him was the friends he’s made. During the event, he said, “we joked and we clapped for each other, high fives, stuff like that. It was great.”

Organ donors helped make that experience possible, Polczynski said — that’s why the world needs more of them.

“A lot of people are afraid,” he said. “They don’t want to give up their organs or anything. I understand how wonderful it is to give this to someone else, whatever you have left. If someone in your family is dying, you hate to see that. But why let it rot in the ground when someone else can use it?”

Staff writer Liz Hayes contributed to this report.

Celanie Polanick can be reached at [email protected] or 724-226-4702.

—–

To see more of The Valley News-Dispatch or to subscribe to the newspaper, go to http://www.pittsburghlive.com/x/valleynewsdispatch/.

Copyright (c) 2008, The Valley News-Dispatch, Tarentum, Pa.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

New Detailed Report on the Neurotechnology Market for 2008-2012

Research and Markets (http://www.researchandmarkets.com/research/83cfae/the_market_for_neu) has announced the addition of the “The Market for Neurotechnology: 2008-2012” report to their offering.

This newly published market research report is the most comprehensive and up-to-date publication available covering the neurotechnology industry. The report takes an in-depth look at the technology, markets, competitors, and growth rates in four key segments of the neurotechnology industry in the years 2008 through 2012. It forecasts the number of systems to be sold, worldwide revenue, compound annual growth rates, and competitor market shares for several key product categories making up the neural prostheses, neuromodulation, neurorehabilitation, and neurosensing segments of the industry.

This report covers in detail all the key public companies and the most significant emerging and more established non-public firms in the industry. The report also features in-depth profiles of major research institutions in the U.S. and abroad involved with neurotechnology developments, and traces the commercial activity that is emerging from each.

The report not only looks at future financial projections, it covers likely technology trends and product developments that will impact the neurotechnology industry in the years ahead, such as:

— Nanowire brain implants guided into position through the cerebral vasculature.

— Optical stimulation devices that solve many of the problems associated with electrical charge buildup.

— Microfluidic interfaces that combine electrical stimulation and drug delivery.

This report examines each of the neurological diseases and disorders that represent a significant market potential for neurotechnology products, including established markets like Parkinson’s disease, chronic pain, and urinary incontinence, as well as emerging markets such as tinnitus, vestibular disorders, obesity, migraine, sleep disorders, and affective disorders. And it is the only report on the neurotechnology industry to forecast new product categories in neurorehabilitation and neurosensing such as brain state analysis systems and neurorobotic systems.

The field of neurotechnology, which we define as the application of electronics and engineering to the human nervous system, is one of the most dynamic and promising areas of technology to emerge in the 21st Century. Neurotechnology uses electrical stimulation and sensing as tools for understanding and controlling nervous system function, as opposed to biotechnology, which focuses on molecular and genetic engineering approaches.

The most noteworthy applications of neurotechnology to date have been neural prostheses such as cochlear implants, and neuromodulation systems, such as implanted stimulators for treatment of chronic pain.

Market Projections:

This report projects that the overall worldwide market for neurotechnology products will be $3.6 billion in 2008 and will reach $8.8 billion in 2012. The report divides the market for neurotechnology into four segments: neural prostheses, neuromodulation, neurorehabilitation, and neurosensing. The largest segment of the market for neurotechnology is currently neuromodulation, followed by neural prostheses, and neurosensing.

Within the neural prostheses product category, cochlear prostheses represent the largest and most mature product category. This report estimates that the worldwide market for cochlear implants will be $725 million in 2008, growing to $1.59 billion in 2012, a 22 percent compound annual growth rate. Two factors that are helping to drive the market for cochlear implants are the rapid growth of implants in children, and the expansion of the market beyond profoundly deaf individuals to severely hearing impaired individuals. Many of the candidates for cochlear implants in this latter category are seniors with hearing loss that can no longer be improved with hearing aids.

Background:

Neurotechnology has grown and matured as an industry as a result of advances in several fields of science and technology, including neuroscience, electrical stimulation, biomaterials, and microelectronics. MEMS technology will have a positive impact on the development of neurotechnology devices.

Neurotechnology is currently in use or under study for the treatment of a number of different medical disorders and diseases. These include spinal cord injury, deafness, blindness, stroke, urinary incontinence, epilepsy, chronic pain, neurological disorders, and psychiatric disorders.

Neurotechnology products and services will experience considerable growth in the worldwide healthcare market in large part because of the continued growth and identification of neurological disorders and conditions. Many of these disorders and conditions will become more pronounced as demographic shifts in the aging of the population, as well as increased life expectancy and demand for a higher quality of life by senior citizens, exert their effects.

As society has become more aware of the prevalence of specific neurological and neuropsychiatric disorders such as chronic pain, depression, dyslexia, and autism, business and government leaders have become more aware of the costs of these conditions to society in terms of lost productivity, treatment, and diminished quality of life. These factors will all contribute to the growth of neurotechnological treatments and therapies for neurological disorders.

Also, successful neural prostheses have been shown to be cost-effective because of the reduction in ongoing costs for healthcare and assistive services. Some studies have shown that these devices pay for themselves with five to seven years.

The healthcare segment of the neurotechnology industry depends heavily on the readiness of private and public health insurance organizations to reimburse patients for the cost of the devices and the procedures associated with implanting, maintaining, and training the device.

The growth of neural prostheses and neuromodulation devices also depends heavily on the degree to which clinicians and their patients are aware of the capabilities of neural prostheses. Because it is new, neurotechnology has not yet achieved the degree of penetration in awareness of both physicians and patients who would be strong candidates.

Opportunities:

One of the greatest opportunities for growth in the market for therapeutic electrical stimulation products is rehabilitation of stroke patients. Neurotechnology stands to offer benefits to the stroke patient both as a functional treatment to temporarily replace lost functions, and as a therapeutic treatment to achieve longer-term rehabilitation of natural functions.

The report believes that the increasing understanding of central neural mechanisms in stroke recovery will lead to dramatic growth for neurotechnology products used in therapeutic stimulation for stroke patients. Because of the time required for more scientific studies, regulatory approvals, and growth of awareness in the clinical communities, the most significant growth will not occur until late 2007 and 2008, when several new products for stroke rehabilitation will arrive on the market.

Competitors:

The market for neurotechnology includes both established competitors and start-up firms. Among the main competitors in the neurotechnology industry are:

— Neural Prostheses: Cochlear Ltd., Advanced Bionics, Bioness, and Med-El

— Neuromodulation: Medtronic, Boston Scientific, Cyberonics, and St. Jude Medical/Advanced Neuromodulation Systems

— Neurosensing: Cardinal Health, Natus Medical, Nihon-Kohden, and Elekta

Future Trends:

Neural/silicon hybrid chips have the potential for dramatically expanding the rate and the quality of information exchange between a computer and human. These devices initially will have application as improved forms of electrodes built with intelligent microelectronic hardware rather than passive devices. Ultimately they offer the potential for greatly enhanced neural prostheses and brain-computer interfaces.

Neural/silicon hybrid chips cultured outside the body offer potential to be used in a new form of computer architecture for neurocomputing applications. The integration of transplanted or cultured neural cells with electronic components could help accomplish artificial intelligence and neural network applications that are currently difficult to implement on a standard digital computer.

 Key Topics Covered:  - Introduction - Industry Background - Neurotechnology Markets - Product Categories - Company Profiles - Market Activity - Research Institutions - Funding Sources - Future Directions - Company Descriptions  Companies Mentioned:  - Medtronic - St. Jude Medical - Boston Scientific - Cyberonics - Cardinal Health - Cochlear Ltd. - Northstar Neuroscience - Greatbacth - Victhom Human Bionics - Med-El - Several Others 

For more information visit http://www.researchandmarkets.com/research/83cfae/the_market_for_neu

This Year Proving Good for Your Ears

By Jason Bracelin

It’s like Christmas in July, and Santa’s here to pour a little sugar (and arsenic) in your ears.

With the year half over, it’s time to take stock of the best of albums of ’08 thus far.

Here are my current favorites:

The Gutter Twins, “Saturnalia”: A mix of bourbon and, well, lots more bourbon, this pairing of the dead-voiced Mark Lanegan and the whiskeyed come-ons of Greg Dulli is like a pox on sobriety. Two of rock’s best, most distinctive vocalists hiss and moan at one another over a bed of serpentine electronics and ominous beats, resulting in the best album of the year to play after midnight, when the skies are as dark as these dudes’ dispositions.

Torche, “Meanderthal”: The best thing about these hard-to- define, stoner pop thunderbolts? They leave us blathering music critic types at a loss for words. Just do the math: The Beatles + U2 + Sleep + Goatsnake = A total must-have.

Lil Wayne, “Tha Carter III”: Weezy takes aim at both Al Sharpton and your grandma on this ceaselessly nasty, gun clacking opus. Seriously, who else would pop a cap in gam gam but this curled-lip MC, who is unhinged in all the best ways here, mapping out the topography of the id with one elastic-voiced rhyme after the next.

Boris, “Smile”: Pretty much a continuation of last year’s equally essential “Pink,” the latest from this Japanese power trio spans everything from pop campfire tunes to amp-devouring guitar freakouts to blood-freezing psychedelia. The premier air guitar album of ’08.

Sam Phillips, “Don’t Do Anything”: An equally biting and beatific divorce album that pulls the shades on marital bliss. “Everything used to make me smile, and then you went away,” Phillips sings early on this sad waltz of a disc, where touches of mournful fiddle and banjo blanket her wizened voice like a funeral shroud.

Nachtmystium, “Assassins: Black Meddle Pt. 1”: Its title is an explicit reference to Pink Floyd’s classic study in texture, atmosphere and paranoia, 1971’s “Meddle,” and the latest from this Chicago avant metal troupe reflects as much, with tense, foreboding clouds of charred synth, lots of stereo panning and tortured shrieks from the abyss. This is what happens when Pink goes black.

Opeth, “Watershed”: Another metal band that wants to be Pink Floyd – and Jethro Tull and Deep Purple and King Crimson and Death. The breadth of this album is hard to overstate: From stately balladry to ornate prog rock to blasting death dirges, this is heavy metal in Cinemascope.

Portishead, “Third”: Singer Beth Gibbons always sounds like she’s just seen a ghost, her voice quavering over deep, roiling bass lines and shadowy electronics. On their first disc in 11 years, Portishead’s pulse-slowing codeine pop is as difficult and arduous as love itself – Gibbons’ perpetual muse – and just as worth it in the end.

Jason Bracelin’s “Sounding Off” column appears on Tuesdays. Contact him at 702-383-0476 or e-mail him at jbracelin@ reviewjournal.com.

(c) 2008 Las Vegas Review – Journal. Provided by ProQuest Information and Learning. All rights Reserved.

New Urgent Care Center Tends To Poor, Homeless

By Kathy Steele, Tampa Tribune, Fla.

Jul. 16–EAST TAMPA — A former police substation is now an urgent care medical center for the homeless and uninsured.

Tampa Family Urgent Care Center opened last week at the Lee Davis Service Center, 3402 N. 22nd St. The facility’s doctors and nurses work for the nonprofit Tampa Community Health Centers.

The clinic — a first for the nonprofit — is a rarity for East Tampa.

“If you drive around the neighborhood here, you don’t find any walk-in clinics anywhere,” said President Charles Bottoms. “The goal is to get our patients in whether they have insurance or not, whether they have money or not.”

The facility will be open from 8 a.m. to 8 p.m. Monday through Friday and 8 a.m. to 5 p.m. Saturday and Sunday. In the future, it could be open 24/7.

The clinic operates on a sliding-fee scale, based on a patient’s ability to pay. But Bottoms said no one is turned away.

The grand opening drew about 30 people, including state Sen. Arthenia Joyner, D-Tampa, and state Rep. Betty Reed, D-Tampa. Jackie Walker, a board member of the nonprofit, grew up on Lake Avenue in East Tampa.

“To be able to give back to my community where I was born and raised, I was brought to tears,” she said.

Construction of the approximately $200,000 center took about two months. There are five examining rooms. At least three medical staff members, including a doctor, will be on-site during operating hours.

Tampa Community Health Centers began in 1984 as a grass-roots effort by medical graduate students who applied for health care grants to serve low-income neighborhoods.

The nonprofit grew to six family health centers, including one at the Lee Davis center. The agency receives federal and state grants and partners with the county and the nonprofit Homeless Coalition of Hillsborough County to provide medical care to the homeless, poor and uninsured.

Reporter Kathy Steele can be reached at (813) 259-7652 or [email protected].

—–

To see more of the Tampa Tribune or to subscribe to the newspaper, go to http://www.tampatrib.com.

Copyright (c) 2008, Tampa Tribune, Fla.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Surgeon Sued for Giving Anesthetized Patient Temporary Tattoo

By Don Sapatkin, The Philadelphia Inquirer

Jul. 16–In a lawsuit filed yesterday, a Camden County woman accused her orthopedic surgeon of “rubbing a temporary tattoo of a red rose” on her belly while she was under anesthesia.

The patient discovered the tattoo below the panty line the next morning, when her husband was helping her get dressed to go home after the operation for a herniated disc, her attorney, Gregg A. Shivers, said in a phone interview yesterday.

“She was extremely emotionally upset by it,” said Shivers. The suit, filed on behalf of Elizabeth Mateo in Camden County Superior Court, seeks punitive and compensatory damages from Steven Kirshner, a board-certified orthopedic surgeon with offices in Marlton and Lumberton, both in Burlington County.

Kirshner does not deny placing the tattoo — and has left washable marks on patients before to improve their spirits, his lawyer, Robert Agre of Haddonfield, said last night. He said none has complained.

“What’s offensive about this complaint is that it suggests something he did was intended to be prurient, and nothing could be further from the truth,” said Agre. “It was intended just to make the patient feel better.”

Nevertheless, said Art Caplan, chairman of the University of Pennsylvania School of Medicine’s Department of Medical Ethics, “you cannot do something like this even as a joke.”

“If it’s true,” said Caplan, whose knowledge of the case was limited to a reporter’s summary, “she’s got a case.”

Caplan recalled news reports of other cases where physicians left an inappropriate mark, such as a football logo, which had a legitimate purpose, such as indicating the placement of an organ for a future cut.

In a highly publicized case in 1999, a doctor in New York City went further by carving his initials into a patient’s abdomen after delivering her baby by Caesarean section.

Mateo, the patient from Pennsauken, declined to comment last night.

Shivers, who practices in Cherry Hill, would describe his client only as a clerical worker in her mid-30s with a husband and young children.

Her suit does not criticize the operation’s quality and names only the surgeon who performed the operation at Virtua Memorial Hospital Burlington County on April 28. The health system released a statement saying “the Mateo family has acknowledged that Virtua was in no way responsible for the incident.”

In an announcement about the civil action, Shivers said that the hospital had “immediately conducted a diligent and responsible investigation” that found no witnesses. “The patient reports that the hospital has treated her with appropriate respect and professionalism as she has gone through this difficult experience,” the statement concluded.

Part of his client’s concern, Shivers said, was knowing what took place.

“We’re assuming that it would have to have happened after surgery,” he said, “because during surgery she would be on her stomach.”

In addition to the lawsuit, Shivers said he mailed a related complaint to the New Jersey Board of Medical Examiners yesterday.

The board said it had no record of past actions against Kirshner, and hadn’t received the complaint in the mail.

The doctor’s attorney, Agre, who had seen neither the board complaint nor the lawsuit, said the doctor had “never been accused of anything.”

“Most of the patients are delighted by Dr. Kirshner’s sense of humor,” he said, adding that the 51-year-old surgeon who lives in Lumberton and did his medical training at Hahnemann University Hospital in Phildelphia is “renowned as a jovial guy and regarded as a doctor who has terrific relations with his patients and with his staff.”

“He vigorously denies that any action of his was intended to offend the patient,” Agre said, noting that the marks the surgeon has left on his patients “are like children’s tattoos. Kids put them on themselves and they wash right off.”

Frank Farley, a psychologist at Temple University who was read a summary of the lawsuit, speculated about why a surgeon who had performed an operation on the back would leave a red rose on his patient’s belly.

“It is not part of the doctor-patient relationship in that case,” said Farley, a former president of the American Psychological Association who studies risk-taking personalities and behavior.

“Unless you think you are Georgia O’Keeffe and you think people’s bodies are your canvas,” he said, “why would you take that risk?”

Contact staff writer Don Sapatkin at 215-854-2617 or [email protected].

—–

To see more of The Philadelphia Inquirer, or to subscribe to the newspaper, go to http://www.philly.com.

Copyright (c) 2008, The Philadelphia Inquirer

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Avoiding Underdiagnosis, Overdiagnosis, and Misdiagnosis of Lung Carcinoma

By Butnor, Kelly J

* Context.-Given the magnitude of the therapeutic and prognostic implications, it is critical that pathologists diagnose lung cancer accurately. This can sometimes be a formidable challenge, as a number of benign entities mimic lung carcinoma and vice versa. Objective.-To present strategies for recognizing benign entities likely to be confused with lung carcinoma, malignancies of the lung prone to misinterpretation as benign, and commonly misclassified pulmonary neoplasms.

Data Sources.-The medical literature and experience from consultative and surgical practice.

Conclusions.-In addition to understanding the clinical context in which a lung biopsy is procured and the radiographic findings, appreciating the histologic distribution of disease and what, if any, pathologic features are present in the background can go a long way toward averting a mis-diagnosis of lung cancer. Recognizing the limitations posed by small samples and communicating clearly to clinicians the level of diagnostic uncertainty are equally as important for establishing an accurate diagnosis of lung cancer.

(Arch Pathol Lab Med. 2008;132:1118-1132)

Call it anything you like; just don’t call it cancer.

Anonymous

The pathology literature is replete with reports of benign entities mimicking lung carcinoma. Because lung cancer is a disease with remarkably poor overall survival that often entails treatment with both surgery and chemotherapy/radiotherapy, the stakes are high to avoid not only overdiagnosis but also underdiagnosis of lung carcinoma. A false-positive diagnosis of lung cancer may result in inappropriately aggressive treatment with attendant risks of morbidity and toxicity that are not inconsequential. Failure to recognize carcinoma of the lung is likely to result in suboptimal treatment and/or treatment delay. It is just as important not to misclassify malignancies involving the lung, as the therapy and prognosis for primary and metastatic pulmonary malignancies and even different histologic types of lung carcinoma substantially differ.

It would be nearly impossible to catalog all of the entities that cause diagnostic confusion in the realm of pulmonary neoplasia. The following sections highlight benign conditions that simulate lung carcinoma, malignant pulmonary tumors mistaken for benign lesions, and malignancies of the lung that mimic one another, which are likely to be encountered in routine surgical pathology practice and how to avoid misdiagnosing them.

OVERDIAGNOSIS OF LUNG CANCER

“Pseudomalignancies” of the lung fall into 2 general categories: reactive processes misinterpreted as cancerous and benign tumors mistaken for malignancy. An adequate clinical history and understanding of the radiologic findings is helpful in the evaluation of any surgical lung biopsy but is of paramount importance when dealing with reactive/benign pulmonary processes. Such information often provides the keys to avoiding an overdiagnosis of malignancy. Questions to consider include the following: What were the presenting signs and symptoms? What has been the time course of disease? Is the patient immunosuppressed? Does he or she show any signs/symptoms of infection? Is there a history of lung or extrapulmonary malignancy and if so, how long ago was it and did the patient receive chemotherapy and/or radiation? Is there a radiographically discrete lesion or is the process diffuse? If a mass lesion is present, what are its contours and does the surrounding lung show any abnormalities?

Another key to avoiding an overdiagnosis of malignancy relates to understanding the limitations of small specimens, such as transbronchial and needle core biopsies. Although it has been estimated that the overall diagnostic yield from transbronchial biopsies is anywhere from 31% to 67%, the rate is exquisitely dependent on a myriad of factors, including the skill of the bronchoscopist; the prebiopsy probability that the pathologic process is malignant; the number, size, and quality of the tissue fragments obtained; and the pathologist’s experience in interpreting small lung biopsies.1-3 Clinicians often place considerable pressure on the pathologist to render a definitive diagnosis on specimens obtained by minimally invasive means. Although no one would argue that having a patient go through multiple procedures to obtain a diagnosis is desirable, in some instances, whether because of inadequate tissue, inappropriate technique/handling resulting in obscuring artifact, or failure to sample the diagnostically informative portion of the lesion, a malignant diagnosis cannot be made with a reasonable level of certainty. In such circumstances, it is entirely appropriate to render a descriptive diagnosis, provided that the reasons for doing so are also commented on. Necessitating a second diagnostic procedure does far less harm to the patient than an overdiagnosis of malignancy.

What follows are selected benign/reactive conditions that simulate malignancy. The reader is referred to other sources for a more detailed examination of such entities.4,5

Squamous Metaplasia Overdiagnosed as Squamous Cell Carcinoma

Squamous metaplasia is a reactive phenomenon that can involve the bronchial and bronchiolar epithelium, as is not infrequently seen in cigarette smokers or in chronic airway inflammatory conditions. It may also develop around healing mucosal ulcers/erosions or involve honeycomb cysts of end-stage lung. The setting in which squamous metaplasia is most apt to be confused with squamous cell carcinoma is in diffuse alveolar damage.6 Squamous metaplasia of the bronchiolar epithelium and/or alveolar ducts in diffuse alveolar damage occurs during the proliferative (organizing) phase around 1 to 2 weeks following the inciting injury (Figure 1, A).7 In some cases, the degree of cytologic atypia can be quite striking (Figure 1, B). Atypical mitoses and infiltrative growth should not be present. Avoiding an overdiagnosis of squamous cell carcinoma rests on the recognition that the squamous atypia is part of an acute lung injury pattern in which other supporting features, such as hyaline membranes, organizing pneumonia, interstitial edema with fibroblastic expansion, and/or type 2 pneumocyte hyperplasia are also seen (Figure 1, C).

Bronchial/Peribronchiolar Metaplasia Overdiagnosed as Adenocarcinoma

Bronchial metaplasia arises in honeycomb cysts of advanced interstitial lung disease, most typically in usual interstitial pneumonia. To those unaccustomed to evaluating end-stage interstitial lung disease or when dealing with small biopsies, the closely apposed cysts set in a background of dense fibrosis in end- stage lung bear some resemblance to the acinar subtype of lung carcinoma (Figure 2, A and B). In contrast to the angulated infiltrative acini of carcinoma, the cysts in honeycomb lung have generally rounded contours. The benign nature of the metaplastic epithelium in honeycomb cysts is confirmed by the presence of cilia, which are usually readily identified at high magnification (Figure 2, A, inset). Another distinguishing feature that may be appreciated in wedge biopsies or larger specimens is the abrupt transition between honeycombed and relatively normal lung in usual interstitial pneumonia (Figure 2, C). By comparison, adenocarcinoma tends to gradually merge with nonneoplastic lung, often exhibiting a bronchioloalveolar carcinoma (BAC)-like growth pattern at its periphery (Figure 2, D).

Peribronchiolar metaplasia (PBM), alternatively referred to as Lambertosis, can be found incidentally in association with an underlying interstitial lung disease or as the sole manifestation of interstitial lung disease.8 In PBM, the lining of the peribronchiolar alveoli are replaced by metaplasia epithelium. Peribronchiolar metaplasia has some similarities to adenocarcinoma and BAC, in particular. The epithelium in PBM ranges from low cuboidal to ciliated columnar (Figure 2, E). Finding the latter is certainly helpful to not overdiagnose PBM as malignancy. In biopsies that are of sufficient size, the exquisitely peribronchiolar location of PBM is also a useful discriminator from BAC, which tends to be more randomly distributed (Figure 2, F).

Reactive Pneumocyte Hyperplasia Overdiagnosed as Adenocarcinoma

Normally, alveoli are lined predominantly by type I pneumocytes but may become populated by hyperplastic type II pneumocytes under a variety of circumstances, including the proliferative (organizing phase) of diffuse alveolar damage, radiation or drug-related toxicity, infection, and various inflammatory/fibrosing conditions.7 The prominence of hyperplastic type II pneumocytes, as compared with type I cells, which are typically inconspicuous, can be concerning for BAC.

Reactive type II pneumocytes are cuboidal to hobnailshaped (Figure 3, A). The degree of atypia they exhibit, particularly in organizing diffuse alveolar damage, is sometimes quite striking. This “too atypical to be malignant” appearance contrasts with the relative cytologic blandness exhibited by many BACs (Figure 3, B). Unlike solitary BACs, which are typically discrete lesions surrounded by unremarkable lung parenchyma, reactive pneumocyte hyperplasia is generally a diffuse process (Figure 3, C). Even BACs with a diffuse pneumonia-like radiographic appearance usually exhibit discontinuous growth along the alveolar septa (Figure 3, D). Other findings related to the underlying condition in which reactive pneumocyte hyperplasia is a feature, whether it be resolving acute lung injury, fibrosis, or inflammation, typically not only accompany but often overshadow reactive pneumocyte hyperplasia. Atypical Adenomatous Hyperplasia Overdiagnosed as Adenocarcinoma

Atypical adenomatous hyperplasia (AAH) is a localized preinvasive proliferation of neoplastic rounded to low columnar nonciliated cells lining alveoli and on occasion respiratory bronchioles (Figure 4, A). Atypical adenomatous hyperplasia is most often an incidental finding in specimens procured for other reasons, found in as many as 19% of men and 30% of women with resected pulmonary adenocarcinomas. 9 Inflammation and fibrosis is usually absent or no more than minimal in AAH.

In simplistic terms, AAH can be likened to atypical ductal hyperplasia of the breast in that it shares some of the genetic alterations present in pulmonary adenocarcinoma, but its histologic features fall short of a diagnosis of malignancy. 10 However, in contrast to preinvasive neoplastic lesions of the breast, the definition of AAH, and for that matter BAC, is a moving target that is neither universally recognized nor uniformly applied. Formerly, AAH was limited to 5 mm or less.11 The current World Health Organization classification has no size restriction but instead defines AAH as a focal lesion that is usually less than 5 mm in diameter, whereas BAC is generally larger than 10 mm.12 Qualitative criteria for AAH are also somewhat vague. Atypical adenomatous hyperplasia exhibits only mild to moderate cytologic atypia and no more than one of the following: marked cellular stratification, high cell density and marked nuclear overlap, coarse chromatin with nucleoli, columnar cell change with cellular crowding, or micropapillary tufting.12 If severe cytologic atypia is present and/ or 2 or more of the previous features are present, BAC should be considered (Figure 4, B).12

The distinction between AAH and BAC is by no means trivial, particularly in cases in which the specimen contains a separate bona fide BAC. Diagnosing an atypical focus as BAC rather than AAH in a lobe that also harbors what would otherwise be a T1 BAC increases the T category to T4 and, in the absence of nodal or distant metastases, elevates the stage from IA to IIIB.13 If a second focus is present in a different lobe of the same lung as the primary BAC, under current American Joint Commission on Cancer guidelines, the patient is categorized as having M1, stage IV disease, which is generally considered inoperable.13,14

Perhaps in the not too distant future sufficient prognostic data will have been acquired to permit the formulation of a classification scheme akin to that used in breast neoplasia, wherein the term BAC is replaced by a strictly defined entity designated as in situ adenocarcinoma.

With the cytomorphologic similarities between AAH and BAC, it is not difficult to see how AAH can be overdiagnosed as BAC in biopsies that do not encompass the entire lesion. Definitive diagnosis of AAH, as well as BAC, should not be rendered on small samples, such as transbronchial biopsies or transthoracic needle core biopsies. In such circumstances, the use of a descriptive term such as atypical pneumocyte proliferation with a comment addressing the problems posed by incompletely sampled lesions that have features of BAC would be appropriate.

Pulmonary Hamartoma Overdiagnosed as Chondrosarcoma

Pulmonary hamartoma can be confused with metastatic chondrosarcoma or other mesenchymal malignancies, especially in small biopsies. Although all of the elements may not be represented in a small sample, hamartomas contain at least 2 mesenchymal components, such as cartilage and fat, with the former typically predominating. Essential to avoiding an overdiagnosis is the recognition that the mesenchymal elements in hamartomas are mature. Unlike chondrosarcoma, the cartilage in pulmonary hamartoma lacks cytologic atypia (Figure 5, A). The typically well-circumscribed, nodular appearance of metastatic chondrosarcoma is similar to hamartoma, but it is unusual for pulmonary metastases to be the first manifestation of disease in chondrosarcoma.15 An awareness that benign respiratory epithelium entrapped in cleftlike spaces, or in endobronchial lesions, overlying squamous metaplasia and/or hyperplasia, are frequent findings in hamartoma will lessen concerns over a biphasic neoplasm(Figure 5, B and C).

Inflammatory Myofibroblastic Tumor Overdiagnosed as Undifferentiated Pleomorphic Sarcoma or Spindle Cell Carcinoma

Inflammatory myofibroblastic tumor (IMT) is a term used to refer to a cadre of pulmonary lesions that have gone under such disparate appellations as inflammatory pseudotumor, plasma cell granuloma, xanthogranuloma, and fibrous histiocytoma. There continues to be debate as to whether IMT represents a reactive/inflammatory lesion or a low-grade mesenchymal malignancy.16 Although these tumors are defined as having myofibroblastic differentiation in common, recent investigations suggest that at least a subset do not show immunohistochemical evidence of myofibroblastic differentiation and are instead comprised predominantly of cells of macrophage- dendritic cell origin.17

Inflammatory myofibroblastic tumors consist of variable proportions of spindle cells in a storiform or fascicular arrangement admixed with collagen and inflammatory cells. Inflammatory cells in IMT can be quite prominent and include lymphocytes, histiocytes, which sometimes take the form of Touton- type giant cells or foamy macrophages, and plasma cells (Figure 6, A). Although the spindle cells in IMT are generally cytologically bland, an intense inflammatory infiltrate may cause them to appear more concerning. The heterogeneous appearance of IMT, coupled with its destruction of the underlying alveolar architecture and capacity to invade extrapulmonary structures, contribute to IMT being mistaken for spindle cell carcinoma or undifferentiated pleomorphic sarcoma, referred to in the past as malignant fibrous histiocytoma. Careful inspection of the spindle cells in IMT will usually disclose a lack of nuclear pleomorphism, bizarre giant cells, and atypical mitoses that typify malignant fibrous histiocytoma (Figure 6, B). As compared with malignant fibrous histiocytoma, when necrosis is present in IMT, it is usually scant, and the mitotic rate is low (

Keratin staining should be interpreted with caution when attempting to distinguish IMT from spindle cell carcinoma of the lung. Cytokeratin immunoreactivity can be notoriously patchy in spindle cell carcinoma, whereas about 30% of IMTs show focal positivity.18 As with malignant fibrous histiocytoma, spindle cell carcinoma typically has a substantially greater degree of nuclear pleomorphism and mitotic activity than IMT. Rather than being interspersed throughout the tumor as in IMT, in spindle cell carcinomas of the lung with a prominent inflammatory infiltrate, the inflammatory cells are often localized to the periphery of the tumor. When positive, ALK1 can be helpful in confirming IMT, but this marker is negative in about 50% to 60% of cases.12,17

Alveolar Adenoma, Papillary Adenoma, and Mucous Gland Adenoma Overdiagnosed as Adenocarcinoma

Alveolar adenoma, papillary adenoma, and mucous gland adenoma are rare benign pulmonary neoplasms that may be mistaken for adenocarcinoma. The first 2 are well-circumscribed parenchymal lesions, whereas the latter is an exophytic endobronchial tumor. Alveolar adenoma is composed of cytokeratin-positive, flattened to hobnail cells lining variably ectatic spaces that often contain eosinophilic material (Figure 7).19 Papillary adenoma is a branching papillary proliferation of cuboidal to columnar cells with fibrovascular cores.20 In addition to their circumscription, alveolar adenoma and papillary adenoma are distinguished from BAC by the absence of cytologic atypia, micropapillary tufting, and discontinuous growth that characterizes BAC.12

With its closely packed glands and mucus-filled cysts, mucous gland adenoma bears a superficial resemblance to adenocarcinoma.21 Aside from a having a typically more peripheral location than mucous gland adenoma, invasive adenocarcinoma features infiltrative glands composed of cytologically atypical, mitotically active cells. Mucous gland adenoma can also be misinterpreted as mucoepidermoid carcinoma, but in addition to mucus cells, the latter features squamous differentiation and intermediate cells.

Sclerosing Hemangioma Overdiagnosed as Adenocarcinoma

Sclerosing hemangioma (SH) can exhibit a variety of growth patterns that often appear in combination in the same lesion. The papillary pattern of SH is most apt to be confused with BACs with papillary features. A distinctive feature of SH is its dual population of bland cuboidal surface cells and round stromal cells within variably sclerotic papillary structures.

Unlike SH, which obliterates the underlying architecture, the overall structure of the parenchyma is preserved in BAC. Immunohistochemically, the neoplastic cells in BAC stain intensely with cytokeratins, but while the surface cells of SH are keratin- positive, the round stromal cells are negative for this marker.22

Carcinoid Tumorlet Overdiagnosed as Carcinoid Tumor

Although a carcinoid tumorlet could conceivably be sampled by a fortuitously placed transbronchial or needle core biopsy, it is most often detected incidentally in wedge biopsies or larger specimens that have been obtained for other reasons. Tumorlets have histologic features identical to those seen in carcinoid tumor, including bland polygonal to spindled cells with finely granular chromatin, scant cytoplasm, absent necrosis, and low mitotic activity (

Meningothelial-like Nodules Overdiagnosed as Carcinoid Tumor

A typically incidental lesion that can be confused with carcinoid tumors or tumorlets, particularly in small biopsies, is a meningothelial-like nodule (MLN), formerly called chemodectoma.24 The current designation refers to the ultrastructural resemblance of MLN cells to meningothelial cells. Usually subcentimeter in size, MLNs are composed of bland cells with more cytoplasm than is found in carcinoids and tumorlets. Like meningothelial cells, MLNs may exhibit a whorled arrangement and nuclear pseudoinclusions. Location is a key feature for separating these lesions. Whereas carcinoids and tumorlets arise adjacent to airways, MLNs are found within the interstitium, typically in a perivenular distribution (Figure 9, A and B). Their identity can be confirmed by immunohistochemistry. Meningothelial-like nodules stain positively for vimentin and are variably positive for epithelial membrane antigen and in contrast to carcinoids and tumorlets, are negative for cytokeratin and neuroendocrine markers.25,26

Crushed Lymphocytes Overdiagnosed as Small Cell Carcinoma

Like the cells in small cell lung carcinoma (SCLC), lymphocytes are fragile and prone to crush artifact. This type of artifact is a frequent problem in transbronchial biopsies (Figure 10, A). Because of the gravity of the diagnosis, when SCLC is being considered in small biopsies that show substantial crush artifact, it is prudent to immunohistochemically exclude lymphocytes as the origin of the crushed cells. This can be accomplished with a limited panel of markers that includes a cocktail of high- and low-molecular-weight cytokeratins, such as AE1/AE3 and CAM 5.2, and leukocyte common antigen. Cytokeratins typically stain SCLC in a finely granular rim and perinuclear dotlike distribution (Figure 10, B). Strong circumferential cytoplasmic and/or membranous staining should prompt a consideration of non-small cell carcinoma (see “Basaloid Carcinoma Misdiagnosed as SCLC” and “Large Cell Neuroendocrine Carcinoma Misdiagnosed as SCLC”). Rarely, particularly poorly preserved SCLCs fail to immunoreact with cytokeratins. Positive staining for leukocyte common antigen, combined with a complete absence of cytokeratin immunoreactivity, is not seen in SCLC and confirms the lymphoid nature of the infiltrate.

Depending on the extent of crush artifact, it may be difficult to determine whether a lymphoid infiltrate appears reactive or is morphologically atypical. In some cases, immunostaining for CD3 and CD20 permits the discrimination of a mixed lymphoid infiltrate from a B- or T-cell predominant population. In samples that appear to show a B- or T-cell predominance but are severely crushed, a descriptive diagnosis of “atypical lymphoid infiltrate” with a comment suggesting additional sampling with submission of fresh tissue for flow cytometric analysis to further evaluate the possibility of lymphoma is reasonable.

An algorithm for evaluating hyperchromatic crushed infiltrates, where limited tissue is almost always an issue, is presented in Figure 11.

Carcinoid Overdiagnosed as SCLC

Albeit at opposite ends of the spectrum in terms of aggressiveness, carcinoid tumor and SCLC are both neuroendocrine tumors that share a propensity to exhibit crush artifact in transbronchial biopsies. Morphologic features that distinguish SCLC from carcinoid tumor, such as necrosis and abundant mitotic figures (usually >60/2 mm^sup 2^) may be difficult to discern in extensively crushed specimens (Figure 12, A and B).12 This problem, coupled with the immunohistochemical overlap in staining for cytokeratins and neuroendocrine markers, are factors that contribute to carcinoid being mistaken for SCLC.

The proliferation marker MIB-1 (Ki-67) can be useful in the evaluation of neuroendocrine tumors with prominent crush artifact.27,28 Even extensively crushed SCLCs typically show a high proliferation index, as evidence by diffuse (>40%-50%) staining for MIB-1 (Figure 11). Sparse (

UNDERDIAGNOSIS OF LUNG CANCER

Not recognizing relatively bland proliferations as malignant, small quantities of malignant cells, or malignant cells growing in an unfamiliar pattern are but a few of the reasons lung cancer is underdiagnosed in pathology specimens. Studies examining how delays in recognizing the symptoms of lung cancer or referring patients suspected to have lung cancer for biopsy adversely affect survival are beginning to appear in the literature.29,30 The frequency and degree to which false-negative pathologic diagnoses impact the prognosis of patients with subsequently confirmed lung cancer has yet to be established.

Adenocarcinoma Underdiagnosed as Desquamative Interstitial Pneumonia

Adenocarcinoma of the lung can occasionally exhibit a growth pattern that mimics other cellular alveolar filling processes (Figure 13, A). There have been cases in which adenocarcinoma is underdiagnosed as desquamative interstitial pneumonia.31 Despite adenocarcinoma occasionally exhibiting a growth pattern similar to desquamative interstitial pneumonia, these entities have important morphologic differences. The nuclear-cytoplasmic ratio in most adenocarcinomas is comparatively high and nucleoli are often apparent. Desquamative interstitial pneumonia, which is a misnomer because the cells that fill alveoli are macrophages rather than sloughed pneumocytes as was originally believed, is characterized by cells with abundant eosinophilic to finely pigmented light brown cytoplasm, small nuclei, and inconspicuous nucleoli (Figure 13, B).32 The macrophages in desquamative interstitial pneumonia are truly intra-alveolar, distinct from the pneumocytes that line the alveolar septa. In adenocarcinoma with a prominent alveolar growth pattern, in addition to filling the alveolar spaces, malignant cells also grow along the alveolar septa replacing normal pneumocytes. Immunohistochemistry can be used in equivocal cases. The macrophages in desquamative interstitial pneumonia stain positively for CD68 and are negative for cytokeratins, whereas the opposite staining profile is observed in adenocarcinoma.

Atypical Carcinoid Underdiagnosed as Typical Carcinoid

Although typical carcinoid (TC) is closer to atypical carcinoid (AC) along the spectrum of neuroendocrine malignancies of the lung than it is to SCLC, there are prognostic differences between TC and AC. The overall 10-year survival rate for AC (35%-59%) is significantly worse than TC (82%-95%).33-35 Not recognizing the histologic features that separate AC from TC when they are present results in the underdiagnosis of AC. Atypical carcinoid is distinguished from TC by the presence of foci of necrosis and/or increased mitoses (2-10/2 mm^sup 2^) as compared with less than 2 mitoses per 2 mm^sup 2^ in TC. By comparison, SCLC typically exhibits more than 60 mitoses per 2 mm^sup 2^ and is more likely to show extensive necrosis. Reliable distinction between AC and TC is dependent on the size and preservation quality of the sample. Distinguishing TC from AC may be difficult on small specimens, which are prone to crush artifact. MIB-1 staining, which is significantly increased in SCLC as compared with TC and AC, cannot be used to differentiate TC from AC because their rates of MIB-1 staining do not significantly differ.28

BAC Underdiagnosed as Reactive Pneumocyte Hyperplasia

The overdiagnosis of reactive pneumocyte hyperplasia as BAC has already been discussed. Its reversal, underdiagnosing BAC as reactive pneumocyte hyperplasia, is also a problem in pulmonary pathology. Although the cells in BAC are usually more cytologically atypical than those seen in AAH, in the spectrum of pulmonary neoplasia, BAC cells can be rather banal-appearing and are paradoxically often blander than reactive pneumocytes.

A helpful feature in recognizing BAC is the discontinuous growth along alveolar septa, termed lepidic spread. Even in cytologically bland cases, the cells in BAC usually contrast sharply with adjacent pneumocytes (Figure 3, D). This is in contradistinction to reactive pneumocyte hyperplasia, which is generally a diffuse process without intervening normal pneumocytes (Figure 3, C).

Intravascular Tumor Underdiagnosed as Thromboemboli

Intravascular tumor can be underdiagnosed by failing to recognize that an abnormality within the pulmonary vasculature is present or by mistaking intravascular tumor for organizing thromboemboli. Pulmonary tumor microemboli, which are reportedly present in as many as one quarter of patients with solid tumors at autopsy, are only rarely detected antemortem.36 In some cases, there is an antecedent history of carcinoma, but on occasion, symptoms related to pulmonary tumor microemboli are the initial manifestation of malignancy. Metastatic breast, lung, and gastric carcinoma account for the majority of reported cases.37 Patients may come to biopsy because of progressive dyspnea or unexplained pulmonary hypertension.37 Apart from the occlusion of small pulmonary arteries, arterioles, and/or alveolar septal capillaries by emboli comprised of neoplastic cells, the lung tissue in patients with pulmonary tumor microemboli may be relatively normal (Figure 14, A). Because there is a general tendency to focus on the airways, alveoli, and interstitium when evaluating lung biopsies, tumor microemboli can be all too easily overlooked. Before reporting that there are no pathologic findings in a lung biopsy, it is crucial to look carefully at the vessels. Uncertainty regarding the nature of the cells comprising a thrombus can be resolved by staining for cytokeratins. The same approach applies to recognizing pulmonary lymphatic carcinomatosis, a condition in which metastatic tumor diffusely involves the lymphatic channels of the lung.38

Intravascular malignancies, especially sarcomas such as pulmonary artery sarcoma, can be mistaken for organizing thromboemboli. Recanalized thrombi often accompany pulmonary artery sarcomas and can cause diagnostic confusion (Figure 14, B).12 Although organizing thromboemboli can exhibit quite cellular foci and areas within pulmonary sarcoma can be hypocellular and collagenized, with proper sampling, frankly sarcomatous growth is evident in the latter (Figure 14, C).

Marginal Zone Lymphoma Underdiagnosed as Nodular Lymphoid Hyperplasia

Although a comprehensive discussion of this topic is beyond the scope of this article, excellent reviews may be found elsewhere.39 Marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) has some striking similarities to nodular lymphoid hyperplasia (NLHP) of the lung that predispose this low-grade malignancy to underdiagnosis (Figure 15, A and B). Like MALT lymphoma, NLHP may obliterate the underlying lung parenchyma. The presence of reactive germinal centers is also not a distinguishing feature. Although reactive germinal centers are more typically associated with reactive conditions, they may be seen in up to 85% of MALT lymphomas.40 A peculiar feature present in as many as one half of MALT lymphomas of the lung, multinucleated giant cells and/ or sarcoidlike granulomas can also be seen in nodular lymphoid hyperplasia (Figure 15, C).40 Lymphoepithelial lesions, which are characterized by airway epithelial invasion by lymphoid cells, are almost invariably present in MALT lymphomas but are reportedly also found in up to 60% of cases of NLHP (Figure 15, D).41 Plasma cells may be intimately admixed with neoplastic cells in MALT lymphoma, further confounding accurate diagnosis.

A feature that can be helpful in separating MALT lymphoma from NLHP, but is only reliably appreciated in wedge biopsies or larger specimens, is the overall disease distribution. MALT lymphoma of the lung exhibits a lymphangitic growth pattern and has a tendency to spread to the pleura in a plaquelike manner, as well as invade the bronchial cartilage (Figure 15, E and F). The presence of any of these features argues against a diagnosis of NLHP.

Unlike NLHP, which is composed of a polymorphous mixture of B and T lymphocytes arranged in a distribution typically seen in and around reactive follicles, the neoplastic small lymphocytes that surround germinal centers in MALT lymphoma are monoclonal B cells that are CD20 positive, typically Bcl-2 positive, and often aberrantly coexpress CD43.41

The immunohistochemical demonstration of monoclonality by way of kappa or lambda light chain restriction can sometimes be vexingly difficult on formalin-fixed, paraffin-embedded tissue. Molecular analysis using polymerase chain reaction is usually successful in showing clonal rearrangement of the immunoglobulin heavy chain gene in paraffin sections.42 The occasional case that is histologically suspicious for MALT lymphoma but in which clonality cannot be definitively established is probably best handled with the input of one’s hematopathologist colleagues.

Mucinous (“Colloid”) Adenocarcinoma Underdiagnosed as Mucostasis

Mucinous (“colloid”) adenocarcinomas of the lung (MCA) share the same diagnostic difficulties as their histologic equivalents in other sites, such as the breast and gastrointestinal tract. Two factors that contribute to the underdiagnosis of MCA are the paucity of neoplastic cells and the typically well-differentiated nature of such tumors. Relative to the copious pools of mucin seen in most MCAs, tumor cells are often quite sparse and at low magnification can be rather inconspicuous (Figure 16, A). Even when the columnar mucinous epithelium that comprises most MCAs is detected, the diagnosis of malignancy is sometimes called into question by the cytologic blandness of the neoplastic cells (Figure 16, B).43

Whether it is because tumor cells are simply not present in the sample, a problem that increases in likelihood with decreasing specimen size, tumor cells are present but are not detected, or tumor cells are not recognized as being malignant, MCA can be mistaken for nonneoplastic disorders that cause excess mucus production and/or deposition in the lung, such as mucostasis. Mucostasis can be seen in a number of conditions, most commonly distal to bronchiectasis or as a feature of various forms of bronchiolitis (Figure 16, C). Abnormal airways filled with mucus that spills out into the surrounding airspaces is certainly helpful if found, but the proximate cause of mucostasis is not always histologically apparent, particularly in small biopsies. Typically, the only type of cells present in mucus resulting from stasis are inflammatory, most common among which are macrophages. The identification of cytokeratin-positive cells in mucin that are not obviously benign bronchial or bronchiolar epithelial cells should prompt thorough sampling to search for additional columnar and/or goblet cells suspended in mucin and/or focally adherent to alveolar walls that would help to establish a diagnosis of malignancy.

MISDIAGNOSIS OF LUNG CANCER

In this era of targeted drug therapy, it is more crucial than ever to correctly identify histologic type in lung carcinoma. Not only do treatment regimens for primary lung cancers and metastases drastically differ, with the development of tyrosine kinase inhibitors that exploit epidermal growth factor receptor mutations in some pulmonary adenocarcinomas, so also does present day management of different histologic types of lung carcinoma.

As important as it is to classify lung carcinomas accurately, it should nonetheless be remembered that lung cancers can exhibit considerable heterogeneity. When sampled extensively, more than one histologic type can be identified in 45% of lung carcinomas.44

Basaloid Carcinoma Misdiagnosed as SCLC

The histologic features of basaloid carcinoma (BC) and the basaloid and small cell variants of squamous cell carcinoma are such that these types of non-small cell lung carcinoma have a notorious propensity for being misdiagnosed as SCLC, especially in small biopsies. Classified as a type of large cell carcinoma, BC is characterized by relatively small cells with hyperchromatic nuclei, inconspicuous nucleoli, and scant cytoplasm, growing as solid nodules or trabeculae with abundant mitoses and prominent peripheral palisading (Figure 17, A).45 Occasional rosettes can be seen and central comedonecrosis is not uncommon. Nuclear molding is said to be absent in BC.12 The basaloid variant of squamous cell carcinoma is a poorly differentiated form of squamous cell carcinoma that has histologic features similar to basaloid carcinoma but also shows at least focal squamous differentiation.46 Both BC and basaloid variant of squamous cell carcinoma, as well as the small cell variant of squamous cell carcinoma, purportedly have a lower nuclear- cytoplasmic ratio and coarser, more vesicular chromatin than SCLC.12

Immunohistochemistry can be extremely helpful in distinguishing SCLC from BC and poorly differentiated variants of squamous cell carcinoma. In contrast to SCLC, which typically shows weak to moderate intensity staining in a perinuclear rim and dotlike pattern for cytokeratins AE1/AE3 and CAM 5.2, the variants of non-small cell lung carcinoma most apt to be confused with SCLC typically demonstrate strong circumferential cytoplasmic and membranous staining (Figure 17, B). Thyroid transcription factor 1 (TTF-1) and cytokeratin 34betaE12 provide additional information. Although about 10% to 25% of SCLCs are TTF-1 negative, nearly all BCs and poorly differentiated squamous cell carcinoma do not express TTF-1.47 The opposite staining results are seen with cytokeratin 34betaE12. Nearly all BCs and poorly differentiated squamous cell carcinomas are cytokeratin 34betaE12 positive, whereas almost all SCLCs are nonimmunoreactive for this marker (Figure 11).47-49 p63, like cytokeratin 34betaE12, stains poorly differentiated squamous cell carcinomas but is negative in SCLC.49 p16Ink4a has also recently been investigated as a discriminatory marker and was found to be nearly always expressed in SCLC but only variably positive in non- small cell lung carcinoma.49

Because of the limited amount of tissue in many cases and the specificity of TTF-1 and cytokeratin 34betaE12, staining for neuroendocrine markers is usually not necessary for distinguishing BC or poorly differentiated squamous cell carcinoma from SCLC and can even be misleading. Up to 25% of SCLCs are negative for neuroendocrine markers, whereas at least focal staining for chromogranin, synaptophysin, and/or other neuroendocrine markers is occasionally seen in non-small cell lung carcinomas, including BC.47

Large Cell Neuroendocrine Carcinoma Misdiagnosed as SCLC

Judging solely on the basis of their names, it would seem that distinguishing large cell neuroendocrine carcinoma (LCNEC) from SCLC is straightforward. However, as both of these tumors are part of the spectrum of neuroendocrine malignancies of the lung, making this distinction can sometimes be difficult. Unlike distinguishing BC from SCLC, which is greatly aided by immunohistochemistry, the separation of LCNEC from SCLC is primarily dependent on morphologic features. Apart from exhibiting more diffuse staining for cytokeratins AE1/AE3 and CAM 5.2 and a somewhat lower frequency of TTF-1 positivity than SCLC, LCNEC is similar to SCLC with respect to positivity for neuroendocrine markers and absent staining for cytokeratin 34betaE12.47 In a recent study that attempted to discriminate LCNEC from SCLC using a large panel of antibodies, only cytokeratin (CK) 18 and E-cadherin demonstrated significantly higher rates of staining in LCNEC than SCLC.50 Despite the statistical differences in staining between LCNEC and SCLC, a substantial proportion of SCLCs were immunoreactive for these markers and thus their clinical utility appears limited. Typically, tumor cells in LCNEC are 3 times larger than a small resting lymphocyte and have a relatively low nuclear-cytoplasmic ratio, vesicular chromatin, and conspicuous nucleoli, whereas SCLC is composed of small cells with a high nuclear-cytoplasmic ratio and finely granular chromatin (Figure 18, A and B). In a small proportion of cases of SCLC, the tumor cells are somewhat larger and exhibit more cytoplasm than is typically expected in SCLC and may even show slightly vesicular chromatin and occasional nucleoli (Figure 18, C). Such features, which are apt to cause confusion with LCNEC, are most likely to be seen in resection specimens, which generally show better preservation and less crush artifact than biopsies obtained bronchoscopically.51

In rare instances, it may not be possible to confidently categorize a tumor with neuroendocrine differentiation as LCNEC or SCLC, particularly in small biopsies in which the morphologic features are obscured by crush artifact. Under such circumstances, it is entirely acceptable to diagnose “neuroendocrine carcinoma, not further classified” and suggest additional sampling or if applicable, refer to concurrent cytologic samples that may contain better quality diagnostic material.

For tumors that show features not classic for SCLC, ancillary findings can be helpful. Nuclear molding and basophilic staining of vessels and stroma, know as the Azzopardi effect, are seldom seen in LCNEC but are not uncommon in SCLC (Figure 18, D and E). Occasional larger cells scattered among smaller cells with typical SCLC features should in no way obviate a diagnosis of SCLC. However, if the proportion of large cells with prominent nucleoli admixed with small cells reaches 10%, combined small cell/large cell carcinoma should be considered.51

Metastatic Prostatic Adenocarcinoma Misdiagnosed as Primary Lung Adenocarcinoma

Although it is rare for prostatic adenocarcinoma lung metastases (PALM) to come to clinical attention before the primary tumor is detected, it is important to be familiar with the most common patterns of PALM, as the extent to which they mimic primary pulmonary carcinoma is underappreciated. The architectural patterns seen most frequently in PALM are microacinar, tubulopapillary, and carcinoid-like.52 The microacinar pattern is characterized by small acinar proliferations of minimally pleomorphic tumor cells with eosinophilic cytoplasm, conspicuous nucleoli, and occasional intraluminal blue mucin (Figure 19, A). The tubulopapillary pattern of PALM, with its stratified tumor cells, prominent nucleoli, and comedonecrosis, resembles metastatic colorectal adenocarcinoma. PALM can also show a nested arrangement reminiscent of carcinoid tumor but, unlike carcinoid, reportedly does not feature finely granular chromatin.52 Neuroendocrine markers can be misleading, as they stain upward of half of prostatic adenocarcinomas.53 Fortunately, nearly all PALMs stain with prostate-specific antigen and prostate acid phophatase.52 The use of prostate markers should be considered in males with TTF-1-negative adenocarcinoma involving the lung. Other findings that may prompt consideration of PALM include a lymphangitic distribution, along with a low degree of nuclear pleomorphism, prominent round nucleoli, distinct cell borders, and a lack of desmoplastic stromal response (Figure 19, B).52

Pulmonary Intestinal-Type Adenocarcinoma Misdiagnosed as Metastatic Colorectal Adenocarcinoma

The array of histologic patterns primary pulmonary adenocarcinoma can manifest is nothing short of remarkable. Uncommonly, primary lung adenocarcinoma can appear morphologically identical to metastatic colorectal adenocarcinoma. Dubbed pulmonary intestinal- type adenocarcinoma, these primary lung carcinomas are apt to be mistaken for metastases if immunohistochemical studies are not performed.54 Pulmonary intestinal-type adenocarcinomas demonstrate stratified columnar cells in a garlandlike arrangement with cribriforming and central “dirty” necrosis (Figure 20, A and B). They often elicit an exuberant host response, as well as a pronounced desmoplastic stromal reaction. Adding to the confusion with colorectal carcinoma is the lack of lepidic growth at the periphery of pulmonary intestinal-type adenocarcinomas. However, in contrast to metastatic colorectal adenocarcinoma, pulmonary intestinal-type adenocarcinoma retains a pulmonary immunophenotype by displaying a TTF-1-positive, CK7-positive, CK20-negative, and CDX- 2-negative staining pattern (Figure 20, C).54

Mucin-Rich Pulmonary Carcinomas Misdiagnosed as Metastatic Mucinous Adenocarcinoma

Mucin-rich primary lung carcinomas are quite a heterogeneous group of tumors that includes mucinous cystoadenocarcinoma, mucinous (“colloid”) adenocarcinoma, signet ring adenocarcinoma, and mucinous BAC. These tumors have disparate immunohistochemical staining profiles, which often do not clearly point to a respiratory or extrapulmonary origin.

Primary mucinous adenocarcinomas of the lung that are comprised of neoplastic goblet cells frequently exhibit staining for markers typically associated with enteric differentiation, including CDX-2, MUC2, and in about half of cases, CK20 (Table).55 A sizable proportion of these tumors (~18%) are CK7 negative.55 Only about 73% are immunoreactive for TTF-1 and in cases that are TTF-1 positive, staining is usually patchy.55 In contrast, the CK7-positive, TTF-1- positive, CDX-2-negative, MUC2-negative staining pattern exhibited by signet ring adenocarcinoma of the lung typifies the immunophenotype seen in most adenocarcinomas of pulmonary origin. Although mucinous BACs are frequently CK20 positive (~80%-90%) and TTF-1 negative (~70%-80%), they reportedly uniformly express CK7, do not stain with CDX-2 or MUC2, and only rarely show weak cytoplasmic villin immunoreactivity.55-57 Although so-called pulmonary adenocarcinomas with enteric differentiation variably stain for markers typically associated with a colorectal origin, like mucinous BAC, pulmonary adenocarcinomas with enteric differentiation are uniformly positive for CK7.58

Thyroid transcription factor 1 positivity in mucin-rich adenocarcinomas that involve the lung supports a pulmonary origin. For TTF-1-negative tumors, which often express a phenotypically confusing array of immunohistochemical markers, the separation of primary mucin-rich lung adenocarcinoma from metastatic mucinous adenocarcinomas originating in the gastrointestinal or pancreaticobiliary tracts, ovary, or breast is most reliably accomplished through the integration of the clinical details and the radiographic distribution of disease.

Mixed Subtype Adenocarcinoma Misdiagnosed as Nonmucinous BAC

Data from the Early Lung Cancer Action Program, a study in which asymptomatic patients undergo computed tomography screening for lung cancer, suggests that BAC is overdiagnosed.14 Of cases submitted by the contributing pathologists as BAC, more than three quarters were reclassified by the Early Lung Cancer Action Program pathology review panel as invasive adenocarcinoma, mixed subtype, on the basis of identifying stromal invasion. The inaccurate diagnosis of BAC is undoubtedly related at least in part to the evolving definition of BAC. Initially described as a well-differentiated adenocarcinoma in the periphery of the lung with a tendency to spread aerogenously and by lymphatic routes, the definition of BAC has since been restricted to what essentially amounts to in situ carcinoma. Bronchioloalveolar carcinoma is currently defined as the growth of neoplastic cells along preexisting alveolar structures (lepidic growth) without evidence of stromal, vascular, or pleural invasion.11,12,59

Whether it is because of a delay in accepting the stringent definition of BAC that was instituted in 1999, a failure to implement it, or a lack of understanding what constitutes stromal invasion by the pathology community, one thing has become certain- misdiagnosing mixed subtype adenocarcinoma as BAC has important prognostic implications. Whereas BAC, as strictly defined by currentWorld Health Organization criteria, has a 100% 5-year survival for tumors 2 cm or less in diameter, the 5-year survival rate for similar size carcinomas that exhibit unequivocal central stromal invasion is only 60%.60 Other studies have demonstrated similar results. Noguchi and colleagues61 showed that patients with pure BAC had 100% 5-year survival, whereas 48% of those with poorly differentiated invasive adenocarcinoma were dead of disease within 5 years.

It is not uncommon for invasive adenocarcinomas to demonstrate a BAC growth pattern at their periphery, small biopsies of which may entirely miss the invasive component (Figure 21, A and B). For this reason, it is inappropriate to make a definitive diagnosis of BAC in biopsies that do not encompass the entire lesion.62 Bronchioloalveolar carcinoma has a tendency to undergo central collapse, a phenomenon that is accompanied by alveolar septal thickening (Figure 21, C). Distinguishing sclerosing BAC from mixed subtype invasive adenocarcinoma with a prominent BAC component can be challenging. Aside from overt obliteration of the alveolar architecture, other features that are helpful in distinguishing invasive adenocarcinoma from BAC include foci of acinar growth, tubulopapillary structures, a fibroblastic stromal reaction, and/or solid nests of tumor cells (Figure 21, D).12,60 Some investigators have advocated the use of elastin stains to highlight disruption of the pulmonary interstitial elastic framework in areas of invasion.60,63

CONCLUDING REMARKS

There is a multitude of other ways in which lung cancer can be underdiagnosed, overdiagnosed, or misdiagnosed, including mistaking reactive atypia in the setting of pneumothorax for adenocarcinoma,64 misinterpreting extensively necrotic squamous cell carcinoma as abscess, failing to detect carcinoma in usual interstitial pneumonia,65misidentifying sarcomatoid carcinoma as sarcoma, overinterpreting florid reactive stromal processes such as organizing pneumonia as malignant, confusing malignant melanoma in all of its various guises as carcinoma, and erroneously interpreting extrapulmonary thoracic malignancies that invade the lung as primary lung carcinoma. The examples presented herein will hopefully provide a framework for recognizing when things are not as they appear in pathologic proliferations of the lung.

I would like to thank Mary Beth Beasley, MD, Thomas Colby, MD, Anthony Gal, MD, Kevin Leslie, MD, Victor Roggli, MD, and Henry Tazelaar, MD, for their insightful suggestions.

References

1. Churg A. Transbronchial biopsy: nothing to fear. Am J Surg Pathol. 2001;25: 820-822.

2. Poletti V, Patelli M, Poggi S, et al. Transbronchial lung biopsy and bronchoalveolar lavage in diagnosis of diffuse infiltrative lung diseases. Respiration. 1988; 54(suppl 1):66-72.

3. Milman N, Faurschou P, Munch EP, et al. Transbronchial lung biopsy through the fibre optic bronchoscope. Results and complications in 452 examinations. Respir Med. 1994;88:749-753.

4. Koss MN, Przygodzki RM. Respiratory system. In: Al-Sam SZ, Lakhani SR, Davies JD, eds. Practical Atlas of Pseudomalignancy: Benign Lesion Mimicking Malignancy. London, England: Arnold; 1998:84- 107.

5. Gal AA, Koss MN. Differential Diagnosis in Pathology: Pulmonary Disorders. Baltimore, Md: Williams & Wilkins; 1997.

6. Ogino S, Franks TJ, Yong M, et al. Extensive squamous metaplasia with cytologic atypia in diffuse alveolar damage mimicking squamous cell carcinoma: a report of 2 cases. Hum Pathol. 2002;33:1052-1054.

7. Katzenstein A-LA. Katzenstein and Askin’s Surgical Pathology of Non-Neoplastic Lung Disease. 4th ed. Philadelphia, Pa: Saunders Elsevier; 2006.

8. Fukuoka J, Franks TJ, Colby TV, et al. Peribronchiolar metaplasia: a common histologic lesion in diffuse lung disease and a rare cause of interstitial lung disease: clinicopathologic features of 15 cases. Am J Surg Pathol. 2005;29:948-954.

9. Chapman AD, Kerr KM. The association between atypical adenomatous hyperplasia and primary lung cancer. Br J Cancer. 2000;83:632-636.

10. Kitamura H, Kameda Y, Ito T, et al. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol. 1999;111:610-622.

11. Travis WD, Colby TV, Corrin B, et al, eds. Histological Typing of Lung and Pleural Tumours. 3rd ed. Berlin, Germany: Springer; 1999.

12. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004. World Health Organization Classification of Tumours.

13. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.

14. Flieder DB, Vazquez M, Carter D, et al. Pathologic findings of lung tumors diagnosed on baseline CT screening. Am J Surg Pathol. 2006;30:606-613.

15. Panelos J, Voulgaris S, Michos E, et al. Chondrosarcoma of the spine: a rare case with unusual presentation. Diagn Pathol. 2006;1:39.

16. Meis-Kindblom JM, Kjellstrom C, Kindblom LG. Inflammatory fibrosarcoma: update, reappraisal, and perspective on its place in the spectrum of inflammatory myofibroblastic tumors. Semin Diagn Pathol. 1998;15:133-143.

17. Farris AB III, Mark EJ, Kradin RL. Pulmonary “inflammatory myofibroblastic” tumors: a critical examination of the diagnostic category based on quantitative immunohistochemical analysis. Virchows Arch. 2007;450:585-590.

18. Travis WD, Colby TV, Koss MN, et al, eds. Non-Neoplastic Disorders of the Lower Respiratory Tract. Washington, DC: American Registry of Pathology; 2002. Atlas of Tumor Pathology; 1st series, fascicle 13.

19. Burke LM, Rush WI, Khoor A, et al. Alveolar adenoma: a histochemical, immunohistochemical, and ultrastructural analysis of 17 cases. Hum Pathol. 1999;30:158-167.

20. Hegg CA, Flint A, Singh G. Papillary adenoma of the lung. Am J Clin Pathol. 1992;97:393-397.

21. England DM, Hochholzer L. Truly benign “bronchial adenoma”: report of 10 cases of mucous gland adenoma with immunohistochemical and ultrastructural findings. Am J Surg Pathol. 1995;19:887-899.

22. Devouassoux-Shisheboran M, de la Fouchardiere A, Thivolet- Bejui F, et al. Endobronchial variant of sclerosing hemangioma of the lung: histological and cytological features on endobronchial material. Mod Pathol. 2004;17:252-257.

23. Churg A, Warnock ML. Pulmonary tumorlet: a form of peripheral carcinoid. Cancer. 1976;37:1469-1477.

24. Torikata C, Mukai M. So-called minute chemodectoma of the lung: an electron microscopic and immunohistochemical study. Virchows Arch A Pathol Anat Histopathol. 1990;417:113-118.

25. Gaffey MJ, Mills SE, Askin FB. Minute pulmonary meningothelial-like nodules: a clinicopathologic study of so-called minute pulmonary chemodectoma. Am J Surg Pathol. 1988;12:167-175.

26. Ionescu DN, Sasatomi E, Aldeeb D, et al. Pulmonary meningothelial-like nodules: a genotypic comparison with meningiomas. Am J Surg Pathol. 2004;28: 207-214.

27. Pelosi G, Rodriguez J, Viale G, et al. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol. 2005;29: 179-187.

28. Arbiser ZK, Arbiser JL, Cohen C, et al. Neuroendocrine lung tumors: grade correlates with proliferation but not angiogenesis. Mod Pathol. 2001;14:1195-1199.

29. Bjerager M, Palshof T, Dahl R, et al. Delay in diagnosis of lung cancer in general practice. Br J Gen Pract. 2006;56:863-868.

30. Salomaa ER, Sallinen S, Hiekkanen H, et al. Delays in the diagnosis and treatment of lung cancer. Chest. 2005;128:2282-2288.

31. Mutton AE, Hasleton PS, Curry A, et al. Differentiation of desquamative interstitial pneumonia (DIP) from pulmonary adenocarcinoma by immunocytochemistry. Histopathology. 1998;33:129- 135.

32. Liebow AA, Steer A, Billingsley JG. Desquamative interstitial pneumonia. Am J Med. 1965;39:369-404.

33. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol. 2000;31:1255-1265.

34. Soga J, Yakuwa Y. Bronchopulmonary carcinoids: an analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg. 1999;5:211-219.

35. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934-944.

36. Shields DJ, Edwards WD. Pulmonary hypertension attributable to neoplastic emboli: an autopsy study of 20 cases and a review of the literature. Cardiovasc Pathol. 1992;1:279-287.

37. Roberts KE, Hamele-Bena D, Saqi A, et al. Pulmonary tumor embolism: a review of the literature. Am J Med. 2003;115:228-232.

38. Munk PL, Muller NL, Miller RR, et al. Pulmonary lymphangitic carcinomatosis: CT and pathologic findings. Radiology. 1988;166:705- 709.

39. Koss MN. Malignant and benign lymphoid lesions of the lung. Ann Diagn Pathol. 2004;8:167-187.

40. Kurtin PJ, Myers JL, Adlakha H, et al. Pathologic and clinical features of primary pulmonary extranodal marginal zone B- cell lymphoma of MALT type. Am J Surg Pathol. 2001;25:997-1008.

41. Begueret H, Vergier B, Parrens M, et al. Primary lung small B- cell lymphoma versus lymphoid hyperplasia: evaluation of diagnostic criteria in 26 cases. Am J Surg Pathol. 2002;26:76-81.

42. Abbondanzo SL, Rush W, Bijwaard KE, et al. Nodular lymphoid hyperplasia of the lung: a clinicopathologic study of 14 cases. Am J Surg Pathol. 2000; 24:587-597.

43. Moran CA, Hochholzer L, Fishback N, et al. Mucinous (so- called colloid) carcinomas of lung. Mod Pathol. 1992;5:634-638.

44. Roggli VL, Vollmer RT, Greenberg SD, et al. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Hum Pathol. 1985;16: 569-579.

45. Brambilla E, Moro D, Veale D, et al. Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance. Hum Pathol. 1992;23:993-1003.

46. Cakir E, Demirag F, Ucoluk GO, et al. Basaloid squamous cell carcinoma of the lung: a rare tumour with a rare clinical presentation. Lung Cancer. 2007; 57:109-111.

47. Sturm N, Lantuejoul S, Laverriere MH, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol. 2001;32:918-925.

48. Sturm N, Rossi G, Lantuejoul S, et al. 34BetaE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma. Histopathology. 2003;42:156-166. 49. Zhang H, Liu J, Cagle PT, et al. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach. Mod Pathol. 2005;18:111-118.

50. Nitadori J, Ishii G, Tsuta K, et al. Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel. Am J Clin Pathol. 2006; 125:682-692.

51. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26:1184-1197.

52. Copeland JN, Amin MB, Humphrey PA, et al. The morphologic spectrum of metastatic prostatic adenocarcinoma to the lung: special emphasis on histologic features overlapping with other pulmonary neoplasms. Am J Clin Pathol. 2002;117:552-557.

53. di Sant’Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol. 1992;23:287-296.

54. Yousem SA. Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study. Mod Pathol. 2005;18:816-821.

55. Rossi G, Murer B, Cavazza A, et al. Primary mucinous (so- called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX-2 homeobox gene and MUC2 expression. Am J Surg Pathol. 2004;28:442-452.

56. Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol. 2001;116:319-325.

57. Simsir A, Wei XJ, Yee H, et al. Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine- needle aspiration biopsy specimens. Am J Clin Pathol. 2004;121:350- 357.

58. Inamura K, Satoh Y, Okumura S, et al. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol. 2005;29:660-665.

59. Liebow AA. Bronchiolo-alveolar carcinoma. Adv Intern Med. 1960;10: 329-358.

60. Sakurai H, Maeshima A, Watanabe S, et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol. 2004;28:198-206.

61. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer. 1995;75:2844-2852.

62. Travis WD, Garg K, Franklin WA, et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol. 2006;1: S13-S19.

63. Eto T, Suzuki H, Honda A, et al. The changes of the stromal elastotic framework in the growth of peripheral lung adenocarcinomas. Cancer. 1996;77:646-656.

64. Shilo K, Colby TV, Travis WD, et al. Exuberant type 2 pneumocyte hyperplasia associated with spontaneous pneumothorax: secondary reactive change mimicking adenocarcinoma. Mod Pathol. 2007;20:352-356.

65. Aubry MC, Myers JL, Douglas WW, et al. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc. 2002;77:763-770.

Kelly J. Butnor, MD

Accepted for publication November 7, 2007.

From the Department of Pathology, University of Vermont/Fletcher Allen Health Care, Burlington.

The author has no relevant financial interest in the products or companies described in this article.

Reprints: Kelly J. Butnor, MD, Department of Pathology, University of Vermont/Fletcher Allen Health Care, ACC Building, EP2- 120, 111 Colchester Ave, Burlington, VT 05401 (e-mail: [email protected]).

Copyright College of American Pathologists Jul 2008

(c) 2008 Archives of Pathology & Laboratory Medicine. Provided by ProQuest Information and Learning. All rights Reserved.

Pulmonary Langerhans Cell Histiocytosis and Other Pulmonary Histiocytic Diseases: A Review

By Allen, Timothy Craig

* Context.-Pulmonary Langerhans cell histiocytosis is the most common and best known pulmonary histocytic lesion; however, the realm of pulmonary histiocytic lesions also includes an assortment of uncommon diseases that may exhibit pulmonary involvement. Objective.-To review pulmonary Langerhans cell histiocytosis and other pulmonary histiocytoses to better ensure correct diagnosis and optimal assessment of prognosis and treatment.

Data Sources.-Literature review and primary material from the author’s institution.

Conclusions.-This review discusses the most common pulmonary histocytosis, pulmonary Langerhans cell histiocytosis, and also reviews the uncommon pulmonary histiocytic lesions, which are distinct from pulmonary Langerhans cell histiocytosis.

(Arch Pathol Lab Med. 2008;132:1171-1181)

Pulmonary Langerhans cell histiocytosis (PLCH) is the most common and best known pulmonary histocytic lesion; however, the realm of pulmonary histiocytic lesions also includes an assortment of uncommon diseases that may exhibit pulmonary involvement. This review discusses the most common pulmonary histocytosis, PLCH, and also reviews the uncommon pulmonary histiocytic lesions that are distinct from PLCH.

The pulmonary histiocytoses are diseases characterized by the accumulation of histiocytes within the airspaces or parenchyma of the lung. This diverse group of disorders includes dendritic cell disorders, macrophage diseases, and storage diseases. The Histocyte Society classifies histiocytic diseases as dendritic cell-related disorders such as Langerhans cell histiocytosis, xanthogranulomatous disorders such as Erdheim-Chester disease, macrophage-related disorders such as Rosai-Dorfman disease, and malignant disorders such as dendritic cell-related histiocytic sarcoma.1,2 Langerhans cell histiocytosis is a term for a variety of diseases characterized by the proliferation and infiltration of Langerhans cells into various organs.3-8 Several terms have been used in the past to denote multisystem lesions predominantly arising in children, including Letterer-Siwe disease, Hand-Schu ller-Christian syndrome, histiocytosis X, and Hashimoto Pritzker syndrome.8 Multisystem Langerhans cell histiocytosis may exhibit lung involvement. Eosinophilic granuloma and histiocytosis X are terms that have frequently been used in the past to designate localized pulmonary lesions.8 The characteristic feature of all lesions designated Langerhans cell histiocytosis, from any site, is the infiltration Langerhans cells-CD1a-positive histiocytes of dendritic lineage derived from CD34-positive bone marrow stem cells. Langerhans cells play a role in the induction of primary antigen-specific immune reactions, play a key role in immunity, and are found in many tissues. These pulmonary dendritic cells are leukocytes that have been found to play a key role in immune response in the lung.9 Pulmonary Langerhans cell histiocytosis, in contrast to the systemic Langerhans cell histiocytoses typically found in childhood that are clonal neoplastic diseases, consists of nonneoplastic collections of reactive Langerhans cells.6,10-13

Pulmonary Langerhans cell histiocytosis is an interstitial lung disease occurring predominantly in adult cigarette smokers.14-16 Smokers have been shown to have an increased total number of T lymphocytes and a decreased helper-induced-suppressor-cytotoxic T lymphocyte (T4/T8) ratio compared with nonsmokers, potentially reducing helper-inducer lymphocytes that facilitate B-lymphocyte proliferation.17 Alveolar macrophages in smokers may be activated by materials in tobacco smoke causing them to release chemotactic factors with a resultant increase in peripheral blood monocytes within the lung.18,19 Pulmonary neuroendocrine cell stimulation by cigarette smoke may cause neuroendocrine cell hyperplasia in some smokers, with resultant increased recruitment of monocyte differentiation into Langerhans cells and associated fibroblast stimulation by bombesin-like peptides.20 Macrophage colony- stimulating factor and platelet-derived growth factor may also play a role in initiating and maintaining PLCH pathology.21 Langerhans cells in PLCH are phenotypically similar to mature lymphostimulatory dendritic cells within lymphoid organs, and the pathogenesis of PLCH may be related to an abnormal immune response by these Langerhans cells.22

Clinically, PLCH is uncommon, comprising approximately 5% of all interstitial lung disease cases, generally occurring in middle-aged men and women.23,24 Presenting symptoms are variable and include dyspnea, nonproductive cough, malaise, fever, weight loss, and night sweats. Patients may present with hemoptysis. Patients may be asymptomatic and be identified radiographically. Pneumothorax, sometimes recurrent, occurs in one fourth of patients during their disease course. Physical examination may also show variable features, including pulmonary rhonchi, rales, and wheezes, as well as decreased breath sounds. With increasing severity of disease, patients typically exhibit decreased diffusing capacity.25 Radiographically, most patients have x-ray abnormalities of varying degrees. Reticular changes, micronodules measuring 2 to 5 mm, and cysts measuring up to 1 cm have been commonly observed in PLCH patients.26 Pulmonary Langerhans cell histiocytosis can rarely progress to end-stage lung change, with characteristic radiologic changes of honeycombing present.

Pulmonary Langerhans cell histiocytosis is typically diagnosed from open lung biopsy, and gross appearance varies according to disease progression.4 Wedge biopsies of early lesions show multiple well-demarcated grey-white to tan-white irregular, stellate nodules ranging from less than 1 cm to about 2 cm. With evolution of PLCH, lesions show increasing amounts of stellate fibrosis and cyst formation. 4 Pathologically, early PLCH lesions consist of discrete bronchiolocentric stellate nodules (Figures 1 and 2). Early lesions are more cellular and less fibrotic than more mature lesions and consist of a variable mix of Langerhans cells, lymphocytes, eosinophils, and plasma cells with a background of generally mild fibrosis (Figures 3 through 5). Fibrosis replaces the cellular nodules as disease progresses, and less cellular stellate nodules are formed (Figure 6). Few Langerhans cell histiocytes and variable numbers of eosinophils may be found in these more fibrotic nodules. Surrounding lung may contain smoker’s pigment-laden alveolar macrophages arranged in a desquamative interstitial pneumonia-like pattern4 (Figure 7). Surrounding lung may retract with resultant airspace enlargement (Figure 8). Coalescence of nodules and the formation of large cysts are later occurrences, with some cases progressing to end-stage lung changes with honeycombing (Figure 9). Pulmonary Langerhans cell histiocytosis patients frequently have changes of early to late stage disease, both of which may be identifiable in a wedge biopsy. Langerhans cells usually are immunopositive with CD1a, Langerin, E-cadherin, and S1004,27,28 (Figures 10 and 11). Birbeck granules, also termed Langerhans cell granules, pentalaminar rod-shaped cytoplasmic organelles with a racket- or rod-shaped appearance, are found ultrastructurally. 29

The primary therapy for PLCH is smoking cessation.4 Anecdotal reports have shown patient improvement from corticosteroid therapy, and patients with progressive disease have been treated with chemotherapy such as cyclophosphamide and methotrexate; however, no randomized study has been performed to assess the benefit of these therapies.4 Pulmonary Langerhans cell histiocytosis patients have variable prognoses. About one fourth of patients will regress spontaneously whether or not they stop smoking, about half of patients will stabilize but not regress spontaneously, and about one fourth of patients will exhibit progressive disease that may ultimately cause honeycombing. 14,30,31 Pleurodesis in PLCH patients presenting with spontaneous pneumothorax may be of benefit.32 The differential diagnosis of PLCH varies depending on whether early PLCH lesions or late lesions, or both, are present in the biopsy. Early, cellular PLCH nodules containing many eosinophils are suggestive of eosinophilic pneumonia; however, in contrast to PLCH, eosinophilic pneumonia generally is composed of collections of eosinophils and macrophages lying within alveolar spaces, as well as an interstitial infiltrate of variable degree made up of lymphocytes, macrophages, and eosinophils. Desquamative interstitial pneumonia should be considered in the differential diagnosis when the biopsy predominantly contains smoker’s pigment-laden macrophages lying within alveolar spaces. It is important to consider that respiratory bronchiolitis-associated interstitial lung disease/ desquamative interstitial pneumonia is another smokingrelated disease and may occasionally coexist with PLCH. In later stage PLCH, with its more fibrotic and scarred lesions, ultimately causing honeycombing, usual interstitial pneumonia becomes a differential diagnosis. Usual interstitial pneumonia is predominantly a subpleural disease usually involving the lower zones of the lungs. Pulmonary Erdheim-Chester disease is a differential diagnosis that is discussed later.33-35

ROSAI-DORFMAN DISEASE

Sinus histiocytosis with massive lymphadenopathy, also termed Rosai-Dorfman disease, is a rare nonmalignant proliferation of histiocytic/phagocytic cells of unknown etiology occurring within lymph node sinuses, lymphatics, and various extranodal sites.36-38 It typically occurs in children and young adults.36,38 No clinical response with antibacterial or antitubercular therapies have been documented, and viral infection and disordered immune regulation have been hypothesized as possible etiologies.36 An exuberant hematopoietic system response to an unknown immunologic trigger has been considered a possible cause.36 The association of Rosai- Dorfman disease with autoimmune lymphoproliferative syndrome, an inherited disorder of lymphocyte programmed cell death primarily occurring in early childhood, and the identification of mutations of the Fas gene in a small subset of Rosai-Dorfman disease patients suggests that Rosai-Dorf man disease may represent an acquired disorder of apoptotic signaling pathway regulation.36,39-42 Rosai- Dorfman disease most frequently presents as painless massive, often cervical, lymphadenopathy.36,43 Nodal disease is frequently self- limited.43 Extranodal involvement of various sites including bone, retro-orbital tissue, skin, lung, and kidneys occurs in approximately 20% to 40% of patients.38,44 Skin and soft tissue, nasal and paranasal sinuses, the eye and ocular adnexa, and bone are the most common extranodal sites of involvement.36 Pulmonary involvement is rare and occurs in approximately 2% to 3% of cases with extranodal disease.36,45,46 It usually presents as solitary or multiple mass lesions in the lung, bronchi, or trachea, typically with coexisting nodal and extranodal disease.45-49 The tracheobronchial tree is most commonly involved with pulmonary Rosai- Dorfman disease, presenting as large single or multiple airway masses; however, diffuse interstitial lung involvement may rarely occur, and primarily pleural disease has been reported.45 Radiographically, mediastinal fullness or nodal enlargement or hilar or perihilar masses may be present.46-49 Diffuse lung involvement may present radiographically as bilateral reticulonodular infiltrates.

Histologically, pulmonary Rosai-Dorfman disease exhibits an infiltrate of faintly staining histiocytes with oval nuclei that may contain mild atypia, one or more nucleoli, and abundant pale eosinophilic cytoplasm.36 The histiocytes lie in an inflammatory background of scattered plasma cells and lymphocytes. Lymphocytes within histiocyte cytoplasm, termed lymphophagocytosis or emperipolesis, is a distinctive feature of Rosai-Dorfman disease36,46 (Figures 12 and 13). Usually located within cytoplasmic vacuoles, these lymphocytes avoid degradation as they transit through the histiocyte.36 Surrounding lung parenchyma generally contains a mixture of inflammatory cells, fibrosis, foamy alveolar macrophages, and a proliferation of type II pneumocytes. Immunopositivity with S100 is the most useful immunomarker for Rosai- Dorfman disease.36 Histiocytes in Rosai-Dorfman disease also typically show immunopositivity with CD68, CD14, CD15, CD163, and alpha^sub 1^-antichymotrypsin and immunonegativity with CD1a and factor XIIIa.36,37

Most cases of Rosai-Dorfman disease limited to nodal disease exhibit spontaneous resolution.36 Pulmonary disease, renal disease, and hepatic disease with associated immunogenic dysfunction frequently show persistent lymphadenopathy or disease dissemination.36 Treatment for Rosai-Dorfman disease varies with disease severity. Uncomplicated cases may be observed; however, disease that is widely disseminated, which manifests organ compression, may require surgical debulking, radiation therapy, or both.36 Chemotherapy has not shown obvious benefit and is not a primary treatment.36 Prognosis varies, but for patients with pulmonary Rosai-Dorfman disease, prognosis is guarded.45 Patient mortality of 45% has been reported, with 33% of patients exhibiting persistent or progressive disease.45,46 The differential diagnosis of pulmonary involvement with Rosai-Dorfman disease includes PLCH, Erdheim-Chester disease, carcinoma, Hodgkin lymphoma, Gaucher disease, and mycobacterial and fungal infections, among others.6 The eosinophils often present in lesions of PLCH are not a usual feature of pulmonary Rosai-Dorfman disease.36 The characteristic bilateral and symmetric osteosclerosis of long bones present with Erdheim- Chester disease is helpful in differentiating it from Rosai-Dorfman disease, as is its lack of emperipolesis. Indeed, emperipolesis is rarely a feature seen outside of the setting of Rosai-Dorfman disease.36

ERDHEIM-CHESTER DISEASE

Erdheim-Chester disease, identified by William Chester in 1930, is a rare, systemic, nonfamilial non-Langerhans cell histiocytosis of unclear, but possibly clonal, etiology that occurs predominantly in middle-aged and older adults.33-35,50-53 Bone pain is the typical presenting complaint, and the disease is characterized clinically and radiographically by symmetric osteosclerosis that involves the metaphyses and diaphyses of long bones.33,35,52 Almost pathognomonic, symmetrical sclerotic or mixed sclerotic and lytic lesions involving the metaphyseal and diaphyseal regions of long bones can be seen on skeletal radiographs. 35 Approximately half of Erdheim-Chester disease patients exhibit extraskeletal disease, including lung, heart, skin, kidney, retroperitoneum, retro-orbital and periorbital tissues, breast, pituitary-hypothalamic axis, sinonasal mucosa, and skeletal muscle.35,53 Twenty percent to 35% of patients exhibit pulmonary involvement.33,35,50,54

Patients having lung involvement typically present with cough and progressive dyspnea, and decreased diffusing capacity is frequently a feature.35,52,55 A pleural effusion may be present.35,52 Chest x- ray often exhibits diffuse interstitial infiltrates with pleural and interlobular septal thickening and may show a relatively nonspecific pattern of interstitial opacities, generally in the upper lung zones.35 Pleural thickening may occur, occasionally being the prevalent radiographic change.33 Interlobular and visceral pleural thickening with patchy reticular and centrilobular opacities, areas of ground glass attenuation, and pleural effusion are frequent findings on chest computed tomography scan.33 Combined with the typical clinical and radiographic skeletal findings, the radiographic findings of smooth interlobular septal thickening and centrilobular nodular opacities, fissural thickening, and pleural effusions are highly suggestive of Erdheim-Chester disease. 56

Transbronchial biopsies of Erdheim-Chester disease are unhelpful in showing the distribution of this interstitial lung disease, but wedge biopsy specimens are able to exhibit diagnostic features.51 Histologically, lung involvement with Erdheim-Chester disease generally shows a histiocytic and lymphocytic infiltrate arranged in a lymphangitic pattern, as well as diffuse interstitial thickening and variable fibrosis, and the accumulation of foamy to clear histiocytes within alveolar spaces35 (Figures 14 and 15). Approximately two thirds of patients with lung involvement have a bronchovascular, subpleural, and/or interlobar septal distribution of the lymphangitic infiltrate.35 Pleural and subpleural fibrosis may be identified extending into underlying lung parenchyma along the interlobular septa.33-35 The histiocytes within the inflammatory infiltrate in Erdheim-Chester disease have abundant palestaining cytoplasm; however, they do not exhibit nuclear folding or eosinophilic cytoplasm that characterize the Langerhans histiocytes of PLCH33,35 (Figures 16 and 17). The histiocytes in Erdheim- Chester disease characteristically exhibit CD68 and factor XIIIa immunopositivity and CD1a immunonegativity33-35 (Figure 18). Immunostain with S100 is variably positive, possibly because of the presence of S100-positive reactive histiocytes within the fibrohistiocytic areas.35 Birbeck granules are not present ultrastructurally within Erdheim-Chester disease histiocytes, in contrast to PLCH Langerhans histiocytes.33,35

Treatments and therapeutic responses are infrequently discussed in case reports of pulmonary involvement with Erdheim-Chester disease51,57; however, reported therapies include steroids, interferon, cytotoxic chemotherapy, surgery, stem cell transplantation, and radiation.35,51 The rarity of cases has precluded therapeutic standardization.51 Poor or variable success has been shown, with the most successful anecdotal cases using a combination of a chemotherapeutic agent and prednisone.35,51 Patients’ courses have been variable, with some patients maintaining stable extraosseous disease over time and other patients exhibiting progressive disease leading to death because of extraosseous, often pulmonary or retroperitoneal, disease. Prognosis in these patients is generally dependent on the extent of extraosseous disease, and approximately 60% of patients die of disease within 3 years, mostly from pulmonary or retroperitoneal disease.33-35,57 One third of patients with lung involvement die of disease within 6 months.35

Differential diagnosis of Erdheim-Chester disease in the lung includes other interstitial lung diseases such as usual interstitial pneumonia and nonspecific interstitial pneumonia, other histiocytic lesions such as Rosai-Dorfman disease and PLCH, sarcoidosis, and storage diseases.35,54 Correct diagnosis typically requires correlation of the patient’s history, physical examination, and radiologic studies with histology and immunohistochemistry.35,57 The characteristic lymphangitic distribution of Erdheim-Chester disease, as well as CD1a immunonegativity and absence of Birbeck granules in histiocytes, are helpful in distinguishing it from PLCH, usual interstitial pneumonia, and other differential diagnoses.

GAUCHER DISEASE

Gaucher disease, the most prevalent lysosomal storage disorder, is an autosomal recessive lipid storage disease caused by glucocerebrosidase deficiency.58-63 The adult form of the disease, type I, typically involves bone, spleen, and liver, and pulmonary involvement is uncommon and generally exhibited only in association with disease in the more common organs.61,62,64-68 Type I disease is especially prevalent in the Ashkenazi Jew population and is much more common than type II and type III disease, differing from those types by sparing of the central nervous system. 61,62 Type II disease, also termed acute neuropathic type, is generally found in children by age 6 months, and type III disease is a juvenile form of disease also termed the subacute neuropathic form.62 A glucocerebroside gene mutation with resultant diminished enzymatic activity causes increased accumulation of glucocerebroside in lysosomes of phagocytic Gaucher cells.62,69 Hepatosplenomegaly, bone pain and pathologic fractures, anemia, and easy bruising are frequently identified symptoms. Patients with severe disease, especially in disease with neuropathic changes, are more likely to exhibit pulmonary disease.63 Histologically, lung involvement with Gaucher disease may be multifaceted.61-65 Gaucher cells may fill alveolar spaces, as well as septa, with resultant interstitial lung disease.62,63 Pulmonary hypertension may occur, with or without the involvement and subsequent occlusion of alveolar septal capillaries or other vessels with Gaucher cells.62,63 Gaucher cells exhibit a “wrinkled paper” appearance, highlighted with periodic acid-Schiff stain (Figure 19). In contrast to alveolar macrophages, Gaucher cells usually exhibit relatively light CD68 immunopositivity. Enzyme replacement therapy has been found to be safe and effective in reducing hepatosplenomegaly and improving hematologic parameters; however, pulmonary manifestations of Gaucher disease have not shown a similar response to such therapy.63,70 Bilateral lung transplant has been reported.62 Research positing that glucocerebrosidase secretion is related to its delivery to lysosomes by interaction with transmembrane protein LIMP-2 suggests the potential for improved future therapy for Gaucher disease patients.71

FABRY DISEASE

Fabry disease is an X-linked metabolic disease caused by alpha- galactosidase A deficiency, with resultant accumulation of glycosphingolipids, predominantly globotriaosylceramide, throughout the body, including the lungs.72-75 Patients with Fabry disease can exhibit a variety of pulmonary signs and symptoms including dyspnea, wheezing, pneumothorax, airway obstruction, and hemoptysis.75 Airway obstruction is more common in older patients, many of whom are smokers.75,76 Frameshift mutations as well as the missense mutation D24V are also associated with airway obstruction.76 Chest x-ray is frequently normal; however, airflow limitation may be demonstrated by pulmonary function studies.75 Chest computed tomography may show ground glass opacities, possibly representing alveolar filling by glycosphingolipid.75 Histologically, diagnostic laminated inclusions can be found in capillary endothelium; type II pneumocytes, ciliated bronchial mu cosal cells, and goblet cells are generally found in bronchial biopsy specimens, brushings, or lavage fluid.72,76-78 Diagnosis via sputum cytology has been reported.72 Enzyme replacement therapy using enzymatically active human alpha- galactosidase A became available in 2003 and has been shown to alleviate pulmonary dysfunction in some patients.73-75

NIEMANN-PICK DISEASE

Niemann-Pick disease is a term used to describe rare, inherited autosomal recessive disorders characterized by an absence or deficiency of the enzyme acid sphingomyelinase and resulting in increased sphingomyelin deposition within reticuloendothelial cells.79-82 Types A and B Niemann-Pick disease are lysosomal storage disorders showing symptoms caused by the accumulations of lipid laden macrophages, called Niemann-Pick cells, in a variety of organs, specifically spleen and liver.80 Type C disease is a complex lipid storage disorder caused by cholesterol trafficking defects because of mutations in the NPC1 and NPC2 genes.79,80 Type A disease usually causes death by about age 3 years; however, patients with type B disease show phenotypic variability and some residual enzyme activity, with patients frequently living into adulthood. 79-81 Lung involvement is relatively frequent in infantile forms of Niemann- Pick disease but is an uncommon finding in adult forms.

Lung disease may be present in patients with type A disease; however, the lungs are typically spared in patients with type C disease, especially in adults.79,80 Lung involvement in patients with type C Niemann-Pick disease has been reported.80-83 Lung involvement is a common finding in patients with type B disease.80 Adult patients with type B disease frequently exhibit hepatosplenomegaly, but lung involvement may be asymptomatic and detected only on chest x-ray.80 Mild, recurrent cough or dyspnea on exertion may be present.80 Chest x-ray and computed tomography scan often show nonspecific bilateral interstitial reticulonodular changes, sometimes with diffuse honeycombing in lung bases, establishing the presence of interstitial lung disease.79-81 Radiologic studies do not assist in determining the severity of disease or predicting clinical outcome.80

Grossly, the lung in Niemann-Pick disease is often heavy and pale.84 Histologically, the lungs frequently show endogenous lipid pneumonia consisting of alveolar filling by Niemann-Pick cells.79,85,86 Areas of interstitial foamy macrophages, variable interstitial fibrosis, and often foamy change within ciliated mucosal epithelium are found.79 Pleura and lymphatics may also be involved.85,86 Niemann-Pick histiocytes are generally enlarged with abundant finely vacuolated cytoplasm and eccentric nuclei87 (Figures 20 and 21). The cells are usually immunopositive with CD68.88 Strong blue staining of Niemann-Pick cells with May-Grunwald Giemsa stain, called “sea blue histiocytosis,” is a nonspecific feature.85,88 Concentric lamellar myelin-like lysosomal inclusions are an ultrastructural feature of the disease.86 Treatment by whole lung lavage has been described, and bone marrow transplantation has been attempted in some patients.79,89,90 Differential diagnosis includes other causes of endogenous lipid pneumonia, including peritumoral disease, and drug therapy, specifically amiodarone therapy with associated toxicity.79 Progression of lung disease is generally slow and unremitting, but cases of rapidly fatal lung disease have been reported.80,91,92

HERMANSKY-PUDLAK SYNDROME

Hermansky-Pudlak syndrome, also termed oculocutaneous albinism syndrome, is a rare heterogeneously inherited autosomal recessive disease characterized by the systemic accumulation of ceroid-filled histiocytes, considered to be a consequence of disturbed formation or trafficking of intracellular vesicles, specifically melanosomes, platelet dense granules, and lysosomes.93-95 Patients frequently have oculocutaneous albinism, with associated decreased visual acuity, congenital nystagmus, and iris transillumination; variable skin and hair hypopigmentation; and bruising.93-96 Patients may have prolonged bleeding time caused by platelet aggregation defects.93,96 Ceroid deposition involves many organs and causes increased morbidity in the lungs, often leading to death in patients’ fourth or fifth decades of life because of pulmonary fibrosis. 93 Pulmonary macrophages are abnormal, and type II pneumocytes are disrupted.93,97 The gene mutation causing Hermansky-Pudlak syndrome is one of the most prevalent single-gene disorders in northwest Puerto Rico.93 Clinical and radiologic features of interstitial lung disease may occur, usually causing disease by the patients’ fourth or fifth decade of life and death by the fifth decade.93 Approximately 50% of patient deaths are because of pulmonary fibrosis.93 The pathogenesis of pulmonary fibrosis is uncertain; however, intracellular disruption of type II pneumocytes by ceroid, causing a cascade of inflammation, cytokine reduction, and fibroblast proliferation, may ultimately cause the development of pulmonary fibrosis.93 A usual interstitial pneumonia-like pattern or a nonspecific interstitial pneumonia-like pattern of fibrosis is seen in the lung histologically. Ceroid-filled histiocytes are usually located within air spaces and interstitial septa (Figures 22 and 23). Prevention or minimization of bleeding is an important therapeutic goal, as is the prevention or minimization of lung fibrosis.93 Therapies such as corticosteroids, cyclophosphamide, cyclosporine, and azathioprine often cause deleterious side effects such as myelosuppression, oncogenesis, and lung toxicity, without inhibiting disease progression.93 Pirfenidone, with anti- inflammatory, antioxidant, and antifibrotic properties, has been investigated with a randomized placebo-controlled trial and has shown an approximately 8% slower decline in pulmonary function in patients compared with a control group.93,98 Bilateral lung transplantation has been reported, with the patient stable at 12 months posttransplant. 95

DIABETIC XANTHROGRANULOMA

Reinila,99 in a study of 339 autopsy lung samples, found perivascular collections of foamy histiocytes in 20 (5.9%) lung samples from diabetic patients versus 3 (1.9%) samples of control patients. The perivascular collections measured an average of 176 [mu]m, and periodic acid-Schiff and iron stains were negative.99 The author hypothesized that some dysfunction in lipid transport through the vessel wall might be causative.99

CHOLESTERYL ESTER STORAGE DISEASE

Cholesteryl ester storage disease is an autosomal recessive storage disease that typically results in chronic liver disease.100 It is caused by partial lysosomal acid lipase/cholesteryl ester hydrolase deficiency because of mutation of the gene encoding for lysosomal acid lipase, located on chromosome 10q23.2-q23.3.100 Wolman disease, in which there is complete enzyme deficiency, is typically fatal within the first 6 months of life.100 Most patients are carriers of exon 8 splice junction mutation, leading to an inframe deletion of exon 8 with the resultant protein having no residual lysosomal acid lipase activity.100-107 Disease usually begins in childhood or adolescence, and both males and females are equally affected.100 Survival to age 30 years is rare.100 Deposition of cholesteryl ester usually occurs within the spleen, liver, bone marrow, and intestine. 108 Lung involvement is rare.109 Intracytoplasmic accumulation of cholesterol esters within alveolar macrophages, fibroblasts, and interstitial cells occurs histologically, and pulmonary arteries may contain focal concentric intimal deposits of foam cells and extracellular lipid109,110 (Figure 24). References

1. Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocytic disorders. Med Pediatr Oncol. 1997;29:157-166.

2. Schmitz L, Favara BE. Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:221-246.

3. Caminati A, Harari S. Smoking-related interstitial pneumonias and pulmonary Langerhans cell histiocytosis. Proc Am Thorac Soc. 2006;299-306.

4. Tazi A. Adult pulmonary Langerhans’ cell histiocytosis. Eur Respir J. 2006; 27:1272-1285.

5. Vassallo R, Ryu JH, Colby TV, et al. Medical progress: pulmonary Langerhans’ cell histiocytosis. N Engl J Med. 2000;346:1969-1978.

6. Yousem SA, Colby TV, Chen YY, et al. Pulmonary Langerhans’ cell histiocytosis: molecular analysis of clonality. Am J Surg Pathol. 2001;25:630-636.

7. Vassallo R, Ryu JH, Schroeder DR, et al. Clinical outcomes of pulmonary Langerhans’-cell histiocytosis in adults. N Engl J Med. 2002;346:484-490.

8. Arico M, Girschikofsky M, Genereau T, et al. Langerhans cell histiocytosis in adults: report from the International Registry of the Histiocyte Society. Eur J Cancer. 2003;39:2341-2348.

9. Vermaelen K, Pauwels R. Pulmonary dendritic cells. Am J Respir Crit Care Med. 2005;172:530-531.

10. Dacic S, Trusky C, Bakker A, et al. Genotypic analysis of pulmonary Langerhans’ histiocytosis. Hum Pathol. 2003;34:1345-1349.

11. Willman CL, Busque L, Griffith BB, et al. Langerhans’ cell histiocytosis (histiocytosis X): a clonal proliferative disease. N Engl J Med. 1994;331:154-160.

12. Yu RC, Chu C, Buluwela L, et al. Clonal proliferation of Langerhans’ cells in Langerhans’ cell histiocytosis. Lancet. 1994;343:767-768.

13. Willman CL. Detection of clonal histiocytes in Langerhans’ cell histiocytosis: biology and clinical significance. Br J Cancer Suppl. 1994;23:S29-S33.

14. Friedman PJ, Liebow AA, Sokoloff J. Eosinophilic granuloma of lung: clinical aspects of primary pulmonary histiocytosis in the adult. Medicine (Baltimore). 1981;60:385-396.

15. Travis WD, Borok Z, Roum JH, et al. Pulmonary Langerhans’ cell histiocytosis (histiocytosis X): a clinicopathologic study of 48 cases. Am J Surg Pathol. 1993;17:971-986.

16. Schonfeld N, Frank W, Wenig S, et al. Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X. Respiration (Herrlisheim). 1993;60:38-44.

17. Miller LG, Goldstein G, Murphy M, Ginns LC. Reversible alterations in immunoregulatory T cells in smoking: analysis by monoclonal antibodies and flow cytometry. Chest. 1 1982;82:526-529.

18. Senior RM, Kuhn C III. The pathogenesis of emphysema. In: Fishman AP, ed. Pulmonary Diseases and Disorders. 2nd ed. New York, NY: McGraw-Hill; 1988:1209-1219.

19. Hoogsteden HC, van Hal PT, Wijkhuijs JM, Hop W, Verkaik AP, Hilvering C. Expression of the CD11/CD18 cell surface adhesion glycoprotein family on alveolar macrophages in smokers and nonsmokers. Chest. 1991;100:1567-1571.

20. Aguayo SM, King TE, Waldron JA, et al. Increased pulmonary neuroendocrine cells with bombesin-like immunoreactivity in adult patients with eosinophilic granuloma. J Clin Invest. 1990;86:838- 844.

21. Barth J, Kreipe H, Radzun HJ, et al. Increased expression of growth factor genes for macrophages and fibroblasts in bronchoalveolar lavage cells of a patient with pulmonary histiocytosis X. Thorax. 1991;46:835-838.

22. Tazi A, Moreau J, Bergeron A, et al. Evidence that Langerhans cells in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: importance of the cytokine microenvironment. J Immunol. 1999;163:3511-3515.

23. Gaensler AE, Carrington CB. Open biopsy for chronic diffuse infiltrative lung disease: clinical, roentgenographic and physiological correlations in 502 patients. Ann Thorac Surg. 1980;30:411-426.

24. Agostini C, Albera C, Bariffi F, et al. First report of the Italian register for diffuse infiltrative lung disorders (RIPID). Monaldi Arch Chest Dis. 2001;56:364-368.

25. Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med. 2000;161:216-223.

26. LaCronique J, Roth C, Battesti JP, Basset F, Chretien J. Chest radiological features of pulmonary histiocytosis, X: a report based on 50 adult cases. Thorax. 1982;37:104-109.

27. Zeppa P, Cozzolino I, Rosso M, et al. Pulmonary Langerhans cell histiocytosis (histiocytosis, X) on bronchoalveolar lavage: a report of 2 cases. Acta Cytol. 2007;51:480-482.

28. Hoover KB, Rosenthal DI, Mankin H. Langerhans cell histiocytosis. Skeletal Radiol. 2007;36:95-104.

29. Birbeck MS, Breathnach AD, Everall JD. An electron microscope study of basal melanocytes and high-level clear cells (Langerhans cells) in vitiligo. J Invest Dermatol. 1961;37:51-64.

30. Huhn D, Konig G,Weig J, SchnellerW. Therapy in pulmonary histiocytosis X. Haematol Bluttransfus. 1981;27:231-237.

31. Von Essen S,WestW, Sitorius M, Rennard SI. Complete resolution of roentgenographic changes in a patient with pulmonary histiocytosis X. Chest. 1990; 98:765-767.

32. Mendez JL, Nadrous HF, Vassallo K, et al. Pneumothorax in pulmonary Langerhans cell histiocytosis. Chest. 2004;125:1028-1032.

33. Egan AJM, Boardman LA, Tazelaar HD, et al. Erdheim-Chester disease: clinical, radiologic, and histopathologic findings in five patients with interstitial lung disease. Am J Surg Pathol. 1999;23:17-26.

34. Rush WL, Andriko JAW, Galateau-Salle F, et al. Pulmonary pathology of Erdheim-Chester disease. Mod Pathol. 2000;13:747-754.

35. Allen TC, Chevez-Barrios P, Shetlar DJ, Cagle PT. Pulmonary and ophthalmic involvement with Erdheim-Chester disease: a case report and review of the literature. Arch Pathol Lab Med. 2004;128:1428-1431.

36. McClain KL, Natkunam Y, Swedlow SH. Atypical cellular disorders. Hematology Am Soc Hematol Educ Program. 2004:283-296.

37. Agarwal A, Pathak S, Gujral S. Sinus histiocytosis with massive lymphadenopathy-a review of seven cases. Indian J Pathol Microbiol. 2006;49:509-515.

38. Huang Q, Change KL, Weiss LM. Extranodal Rosai-Dorfman disease involving the bone marrow: a case report. Am J Surg Pathol. 2006;30:1189-1192.

39. Maric I, Pittaluga S, Dale J, Straus SE, Jaffe ES. Sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. Mod Pathol. 2004;17:58A.

40. Bettinardi A, Brugnoni D, Qiros-Roldan E, et al. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood. 1997;89:902-909.

41. Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ. 2003;10: 124-133.

42. Sneller MC, Wang J, Dale JK, et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997;89:1341- 1348.

43. Oner AY, Akpek S, Tali T. Rosai-Dorfman disease with epidural and spinal bone marrow involvement: magnetic resonance imaging and diffusion-weighted imaging features. Acta Radiol. 2007;48:331-334.

44. Ben Ghorbel I, Naffati H, Khanfir M, et al. Disseminated form of Rosai-Dorfman disease: a case report. Rev Med Interne. 2005;26:415-419.

45. Ohori NP, Jing Y, Landreneau RJ, Thaete FL. Rosai-Dorfman disease of the pleura: a rare extranodal presentation. Hum Pathol. 2003;1210-1211.

46. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990; 19-73.

47. Travis WD, Colby TV, Koss MN, et al. Non-Neoplastic Disorders of the Lower Respiratory Tract. Washington, DC: Armed Forces Institute of Pathology; 2002:144-147. Atlas of Nontumor Pathology; 1st series, fascicle 2.

48. Buchino JJ, Byrd RP, Kmetz DR. Disseminated sinus histiocytosis with massive lymphadenopathy: its pathologic aspects. Arch Pathol Lab Med. 1982;106: 13-16.

49. Wright DH, Richards DB. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case with widespread nodal and extra nodal dissemination. Histopathology. 1981;5:697-709.

50. Rao NR, Chang C, Uysal N, et al. Fulminate multisystem non- Langerhans cell histiocytic proliferation with hemophagocytosis: a variant form of Erdheim Chester disease. Arch Pathol Lab Med. 2005;129:e39-e43.

51. Kong PM, Pinheiro L, Kaw G, Sittampalam K, Teo CHY. Erdheim- Chester disease: a rare cause of interstitial lung disease. Singapore Med J. 2007;48:e57-e59.

52. Saboerali MD, Koolen MGJ, Noorduyn LA, van Delden OM, Bogaard HJ. Pleural thickening in a construction worker: it is not always mesothelioma. Neth J Med. 2006;64:88-90.

53. Chung JH, Park MS, Shin DH, et al. Pulmonary involvement with Erdheim-Chester disease. Respirology. 2005;10:389-392.

54. Shaburek RD, Brewer HB, Gochuico BR. Erdheim-Chester disease: a rare multisystem histiocytic disorder associated with interstitial lung disease. Am J Med Sci. 2001;321:66-76.

55. Devouassoux G, Laintenjoul S, Chatelain P, et al. Erdheim- Chester disease: a primary macrophage disorder. Am J Respir Crit Care Med. 1998;157:650-653. 56. Wittenberg KH, Swensen SJ, Myers JL, et al. Pulmonary involvement with Erdheim-Chester disease: radiographic and CT findings. Am J Roentgenol. 2000; 174:1271-3331.

57. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al. Erdheim-Chester disease: clinical and radiologic characteristics of 59 cases. Medicine. 1996;75: 157-169.

58. Amir G, Ron N. Pulmonary pathology in Gaucher’s disease. Hum Pathol. 1999;30:666-670.

59. Guggenbuhl P, Grosbois B, Chales G. Gaucher disease. Joint Bone Spine. 2008;75:116-124.

60. Mignot C, Doummar D, Maire I, et al. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev. 2006;28:39- 48.

61. Miller A, Brown LK, Pastores GM, Desnick RJ. Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease. Clin Genet. 2003;63:368-376.

62. Rao AR, Parakininkas D, Hintermeyer M, Segura AD, Rice TB. Bilateral lung transplant in Gauchers type-1 disease. Pediatr Transplant. 2005;9:239-243.

63. Dinwiddle R, Sonnappa S. Systemic diseases and the lung. Paediat Resp Rev. 2005;6:181-189.

64. Fisher MR, Sider L. Diffuse reticulonodular infiltration associated with splenomegaly. Chest. 1983;84:609-610.

65. Schneider EL, Epstein CJ, Kaback MJ, et al. Severe pulmonary involvement in Gaucher’s disease: report of three cases and review of the literature. Am J Med. 1977;63:475-480.

66. Wolson AA. Pulmonary findings in Gaucher’s disease. Am J Roentgenol. 1975;123:712-715.

67. Roberts WC, Fredrickson DS. Gaucher’s disease of the lung causing severe pulmonary hypertension with associated acute pericarditis. Circulation. 1967;35: 783-789.

68. Lee RE, Yousem SA. The frequency and type of lung involvement in patients with Gaucher’s disease. Lab Invest. 1988;58:54A.

69. Beutler E. Gaucher disease. Curr Opin Hematol. 1997;4:19-23.

70. Goitein O, Elstein D, Abrahamov A, et al. Lung involvement and enzyme replacement therapy in Gaucher’s disease. Q J Med. 2001;94:407-415.

71. Griffiths GM. Gaucher disease: forging a new path to the lysosome. Cell. 2007;131:67-649.

72. Kelly MM, Leigh R, McKenzie R, et al. Induced sputum examination: diagnosis of pulmonary involvement in Fabry’s disease. Thorax. 2000;55:720-721.

73. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8:539-548.

74. Mohrenschlager M, Pontz BF, Lanzi I, et al. Fabry disease: case report with emphasis on enzyme replacement therapy and possible future therapeutic options. J Dtsch Dermatol Ges. 2007;5:594-597.

75. Kim W, Pyeritz RE, Bernhardt BA, Casey M, Litt HI. Pulmonary manifestations of Fabry disease and positive response to enzyme replacement therapy. Am J Med Genet Part A. 2007;143A:377-381.

76. Brown LR, Miller A, Bhuptani A, et al. Pulmonary involvement with Fabry disease. Am J Respir Crit Care Med. 1997;155:1004-1010.

77. Peters FP, Sommer A, Vermeulen A, et al. Fabry’s disease: a multidisciplinary disorder. Postgrad Med J. 1997;73:710-712.

78. Rosenberg DM, Ferrans VJ, Fulmer JD, et al. Chronic airflow obstruction in Fabry’s disease. Am J Med. 1980;68:898-905.

79. Nicholson AG, Florio R, Hansell DM, et al. Pulmonary involvement by Niemann-Pick disease: a report of six cases. Histopathology. 2006;596-603.

80. Guillemot N, Troadec C, de Villemeur TB, Clement A, Fauroux B. Lung disease in Niemann-Pick disease. Pediatr Pulmonol. 2007;42:1207-1214.

81. Mendelson DS, Wasserstein MP, Desnick RJ, et al. Type B Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing. Radiology. 2006;238:339-345.

82. Uyan ZS, Karadag B, Ersu R, et al. Early pulmonary involvement in Niemann-Pick type B disease: lung lavage is not useful. Pediatr Pulmonol. 2005;40: 169-172.

83. Palmeri S, Tarugi P, Sicurelli F, et al. Lung involvement in Niemann-Pick disease type C1: improvement with bronchoalveolar lavage. Neurol Sci. 2005; 26:171-173.

84. Crocker AC, Farber S. Niemann-Pick disease: a review of eighteen patients. Medicine (Baltimore). 1958;37:1-95.

85. Minai OA, Sullivan EJ, Stoller JK. Pulmonary involvement in Niemann-Pick disease: case report and literature review. Resp Med. 2000;94:1241-1251.

86. Skikne MI, Prinsloo I, Webster I. Electron microscopy of lung in Niemann-Pick disease. J Pathol. 1972;106:119-122.

87. Niggemann B, Rebien W, Rahn W, et al. Asymptomatic pulmonary involvement in 2 children with Niemann-Pick disease type B. Respiration. 1994; 61:55-57.

88. Long RG, Lake BD, Petetit JE, et al. Adult Niemann-Pick disease: its relationship to the syndrome of the sea-blue histiocyte. Am J Med. 1977;62:627-635.

89. Nicholson AC, Wells AU, Hooper J, et al. Successful treatment of endogenous lipoid pneumonia due to Niemann-pick Type B disease with whole-lung lavage. Am J Respir Crit Care Med. 2002;165:128- 131.

90. Vellodi A, Hobbs JR, O’Donnell NM, et al. Treatment of Niemann-Pick disease type B by allogenic bone marrow transplantation. Br Med J (Clin Res Ed). 1987;295:1375-1376.

91. Terry RD, Sperry WM, Brodoff B. Adult lipidosis resembling Niemann-Pick’s disease. Am J Pathol. 1954;30:263-285.

92. Verger P, Bentegeat J, Kermarec J, Serville F. Niemann-Pick disease in a 4-year old child without nervous manifestations: considerable significance of pulmonary respiratory signs. Arch Fr Pediatr. 1965;22:1109-1110.

93. Pierson DM, Ionescu D, Qing G, et al. Pulmonary fibrosis in Hermansky-Pudlak syndrome. Respiration. 2006;73:3882-395.

94. Wei ML. Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle dysfunction. Pigment Cell Res. 2006;19:19- 42.

95. Lederer DL, Kaut SM, Sonett JR, et al. Successful bilateral lung transplantation for pulmonary fibrosis associated with Hermansky-Pudlak syndrome. J Heart Lung Transplant. 2005;24:1697- 1699.

96. Brantly M, Villia NA, Shotelersuk V, et al. Pulmonary function and high resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansky-Pudlak syndrome, due to mutations in HPS-1. Chest. 2000;117:129-136.

97. Bachli EB, Brack T, Eppler E, et al. Hermansky-Pudlak syndrome type 4 in a patient from Sri Lanka with pulmonary fibrosis. Am J Met Genet. 2004;127A: 201-207.

98. Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab. 2002;76: 234-242.

99. Reinila A. Perivascular xanthogranulomatosis in the lungs of diabetic patients. Arch Pathol Lab Med. 1976;100:542-543.

100. Muntoni S, Wiebusch H, Jansen-Rust M, et al. Prevalence of cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol. 2007;27:1866-1868.

101. Seedorf U, Wiebusch H, Muntoni S, et al. A novel variant of lysosomal acid lipase (Leu336 ? Pro) associated with acid lipase deficiency and cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol. 1995;15:773-778.

102. Muntoni S, Wiebusch H, Funke H, et al. Homozygosity for a splice junction mutation in exon 8 of the gene encoding lysosomal acid lipase in a Spanish kindred with cholesteryl ester storage disease (CESD). Hum Genet. 1995;95:491-494.

103. Pagani G, Garcia R, Pariyarath R, et al. Expression of lysosomal acid lipase mutants detected in three patients with cholesteryl ester storage disease. Hum Mol Genet. 1996;5:1611-1617.

104. Klima H, Ullrich K, Aslanidis C, et al. A splice junction mutation causes deletion of a 72-base exon from the mRNA for lysosomal acid lipase in a patient with cholesteryl ester storage disease. J Clin Invest. 1993;92:2713-2718.

105. Gasche C, Aslanidis C, Kain R, et al. A novel variant of lysosomal acid lipase in cholesteryl ester storage disease associated with mild phenotype and improvement on lovastatin. J Hepatol. 1997;27:744-750.

106. Redonnnet-Vernhet I, Chatelut M, Basile JP, Salvayre R, Levade T. A novel lysosomal acid lipase gene mutation in a patient with cholesteryl ester storage disease. Hum Mutat. 1998;11:335-336.

107. Ameis D, Brockmann G, Knoblich R, et al. A 5 splice-region mutation and a dinucleotide deletion in the lysosomal acid lipase gene in two patients with cholesteryl ester storage disease. J Lipid Res. 1995;36:241-250.

108. Elleder M, Chlumska A, Hyanek J, et al. Subclinical course of cholesteryl ester storage disease in an adult with hypercholesterolemia, accelerated atherosclerosis, and liver cancer. J Hepathol. 2000;32:528-534.

109. Michels VV, Driscoll DJ, Ferry GD, Duff DF, Beaudet AL. Pulmonary vascular obstruction associated with cholesteryl ester storage disease. J Pediatr. 1979; 94:621-623.

110. Cagle PT, Ferry GD, Beaudet AL, et al. Clinicopathologic conference: pulmonary hypertension in an 18-year old girl with cholesteryl ester storage disease (CESD). Am J Med Genet. 1986;24:711-722.

Timothy Craig Allen, MD, JD

Accepted for publication February 14, 2008.

From the Department of Pathology, The University of Texas Health Science Center at Tyler.

The author has no relevant financial interest in the products or companies described in this article.

Reprints: Timothy Craig Allen, MD, JD, Department of Pathology, The University of Texas Health Science Center at Tyler, 11937 US Hwy 271, Tyler, TX 75708 (e-mail: [email protected]).

Copyright College of American Pathologists Jul 2008

(c) 2008 Archives of Pathology & Laboratory Medicine. Provided by ProQuest Information and Learning. All rights Reserved.

Primary and Metastatic Lung Tumors in the Pediatric Population: A Review and 25-Year Experience at a Large Children’s Hospital

By Dishop, Megan K Kuruvilla, Supriya

* Context.-Primary lung neoplasms are rare in children, but they comprise a broad and interesting spectrum of lesions, some of which are familiar from other tissue sites, and some of which are unique to the pediatric lung. Objective.-To determine the relative incidence of primary and metastatic lung tumors in children and adolescents through a single-institution case series, to compare these data to reports in the medical literature, to discuss the clinical and pathologic features of primary tumors of the tracheobronchial tree and lung parenchyma in children, and to provide recommendations for handling pediatric lung cysts and tumors.

Data Sources.-A 25-year single institutional experience with pediatric lung tumors, based on surgical biopsies and resections at Texas Children’s Hospital from June 1982 to May 2007, an additional 40 lung tumors referred in consultation, and a review of the medical literature.

Conclusions.-A total of 204 pediatric lung tumors were diagnosed at our institution, including 20 primary benign lesions (9.8%), 14 primary malignant lesions (6.9%), and 170 secondary lung lesions (83.3%). The ratio of primary benign to primary malignant to secondary malignant neoplasms is 1.4:1:11.6. The common types of lung cancer in adults are exceptional occurrences in the pediatric population. The most common primary lung malignancies in children are pleuropulmonary blastoma and carcinoid tumor. Other primary pediatric lung tumors include congenital peribronchial myofibroblastic tumor and other myofibroblastic lesions, sarcomas, carcinoma, and mesothelioma. Children with primary or acquired immunodeficiency are at risk for Epstein-Barr virus-related smooth muscle tumors, lymphoma, and lymphoproliferative disorders. Metastatic lung tumors are relatively common in children and also comprise a spectrum of neoplasia distinct from the adult population.

(Arch Pathol Lab Med. 2008;132:1079-1103)

Primary lung neoplasms are rare in children. Lung masses in children are approximately 10 times more likely to represent a benign developmental or reactive lesion than a neoplasm, with a ratio of primary tumors to metastatic tumors to nonneoplastic lesions of 1:5:60.1 Common malformations forming solid and cystic masses of the pediatric lung include bronchogenic cyst, segmental bronchial atresia, intralobar and extralobar pulmonary sequestration, congenital pulmonary airway malformation (congenital cystic adenomatoid malformation), and congenital lobar overinflation. The vast majority of solid parenchymal lung masses in children represent inflammatory, infectious, or reactive processes, with a differential diagnosis, including granulomatous inflammation (fungal, mycobacterial, parasitic, sarcoidosis, vasculitis); abscess; pneumonia (bacterial, viral); septic embolus; infarction; or hematoma. 2 Of the lung neoplasms in children, metastatic tumors far exceed the number of primary lesions. Of the primary lung tumors in children reported in the literature, malignancies exceed the number of benign neoplasms, with a ratio of approximately 3:1.3 The most common benign tumor of the pediatric lung is inflammatory myofibroblastic tumor (52%), and the most common primary malignancies are carcinoid tumor and pleuropulmonary blastoma.3 Based on German registry data, malignant tumors of the trachea, bronchus, and lungs represent 0.2% of all malignancies in children.4 The mortality rate for primary benign lung neoplasms in children is low (8.7%), and the mortality rate for primary malignant tumors is approximately 30% overall. Excluding the “bronchial adenomas,” which are associated with a favorable prognosis, the mortality rate of the malignant tumors rises to approximately 50%.3

Given the rarity of primary lung neoplasms in children, clinical detection remains a challenge. Some cases are asymptomatic and detected only incidentally on imaging studies. Other nonspecific respiratory symptoms may be attributed initially to asthma or other inflammatory processes, resulting in a delay of diagnosis until only after symptoms persist or are unresponsive to conventional therapy. Even if a mass is recognized, endobronchial lesions and cystic parenchymal lesions may be radiographically indistinguishable from reactive processes or lung malformations. The possibility of a lung neoplasm should be considered clinically in any child presenting with wheezing, persistent cough, hemoptysis, or recurrent pneumonia. Regardless of the clinical working diagnoses, the pathologist should remain vigilant to the possibility of a primary lung neoplasm in a child, particularly in assessing cystic lung lesions.

Several clinical reviews of pediatric lung neoplasms are available.1,3-12 Pathologic features of pediatric lung neoplasms have also been reviewed previously by Dehner almost 20 years ago.13 The objectives of this review are (1) to provide additional relative incidence data for both primary and metastatic lung neoplasms from a single large institutional experience, (2) to provide an update on our current understanding of pathologic features and diagnostic terminology for these rare tumors, and (3) to provide recommendations for the practicing surgical pathologist on handling cystic and/or solid masses of the pediatric lung.

TEXAS CHILDREN’S HOSPITAL EXPERIENCE: 25 YEARS OF PRIMARY AND METASTATIC LUNG TUMORS

Incidence data on primary lung tumors in children are limited in the medical literature due to the predominance of individual case reports and diagnosis-specific case series. As a result, cumulative historical data from literature reviews are difficult to interpret due to an uneven representation of these rare lesions and significant differences in diagnostic criteria and terminology, which have evolved during the decades typically encompassed by such reviews. For example, bronchogenic carcinoma has been reported to occur with some frequency in other reviews of pediatric lung tumors, but it appears to be overrepresented in the literature relative to current experience. Other than the low-grade neuroendocrine carcinomas (carcinoid tumors), primary lung carcinoma is vanishingly rare and a reportable occurrence in children. Table 1 presents a classification of pediatric lung neoplasms according to histogenesis, adapted from Tischer et al.4 A previous review of 465 pediatric lung specimens from a single institution (a 250-bed children’s hospital in Cape Town, South Africa) during a 31-year period revealed a total of 8 primary lung tumors (6 originating at this institution and 2 reviewed in consultation) and 35 metastatic tumors.1 Primary lung tumors in this series included 50% malignant and 50% benign lesions: plasma cell granuloma (3), pleuropulmonary blastoma (2), mucoepidermoid carcinoma (1), endobronchial fibrosarcoma (1), and capillary hemangioma (1). Metastatic tumors included Wilms tumor (16), osteosarcoma (9), rhabdomyosarcoma (5), neuroblastoma (4), and hepatoblastoma (1).1

In an attempt to provide additional relative incidence data, a similar review of the experience at Texas Children’s Hospital (Houston) was performed for a 25-year period (June 1982-May 2007). Texas Children’s Hospital is a large tertiary care center with 639 licensed hospital beds, including a 36-bed inpatient hematology- oncology unit and a 15-bed bone marrow transplant unit. The Texas Children’s Cancer Center receives approximately 25 000 outpatient visits annually. Based on registry data from 2000 to 2004, an average of 289 children were diagnosed with malignancies annually at our institution, including 91 new solid tumor diagnoses per year. Primary and metastatic lung lesions were identified by performing a natural language search of the anatomic pathology information system for the dates specified, using terms for site (lung, trachea, bronchus, bronchial, pleura); general descriptors (cancer, tumor, neoplasm, benign, malignant, malignancy, mass, nodule, metastatic, juvenile, infantile); and specific tumor types (carcinoma, blastoma, sarcoma, lymphoma, hamartoma, adenoma, pleuropulmonary, lymphoproliferative, Hodgkin/Hodgkin’s, leukemia, Wilms, neuroblastoma, hepatoblastoma, osteosarcoma, rhabdomyosarcoma, fibrosarcoma, chondrosarcoma, leiomyoma, leiomyosarcoma, liposarcoma, lipoblastoma, glioblastoma, clear cell, neuroendocrine, carcinoid, melanoma, myofibroblastic, adenocarcinoma, histiocytosis, mesothelioma, Kaposi/Kaposi’s, granular cell tumor/myoblastoma, and papilloma/papillomatosis). Patients with juvenile respiratory papillomatosis were included if the excised squamous papillomas were specifically designated from tracheal, bronchial, or pulmonary sites. Other patients with papillomas excised only from the larynx/ vocal cords, oropharynx, nasopharynx, esophagus, and/or other sites not specified were excluded from tabulation.

During this 25-year period, the total number of surgical pathology specimens was 227 655, with annual specimen numbers ranging from 5309 in 1982 to 14 055 in 2006. We received a total of 3980 surgical specimens designated from the trachea, bronchus, or lung (1.7%), including both biopsies and resections. Of these, 507 specimens were from lung transplant recipients (12.7%), and 3473 were from other patients (87.3%). There were 273 biopsy and resection specimens for primary or metastatic neoplasms of the lung, representing 6.9% of all tracheobronchial and lung specimens. Pathologic slides were examined for the primary benign and malignant tumors to ensure accuracy of diagnosis. Among these, 1 “mesenchymoma” was reclassified as lipoblastoma, and 2 cases of “spindle cell sarcoma” included one with myofibroblastic differentiation and another subclassified as a fibrosarcoma. The spectrum of tracheobronchial or lung parenchymal tumor diagnoses is summarized in Table 2, including the number of individual patients and age distribution for each lesion. Of these lung tumors, 34 (16.7%) were primary lung tumors, and 170 (83.3%) reflected metastatic disease or secondary involvement by a hematolymphoid or histiocytic process. Of the primary tumors, 20 (59%) were benign, and 14 (41%) were malignant. During this 25-year period, the average annual incidence of new primary lung malignancies (n = 14) in our pediatric population was 0.56 per year. Based on this average annual incidence of lung malignancies and the recent average annual incidence of all new malignancies (289 per year) at our institution, we estimate that primary pediatric lung malignancies account for 0.19% of all new pediatric malignancies diagnosed annually.

The ratio of primary benign to primary malignant to secondary (metastatic) malignant tumors was 20:14:162 (or 1.4:1:11.6), indicating that excisions for metastatic tumors were almost 12 times more common than primary malignant tumors. The most common benign lesions were squamous papillomas associated with human papilloma virus infection (juvenile respiratory papillomatosis), inflammatory myofibroblastic tumor, and Epstein-Barr virus (EBV)-associated smooth muscle tumors. The 8 patients with respiratory papillomas often had multiple surgical procedures, ranging from 1 to 5 excisions and averaging 2.9 per patient. The most common primary malignancies of the lung were pleuropulmonary blastoma (57.1%) and carcinoid tumor (14.3%). Pleuropulmonary blastoma accounted for 72% (8/11) of parenchymal malignancies, and carcinoid tumor accounted for 67% (2/3) of tracheobronchial malignancies. One mucoepidermoid carcinoma and one type I pleuropulmonary blastoma have been reported previously in the medical literature.14,15 In our patient population, Wilms tumor and osteosarcoma were the 2 most common solid tumor diagnoses leading to surgical excision of metastatic lung disease, accounting for 31.2% and 20.3% of these patients, respectively. Due to the role of surgical oncologic management for metastatic osteosarcoma, it should be noted that the 28 patients with osteosarcoma had a total of 57 thoracic surgeries for excision of metastases, ranging from 1 to 6 surgeries per patient.

Consultation cases referred from other institutions were also reviewed during a similar time period and were tabulated separately from institutional cases (Table 3). These tumors included the following additional diagnoses not represented in our institutional data set: congenital peribronchial myofibroblastic tumor, synovial sarcoma, solitary fibrous tumor, bronchioloalveolar carcinoma, and pleuropulmonary blastoma type II, as well as Burkitt lymphoma and metastatic juvenile secretory breast carcinoma. A summary of the data is also provided in comparison to prior literature review (Table 4).

Clinical and pathologic features of these and other pediatric lung tumors reported in the medical literature are reviewed below, beginning with tracheobronchial lesions and followed by specific benign and malignant parenchymal lesions.

TRACHEOBRONCHIAL MASSES IN CHILDREN

Juvenile Respiratory Papillomatosis

Respiratory papillomatosis is caused by human papillomavirus infection, typically acquired during delivery, and results in multiple recurrent squamous papillomas (Figure 1, A and B), most often of the larynx and trachea but also involving the distal bronchial tree and esophagus in some cases, especially after longstanding duration of disease. Their clinicopathologic features are distinctive, and there is little difficulty in the differential diagnosis with other types of neoplasms. Spread into the lung parenchyma occurs rarely (Figure 1, C and D), and may produce solid nodules or cystic air-filled cavities.2 Malignant transformation to squamous cell carcinoma has been reported, in some cases related to prior radiation therapy, and is distinguished by marked cellular pleomorphism and atypia, loss of maturation, dyskeratosis, and invasion into the bronchial wall or lymphatic channels. Treatment for squamous papillomas may include surgical excision, CO2 laser vaporization, and/or adjuvant antiviral or interferon therapy.10

Hamartoma

Hamartomas contain disorganized tissues intrinsic to the lung and show peak incidence in the fourth to sixth decades.7 They are typically lobulated and encapsulated masses, which may be endobronchial or intraparenchymal. They are rare in children, but they may present as large parenchymal masses with respiratory distress. Chest computed tomography classically shows fat and “popcorn” calcifications, which suggest the diagnosis. Microscopically, cartilage, fat, and fibrous tissue are typically the most prominent components, although smooth muscle, bone, and entrapped respiratory epithelium also may be seen. Tumors with a single dominant component may be diagnosed as a chondroma, fibroma, or lipoma, although careful search may demonstrate foci of other mesenchymal elements.

Chondroma

Chondromas are benign cartilaginous tumors that occur as single or multiple encapsulated lesions that arise in continuity with bronchial cartilage and do not have other mesenchymal elements, as in the hamartomas described above (Figure 1, E). Pulmonary chondromas have been described in the Carney triad, a syndrome almost exclusively seen in young females comprising functioning paraganglioma, epithelioid gastrointestinal stromal tumor, and pulmonary chondroma.16,17 Due to potential complications of the associated lesions, children with pulmonary chondroma may benefit from periodic screening for metachronous development of paragangliomas or gastrointestinal stromal tumors.

Other Benign Tracheobronchial Lesions

Other benign tracheobronchial tumors reported in children include leiomyoma, granular cell tumor, and mucous gland adenoma. Primary solitary leiomyomas are benign smooth muscle tumors, histologically similar to leiomyomas in other locations, which may be asymptomatic or present as endobronchial masses with obstruction. Leiomyomas associated with EBV infection are discussed below. Multiple fibroleiomyomatous hamartomas (benign metastasizing leiomyomas) have been described in a child with a history of rhabdomyosarcoma.18 Bronchial granular cell tumors are reported rarely and have histologic features similar to those described in the oral cavity, comprising sheets of round cells with small nuclei and abundant granular eosinophilic cytoplasm. 7,9,19-21 The term bronchial adenoma is a misnomer previously used to refer collectively to 4 distinct lesions (carcinoid tumor, mucoepidermoid carcinoma, adenoid cystic carcinoma, and mucous gland adenoma). Bronchial mucous gland adenoma is the only benign lesion among these, and only 2 cases were described in a literature review up to 1983.7 Histologically, mucous gland adenomas are composed of a well-circumscribed mass of distended mucus-filled cysts and tubules lined by a single layer of columnar goblet cells. The differential diagnosis of endobronchial masses in children also includes reactive vascular lesions, including granulation tissue and pyogenic granuloma, chronic foreign body reaction, and granulomatous inflammation, for example, due to histoplasmosis or mycobacteria.10

Carcinoid Tumor

Carcinoid tumors are considered low-grade neuroendocrine carcinomas due to their potential for locally aggressive growth and low potential for metastasis. These lesions are typically obstructive endobronchial masses of older children and adolescents (Figure 1, F), presenting with symptoms of wheezing, cough, hemoptysis, or pneumonia. 6,7,9,22-24 The carcinoid syndrome caused by production of neurosecretory peptides is very rare in the absence of metastatic disease. Carcinoid tumors have been reported to account for up to 80% to 85% of primary malignant lung tumors in children, although this is likely an overestimate. They may arise from the lobar bronchi (75%), mainstem bronchi (10%), or within the lung parenchyma (15%).6 Microscopic features include sheets, nests, and cords of monotonous small cells with stippled nuclear chromatin and a delicate vascular network in the background (Figure 1, G). Treatment is primarily surgical, and endoscopic resection is not recommended due to risk of hemorrhage and incomplete resection. Depending on location and size, complete excision and removal of involved lymphatics may be achieved with bronchial sleeve resection, lobectomy, or even pneumonectomy. Local invasion or distant metastasis has been reported in a significant percentage of children (27%), and overall survival in children is approximately 90%.6,9

Mucoepidermoid Carcinoma

Mucoepidermoid carcinoma (MEC) is reported to represent approximately 10% of malignant lung neoplasms in children. This tumor is rare in children, with just more than 30 cases of tracheobronchial MEC reported in the medical literature. Similar to carcinoid tumors, presenting symptoms may include recurrent pneumonia, respiratory distress, persistent cough, wheezing, or hemoptysis. Mucoepidermoid carcinoma arises in the tracheobronchial tree from the salivary-type mucous cells of the submucosa, most commonly occurring in the mainstem bronchus or a proximal lobar bronchus. These tumors are typically exophytic polypoid masses that cause bronchial obstruction (80% of cases).14,23,24 Grading of MEC in the tracheobronchial tree is similar to that in other salivary gland sites and is divided into low-, intermediate-, and high-grade tumors. Low-grade MEC is composed of predominantly mucous cells arranged in large cystic spaces, and it is the most common type described in the tracheobronchial tree in children.9 Intermediate- grade MEC is composed of predominantly intermediate cells and occasional mucous cells, forming a solid pattern with infrequent cysts and glands (Figure 1, H and I). High-grade MEC contains predominantly epidermoid cells and infrequent intermediate cells arranged in solid sheets, and it is characterized by increased pleomorphism and high mitotic activity. The low-grade tumors tend to have local tissue invasion but only rare metastasis.14 Treatment is primarily surgical, with chemotherapy and radiotherapy reserved for those tumors with incomplete resection.25 The 5-year survival rate of adults with MEC is 88%.25 The prognosis in children appears to be more favorable, with no deaths reported in the literature after surgical resection alone. Adenoid Cystic Carcinoma

Adenoid cystic carcinoma is a slowly growing infiltrative salivary gland-type neoplasm that is rare in the tracheobronchial tree. Histologic features are similar to those seen in the salivary glands, consisting of cribriform, glandular, and solid patterns of small hyperchromatic cells. There is a tendency for submucosal spread, circumferential bronchial involvement, and late local recurrence. At the time of literature review in 1983, only 4 cases were reported in children.7 Treatment is complete surgical excision with or without adjuvant radiation therapy.25 Due to the infiltrative nature and tendency for local recurrence, frozen section examination may be helpful in assuring negative bronchial margins at the time of surgery. Adenoid cystic carcinoma has a higher likelihood of distant metastasis compared with mucoepidermoid carcinoma and has poorer survival (55% 5-year survival).25

MYOFIBROBLASTIC TUMORS

Inflammatory Myofibroblastic Tumor

Previously called inflammatory pseudotumor or plasma cell granuloma, inflammatory myofibroblastic tumor is a slowgrowing tumor which shows characteristics of both reactive and neoplastic lesions.26-28 Although theorized to result from a repair response, antecedent injury cannot be documented in most cases. Although many tumors are asymptomatic (30%), others present with symptoms of cough or fever. Excluding respiratory papillomatosis, it is estimated that inflammatory myofibroblastic tumor accounts for approximately 52% to 70% of benign primary lung tumors reported in the literature in children.3,14 Most children with pulmonary inflammatory myofibroblastic tumor are older than 5 years (75%), but cases involving a few infants and young children are reported, and there is an equivalent sex distribution.7 Chest x-ray typically demonstrates a solitary well-circumscribed nodule, ranging in size from 1 to 12 cm. Grossly, these nodular lesions may be either endobronchial (17%; Figure 2, A) or intraparenchymal (83%).3,7 Histologic features include a proliferation of bland spindled and stellate cells with abundant eosinophilic cytoplasm, admixed with scattered inflammatory cells, including lymphocytes and, occasionally, prominent plasma cells and eosinophils (Figure 2, B). Immunohistochemistry for smooth muscle actin and/or muscle-specific actin may be helpful in demonstrating the myofibroblastic nature of these cells. Treatment is primarily surgical, and complete but conservative surgical excision is recommended. Inflammatory myofibroblastic tumors have a tendency for local recurrence if incompletely excised.

Myofibromatosis

Myofibromas are relatively common benign soft tissue tumors in children, most often presenting as a firm nodular mass in the subcutaneous or deep soft tissue. Although most often solitary, they may be multifocal and involve both soft tissue and visceral organs, so-called myofibromatosis (Figure 2, C). Myofibromatosis is more often diagnosed in infants and young children than in older children. The cellularity of these lesions varies, often showing some hypocellular hyalinized zones as well as other zones of hypercellularity. Characteristic protrusion of bland spindled cells into adjacent vasculature is occasionally seen and should not be interpreted as an aggressive feature. Hemangiopericytomatous vasculature may be prominent. Pulmonary involvement by myofibromatosis may be a manifestation of multifocal systemic disease or regional involvement of the chest wall. Multifocality in the lung should not be misinterpreted as aggressive or metastatic disease.

Congenital Peribronchial Myofibroblastic Tumor

Congenital peribronchial myofibroblastic tumor is a very rare and distinctive benign lung tumor of the fetus and infant, with only approximately 25 cases reported previously in the medical literature.29-33 It has been described under various terminology, including massive congenital mesenchymal malformation of the lung, hamartoma of the lung, bronchopulmonary leiomyosarcoma, and primary bronchopulmonary fibrosarcoma.29 The tumor is thought to arise from the pluripotent mesenchyme found around the developing bronchi at approximately 12 weeks’ gestation, with potential for both smooth muscle and cartilaginous differentiation. Interestingly, congenital peribronchial myofibroblastic tumor is morphologically similar to 2 other types of myofibroblastic tumors presenting in the neonatal period: congenital mesoblastic nephroma (classic type) and congenital spindle cell tumor of the intestinal tract. Congenital peribronchial myofibroblastic tumor typically presents in utero or at birth as a large 5- to 7-cm unilateral lung mass with mediastinal shift and resulting in intrauterine polyhydramnios, hydrops, or immediate respiratory failure at delivery. Grossly, nearly the entire lung or a large portion of the lung is typically enlarged and replaced by a firm rubbery mass with a yellow-tan to gray whorled cut surface containing bands of fibrous-appearing tissue (Figure 2, D). Microscopically, bland spindled cells form large fascicles following the planes of the bronchovascular bundles, interlobular septa, and pleura, often forming a distinctive lobular compartmentalization of the lung parenchyma (Figure 2, E). The tumor fascicles are extrinsic to the airways but surround, displace, and distort the airway structures. Malformed and enlarged cartilage plates adjacent to entrapped airways are a prominent component of some tumors. Occasional foci of extramedullary hematopoiesis may be seen. Mitotic figures may be frequent, but there is no cytologic atypia or atypical mitoses. The lesion tends to be more uniform in cellularity, in contrast to other myofibroblastic tumors. Immunohistochemistry shows diffuse positivity for vimentin and focal desmin, muscle-specific actin, or smooth muscle actin positivity.30,32 Flow cytometric DNA ploidy analysis has shown a normal diploid population.32 Cytogenetic study in 1 case has shown a complex rearrangement of chromosomes 4, 8, and 10.30 Electron microscopy shows spindled cells with dilated rough endoplasmic reticulum, scarce mitochondria, occasional lipid droplets, and scant cytoplasmic filaments, some with dense bodies and attachment plaques, consistent with myofibroblastic differentiation. 29,30,32 Although the lesion is cytologically bland, the large size often results in respiratory or hemodynamic compromise and has resulted in a high mortality rate in reported cases (55% in 1 series).32 If early resection is achieved, typically by pneumonectomy or bilobectomy, long-term survival is expected.30

NEUROGENIC TUMORS

Neurogenic tumors of the lung may include neurofibroma, schwannoma, malignant peripheral nerve sheath tumors, and mucosal neuromas. A series of intrapulmonary neurogenic tumors has shown 26% (9/34) occurring in children younger than 16 years.34 Of these 9 tumors in children, all were benign, including 4 neurofibromas and 5 schwannomas. Although most pulmonary neurofibromas are nonsyndromic, the possibility of neurofibromatosis should always be considered in a child with a pulmonary neurofibroma.

VASCULAR LESIONS

Hemangiomas

Infantile hemangioma is a lobular proliferation of small capillaries that typically appears in the first weeks of life and shows a period of involution during the ensuing months (Figure 3, A). The early proliferating lesions may be highly cellular and mitotically active, whereas involuting lesions have less capillary density with more widely spaced and dilated thick-walled capillaries. Both proliferative and involuting lesions are characterized by endothelial positivity for the glucose transporter Glut-1 (Figure 3, B), a marker that distinguishes the infantile hemangioma from most other vascular anomalies, including rapidly involuting and noninvoluting congenital hemangiomas, vascular malformations, and pyogenic granulomas. While infantile hemangiomas are most commonly found in the skin and soft tissue, visceral involvement also occurs, both as isolated lesions and as a component of multifocal systemic distribution of disease (hemangiomatosis).35 Tracheobronchial and parenchymal hemangiomas are identified occasionally due to symptoms of obstruction or recurrent hemoptysis.1,10 Lesions of the subglottis and upper trachea are more common than the distal tracheal or endobronchial lesions.10 Intraparenchymal hemangiomas are very rare, but may be a component of multifocal systemic lesions in diffuse neonatal hemangiomatosis.

It should be noted that pulmonary capillary hemangiomatosis is a different entity than the multifocal infantile hemangiomas of diffuse neonatal hemangiomatosis. Pulmonary capillary hemangiomatosis is a rare, poorly defined lesion associated with pulmonary hypertension and composed of a diffuse proliferation of capillaries within the alveolar walls without formation of a mass lesion.36,37 Primarily seen in adults, pulmonary capillary hemangiomatosis has been associated with pulmonary veno-occlusive disease in some cases, and it may represent a postobstructive reactive proliferation of capillaries distal to thrombosis. Lymphatic Malformations and Lymphangiomatosis

Although lymphatic malformations are common lesions in infants and young children, solitary lymphatic malformations (lymphangiomas) occur rarely in the lung, forming localized multicystic masses (Figure 3, C). In contrast, lymphangiomatosis is a proliferation of lymphatic channels involving the lung more diffusely, typically in a septal and pleural pattern of distribution. Secondary hemorrhage and muscularization of the lymphatic channels in lymphatic malformations may produce confusion with a venous malformation, and the lymphatic marker D2-40 is helpful in confirming the lymphatic origin of the vessels.

Vascular Malformations

Like hemangiomas and lymphatic malformations, venous or mixed vascular malformations may produce mass lesions in the lung parenchyma. Arteriovenous malformations may be multiple and produce right-to-left shunting, resulting in high-output cardiac failure and cyanosis. They are more often diagnosed by imaging techniques and are diagnosed uncommonly in surgical pathology specimens (Figure 3, D and E). The presence of multiple arteriovenous malformations should raise consideration of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome).

OTHER BENIGN PARENCHYMAL TUMORS

Teratomas within the lung parenchyma are reported as isolated cases, including only 2 case reports before 1983.7,39-41 Pericardial or anterior mediastinal teratomas are more common, and they may show secondary involvement of the adjacent lung parenchyma by direct extension. Primary teratomas of the lung are typically large cystic and solid masses confined to the lung parenchyma, and most contain derivatives of all 3 germ cell layers. Primary malignant germ cell tumors of the lung are exceedingly rare, although choriocarcinoma has been reported.

Lipoblastoma is a benign tumor of adipose tissue typically characterized by an admixture of immature lipoblast in a vascular myxoid matrix, juxtaposed with zones of mature adipose tissue. Lipoblastomas occur most often in the soft tissue of infants and young children, but they may also involve the viscera, including the lung (Figure 4, A).

Ectopic tissues occasionally form nodular lesions of the lung. Rhabdomyomatous dysplasia is a rare entity composed of benign skeletal muscle cells within the lung parenchyma, most often seen incidentally within lung malformations, such as extralobar sequestration. Rarely, rhabdomyomatous dysplasia forms a nodular focus of skeletal muscle cells in otherwise normal lung (Figure 4, B and C). Ectopic adrenal gland tissue and ectopic glial tissue have also been reported as nodular lesions in the lung.38

PLEUROPULMONARY BLASTOMA

Pleuropulmonary blastoma (PPB) is a rare malignant embryonal mesenchymal neoplasm of the lung and pleura occurring almost exclusively in children that was described as a unique entity distinct from pulmonary blastoma in 1988.42 In contrast to the adult- type biphasic pulmonary blastoma (PB), PPB is a polyphenotypic mesenchymal malignancy without an epithelial component. It has been reported previously in the medical literature under a variety of descriptors, including pulmonary blastoma, mesenchymal cystic hamartoma, malignant mesenchymoma, and sarcomas (myxosarcoma or rhabdomyosarcoma) arising in congenital cystic malformations.43-47 Pleuropulmonary blastoma is diagnosed primarily in infants and toddlers, and rarely beyond age 12 years. Occurrence in adults is reported but extremely rare.48 These lesions may be detected incidentally in utero or postnatally. 15 Symptomatic presentation may result from spontaneous pneumothorax in the cystic lesions.49

Pleuropulmonary blastoma is subclassifed based on the spectrum of gross morphology: purely cystic lesions (type I), solid and cystic lesions (type II), and purely solid lesions (type III).49 Age at presentation varies depending on morphologic type, with the type I lesions most often diagnosed in infancy (average age, 10 months), and the type II and type III lesions more often diagnosed in toddlers (average ages, 34 and 44 months, respectively).50,51 Grossly, the low-grade cystic lesions (type I) are typically peripheral and pleural-based lesions, sometimes protruding from the pleural surface (Figure 5, A). They are entirely cystic, with no solid components or nodules and are grossly indistinguishable from the large-cyst (Stocker type I) congenital pulmonary airway malformation (CPAM). Microscopically, they are virtually identical to what has been described as the peripheral cyst (Stocker type IV) CPAM. Type I PPBs have thin cyst walls lined by predominantly alveolar-type epithelium and containing focal areas of hypercellularity and hypervascularity (Figure 5, B and C). The hypercellular foci are composed of hyperchromatic compact spindled cells and small round cells, often forming a cambium-like layer beneath the epithelium lining the cyst walls. Foci of immature- appearing cartilage are present in some cases. The higher grade lesions (type II and type III) have solid components on gross examination. Although entirely solid, the type III PPB may have areas of necrosis and cystic degeneration. The solid components of both type II PPB (Figure 5, D) and type III PPB (Figure 5, E through H) also show higher grade cytologic features, with sheets of spindled and pleomorphic, sometimes anaplastic cells, resembling rhabdomyosarcoma. Fibrosarcoma-like areas and chondroid nodules are other recognized patterns. It should be noted that type I lesions may progress to the higher grade type II or type III lesions, particularly if incompletely excised.

Immunohistochemistry of PPB demonstrates vimentin in the primitive cell component, as well as myogenic differentiation in some cases, specifically with expression of desmin, muscle specific actin, smooth muscle actin, myogenin, and/or myoglobin. Electron microscopy may also show evidence of rhabdomyoblast differentiation with myofibrils and z-band formation, as well as loose granular matrix and abundant rough endoplasmic reticulum, indicating chondrocytic differentiation.49,50 Cytogenetic analysis of PPB has been described in a small number of cases, primarily of higher grade lesions. Although a tumor-specific translocation has not been identified, there may be a variety of karyotypic abnormalities (trisomy 8, trisomy 2, and 17p deletions), and mutations in p53 have been described. 52-54

Pleuropulmonary blastoma may be solitary or multiple, and additional lesions may be discovered synchronously or metachronously in the same patient. Interestingly, PPB may have familial predisposition, and genetic studies are ongoing through the International Pleuropulmonary Blastoma Registry.55 In approximately 25% of cases, PPB is associated with other extrapulmonary lesions in the same patient or family members.49 The most common associated lesion is cystic nephroma, but other embryonal tumors (sarcomas, medulloblastoma, malignant germ cell tumors), thyroid neoplasms, leukemia, Hodgkin lymphoma, and Langerhans cell histiocytosis (LCH) have been associated with PPB.56

Clinically, the diagnosis of PPB is infrequently entertained preoperatively.15 Pathologists must consider the diagnosis of PPB for any child with a spherical unilocular or multiloculated cystic lesion, mixed solid and cystic lesion, or large solid mass in the lung, particularly if the lesion distorts the contour of the lung, is positioned peripherally, or is found to protrude from the pleural surface. The differential diagnosis includes the more common benign cystic lung malformations, as well as other rare primary sarcomas of the lung. The most common submitting diagnosis and the principal pathologic differential diagnosis for cystic type I PPB is CPAM (also called congenital cystic adenomatoid malformation [CCAM]).57 The large-cyst (Stocker type I) CPAM and the peripheral cyst type (Stocker type IV) CPAM are grossly identical to cystic PPB. The large-cyst CPAM is distinguished easily microscopically by a cyst lining composed predominantly of respiratory type epithelium, with or without focal mucigenic epithelium, often resembling small foci of gastric foveolar epithelium. The respiratory epithelial lining shows interdigitation with surrounding airspaces, which may be secondarily enlarged and maldeveloped. The peripheral cyst (Stocker type IV) CPAM is much more problematic to distinguish from cystic PPB and, in fact, it has been suggested that many examples of type IV CPAM may actually represent unrecognized or insufficiently sampled cystic PPBs.58,59 Stocker describes CPAM type IV as having thin cyst walls lined by alveolar-type epithelium and with increased vascularity of the septa. Cystic PPB has a similar architecture, but it is distinguished by the identification of hypervascular and hypercellular foci of primitive cells in the cyst walls, a focal and subtle finding in many cases due to the low-grade cytology. Any lesion mimicking type IV CPAM on initial microscopic sections requires extensive sampling to exclude the presence of these hypercellular foci. The differential diagnosis of the solid and cystic or purely solid lesions includes other primary sarcomas of the lung, including rhabdomyosarcoma and synovial sarcoma. Some cases initially reported as rhabdomyosarcoma of the lung likely represent highgrade PPB.49,60 The lesion described in the literature as “mesenchymal hamartoma of the lung” in children is also more appropriately classified as PPB.61,62 Finally, as mentioned above, PPB should be distinguished from the rare adult-type PB, a tumor most often presenting in the fourth or fifth decade of life, which has an associated epithelial component not present in the childhood lesion.63,64 Entrapment of alveolar or bronchiolar epithelium by PPB may also mimic PB. In the pediatric population, a sarcomatous lesion with a glandular-appearing epithelial component mimicking biphasic PB should prompt consideration of synovial sarcoma. Treatment for PPB is primarily surgical for the cystic (type I) lesions, although adjuvant chemotherapy may be advantageous in cases with incomplete resection. Certainly, the higher grade (type II and type III) lesions require adjuvant chemotherapy after resection, and radiation therapy is recommended for residual disease. In either case, close clinical follow-up is warranted due to potential for recurrence, metastasis, multifocality, and associated extrapulmonary lesions. Low-grade cystic lesions may recur as a higher grade lesion, and this potential justifies chemotherapy for some type I tumors. Metastasis occurs in approximately 30% of types II and III tumors, and may occur late in the disease course. The most commonly reported sites of metastasis include the central nervous system and bone.50 Five-year survival rate is 83% for type I PPB and 42% for types II and III PPB.50

PRIMARY SARCOMAS

Synovial Sarcoma

Although rare, synovial sarcoma is one of the more common primary sarcomas of the lung in children. Diagnostic features are similar to those seen in other sites, and morphology may be monophasic or biphasic (Figure 6, A and B). Immunohistochemistry for cytokeratin, epithelial membrane antigen, CD99, and BCL2 are typically positive. Cytogenetic analysis and/or molecular diagnostic testing is helpful in demonstrating the characteristic t(X;18) translocation, producing an SSX-SYT fusion transcript.

Ewing Sarcoma Family of Tumors

The Ewing sarcoma family of tumors includes Ewing sarcoma of bone and soft tissue, as well as peripheral primitive neuroectodermal tumor. These tumors are unified by the rearrangement of the Ewing sarcoma gene with one of a variety of fusion partner genes, most commonly Fli-1, produced by a characteristic t(11;22)(q24 ; q12) translocation. By immunohistochemistry, the Ewing sarcoma family of tumors characteristically demonstrates membranous staining with CD99, an important diagnostic feature in clinical practice. In addition, primitive neuroectodermal tumors show evidence of neural differentiation, either by immunohistochemistry or electron microscopy. On a practical level, distinguishing primitive neuroectodermal tumor from Ewing sarcoma is unnecessary, as treatment is the same for both, and there is conflicting evidence for any prognostic difference between primitive neuroectodermal tumor and Ewing sarcoma. Although the Ewing sarcoma family of tumors may occur anywhere in the body, including soft tissue, bone, and viscera, the chest wall is one site of predilection, so-called Askin tumor of the thoracopulmonary region. Chest wall involvement may result in a mass with intrathoracic growth, lytic destruction, and fusiform expansion of ribs, cortical thickening, little or no periosteal reaction, and pleural effusion. 8 Involvement of the pleural cavity with extension into the lung parenchyma is not uncommon and may lead to partial resection of lung with chest wall resection. Rarely, these tumors may arise primarily in the lung, but they most often originate in the rib or chest wall.

Rhabdomyosarcoma

While several cases of pulmonary rhabdomyosarcoma reported in the literature likely actually represent cases of pleuropulmonary blastoma, true primary rhabdomyosarcoma of the lung also occurs, often manifesting as an endobronchial mass.7,65,66 Pulmonary rhabdomyosarcoma is estimated to represent approximately 0.5% of all rhabdomyosarcomas in children.3 After Ewing sarcoma family of tumors, rhabdomyosarcoma is the second most common malignancy of the chest wall in children, and it may produce direct involvement of the thoracic cavity or pulmonary metastasis in this setting.8

Leiomyosarcoma

A few cases of bronchopulmonary leiomyosarcoma have been reported in children.67-71 Rare cases in newborns may, in fact, represent congenital myofibroblastic tumor, rather than true leiomyosarcoma.67 Potentially arising from either bronchial or vascular smooth muscle, these lesions may be located in the tracheobronchial tree or in the parenchyma. Leiomyosarcoma in older children may show aggressive local invasion, metastasis, and poor prognosis. Nuclear atypia, necrosis, and hemorrhage distinguish leiomyosarcoma from both leiomyomas and the myofibroblastic tumors. Epstein-Barr virus is associated with some lesions in the immunocompromised population (see below).

Bronchopulmonary Fibrosarcoma

Primary bronchial fibrosarcoma in children is considered to be the equivalent of congenital infantile fibrosarcoma of soft tissues. It is quite rare, with 26 cases reported in the literature to 1989.1 Grossly, bronchopulmonary fibrosarcoma may form an endobronchial polyp or intraparenchymal mass. Histologically, it is composed of cellular sheets and interlacing bundles of spindle cells, often with focal hemorrhage. The mortality associated with bronchopulmonary fibrosarcoma is 21%, with metastatic disease reported in 2 of 26 cases.72

Other Sarcomas

A number of other types of sarcomas have been reported as primary lung neoplasms in children, including angiosarcoma, Kaposi sarcoma, malignant peripheral nerve sheath tumor, and liposarcoma.73 The spectrum of pulmonary and thoracic sarcomas has been reviewed elsewhere. 74,75

BRONCHOGENIC CARCINOMA

Bronchogenic carcinoma is most common in adults 55 to 75 years of age, and it is rare in individuals younger than 40 years, accounting for 1.2% of all patients with lung cancer.76-88 Patients 18 to 30 years old diagnosed with lung cancer have a higher incidence of female sex, no association with smoking history, and more favorable prognosis.89 Survival in these young patients is associated primarily with stage, but it is not dependent on sex, age younger or older than 30 years, smoking history, histologic type, or degree of differentiation.90 Lung cancer in children and adolescents younger than 18 years is extremely rare, with 0.16% of all lung cancers occurring in the first decade of life and 0.7% in the second decade.91 As of 1983, a review of the medical literature included 47 children reported to have “bronchogenic carcinoma,” representing approximately 17% of reported primary lung malignancies in children. 3,7 Almost certainly an overestimate of true incidence, this percentage appears to be inflated by cases in the older medical literature. The actual incidence of bronchogenic carcinoma in children is difficult to determine and is limited to individual case reports and small case series in the modern era.92 A 21-year review of pediatric primary epithelial lung malignancies from Memorial Sloan-Kettering Cancer Center yielded a total of 11 patients (age range, 12-21 years) with pathologic diagnoses of adenocarcinoma (4, including 1 well-differentiated fetal adenocarcinoma), basaloid carcinoma (2), carcinoid tumor (4), and MEC (1).93 A 24-year review of the records from Boston Children’s Hospital (1957-1981) revealed 6 primary bronchial tumors in children, with no cases of bronchogenic carcinoma.9 In 1999, Mizushima et al89 reported a large series of young lung cancer patients (26 patients younger than 30 years), none of whom were younger than 18 years. Our current 25- year cumulative experience, including both institutional and consultation cases, includes 23 primary lung malignancies, but only 1 case of bronchial squamous cell carcinoma in a 6-year-old child, and no cases of adenocarcinoma.

Reported cases of pediatric lung carcinoma in the medical literature are most commonly undifferentiated carcinoma, followed by adenocarcinoma and squamous cell carcinoma. It is difficult to determine whether the historical cases of undifferentiated carcinoma truly represent small cell carcinoma or perhaps atypical carcinoid tumors. Adenocarcinoma may result in consolidation of a lobe or “white-out” of a lung, with or without pleural effusion.92 The 3 patients with conventional pulmonary adenocarcinomas in the Memorial Sloan-Kettering series all presented with stage IV disease, and 2 had rapidly progressive fatal disease within 2 months of diagnosis.93 Well-differentiated fetal adenocarcinoma, also called pulmonary endodermal tumor, is an extremely rare variant of adenocarcinoma for which there are only isolated reports in children. 93,94 Thought to be related to pulmonary blastoma, this tumor is composed of complex branching tubules and glands and has been compared with fetal lung in the pseudoglandular stage of development. Unlike conventional pulmonary adenocarcinoma, well- differentiated fetal adenocarcinoma has a relatively good prognosis, with only 15% mortality.93 Bronchioloalveolar carcinoma has been reported rarely arising from CPAM (Figure 7, A through C).94-104 The mucigenic epithelium of the type I CPAM is the purported precursor cell for bronchioloalveolar carcinoma in this setting.105-107

Squamous cell carcinoma (Figure 7, D) seems to account for a smaller proportion of lung carcinoma cases in children (12%) relative to adults (35%-50%).7 Only 6 cases of bronchogenic squamous cell carcinoma were reported in children until 1995, with an age range of 1 to 15 years.108 A pathogenetic relationship with human papillomavirus has been proposed, given the known potential for progression of respiratory papillomatosis to squamous cell carcinoma.109 A minute squamous cell carcinoma has also been reported in the wall of a congenital lung cyst.110 Basaloid carcinoma, a rare variant of non-small cell lung carcinoma described in 1992, has been reported recently in the pediatric population.93 It is an aggressive tumor thought to arise from the basal bronchial epithelial stem cells and is characterized microscopically by small cells growing in a characteristic nesting pattern with peripheral palisading.93

Primary lung carcinoma in children may be aggressive, with frequent metastatic disease at diagnosis, high mortality (90%), and average survival of 7 months after diagnosis. 3,7 Symptoms may include cough, chest pain, pneumonia, or hemoptysis due to local effects, but initial presentation may also be heralded by bone pain, weight loss, or anemia due to metastatic disease. Delay in diagnosis and metastasis at presentation has led to generally poor survival in the few cases of bronchogenic carcinoma in children reported.108 DIFFUSE MALIGNANT MESOTHELIOMA

Primary pleural neoplasms in the pediatric population are quite rare, representing 2 of 1925 pleural lesions in 1 series.111 Diffuse malignant mesothelioma is extremely rare in children, with only 4.5% of mesotheliomas in 1 series occurring in patients younger than 21 years.112 There is no clear causal relationship with asbestos exposure in children, although a history of possible asbestos exposure has been reported in isolated pediatric cases.113 Diffuse malignant mesothelioma may also occur as a second malignancy following radiation therapy, and there is one report of pediatric mesothelioma associated with prenatal isoniazid exposure.114 Three large series of diffuse malignant mesothelioma in children have shown pleural involvement in 72% of cases (18/25 total patients), with an age range of 4 to 19 years.113,115,116 Reported mortality in children ranges from 50% to 71%.113,115,116 Histologic patterns are similar to those seen in adults, and they have included epithelial, mixed, and fibrous types, as well as papillary, tubuloglandular, solid, and sarcomatoid patterns. 4,113,115

PRIMARY LUNG TUMORS IN IMMUNOSUPPRESSED AND IMMUNOCOMPROMISED CHILDREN

Lymphoma and Lymphoproliferative Disorders

All immunodeficiency states carry a higher risk of lymphoma relative to the immunocompetent population, including patients with human immunodeficiency virus (HIV) infection, solid organ transplant, bone marrow transplant, and congenital immunodeficiencies. These lymphomas are most often high-grade or intermediategrade non-Hodgkin lymphomas, typically diffuse large Bcell lymphomas, and often involve extranodal sites. Burkitt lymphoma, Burkitt-like lymphoma, Hodgkin lymphoma, and human herpesvirus 8-associated primary effusion lymphoma also are reported with higher incidence in the HIV-infected population.117

Epstein-Barr virus-driven lymphoproliferative disorders occur most commonly in immunosuppressed recipients of solid organ or bone marrow transplants (posttransplant lymphoproliferative disorder [PTLD]), as well as children with primary immunodeficiency (Figure 8, A). In general, PTLD is most common after heart, lung, or heartlung transplantation (5%-13% of patients) and less common after liver, kidney, or bone marrow transplantation (1%-3%).117 Lung involvement by PTLD manifests as periairway and parenchymal nodular and interstitial lymphoid infiltrate, and primary involvement of the lung is highest in lung transplant or heart-lung transplant recipients. The pathogenesis of PTLD is related to EBV-stimulated B- lymphocyte proliferation, which is unopposed due to iatrogenic inhibition of regulatory T-lymphocyte function, and the biologic spectrum ranges from polymorphous to monomorphous and may be polyclonal, oligoclonal, or monoclonal. The monoclonal forms most often resemble diffuse large B-cell lymphoma and may be associated with regions of necrosis. Epstein-Barr virus DNA probes are positive in most PTLDs but may be negative, particularly late (more than 5 years) after transplantation. Flow cytometric analysis is an essential component of the diagnostic evaluation of suspected PTLD and allows determination of clonality. Reduction of immunosuppression is the first-line management of these disorders, with or without anti-CD20 antibody therapy (rituximab), although cytotoxic chemotherapy may also be necessary for treatment of persistent lesions and the more aggressive monoclonal forms of PTLD.

Smooth Muscle Tumors

(Leiomyoma and Leiomyosarcoma)

Epstein-Barr virus-associated smooth muscle tumors have been described in children with HIV/AIDS (Figure 8, B and C), as well as solid organ transplant recipients and children with primary immunodeficiency.118-122 These tumors may be solitary or multifocal, and site of predilection include the gastrointestinal and respiratory tracts. Similar to the EBV-driven lymphoproliferative tumors, there is a spectrum from benign to malignant morphology, that is, leiomyoma and leiomyosarcoma, and there is potential for regression of tumors with modulation of immunosuppression. Epstein- Barr virus DNA probes are typically strongly positive in these tumors (Figure 8, D).

Kaposi Sarcoma

Kaposi sarcoma associated with human herpesvirus 8 infection may occur in HIV-infected patients and following solid organ transplantation. Although cutaneous Kaposi sarcoma typically predominates clinically, visceral involvement may occur, most often affecting lymph nodes, the gastrointestinal tract, or the lungs. Pulmonary involvement may produce endobronchial or parenchymal violaceous lesions, and it is a cause of pulmonary hemorrhage, cough, and dyspnea in this population.

SECONDARY INVOLVEMENT OF THE LUNG IN SYSTEMIC DISEASE

Langerhans Cell Histiocytosis

In adults, LCH in the lung typically occurs as a solitary nodule in smokers, previously called eosinophilic granuloma.123 In children, LCH in the lung typically reflects involvement by systemic disease rather than isolated lung involvement.124 Langerhans cell histiocytosis occurs most often in infants and young children, and presenting signs may include a rash, bone lesions, or pituitary involvement. Skeletal survey may show punched-out lytic bone lesions of the skull or other long bones. If there is lung involvement, chest computed tomography may show a reticulonodular pattern with nodules ranging from 1 to 10 mm in diameter, larger cavitary nodules, pneumatoceles, bilateral cystic disease, and/or pneumothorax.8 Histologically, LCH typically demonstrates patchy infiltrates involving the interstitium, pleura, and bronchovascular bundles (Figure 9, A). Extension of LCH cells into the alveolar spaces is often associated with the infiltrates expanding the alveolar walls. The histiocytes have typical indented and grooved nuclei and may be admixed with occasional eosinophils. If necessary, confirmation of Langerhans cell phenotype is achieved using immunohistochemistry for CD1a (Figure 9, B) or Langerin (CD207). S100 is also positive but less specific than CD1a or CD207. Electron microscopy demonstrates characteristic pentalaminar rods with bulbous ends (Birbeck granules) formed by internalized invaginations of the cell membrane. The differential diagnosis of interstitial infiltrates and histiocytic nodules includes leukemia, granulomatous processes, and non-LCH, such as juvenile xanthogranuloma (Figure 9, C and D).

Leukemia and Lymphoma

Although pulmonary infiltrates in leukemia patients prompt primary consideration of infection, leukemic infiltration of the lung may cause a similar pattern radiographically. Lung involvement by leukemia usually manifests as patchy interstitial, septal, or pleural infiltrates (Figure 10, A and B), in contrast to non- Hodgkin and Hodgkin lymphoma, which tend to form larger, well- circumscribed nodules obscuring the background lung parenchyma (Figure 10, C and D). An associated mediastinal mass or hilar adenopathy are variable features. The differential diagnosis for lymphoma involving the lung in children includes primarily Hodgkin lymphoma, non-Hodgkin lymphoma (acute lymphoblastic lymphoma, Burkitt lymphoma [Figure 10, E], diffuse large B-cell lymphoma), and PTLD. Other types of pulmonary lymphoid proliferations have been reviewed by Colby and Yousem.125

METASTATIC SOLID TUMORS OF CHILDHOOD

Metastatic tumors account for approximately 80% of all lung tumors in children and more than 95% of malignant tumors of the lung in this population.14 Although a wide variety of sarcomas and embryonal tumors of childhood produce lung metastases in children, Wilms tumor and osteosarcoma are the most frequent.2 Metastases appear as single or multiple circumscribed nodules, often peripheral and preferentially involving the lower lobes in those with hematogenous spread.2 A reticular or military pattern may occur with those demonstrating lymphangitic spread. Cavitation and pneumothorax are rare but are features most often associated with Wilms tumor, Hodgkin lymphoma, and osteosarcoma.6

Metastasectomy

While some metastatic lung nodules are excised for diagnosis and staging, others are removed as a part of oncologic management to achieve long-term survival and effect cure. Kayton126 has recently provided an excellent review of clinical indications and surgical techniques used for pulmonary metastasectomy in pediatric patients. This approach began in the 1950s but achieved greater popularity after 1971, when survival advantage was reported in osteosarcoma patients with excision of metastatic lesions (3-year survival of 45% vs 5%, with and without metastasectomy).126 Long-term survival (more than 20 years from diagnosis) can also be achieved in some patients with aggressive and repeated excision of lung nodules. It is also now recognized that the effectiveness of surgical management for metastatic tumor is dependent on histologic type. Currently, pulmonary metastasectomy remains most common for osteosarcoma due to the demonstrated survival advantage of repeated wedge excisions for metastatic disease. Metastasectomy also plays a central role in management for other tumor types that are resistant to chemotherapy and radiation therapy, such as adrenocortical carcinoma and chondrosarcoma. Conversely, surgical management of metastatic disease is uncommon for chemosensitive and radiosensitive malignancies, such as Wilms tumor, Ewing sarcoma, neuroblastoma, rhabdomyosarcoma, thyroid carcinoma, and germ cell tumors. Clinical features and management principles are discussed briefly below for pulmonary metastasis in selected pediatric solid tumors. Osteosarcoma

In addition to the sporadic cases, osteosarcoma occurs with increased frequency in children with p53 mutations in the Li- Fraumeni syndrome, in children with Rothmund-Thomson syndrome, in retinoblastoma patients, and as a second malignancy in children treated with alkylating agents. Approximately 10% to 15% of children with osteosarcoma will have pulmonary metastasis at presentation (Figure 11, A and B).127 Pulmonary metastases are typically asymptomatic and detected by imaging studies. Large studies have demonstrated a strong correlation between complete resection of primary and metastatic lesions at presentation and overall survival.126 Repeated excision of additional lung metastases is often necessary and provides additional survival benefit. Excision of metastatic lesions should be complete due to the proven survival benefit, and is indicated even after demonstrated chemotherapy response.

Wilms Tumor

The lung is the most common site of metastasis in Wilms tumor (Figure 11, C), the second most common malignant solid tumor of childhood. Pulmonary metastases are typically detected by imaging rather than by clinical symptomatology. Patients with favorable histology Wilms tumor and pulmonary metastasis have a good prognosis, with approximately 75% 4-year survival.128 Pulmonary nodules in patients with Wilms tumor may be excised for staging at initial diagnosis, but there is a limited role for metastasectomy for oncologic management in the United States. Metastasectomy for Wilms tumor is more commonly used in European centers to spare effects of radiation therapy, but North American centers have not adopted this approach as standard therapy. Based on National Wilms Tumor Study group data, patients with favorable histology Wilms tumor have excellent survival after chemotherapy and/or radiation therapy only, with acceptably low rates of radiation pneumonitis. Nevertheless, excision of metastases has been used selectively in individual Wilms tumor patients with lesions refractory to chemotherapy or radiation therapy, or in patients prior to bone marrow transplant.126

Neuroblastoma

Children with neuroblastoma rarely present with lung metastases, with an incidence at diagnosis of only 0.4% to 3.2%.126 When involving the lung, metastatic neuroblastoma also typically involves other organs, in which case systemic chemotherapy is more appropriate than pulmonary metastasectomy. In the case of isolated pulmonary nodules, however, excisional biopsy may be indicated to confirm diagnosis and staging prior to chemotherapy.

Rhabdomyosarcoma

Prognosis for rhabdomyosarcoma patients with pulmonary metastasis is generally poor, and concurrent extrapulmonary disease is common. Relative to children with extrapulmonary metastases, children with isolated pulmonary disease more commonly have nonalveolar histology, parameningeal primary site, and lack of lymph node involvement. Overall survival is better for patients younger than 10 years in this group and for those who received radiation therapy. There is currently no standard role for surgical resection of metastases other than for biopsy confirmation of diagnosis and perhaps resection of isolated lesions.126

Ewing Sarcoma Family of Tumors

Ewing sarcoma (Figure 11, D and E) is generally sensitive to both chemotherapy and radiation therapy, and these are the mainstays of management for metastatic disease, as survival advantage after pulmonary metastasectomy has not been clearly demonstrated. Surgical excision of metastatic lesions at this time is typically performed for confirmation of diagnosis and remains controversial for resection of limited pulmonary disease.

Other Soft Tissue Sarcomas

Metastasectomy is a component of therapy for other types of sarcomas, including alveolar soft part sarcoma, synovial sarcoma, chondrosarcoma, fibrosarcoma, and malignant fibrous histiocytoma, and the approach is generally similar to that used for osteosarcoma.126 In particular, alveolar soft part sarcoma has a high incidence of lung metastasis (60% of pediatric patients), and because it shows incomplete response to chemotherapy, surgical resection is a necessary component of oncologic management. 126

Hepatoblastoma

Pulmonary metastases of hepatoblastoma may completely respond to chemotherapy, allowing long-term survival. For unresponsive or partially responsive tumors, however, extended survival may be achieved by pulmonary metastasectomy following chemotherapy, leading to a combined approach in such patients.

Thyroid Carcinoma

Mortality is very low for pediatric thyroid cancer. Despite frequent lymph node metastasis, prognosis is generally favorable, and very few patients develop distant metastasis. When present, pulmonary metastases tend to produce a miliary pattern of disease which would not allow resection by metastasectomy. Instead, the primary therapeutic modality for pulmonary metastases of thyroid carcinoma is radioactive iodine (131I) treatment, and it allows complete radiographic resolution of disease and long-term survival in many cases. Metastasectomy is reported for diagnostic purposes, but otherwise it is not a routine component of oncologic management.

Adrenocortical Carcinoma

Pulmonary metastases are relatively frequent in patients with stage IV adrenocortical carcinoma (Figure 11, F) and, based on experience with adults, excision of these lesions results in dramatically increased 5-year survival (71% vs 0%, with and without metastasectomy).126Metastasectomy is recommended early after detection and should be complete, preventing recurrence and/or tumor spillage into the thoracic cavity.

Chemotherapy Effect

If a metastatic nodule is removed after chemotherapy, evidence of treatment effect may include necrosis, fibrosis, or hemosiderin deposition. Cytodifferentiation after chemotherapy occurs in some embryonal neoplasms, for exampl

Benign Tumors and Tumorlike Conditions of the Lung

By Borczuk, Alain C

* Context.-Benign tumors and tumorlike conditions of the lung are encountered in the pathologic evaluation of asymptomatic and symptomatic lung nodules. Since many of these lesions are uncommon, they can be diagnostically challenging. Objective.-To review the current classification of benign lung tumors, with emphasis on histopathology and useful ancillary studies.

Data Sources.-The current World Health Organization classification system for lung neoplasms and review of relevant publications.

Conclusions.-Despite improved imaging techniques, benign lung nodules are encountered in wedge biopsy and resection specimens. Histopathology, immunohistochemistry, and molecular techniques ensure accurate pathologic diagnosis and have shed light on the histogenesis of these unusual lesions.

(Arch Pathol Lab Med. 2008;132:1133-1148)

Benign neoplasms of the lung represent a relatively uncommon group of tumors of epithelial and mesenchymal origin. These tumors are generally small (less than 3 cm) and, depending on their typical site of origin (endobronchial vs lung parenchymal), can be associated with symptoms of endobronchial involvement such as cough, postobstructive pneumonia, and hemoptysis or can be asymptomatic solitary pulmonary nodules. In addition to true neoplasms, inflammatory, fibrotic, and reactive tumoral lesions can form lung nodules.

HISTORICAL PERSPECTIVE AND OVERVIEW

Since the advent of diagnostic imaging, lung nodules have been detected. In the era prior to computed tomographic (CT) scanning, lesions detected on chest x-ray films were diagnostic dilemmas often requiring resection. In a series published in 1963, Steele1 described the outcome of 882 male patients with asymptomatic solitary pulmonary nodules (less than 3 cm). Benign lesions constituted 64% of these lesions, most were granulomatous. Of the neoplastic proliferations, 10% were benign, many of which were hamartomas. A similar review published in 1964, summarizing the experience from 1948 to 1963, reported 62% of nodules detected on chest x-ray films as benign.2 These benign lesions were also frequently granulomatous. More than a decade later, in 1975, Higgins et al3 published a series demonstrating 68% of the lesions discovered as benign.

In a review of the 10-year surgical experience at the Mayo Clinic (Rochester, Minn), Arrigoni et al4 described 130 patients with benign lung tumors. The following is the distribution of tumors from that series: hamartomas (76%), benign fibrous mesothelioma/solitary fibrous tumor (SFT; 12.3%), inflammatory pseudotumor (IPT; 5.4%), lipoma (1.5%), leiomyoma (1.5%), and single cases of hemangioma, adenoma of the mucous glands, and mixed tumor. It was noted that the majority of the neoplasms were asymptomatic, and endobronchial location was observed in only 6% of these tumors.

Advances in imaging techniques (CT scanning and positron emission tomography scanning) as well as development of less invasive diagnostic techniques (transbronchial biopsy, percutaneous needle biopsies, and video-assisted thoracoscopic surgery) have had impacts on the detection and management of both asymptomatic solitary pulmonary nodules and endobronchial lesions. Overall, benign lesions represent a smaller percentage of resected nodules, as interval change between studies can be used as a parameter to assess growth, stability, or disappearance. In a radiologic series of CT-detected solitary pulmonary nodules, analysis of the 103 lesions considered to be benign included 35% that did not require biopsy because of interval resolution between scans, granulomas (23%), hamartomas (14%), specific infection (7%), infarct (4%), organizing pneumonia (2%), and single cases of nodular amyloid, SFT, intraparenchymal lymph node, leiomyoma, and IPT. In that series, lesions smaller than 2 cm were likely to be benign, while of lesions larger than 2 cm, only 14% were benign.5 In a similar series published in 1999, an examination of 254 resected nodules showed 45% were benign, with hamartomas (8%), intraparenchymal lymph node (6%), and granulomas, scars, organizing pneumonia, and tumorlets reported. The proportion of nodules that were malignant also increased with size stratification.6

A 2003 study of 429 patients with indeterminate solitary pulmonary nodules requiring video-assisted thoracoscopic surgery identified 370 benign lesions, which included hamartomas, granulomas, scars, and a case of nodular amyloid. In that series, age older than 55 years, size greater than 2 cm, and a history of cancer were all features associated with malignancy.7

In 2006, Yi et al8 studied solitary pulmonary nodules by high- resolution CT scan as well as integrated CT scan/positron emission tomography. Of the 119 nodules, 40 were benign (34%). Of the benign lesions, 50% were determined to be benign by serial follow-up scans. Of the remaining lesions, organizing pneumonia, hamartomas, and granulomas (5 cases each), aspergilloma (2), and 1 each of alveolar adenoma, IPT, and sclerosing hemangioma (SCH; pneumocytoma) were reported.

Finally, in a series of CT screen-detected nodules from the Mayo Clinic, 40 resected nodules were reported, 8 (21%) of which were benign and included granulomas, hamartoma, intraparenchymal lymph node, infarct, and scar.9

What these studies collectively demonstrate is that improvements in imaging techniques have reduced the proportion of benign lesions among resected asymptomatic nodules. However, if we compare the tissue diagnoses of these resected nodules, granulomatous disease and hamartomas are consistently the most frequent among the benign diagnoses. Although the scope of this review cannot encompass pulmonary infections, it is noteworthy that specific infections identified in these studies include tuberculosis, histoplasmosis, coccidioidomycosis, and cryptococcosis among granulomatous lesions as well as aspergilloma and more rarely dirofilaria. In addition, intraparenchymal lymph nodes and infarcts are also among the benign nodules in several series and are usually readily identifiable lesions histologically.

If we then focus on the remaining benign tumors and tumorlike conditions, it is of interest to compare the classification of these lesions from the Armed Forces Institute of Pathology by Averill Liebow in 1952,10 in a surgical review by Don Miller in 1969,11 and in the current World Health Organization classification from 1999/ 2004,12,13 as summarized in the Table, which shows the evolution of the current classification.

BENIGN EPITHELIAL TUMORS

Papillomas (Squamous, Glandular, Mixed)

It has long been recognized that papillomas occur in the lower respiratory tract, albeit more rarely than in the upper tract. These are generally exophytic tumors in the more proximal airways, but cases have been described of distal papillomas as well as cases with a more inverted growth pattern. They can be solitary or multiple, with multifocality associated with multiple papillomas of the upper respiratory/aerodigestive tract. When these completely obstruct the airway, postobstructive pneumonia can result.

In a review of 11 cases of lower respiratory papillomas, al- Saleem et al14 described multiple papillomas as rare in isolation of upper tract involvement. Tracheobronchial predominance was reported rather than lung parenchymal disease. Men were more frequently affected than women, and 7 of 11 cases were in children. Their review of existing literature indicated that 2% to 8% of cases with upper aerodigestive papillomatosis had lower airway involvement. This observation was confirmed more recently in a review of 448 children with upper airway papillomatosis, in which 9% had lower airway involvement and 2% had pulmonary involvement.15

In a review of solitary papillomas of adults, Flieder et al16 described a central location and male predominance for squamous papillomas, the majority of which were exophytic. In that review, cases were separated into squamous papillomas, glandular papillomas, and mixed type. The squamous and mixed papillomas had a male predominance, and the squamous type was associated with human papillomavirus (HPV) infection, while the glandular type was not. Glandular papillomas were the rarest. Inverted growth patterns were described but were also considered to be rare.

Given the association of squamous carcinoma with squamous papillomas, markers associated with transformation have been investigated both as predictive and confirmatory markers. Human papillomavirus typing has been investigated, and it has been proposed that HPV types 16, 18, 31, 33, and 35 may represent high- risk HPV types in these lesions,17 as they are in other sites. Additionally, it has been suggested that HPV-11 may be associated with malignant transformation in squamous papillomas of the lung and upper airway.18-20 While nuclear accumulation of p53 by immunohistochemistry, loss of Rb immunoreactivity, and decrease in p21 have all been described in lesions that have transformed to malignancy, it is unclear whether these markers are helpful as a predictor of malignant transformation prior to morphologic changes of dysplasia.18,21,22 As these markers are imperfect predictors of malignant transformation, difficult cases in which papillomas are not easily distinguished from carcinomas remain. As a result of uncertain malignant potential as well as their potential for recurrence, conservative complete excision of papillomas is recommended. Histopathology.-Exophytic papillomas have in common an epithelial layer covering a central fibrovascular core that forms a frondlike architecture that protrudes into the lumen of the airway (Figure 1, A). Squamous papillomas are lined by stratified squamous epithelium, sometimes keratinized, and in some lesions, viral cytopathic changes can be identified (Figure 1, B). Human papillomavirus in situ hybridization can be a useful adjunct test in this setting (Figure 1, C).

While dyskeratotic cells and mitoses can be seen in papillomas, this needs to be distinguished from high-grade squamous dysplasia and invasive squamous carcinoma. It is acknowledged that this can be difficult in some exophytic cases and with downward/endophytic/ inverted growth, atypical cytology can complicate the decision.

Peripheral lesions arise in bronchioles (Figure 1, D). While stratified and nonkeratinizing squamous, the lining is more uniform with less defined strata (Figure 1, E). In some lesions, the nonkeratinizing surface may flatten into a horizontally oriented single cell layer, and this in the past has been called transitional cell papilloma. As this lesion is squamous ultrastructurally, these have been included in the squamous group (Figure 1, F). When the epithelial lining is composed of a single layer of columnar nonciliated epithelial cells, the lesions have been classified as glandular papillomas. When combinations of squamous and glandular lining are seen, these lesions are designated mixed squamous and glandular papilloma.

In the differential diagnosis of papillomas is an exophytic endobronchial lesion made up of fronds lined by respiratory-type mucosa with fibrovascular and fibroblastic cores (Figure 1, G). These fibroblastic polyps of the large airways may represent reactive tumorlike conditions and are distinguished from papillomas by their pseudostratified ciliated respiratory lining (Figure 1, H). Areas of squamous metaplasia may be seen in fibroepithelial polyps (Figure 1, I), but the additional presence of ciliated respiratory lining is evidence of a fibroepithelial polyp rather than a papilloma.

Sclerosing Hemangioma (Pneumocytoma)

Since its first description in 1956,23 the histogenesis of this benign lung neoplasm has been debated. Although potential cells of origin have included endothelial, mesothelial, mesenchymal, epithelial, and neuroendocrine, the data support an epithelial, type II pneumocyte origin of this tumor.24-28 This neoplasm has a female predominance with an average age at presentation in the fifth decade, ranging from the second to the eighth decade.25,29 It is typically an asymptomatic solitary nodule, although multiple lesions have been described in less than 5% of cases.29,30 Sclerosing hemangiomas have an average size of 3 cm, are rarely larger than 5 cm, and are occasionally predominantly cystic.31 They are gray to tan-yellow and can contain punctuate hemorrhage. These tumors are thought to be benign, although rare cases with lymph node metastasis have been described.25,31

Histopathology.-Sclerosing hemangiomas are well circumscribed but not encapsulated (Figure 2, A), with adjacent lung containing blood and hemosiderin-laden macrophages. The hallmark of these tumors is the presence of 2 morphologic populations, one that is cuboidal epithelium, resembling type II pneumocytes, and the other uniform round to oval stromal cells that are bland with pale eosinophilic cytoplasm. Four patterns have been described: solid, hemorrhagic, papillary, and sclerotic. In the papillary areas, the cuboidal epithelium lines a core composed of the pale round stromal cells. The solid areas are often composed of sheets of these round stromal cells (Figure 2, D). The hemorrhagic areas have hemosiderin accumulation and dilated spaces filled with blood. While in such areas the cuboidal cells can become attenuated resembling endothelium (thus leading to the characterization as a hemangioma), the cells are in fact epithelial (Figure 2, C). Sclerotic areas contain dense collagen (Figure 2, B). What is interesting about these patterns is that virtually all tumors have a combination of several of these patterns. For example, while the sclerotic pattern is virtually never the predominant pattern, it is almost always at least focally present. In this sense it is the variety of patterns within a single tumor combined with the 2 distinct bland cell populations that lead to the consideration of this lesion in the differential diagnosis of a neoplasm.

Immunohistochemistry and electron microscopy have provided insights into the origin of these tumors. While the cuboidal epithelial cells are cytokeratin, epithelial membrane antigen, and thyroid transcription factor 1 (TTF-1) positive, the round stromal cells are typically cytokeratin negative, epithelial membrane antigen positive, and TTF-1 positive (Figure 2, D, inset). Although the epithelial cells are also positive for Clara cell 10-kd protein (CC10) and surfactant proteins, the round cells are negative for these markers.25,28,31 This has led to the suggestion that these tumors are derived from type II pneumocytes, with the round cell component representing a primitive/less differentiated type II cell/ Clara cell precursor.25,28,32 What has been demonstrated is that both components represent a clonal proliferation derived from the same clone, indicating that these lesions are neoplasms, and that both cellular components are neoplastic rather than reactive.33

Another feature of these round cells is immunoreactivity for progesterone receptor and less frequently for estrogen receptor. This has led to speculation that SCHs may be hormonally responsive and provides an explanation for the female predominance of this entity.34

A subset of cases has been seen in association with carcinoid tumorlets. In some cases adipose tissue can be seen.25

The variety of patterns within these lesions and relatively bland histology raise differential diagnoses that include hamartoma, carcinoid, and alveolar adenoma. Although hamartomas can also have entrapped fat and epithelial cells, the epithelium in hamartomas is more often bronchial/bronchiolar cells than type II cells, and hamartomas frequently contain cartilage. Hamartomas usually do not have the combination of patterns described in SCH. The recognition that the uniform round cell population is cytokeratin negative, neuroendocrine marker negative, and TTF-1 positive alongside a cuboidal epithelial proliferation that has a more typical type II pneumocyte profile makes this neoplasm sufficiently distinctive to exclude the other tumors in its differential diagnosis.

Alveolar Adenoma

Alveolar adenomas are unusual neoplasms that are typically identified in the periphery of the lung. Originally described in 1986 by Yousem and Hochholzer35 and then subsequently characterized by immunohistochemistry by Burke et al,36 these tumors have been identified in adults ranging in age from 39 to 74 years, usually as an asymptomatic solitary pulmonary nodule. Alveolar adenomas are soft, multicystic, and lobulated. No definite gender predilection has been identified.

The histogenesis of alveolar adenoma remains controversial. Although classified among epithelial neoplasms, it has also been suggested that it in fact represents a mesenchymal neoplasm with epithelial ingrowth or entrapment. Data suggesting that alveolar adenoma is a true neoplasm has been shown in 1 case37 with an unbalanced (10:16) translocation. A microdissection study38 suggested different cells of origin for the epithelium and stroma but did not reveal which population was more likely neoplastic.

Histopathology.-At low power, these tumors appear circumscribed and are not encapsulated. The first impression is of a multicystic structure, with variably sized cysts largest at the center of the lesion (Figure 3, A). At higher magnification, the cystic spaces are lined by a cuboidal and sometimes hobnailed epithelial cell population. Papillary formations are absent (Figure 3, B and C). The spaces themselves can be empty or can contain eosinophilic material. In between the cysts is a bland, spindled cell stroma that has rare to absent mitotic activity. Variable numbers of inflammatory cells can be seen amid the stromal areas. Marked hypercellularity of the stroma is absent, and the stromal areas are usually spindled rather than epithelioid (Figure 3, C). Blood-filled lakes are absent, and hemosiderin accumulation is not a component. Occasionally, scarring can be seen, but not as prominently as in SCH.

It was noted in the original description that these lesions were most often interpreted as lymphangiomas until it was recognized that the lining cells were epithelial rather than endothelial. Immunohistochemistry has confirmed that the lining cells are cytokeratin positive, TTF-1 positive, surfactant protein B and C positive, and CC10 negative. The stromal areas are negative for the above markers.

The differential diagnosis of alveolar adenoma includes SCH (pneumocytoma), and mesenchymal tumors including hamartomas and, as previously mentioned, lymphangiomas. In SCH, the epithelial patterns are more varied, including papillary formations and the blood- filled spaces that led to their mischaracterization as hemangiomas. In addition, while cytokeratin immunoreactivity is exclusively seen in the lining cells in both lesions, TTF-1 immunoreactivity can be demonstrated in both epithelial and stromal components, while in alveolar adenoma, only epithelial cells are immunoreactive. In hamartomas, the epithelium is often bronchiolar, and the stromal areas contain adipose tissue and cartilage. Lymphangiomas are endothelial lined and therefore cytokeratin negative and positive for endothelial markers.

Type II Pneumocyte Papilloma

This is a rare benign neoplasm composed of type II pneumocyte- lined papillae.39 The tumor is solitary, peripheral, circumscribed, and generally small (1.5 cm). It is composed of uniform cuboidal cells with foamy cytoplasm consistent with type II cells, and TTF-1 immunohistochemistry is positive in these cells. Intranuclear cytoplasmic inclusions can be seen, but no atypia. In contrast to SCH, TTF-1-positive stromal cells are not seen. Salivary Gland-Type Tumors

While mucoepidermoid carcinomas and adenoid cystic carcinoma are uncommon malignant salivary gland-type central lung tumors, benign salivary gland-type tumors are very rare. The mucous gland adenoma and pleomorphic adenoma are included in the current World Health Organization classification. The mucous gland adenoma is described as a central tumor composed of uniform mucin-filled glands lined by mucous secreting cells. An important criterion is the absence of squamous or intermediate cells, in contrast with the more common mucoepidermoid carcinoma. Pleomorphic adenomas are very rare central benign tumors with a biphasic growth pattern. Although similar to their more common salivary gland counterparts, the tumors described in the lung are less likely to have well-formed cartilaginous components, and the epithelial component more likely forms cords and islands rather than well-defined ducts.40 Circumscription, smaller size (

Mucinous Cystadenoma

This rare epithelial neoplasm of the lung most often presents as a peripheral asymptomatic cystic nodule, as illustrated in Figure 4, A. In a review of 76 cases of mucinous cystic tumors of the lung (>90% extracellular mucin), most were malignant or harbored significant atypia.41 Although 10 cases were considered benign, the frequency of malignancy in this setting warrants extensive or complete sampling of cystic mucinous neoplasms. Of the lesions considered benign, an absence of atypia, paucicellularity, absence of solid areas, absence of stratification, absence of invasion, and a low proliferation index (Ki-67

Thyroid transcription factor 1 immunohistochemistry and cytokeratin 7 are frequently positive in these tumors. It was noted in one series that caudal type homeobox 2 was also positive in some cases and, therefore, caudal type homeobox 2 immunoreactivity does not rule out a primary lung origin.42

Hamartoma

The term hamartoma refers to a nonneoplastic disordered collection of benign tissue normally present in a particular organ, forming a nodule. It appears, however, that pulmonary hamartomas are benign mesenchymal neoplasms. As noted in the section on historical perspective, hamartomas are frequently encountered among benign nodules removed from the lung. These tumors are more often peripheral than central, with an endobronchial location in fewer than 10% of cases. The most common presentation is a solitary nodule, and most cases are smaller than 4 cm with an average of 1.5 cm. They are often easily removed from surrounding parenchyma and vary in color depending on their cellular composition. Hamartoma is seen more commonly in men (M/F, 2:1), and is not usually encountered in pediatric patients.43,44 The pattern of calcification on radiographic examination (“popcorn” calcification) is characteristic in about 30% of cases. Endobronchial hamartomas may be on average smaller, perhaps due to the higher likelihood of clinical symptoms, allowing for earlier detection.

Histopathology.-Hamartomas contain a mixture of cartilage, fat, myxoid connective tissue, smooth muscle, and epithelium. They are often lobulated and the epithelium, which is usually bronchial/ bronchiolar, may represent entrapped epithelium lining the clefts of these lobules. Cartilage is the most common mesenchymal tissue in these lesions but is not required for the diagnosis. The diagnosis relies on finding at least 2 benign mesenchymal tissues in the lesion and the characteristic growth pattern (Figure 5, A through C). Endobronchial lesions more commonly contain adipose tissue than cartilage.

The presence of only one mesenchymal tissue type raises the possibility of lipoma, leiomyoma, or chondroma. Mesenchymal tumors of the lung can have entrapped epithelial elements; therefore, that finding alone is not sufficient to determine that a lesion is a hamartoma. Chondromas may be part of the Carney triad when seen in young women, and therefore this needs to be considered in pure chondroid lesions. Although smooth muscle nodules have been named leiomyomatous hamartomas, in women the diagnosis of “benign metastasizing leiomyoma” in association with uterine leiomyomas needs to be strongly considered.

Cytogenetic abnormalities that have been identified in pulmonary hamartomas include rearrangements at 12q1545 and 6p21.46,47 These rearrangements appear to involve HMGI-C at 12p15 and HMGI-Y at 6p21.48,49 These proteins are nonhistone nuclear proteins that participate in the regulation of gene expression via alteration of chromatin structure. These data support the contention that hamartomas are neoplastic, and similar abnormalities found in other mesenchymal tumors point to the mesenchymal component as neoplastic.

Solitary Fibrous Tumor of the Lung

Solitary fibrous tumors are typically pleural-based tumors, but intrapulmonary examples have been described. 50,51 Pulmonary SFTs are generally peripheral; they are sometimes on the pulmonary parenchymal side of the pleura but in some instances are completely separate from the pleura. They are firm and white with a whorled appearance. Solitary fibrous tumors may derive from submesothelial fibroblasts.

Histopathology.-The tumors are typically well circumscribed (Figure 6, A) and at low power may appear variably cellular with dense cellular areas alongside hyalinized fibrosis (Figure 6, B). The neoplastic cells are bland spindled cells with moderate amounts of cytoplasm. The ingrowth of epithelial cells in tumor clefts in intrapulmonary cases has led to the observation that these tumors resemble fibroadenomas or phyllodes tumor of the breast. The characteristic immunoreactivity of the neoplastic cells for CD34 confirms the diagnosis of SFT (Figure 6, C).

The differential diagnosis of SFT can include nerve sheath tumors, IPT, and pulmonary hyalinizing granuloma. Immunohistochemistry can resolve the differential diagnosis with nerve sheath tumors. Solitary fibrous tumors do not have the inflammatory infiltrate of IPT and are generally more cellular and less sclerotic than pulmonary hyalinizing granuloma. Distinguishing benign from malignant SFTs can be difficult, but this topic is beyond the scope of this review.

Clear Cell (Sugar Tumor)

These rare tumors of the lung are typically asymptomatic peripheral nodules (

Other Mesenchymal Tumors

Nerve Sheath Tumors.-These are rare intrapulmonary tumors (

Leiomyomas.-Primary solitary pulmonary leiomyomas can be endobronchial or parenchymal. The mitotic rate of benign neoplasms should be fewer than 5 in 50 high-power fields.56 Multiple smooth muscle tumors of the lung in women with history of uterine leiomyomas are more likely part of the entity of benign metastasizing leiomyoma.

Chondromas.-Chondromas are tumors composed of hyaline or myxohyaline cartilage without epithelial elements or other mesenchymal elements. Although these can represent isolated, sporadic tumors, such tumors with myxoid stroma in young women require examination for the Carney triad (gastric smooth muscle tumors, paraganglioma, chondromas).57

Lipomas.-These can be intraparenchymal or endobronchial, the latter being more common.58 These tumors must be composed solely of adipose tissue; any component of lobulated cartilage or epithelial ingrowth on cleftlike spaces raises the possibility of an adipose tissue-rich hamartoma.

Granular Cell Tumors.-In the Table, both the 1952 and 1969 benign tumor classifications included granular cell myoblastoma (granular cell tumor), although these do not appear to be common benign lung tumors. In limited series of cases, these tumors occur in adults (average age, 40 years) with a male predominance.59 They are usually central tumors and therefore more likely to be symptomatic with cough, obstruction, or hemoptysis. They are often irregular and locally invasive and therefore can recur after conservative resection, but they do not metastasize.

Histopathology.-Granular cell tumors are composed of large cells with abundant granular eosinophilic cytoplasm and bland nuclei (Figure 7). They are periodic acid-Schiff positive and by immunohistochemistry, S100 (Figure 7, inset) and vimentin positive and cytokeratin negative. The ultrastructure and immunohistochemistry of granular cell tumor supports a schwannian rather than muscle derivation.

Minute Meningothelial Nodules and Meningioma

The entity of minute meningothelial nodule (previously chemodectoma) has gained greater recognition with improved lung imaging. These small proliferations are generally smaller than 0.3 cm, are perivenular and are frequently multiple. While usually discovered incidentally, in some instances they do represent the target lesion detected by high-resolution CT scan. They are more commonly found in women than in men.60 Histopathology.-These are ill- defined lesions that expand alveolar walls, rendering a stellate appearance (Figure 8, A). The cells have poorly demarcated cell borders and often are grouped in nests and fascicles with intervening collagen. The cells are bland, and no mitotic activity is identified. Cells can be arranged in whorled patterns (Figure 8, B).

These proliferations are epithelial membrane antigen positive and vimentin positive while negative for cytokeratin, actin, and neuroendocrine markers. The immunohistochemistry combined with ultrastructural appearance has led to the designation as meningothelial proliferations rather than paragangliomas.

Molecular studies have demonstrated that some of these lesions are clonal while others are not, raising the possibility that these are reactive lesions, not neoplastic.61 Loss of heterozygosity study has suggested minute meningothelial nodule is reactive with possible transition to neoplasia with increased loss of heterozygosity events in multifocal disease.62 The relationship of minutemeningothelial nodule to the rarer primary pulmonary meningioma is not certain; by loss of heterozygosity data, meningiomas have more loss of heterozygosity events at different loci than minute meningothelial nodules or multifocal minute meningothelial nodules do.62 Primary pulmonary meningiomas are circumscribed, peripheral nodules, more common in women, and composed of whorls and fascicles of cells. Psammoma bodies are seen in pulmonary meningiomas.63

Nodular Lymphoid Hyperplasia

Review of this entity requires the initial disclaimer that most dense lymphoid proliferations of the lung previously designated as pseudolymphoma are actually low grade lymphomas, usually of the MALT type. However, after such lesions are characterized using molecular gene rearrangement study for immunoglobulin (Ig) H, flow cytometry, and immunohistochemistry for kappa and lambda, there remain a small number of lesions where clonality cannot be demonstrated.64

Histopathology.-In nodular lymphoid hyperplasia, the nodules are usually smaller than 3.0 cm and solitary, although satellite foci can be identified in some cases. They are densely cellular and at low-power view, reactive germinal centers are identifiable (Figure 9, A through C). Higher magnification reveals a substantial plasmacytosis in between these follicles, and some degree of fibrosis. Russell bodies are seen (Figure 9, D), but not Dutcher bodies (nuclear inclusions). No lymphoepithelial lesions are identified in these lymphoid nodules.

The possibility that some cases of nodular lymphoid hyperplasia represent an exuberant response to a foreign antigen (eg, aspiration) has been raised. The case illustrated in Figure 9, B, shows an area of fibrosis with calcification that appeared to be the nidus/epicenter for the nodular lymphoid hyperplasia lesion.

Inflammatory Pseudotumor

These tumors represent a complex entity that likely includes reactive and neoplastic conditions. In 1988, Matsubara et al65 described 3 types of IPT: organizing pneumonia, lymphoplasmacytic, and fibrohistiocytic. The organizing pneumonia type may be currently classified as focal organizing pneumonia (see next section). More than one third of patients with IPT had symptoms (pain, pneumonia, cough), and one quarter had previous respiratory infection. These tumors are usually smaller than 5.0 cm, are deceptively circumscribed grossly, and vary in color from yellow to white. Hemorrhage and necrosis can be seen.

Conclusions of one series are a frequent occurrence in children, more frequently parenchymal than endobronchial (but both occur), and will enlarge if left unresected. In addition, local invasion is frequently seen, and recurrence can occur.66

Histopathology.-Low-power view of these tumors often demonstrates infiltrative growth (Figure 10, A). Inflammatory pseudotumors often have mixtures of patterns and are classified by the predominance of a storiform pattern versus inflammatory infiltrate. Cases with a dense plasma cell infiltrate can overshadow the presence of a spindle cell population (Figure 10, B). One study reported IgG4- positive plasma cells in pulmonary IPT,67 lymphoplasmacytic/plasma cell granuloma type. In the fibrohistiocytic/storiform type, IPTs are composed of bland fascicles of cells in a storiform pattern (Figure 10, C). Giant cells can be seen. In benign lesions, the mitotic rate is low (

Evidence of the neoplastic nature of IPT includes cytogenetic abnormalities,69,70 2p23/ALK1 rearrangements, and ALK1 overexpression.71,72 Cases with ALK1 rearrangements correspond well to those with cytoplasmic immunoreactivity for ALK1. Examination of published IPT cases of the lung with either cytogenetic abnormality or positive ALK1 immunohistochemistry reveals about 13 (36%) of 36 pediatric and 5 (36%) of 14 adult pulmonary IPTs showed either cytogenetic/fluorescent in situ hybridization abnormality and/or immunoreactivity for ALK1 (although precise age data specifically for the lung cases is not available in all series).69,71-79 A recent study of 59 IPTs (including 13 pulmonary cases) indicated that ALK1- positive tumors were more common in younger patients and that ALK1- negative cases had a higher metastatic rate74 overall.

Although IPTs are a potentially heterogeneous category of tumors, a significant subset of pulmonary IPT cases are true myofibroblastic neoplasms and when associated with inflammation can be designated as inflammatory myofibroblastic tumors. This is certainly most strongly suggested by cytogenetic studies, recurrences, and reports of metastatic disease. It is apparent that a spectrum from benign to malignant is also possible in these tumors. The above criteria may be helpful in predicting biologic behavior; however, the propensity for recurrence and local invasion warrant complete resection of these tumors.

Focal Organizing Pneumonia

Organizing pneumonia is a subacute pattern of lung injury that can be associated with multiple etiologies including atypical and resolving infection, collagen vascular disease, and eosinophilic pneumonia. Idiopathic cases are also seen. While typically multifocal, organizing pneumonia can be localized in some patients (14% of 74 patients from a Mayo Clinic series).80 In that setting, focal organizing pneumonia/localized organizing pneumonia can be in the differential diagnosis of a solitary pulmonary nodule.

Histologically, focal organizing pneumonia forms a nodule that is defined, irregular, and nonencapsulated (Figure 11, A). It consists of fibroblastic intraalveolar proliferations that fill alveolar spaces, alveolar ducts, and respiratory bronchioles. In some areas, involvement of terminal bronchioles can also be identified (Figure 11, B). Lymphocytic inflammation can be seen, as well as macrophage accumulation.

Organizing pneumonia is a steroid-responsive reactive process. Although some authors have placed focal organizing pneumonia among the types of IPT, attempts to refine the IPT category to include inflammatory myofibroblastic tumors as neoplasms would warrant separating focal organizing pneumonia into a separate reactive category.

Apical Cap

Examination of wedge biopsy specimens from upper lobes as well as autopsy and lobectomy specimens often reveals areas of apical fibroelastosis. Although variable in size and often incidentally discovered, on occasion apical fibroelastosis is detected as an irregular apical, usually upper lobe, nodule or more rarely in the apices of lower lobes. Although the prevalence of apical caps is difficult to determine as they are likely underreported when present in a lobe otherwise removed for carcinoma, they are occasionally resected as part of a workup to exclude neoplasia. In a retrospective review of pulmonary pathology specimens at the University of Pittsburgh,81 19 cases of apical fibrosis were identified, and in 13 cases it represented the lesion targeted by the excision. These patients were cigarette smokers with an average age of 65 years with equal gender distribution. Eleven of 13 cases were upper lobe, with 2 cases from superior segments of the lower lobe.

Histopathology.-These lesions are subpleural (Figure 12, A) and frequently have triangular contours, with a broad pleural base (Figure 12, A). They have irregular borders and radiologically appear spiculated. At the interface with adjacent lung tissue the alveolar spaces show focal emphysema. The apical fibrosis is distinctive as it contains abundant elastic tissue, haphazardly arranged (Figure 12, B). These lesions may become calcified and ossified and overlying pleura can be thickened, resembling hyalinized pleural plaque.

While the cause of apical caps is not certain, the configuration of the lesions, the association with vessels with old thrombosis, and the suggestion of an underlying elastic tissue pattern of preexisting alveoli raise the possibility of old infarcts/chronic ischemia as a cause of these lesions.

Nodular Amyloidosis

Amyloidosis is an abnormal accumulation of protein in tissues. In the lung, patterns of accumulation include parenchymal, tracheobronchial, and vascular. Pulmonary amyloidosis may reflect a manifestation of systemic amyloidosis but can also represent organ- isolated disease. Nodular amyloidosis can be organ isolated and idiopathic, a result of chronic inflammation, or part of systemic disease (such as Sjogren syndrome, multiple myeloma, lymphoma, or light chain disease).82 Nodular amyloidosis can be detected as a solitary lung nodule.83,84 Grossly, nodular amyloid is described as waxy and variably gray-white or tan. Of note, these nodules have been positive by positron emission tomography scanning.85 Nodular amyloidosis is usually of primary amyloidosis type. However, serum and urine testing in these patients does not show a monoclonal protein in many cases. Histopathology.-Amyloidosis is characterized by accumulation of amorphous eosinophilic material that is devoid of cellularity (Figure 13, A). The material is not fibrillar by light microscopy. Amyloid nodules can be associated with a lymphoplasmacytic infiltrate (Figure 13, B), giant cells (Figure 13, C), and ossification (Figure 13, D).

Pulmonary Hyalinizing Granuloma

This entity is characterized by single or multiple nodules of circumscribed dense collagen surrounded by variable amounts of chronic inflammation. These nodules are detected in adults, average age 45 years. Patients are often symptomatic with chest pain or dyspnea. An association with sclerosing mediastinitis has been reported. However, pulmonary hyalinizing granuloma is an idiopathic condition, and no microorganisms are detected on special stains.86,87 Grossly, the nodules are solid, firm, and white to gray.

Histopathology.-The nodules are circumscribed (Figure 14, A) and frequently associated with a rim of lymphocytes at their periphery. The nodules are composed of dense ropy collagen without palisaded histiocytes or necrosis (Figure 14, B).

Although SFTs can have areas of dense collagen, pulmonary hyalinizing granuloma is less cellular. Also, cells of SFT are CD34 positive.

Rounded Atelectasis

Rounded atelectasis is a peripheral subpleural area of lung tissue that becomes folded into an area of visceral pleura fibrosis. These lesions are usually incidentally detected and are seen in men more frequently than women. Asbestos exposure causing parietal pleural plaques followed by visceral pleural adhesion is the typical scenario, although not all patients have documented asbestos exposure. Most cases are from the lower lobes, although lingula and right middle lobe involvement can occur. Although awareness of this entity has made it possible to recognize rounded atelectasis by the chest CT scan characteristics of airways drawn into the lesion, some cases come to surgical resection.88 As these lesions are caused by entrapped lung that becomes folded into pleural adhesions, at the time of surgery the lysis of adhesions and reexpansion of the folded lung causes the nodule to disappear.

Histopathology.-The histology of the lesion is nonspecific (Figure 15, A and B). If wedge biopsy/resection or lobectomy is performed, the histopathology may reveal pleural fibrosis with folding or wrinkling and underlying atelectatic lung. Pleura away from the lesion may be normal. 89 The combination of pleural fibrosis, possibly parietal pleural plaque, lower lobe location, and the description of a disappearing nodule are part of the clinicopathologic correlation needed to render this diagnosis.

References

1. Steele JD. The solitary pulmonary nodule: report of a cooperative study of resected asymptomatic solitary pulmonary nodules in males. J Thorac Cardiovasc Surg. 1963;46:21-39.

2. Seybold WD. Solitary or “coin” lesions of the lung: analysis of 2258 recorded cases. Postgrad Med. 1964;36:424-430.

3. Higgins GA, Shields TW, Keehn RJ. The solitary pulmonary nodule: 10-year follow-up of veterans administration-armed forces cooperative study. Arch Surg. 1975;110:570-575.

4. Arrigoni MG, Woolner LB, Bernatz PE, Miller WE, Fontana RS. Benign tumors of the lung: a 10-year surgical experience. J Thorac Cardiovasc Surg. 1970; 60:589-599.

5. Siegelman SS, Khouri NF, Leo FP, Fishman EK, Braverman RM, Zerhouni EA. Solitary pulmonary nodules: CT assessment. Radiology. 1986;160:307-312.

6. Ginsberg MS, Griff SK, Go BD, Yoo HH, Schwartz LH, Panicek DM. Pulmonary nodules resected at video-assisted thoracoscopic surgery: etiology in 426 patients. Radiology. 1999;213:277-282.

7. Cardillo G, Regal M, Sera F, et al. Videothoracoscopic management of the solitary pulmonary nodule: a single-institution study on 429 cases. Ann Thorac Surg. 2003;75:1607-1611; discussion 1611-1612.

8. Yi CA, Lee KS, Kim BT, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med. 2006;47:443-450.

9. Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT:Mayo Clinic experience. Radiology. 2003;226:756-761.

10. Liebow A. Tumors of the Lower Respiratory Tract. Vol 5. Washington, DC: Armed Forces Institute of Pathology; 1952:189.

11. Miller DR. Benign tumors of lung and tracheobronchial tree. Ann Thorac Surg. 1969;8:542-560.

12. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18:1059-1068.

13. Beasley MB, Brambilla E, Travis WD. The 2004World Health Organization classification of lung tumors. Semin Roentgenol. 2005;40:90-97.

14. al-Saleem T, Peale AR, Norris CM. Multiple papillomatosis of the lower respiratory tract: clinical and pathologic study of 11 cases. Cancer. 1968;22: 1173-1184.

15. Soldatski IL, Onufrieva EK, Steklov AM, Schepin NV. Tracheal, bronchial, and pulmonary papillomatosis in children. Laryngoscope. 2005;115:1848-1854.

16. Flieder DB, Koss MN, Nicholson A, Sesterhenn IA, Petras RE, Travis WD. Solitary pulmonary papillomas in adults: a clinicopathologic and in situ hybridization study of 14 cases combined with 27 cases in the literature. Am J Surg Pathol. 1998;22:1328-1342.

17. Popper HH, Wirnsberger G, Juttner-Smolle FM, Pongratz MG, Sommersgutter M. The predictive value of human papilloma virus (HPV) typing in the prognosis of bronchial squamous cell papillomas. Histopathology. 1992;21:323-330.

18. Lele SM, Pou AM, Ventura K, Gatalica Z, Payne D. Molecular events in the progression of recurrent respiratory papillomatosis to carcinoma. Arch Pathol Lab Med. 2002;126:1184-1188.

19. Byrne JC, Tsao MS, Fraser RS, Howley PM. Human papillomavirus- 11 DNA in a patient with chronic laryngotracheobronchial papillomatosis and metastatic squamous-cell carcinoma of the lung. N Engl J Med. 1987;317:873-878.

20. Cook JR, Hill DA, Humphrey PA, Pfeifer JD, El-Mofty SK. Squamous cell carcinoma arising in recurrent respiratory papillomatosis with pulmonary involvement: emerging common pattern of clinical features and human papillomavirus serotype association. Mod Pathol. 2000;13:914-918.

21. Go C, Schwartz MR, Donovan DT. Molecular transformation of recurrent respiratory papillomatosis: viral typing and p53 overexpression. Ann Otol Rhinol Laryngol. 2003;112:298-302.

22. Gupta D, Holden J, Layfield L. Topoisomerase alpha II, retinoblastoma gene product, and p53: potential relationships with aggressive behavior and malignant transformation in recurrent respiratory papillomatosis. Appl Immunohistochem Mol Morphol. 2001;9:86-91.

23. Liebow AA, Hubbell DS. Sclerosing hemangioma (histiocytoma, xanthoma) of the lung. Cancer. 1956;9:53-75.

24. Palacios JJ, Escribano PM, Toledo J, Garzon A, Larru E, Palomera J. Sclerosing hemangioma of the lung: an ultrastructural study. Cancer. 1979;44:949-955.

25. Devouassoux-Shisheboran M, Hayashi T, Linnoila RI, Koss MN, TravisWD. A clinicopathologic study of 100 cases of pulmonary sclerosing hemangioma with immunohistochemical studies: TTF-1 is expressed in both round and surface cells, suggesting an origin from primitive respiratory epithelium. Am J Surg Pathol. 2000;24:906- 916.

26. Yousem SA, Wick MR, Singh G, et al. So-called sclerosing hemangiomas of lung: an immunohistochemical study supporting a respiratory epithelial origin. Am J Surg Pathol. 1988;12:582-590.

27. Satoh Y, Tsuchiya E, Weng SY, et al. Pulmonary sclerosing hemangioma of the lung: a type II pneumocytoma by immunohistochemical and immunoelectron microscopic studies. Cancer. 1989;64:1310-1317.

28. Chan AC, Chan JK. Pulmonary sclerosing hemangioma consistently expresses thyroid transcription factor-1 (TTF-1): a new clue to its histogenesis. Am J Surg Pathol. 2000;24:1531-1536.

29. Katzenstein AL, Gmelich JT, Carrington CB. Sclerosing hemangioma of the lung: a clinicopathologic study of 51 cases. Am J Surg Pathol. 1980;4:343-356.

30. Noguchi M, Kodama T, Morinaga S, ShimosatoY, Saito T, Tsuboi E. Multiple sclerosing hemangiomas of the lung. Am J Surg Pathol. 1986;10:429-435.

31. Nicholson AG, Magkou C, Snead D, et al. Unusual sclerosing haemangiomas and sclerosing haemangioma-like lesions, and the value of TTF-1 in making the diagnosis. Histopathology. 2002;41:404-413.

32. Yoo SH, Jung KC, Kim JH, et al. Expression patterns of markers for type II pneumocytes in pulmonary sclerosing hemangiomas and fetal lung tissues. Arch Pathol Lab Med. 2005;129:915-919.

33. Niho S, Suzuki K, Yokose T, Kodama T, Nishiwaki Y, Esumi H. Monoclonality of both pale cells and cuboidal cells of sclerosing hemangioma of the lung. Am J Pathol. 1998;152:1065-1069.

34. Leong AS, Chan KW, Seneviratne HS. A morphological and immunohistochemical study of 25 cases of so-called sclerosing haemangioma of the lung. Histopathology. 1995;27:121-128.

35. Yousem SA, Hochholzer L. Alveolar adenoma. Hum Pathol. 1986;17: 1066-1071.

36. Burke LM, Rush WI, Khoor A, et al. Alveolar adenoma: a histochemical, immunohistochemical, and ultrastructural analysis of 17 cases. Hum Pathol. 1999;30:158-167.

37. Roque L, Oliveira P, Martins C, Carvalho C, Serpa A, Soares J. A nonbalanced translocation (10;16) demonstrated by FISH analysis in a case of alveolar adenoma of the lung. Cancer Genet Cytogenet. 1996;89:34-37.

38. Cavazza A, Paci M, De Marco L, et al. Alveolar adenoma of the lung: a clinicopathologic, immunohistochemical, and molecular study of an unusual case. Int J Surg Pathol. 2004;12:155-159.

39. Noguchi M, Kodama T, Shimosato Y, et al. Papillary adenoma of type 2 pneumocytes. Am J Surg Pathol. 1986;10:134-139. 40. Moran CA, Suster S, Askin FB, Koss MN. Benign and malignant salivary gland- type mixed tumors of the lung: clinicopathologic and immunohistochemical study of 8 cases. Cancer. 1994;73:2481-2490.

41. Gao ZH, Urbanski SJ. The spectrum of pulmonary mucinous cystic neoplasia: a clinicopathologic and immunohistochemical study of 10 cases and review of literature. Am J Clin Pathol. 2005;124:62- 70.

42. Rossi G, Murer B, Cavazza A, et al. Primary mucinous (so- called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX2 homeobox gene and MUC2 expression. Am J Surg Pathol. 2004;28:442-452.

43. Gjevre JA, Myers JL, Prakash UB. Pulmonary hamartomas. Mayo Clin Proc. 1996;71:14-20.

44. van den Bosch JM, Wagenaar SS, Corrin B, Elbers JR, Knaepen PJ, Westermann CJ. Mesenchymoma of the lung (so-called hamartoma): a review of 154 parenchymal and endobronchial cases. Thorax. 1987;42:790-793.

45. Fletcher JA, Longtine J,Wallace K, Mentzer SJ, Sugarbaker DJ. Cytogenetic and histologic findings in 17 pulmonary chondroid hamartomas: evidence for a pathogenetic relationship with lipomas and leiomyomas. Genes Chromosomes Cancer. 1995;12:220-223.

46. Kazmierczak B, Bol S, Wanschura S, Bartnitzke S, Bullerdiek J. PAC clone containing the HMGI(Y) gene spans the breakpoint of a 6p21 translocation in a uterine leiomyoma cell line. Genes Chromosomes Cancer. 1996;17:191-193.

47. Fletcher JA, Pinkus GS, Donovan K, et al. Clonal rearrangement of chromosome band 6p21 in the mesenchymal component of pulmonary chondroid hamartoma. Cancer Res. 1992;52:6224-6228.

48. Kazmierczak B, Rosigkeit J, Wanschura S, et al. HMGI-C rearrangements as the molecular basis for the majority of pulmonary chondroid hamartomas: a survey of 30 tumors. Oncogene. 1996;12:515- 521.

49. Kazmierczak B, Wanschura S, Rommel B, Bartnitzke S, Bullerdiek J. Ten pulmonary chondroid hamartomas with chromosome 6p21 breakpoints within the HMG-I(Y) gene or its immediate surroundings. J Natl Cancer Inst. 1996;88: 1234-1236.

50. Goodlad JR, Fletcher CD. Solitary fibrous tumour arising at unusual sites: analysis of a series. Histopathology. 1991;19:515- 522.

51. van de Rijn M, Lombard CM, Rouse RV. Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum, and lung. Am J Surg Pathol. 1994;18: 814-820.

52. Gaffey MJ, Mills SE, Askin FB, et al. Clear cell tumor of the lung: a clinicopathologic, immunohistochemical, and ultrastructural study of 8 cases. Am J Surg Pathol. 1990;14:248-259.

53. Gaffey MJ, Mills SE, Zarbo RJ, Weiss LM, Gown AM. Clear cell tumor of the lung: immunohistochemical and ultrastructural evidence of melanogenesis. Am J Surg Pathol. 1991;15:644-653.

54. Bonetti F, Pea M, Martignoni G, et al. Clear cell (“sugar”) tumor of the lung is a lesion strictly related to angiomyolipoma- the concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC). Pathology. 1994;26:230- 236.

55. Roviaro G, Montorsi M,Varoli F, Binda R, Cecchetto A. Primary pulmonary tumours of neurogenic origin. Thorax. 1983;38:942-945.

56. Gal AA, Brooks JS, Pietra GG. Leiomyomatous neoplasms of the lung: a clinical, histologic, and immunohistochemical study. Mod Pathol. 1989;2:209-216.

57. Carney JA. The triad of gastric epithelioid leiomyosarcoma, functioning extra-adrenal paraganglioma, and pulmonary chondroma. Cancer. 1979;43:374-382.

58. Kim NR, Kim HJ, Kim JK, Han J. Intrapulmonary lipomas: report of 4 cases. Histopathology. 2003;42:305-306.

59. Thomas de Montpreville V, Dulmet EM. Granular cell tumours of the lower respiratory tract. Histopathology. 1995;27:257-262.

60. Gaffey MJ, Mills SE, Askin FB. Minute pulmonary meningothelial-like nodules: a clinicopathologic study of so-called minute pulmonary chemodectoma. Am J Surg Pathol. 1988;12:167-175.

61. Niho S, Yokose T, Nishiwaki Y, Mukai K. Immunohistochemical and clonal analysis of minute pulmonary meningothelial-like nodules. Hum Pathol. 1999; 30:425-429.

62. Ionescu DN, Sasatomi E, Aldeeb D, et al. Pulmonary meningothelial-like nodules: a genotypic comparison with meningiomas. Am J Surg Pathol. 2004;28: 207-214.

63. Lockett L, Chiang V, Scully N. Primary pulmonary meningioma: report of a case and review of the literature. Am J Surg Pathol. 1997;21:453-460.

64. Abbondanzo SL, Rush W, Bijwaard KE, Koss MN. Nodular lymphoid hyperplasia of the lung: a clinicopathologic study of 14 cases. Am J Surg Pathol. 2000;24:587-597.

65. Matsubara O, Tan-Liu NS, Kenney RM, Mark EJ. Inflammatory pseudotumors of the lung: progression from organizing pneumonia to fibrous histiocytoma or to plasma cell granuloma in 32 cases. Hum Pathol. 1988;19:807-814.

66. Cerfolio RJ, Allen MS, Nascimento AG, et al. Inflammatory pseudotumors of the lung. Ann Thorac Surg. 1999;67:933-936.

67. Zen Y, Kitagawa S, Minato H, et al. IgG4-positive plasma cells in inflammatory pseudotumor (plasma cell granuloma) of the lung. Hum Pathol. 2005;36: 710-717.

68. Gal AA, Koss MN, McCarthy WF, Hochholzer L. Prognostic factors in pulmonary fibrohistiocytic lesions. Cancer. 1994;73:1817- 1824.

69. Snyder CS, Dell’Aquila M, Haghighi P, Baergen RN, Suh YK, Yi ES. Clonal changes in inflammatory pseudotumor of the lung: a case report. Cancer. 1995; 76:1545-1549.

70. Su LD, Atayde-Perez A, Sheldon S, Fletcher JA, Weiss SW. Inflammatory myofibroblastic tumor: cytogenetic evidence supporting clonal origin. Mod Pathol. 1998;11:364-368.

71. Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001;14:569-576.

72. Yousem SA, Shaw H, Cieply K. Involvement of 2p23 in pulmonary inflammatory pseudotumors. Hum Pathol. 2001;32:428-433.

73. Kinoshita Y, Tajiri T, Ieiri S, et al. A case of an inflammatorymyofibroblastic tumor in the lung which expressed TPM3- ALK gene fusion. Pediatr Surg Int. 2007; 23:595-599.

74. Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 2007;31:509-520.

75. Chun YS, Wang L, Nascimento AG, Moir CR, Rodeberg DA. Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis. Pediatr Blood Cancer. 2005;45:796-801.

76. Kato S, Kondo K, Teramoto T, et al. A case report of inflammatory pseudotumor of the lung: rapid recurrence appearing as multiple lung nodules. Ann Thorac Cardiovasc Surg. 2002;8:224-227.

77. Chan JK, Cheuk W, Shimizu M. Anaplastic lymphoma kinase expression in inflammatory pseudotumors. Am J Surg Pathol. 2001;25:761-768.

78. Cook JR, Dehner LP, Collins MH, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol. 2001;25:1364-1371.

79. Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol. 2000;157: 377-384.

80. Lohr RH, Boland BJ, Douglas WW, et al. Organizing pneumonia: features and prognosis of cryptogenic, secondary, and focal variants. Arch Intern Med. 1997;157:1323-1329.

81. Yousem SA. Pulmonary apical cap: a distinctive but poorly recognized lesion in pulmonary surgical pathology. Am J Surg Pathol. 2001;25:679-683.

82. Dacic S, Colby TV, Yousem SA. Nodular amyloidoma and primary pulmonary lymphoma with amyloid production: a differential diagnostic problem. Mod Pathol. 2000;13:934-940.

83. Cordier JF, Loire R, Brune J. Amyloidosis of the lower respiratory tract: clinical and pathologic features in a series of 21 patients. Chest. 1986;90:827-831.

84. Podbielski FJ, Nelson DG, Pearsall GF Jr, Marquez GD, Connolly MM. Nodular pulmonary amyloidosis. J Thorac Cardiovasc Surg. 1997;114:289-291.

85. Asad S, Aquino SL, Piyavisetpat N, Fischman AJ. False- positive FDG positron emission tomography uptake in nonmalignant chest abnormalities. AJR Am J Roentgenol. 2004;182:983-989.

86. Yousem SA, Hochholzer L. Pulmonary hyalinizing granuloma. Am J Clin Pathol. 1987;87:1-6.

87. Ikard RW. Pulmonary hyalinizing granuloma. Chest. 1988;93:871- 872.

88. Hillerdal G. Rounded atelectasis: clinical experience with 74 patients. Chest. 1989;95:836-841.

89. Menzies R, Fraser R. Round atelectasis: pathologic and pathogenetic features. Am J Surg Pathol. 1987;11:674-681.

Alain C. Borczuk, MD

Accepted for publication January 8, 2008.

From the Department of Surgical Pathology, Columbia University Medical Center, New York, NY.

The author has no relevant financial interest in the products or companies described in this article.

Reprints: Alain C. Borczuk, MD, Columbia University Medical Center, 630 W 168th St, New York, NY 10032 (e-mail: ab748@columbia. edu).

Copyright College of American Pathologists Jul 2008

(c) 2008 Archives of Pathology & Laboratory Medicine. Provided by ProQuest Information and Learning. All rights Reserved.

Pulmonary Sarcomatous Tumors

By Litzky, Leslie A

* Context.-Sarcomatous pulmonary neoplasms are a rare and diagnostically challenging group of tumors. Primary pulmonary sarcomas must be distinguished from the more frequent occurrence of sarcoma metastatic to the lung, primary pulmonary sarcomatoid carcinoma, and diffuse malignant mesothelioma involving the lung. In current practice, the general availability of ancillary diagnostic techniques, such as immunohistochemistry and molecular analysis, can reliably classify many sarcomatoid lesions. Objective.-To review the literature and report on additional primary material about the application of immunohistochemistry and molecular analysis in the differential diagnosis pulmonary sarcomatous neoplasms.

Data Sources.-Literature review of relevant articles indexed in PubMed (National Library of Medicine) between 1961 and 2007 and primary material from the author’s institution.

Conclusions.-This review discusses specific criteria for the diagnosis of primary lung sarcomas and offers a practical approach to excluding other sarcoma-like lesions involving the lung. The pathologist has an essential role in evaluating these tumors and will often be the first to suggest an unusual, alternative diagnosis, which may have significant implications for patient care, therapy, and prognosis.

(Arch Pathol Lab Med. 2008;132:1104-1117)

Sarcomatous pulmonary neoplasms are a rare but diverse and diagnostically challenging group of tumors. Primary pulmonary sarcomas must be distinguished from the more frequent occurrence of sarcoma metastatic to the lung, primary pulmonary sarcomatoid carcinoma, and diffuse malignant mesothelioma involving the lung. Spindle cell tumors of the pleura, as well as those tumors primary from the chest wall or mediastinum, may present as either localized or diffuse masses and, depending on the extent of thoracic involvement, may be difficult to distinguish from those of pulmonary origin. This review discusses specific criteria for the diagnosis of primary lung sarcomas and offers a practical approach to excluding other sarcoma-like lesions involving the lung.

HISTORICAL PERSPECTIVE AND CURRENT PRACTICE

From a clinical, radiographic, and pathologic perspective, metastases and primary pulmonary carcinomas far exceed the incidence of primary pulmonary sarcomas. In practice, a tumor that is initially thought to be a primary sarcoma of the lung can prove, on further inquiry into patient history, to be a late metastasis from a primary soft tissue tumor or, on further sampling, to be a sarcomatoid carcinoma. The widespread use of immunohistochemistry and, more recently, molecular diagnosis has altered previous diagnostic categories. In current practice, many tumors that were classified in older literature as fibrosarcoma, malignant fibrous histiocytoma, or hemangiopericytoma are now more reliably classified as other entities. The availability of multiple cytokeratin antibody tests has improved the identification of sarcomatoid carcinomas and diffuse malignant mesothelioma. The introduction of CD34 has facilitated the recognition of both benign and malignant intrathoracic, fibrous tumors. It is now possible to assemble a substantial panel of immunohistochemical markers that, in the appropriate histologic context, will reliably identify tumors of vascular, muscular, or neural origin. The wider availability of paraffin-based molecular assays for the characteristic translocation found in synovial sarcoma has led to an appreciable increase in its diagnosis. Improved radiographic techniques, including vascular imaging, have led to more precise localization of malignancies that arise in an intravascular location and allowed for further separation of pulmonary endovascular sarcomas from other parenchyma- based pulmonary sarcomas. Pulmonary artery sarcomas will not be specifically discussed, but a study of these similarly uncommon tumors has recently been published.1 Despite, these diagnostic refinements, the relative rarity of primary pulmonary sarcomas makes it difficult to assemble statistically meaningful case studies and to fully understand the natural history and biology of these tumors.

As a general rule that is true for all lung lesions, the pathologist should be certain to obtain all clinical history when confronted with a malignant spindle cell lesion in the lung. Any history of a previous malignancy or procedure is potentially relevant, including a remote history of a previously treated sarcoma, which can recur after a long latency. In particular, a spindle cell lesion of the lung in a woman should always prompt an inquiry into gynecologic history. Pertinent questions include whether there has been a hysterectomy for a “benign disease” and the date of the most recent gynecologic examination. Sarcomas metastatic to the lung outnumber primary pulmonary sarcomas and, depending on one’s index of suspicion, the pathologist may need to take a more active role in prompting clinical colleagues to consider an occult or remote soft tissue primary. The pathologist should insist on radiographic correlation, particularly when handling a cytology sampling or core needle biopsy. Is the lesion clearly parenchymal, or is there pleural or bone and soft tissue involvement? Is there adenopathy or other mediastinal abnormalities? Other primary intrathoracic sites, including the heart and great vessels, mediastinum, esophagus, chest wall, and pleura, must be considered when the radiographic findings are difficult to interpret or the lesion difficult to localize.

The size of the tissue during the initial diagnostic procedure may preclude complete characterization of the lesion, but, once a hematopoietic malignancy has been excluded, that is usually of limited consequence if the patient is a candidate for surgery and a larger biopsy or attempt at resection is clinically indicated. Although most diagnostic workup on tissue from any subsequent, larger specimen can be performed reliably on appropriately formalin- fixed, paraffin-embedded tissue, it is still reasonable to procure fresh tumor tissue, if available, for future studies or for electron microscopy, which may prove useful in difficult cases. Pathologic examination of the resected specimen must include a full sampling of the lesion. Statistically, most spindle cell lesions of the lung will prove to be poorly differentiated carcinomas with sarcomatous differentiation (sarcomatoid carcinomas). Extensive sampling will often reveal recognizable foci of an epithelial tumor, particularly if any endobronchial component is thoroughly sectioned or more differentiated areas in a high-grade tumor are detected. After histologic examination, if necessary, the immunohistochemical evaluation should proceed in the manner familiar to most pathologists for any spindle cell lesion. The workup for specific pulmonary sarcomas will be reviewed in each section, but as a starting point, the diagnostic panel for a sarcomatous tumor in the lung should include multiple cytokeratins tests, as well as epithelial membrane antigen (EMA) staining, with the caveat that focal cytokeratin or EMA positivity can be problematic. Caution should be exercised to avoid overinterpreting what may be entrapped, reactive alveolar or bronchial cells. Similarly, cytokeratin positivity can be demonstrated in a variety of sarcomas. There are, however, occasional cases of sarcomatous lesions in the lung in which even extensive use of ancillary diagnostic techniques fails to provide a definitive diagnosis or only reduces the differential diagnosis to 2 entities that cannot be further distinguished. Nevertheless, as will be readily apparent in this review, these tumors are generally not distinguishable by clinical presentation, radiographic findings, or even gross appearance. The pathologist is critical to the histologic evaluation of these tumors and will most likely be the first to suggest an unusual, alternative diagnosis, which can have significant implications for patient care, therapy, and prognosis.

PRIMARY PULMONARY SARCOMATOID CARCINOMA

Tumors that have sarcoma-like elements, such as malignant spindle or giant cells, or that have a sarcomatous component that consists of a neoplastic but differentiated connective tissue phenotype, such as neoplastic bone, cartilage, or striated muscle, have been described in many primary organ sites, including the lung. The classification of these poorly differentiated primary non-small cell lung tumors, which contain a component of sarcoma or sarcoma-like elements, had been a matter of some controversy in earlier literature, and these tumors had been described under a variety of names. The 1999 and 2004World Health Organization (WHO) classifications of lung tumors set forth criteria for the classification of these tumors in an attempt to foster uniformity and to provide more refined prognostic information in the future.2,3 The 1999 revision established a minimum requirement of 10% for the certain elements, such as spindle cells or giant cells, for a tumor to be appropriately classified. The 2004 WHO revision recommended the term sarcomatoid carcinoma to categorize these tumors. As defined in the 2004 WHO criteria, sarcomatoid carcinomas are a group of poorly differentiated non-small cell lung carcinomas that contain a component of sarcoma or sarcoma-like (spindle or giant cell or both) differentiation. There are 5 recognized subgroups-pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma-and these 5 subgroups represent a morphologic continuum.3 Tumors that are composed exclusively of spindle cells or giant cells are termed spindle cell carcinoma and giant cell carcinoma, respectively. These pure forms are extremely rare. A tumor consisting of a poorly differentiated squamous cell carcinoma, adenocarcinoma, or large cell carcinoma admixed with spindle cells or giant cells (comprising >/=10% of the tumor) is termed pleomorphic carcinoma. Carcinosarcoma is defined as a malignant tumor with a mixture of carcinoma and sarcoma containing differentiated sarcomatous elements, such as malignant cartilage, bone, or skeletal muscle. In addition to the histologic recognition of these malignant, sarcomatous elements, immunohistochemistry with epithelial markers (multiple cytokeratin antibodies, carcinoembryonic antigen [CEA], and EMA) is often used to confirm epithelial differentiation. The WHO classification relies on histologic criteria using routine light microscopy and does not require the demonstration of positive immunohistochemical staining for cytokeratin if there is a component of squamous cell carcinoma, adenocarcinoma, or large cell carcinoma present. When cytokeratin stains are negative, however, it may be difficult to separate these tumors from primary or metastatic sarcoma. The overall frequency of more specific sarcomatous differentiation is rhabdomyosarcoma, followed by osteosarcoma or chondrosarcoma or combinations of osteosarcoma and chrondrosarcoma.4 The sarcomatous elements of these tumors share the same immunohistochemical profile as their primary malignant mesenchymal counterparts, for example, the cartilage will stain positive for S100. Pulmonary blastoma is defined as a biphasic tumor containing a primitive epithelial component, which may resemble well-differentiated fetal adenocarcinoma, and a primitive mesenchymal stroma that occasionally has foci of osteosarcoma, chondrosarcoma, or rhabdomyosarcoma. This tumor presents mainly in adults and should be distinguished from pleuropulmonary blastoma, a malignant tumor of infancy and early childhood.5 Sarcomatoid carcinomas of the lung are rare, representing less than 1.5% of all patients with non-small cell lung cancer, with about 30 case reports and larger series in the literature that have variably characterized these tumors. 4,6-32 Sarcomatoid carcinomas have no distinguishing radiologic features and have been reported in both central and peripheral locations. With the exception of pulmonary blastoma, which appears to be most frequent in the fourth decade and occurs equally in women and men, the other variants tend to present in the sixth and seventh decade. In the most recent large study of sarcomatoid carcinoma, which focused on prognosis in relationship to other non-small cell lung carcinomas, men were not predominant, which had been the case in prior series.32 There is a strong association with tobacco use. Most patients with sarcomatoid carcinomas are cigarette smokers, and therefore, it is reasonable to maintain a high index of suspicion for sarcomatoid carcinoma when evaluating a malignant, sarcomatous tumor in the lung of a smoker. Most sarcomatoid carcinomas are between 3 and 11 cm, with a size range from 2 to 16 cm. The tumors are usually gray-white, and areas of hemorrhage or necrosis are frequent (Figure 1).

Careful sampling remains the practical key to distinguishing these tumors from a primary pulmonary sarcoma. Previously published reports with histologic analysis of these tumors underscore the need for careful sampling. The malignant stroma is often the predominant component in the carcinosarcoma, and the foci of carcinoma are small (Figures 2 through 5). Similarly, the poorly differentiated spindle cell component may predominate, and a careful search is required to identify the heterologous elements. Although the malignant stroma often constitutes most of the lesion, thorough sectioning of at least 1 section per centimeter of tumor diameter, particularly of the endobronchial component, if present, usually demonstrates small, identifiable foci of squamous cell carcinoma, adenocarcinoma, large cell carcinoma, or the distinctive fetaltype glands found in pulmonary blastoma. After extensive sampling of these epithelial elements, strong cytokeratin positivity is most helpful in making the diagnosis of sarcomatoid carcinoma. Even with the demonstration of cytokeratin positivity, other cytokeratin-positive sarcomas might remain within the differential diagnosis, depending on the tumor’s histologic appearance. Evaluation for the characteristic (X;18)(p11.2;q11.2) translocation may prove useful in some cases when synovial sarcoma is in the differential diagnosis. Sarcomatoid carcinomas can express vimentin and smooth muscle markers. This positivity should not be used to exclude the diagnosis of sarcomatoid carcinoma. Pulmonary blastoma, in particular, may be positive for neuroendocrine markers, such as chromogranin, further confounding the differential diagnosis. It is difficult to compare the behavior of these poorly differentiated carcinomas to primary pulmonary sarcomas, but the separation of sarcomatoid carcinoma from other histologic types of non-small cell carcinoma has clinical relevance. It is generally agreed in the available literature that sarcomatoid carcinoma, stage for stage, has a higher risk for both local and distant recurrence, resulting in a poorer prognosis.32

DIFFUSE MALIGNANT MESOTHELIOMA

In overall incidence, diffuse malignant mesothelioma is more common than primary pulmonary sarcoma, and the differential diagnosis of a biopsy from an adult with an ill-defined pleuroparenchymal or mediastinal mass should routinely include diffuse malignant mesothelioma. As has been emphasized in the diffuse malignant mesothelioma literature, a history of asbestos exposure should not affect consideration or exclusion of this diagnosis.33 Sarcomatoid diffuse malignant mesothelioma is the subtype most likely to be considered in the differential diagnosis of a sarcomatous lesion and, in rare instances, a biphasic diffuse malignant mesothelioma. Sarcomatoid diffuse malignant mesotheliomas can have a variety of histologic patterns that overlap with pulmonary sarcomas. The most common pattern is a fibrosarcoma-like pattern of spindle cells arranged in storiform, fascicular, or haphazard patterns (Figure 6). Other less-common variants include a malignant fibrous histiocytoma-like tumor and diffuse malignant mesotheliomas with malignant smooth muscle, chondroid, osseous, or rhabdomyoblastic differentiation. An immunohistochemical panel for the initial evaluation of a sarcomatoid diffuse malignant mesothelioma should include cytokeratins, calretinin, and D2-40. Multiple cytokeratin antibodies, including AE1/3, CAM 5.2 (or cytokeratin [CK] 18), and CK7, should be used because cytokeratin expression can be focal, weak, or variable.34 Other affirmative markers that are used in the evaluation of epithelioid diffuse malignant mesothelioma, such as Wilms tumor (WT1) and CK5/6, as well as adenocarcinoma markers, such as BER-Ep4, CEA, and MOC-31, are unnecessary and should not be included in the workup. A histologically malignant sarcomatoid tumor that is convincingly positive for cytokeratin usually limits the differential diagnosis to sarcomatoid diffuse malignant mesothelioma, sarcomatoid carcinoma, synovial sarcoma, and other metastatic carcinomas. D2-40 and calretinin have been the 2 affirmative mesothelial markers most consistently expressed in sarcomatoid diffuse malignant mesotheliomas, although the percentage of positive cases is low when compared with the epithelial subtype.35,36 In a recent, large tissue- microarray study that included more than 300 diffuse malignant mesotheliomas, calretinin expression was found in 57% of sarcomatoid tumor areas and D2-40 immunostaining was present in 30% of the sarcomatoid tumor areas.37 False positives can occur when benign, entrapped lymphatics or reactive mesothelial elements are misinterpreted. Without convincing calretinin and D2-40 positivity, it is difficult to separate the spindled cell component of a partially sampled sarcomatoid carcinoma from sarcomatoid diffuse malignant mesothelioma. Heterologous elements may be present in both tumors. A possible distinguishing feature may be the identification of areas in which the malignant cells are infiltrating through densely collagenized fibrosis, as is characteristic of desmoplastic diffuse malignant mesothelioma (Figure 7). This pattern is quite typical of diffuse malignant mesothelioma and favors that diagnosis, although ultimately, in this instance, the diagnosis may have to incorporate other gross and clinical features. Synovial sarcomas of the pleura (or primary pulmonary synovial sarcomas involving the pleura) usually present as localized solid tumors, but synovial sarcomas can present with diffuse pleural thickening that is similar to diffuse malignant mesothelioma. As will be discussed in the section on synovial sarcoma, the diagnosis of synovial sarcoma is confirmed in most instances by molecular testing. Conversely, a histologically malignant sarcomatoid tumor that is either focally positive or negative for cytokeratin should be cautiously interpreted. Focal cytokeratin positivity has been reported in many different types of sarcomas, or alternatively, focal cytokeratin positivity could represent entrapment of benign pleural elements. In this instance, if possible, additional blocks should be selected, and cytokeratin antigen-retrieval techniques, as well as antibody source and dilutions, should be considered. A vimentin stain is useful in assessing the general antigenic integrity of the tissue. Particularly in the absence of convincing cytokeratin positivity, calretinin or D2-40 positivity alone should not be interpreted as evidence of mesothelial differentiation. These markers are variably positive in many different types of sarcomas, and other immunohistochemical markers, such as CD31, CD34, desmin, myoglobin, and S100 should be added. The expanded differential diagnosis might include other sarcomas (epithelioid hemangioendothelioma, angiosarcoma, synovial sarcoma, liposarcoma, myogenic or neurogenic tumors, malignant solitary fibrous tumor) and melanoma. It should be noted that some muscle markers are positive, at least focally, and on occasion, more diffuse, in sarcomatoid diffuse malignant mesotheliomas.38 These markers include muscle-specific actin (HHF35) and alpha-smooth muscle actin. Desmin positivity in pure sarcomatoid diffuse malignant mesotheliomas is quite rare.39 In the final analysis, cytokeratin-negative sarcomatoid diffuse malignant mesotheliomas have been documented, and this seems to be particularly true of sarcomatoid diffuse malignant mesotheliomas with osteosarcomatous differentiation.34,40,41 PRIMARY LEIOMYOSARCOMA OF THE LUNG

Malignant tumors with smooth muscle differentiation are reliably diagnosed in the lung using criteria that are familiar to pathologists for similar tumors that arise in other sites, such as the uterus, gastrointestinal tract, or soft tissue. As noted in the introduction, the more important issue is usually excluding a metastasis from another site, which is impossible to do without the benefit of a careful and complete clinical history as well as thorough radiographic imaging. If metastasis can be confidently excluded, then pulmonary leiomyosarcomas can be subdivided into those that are primary within the pulmonary artery and those that originate within a bronchus or the pulmonary parenchyma. Moran et al42 reviewed 18 patients with primary leiomyosarcomas of the lung. In that study, there was a wide age range of 5 to 76 years, with a mean age of 50 years. Most patients were asymptomatic, and the lesions were discovered by routine physical and radiographic examination. As would be anticipated, only those patients with tumors that were endobronchial or bulky and locally invasive presented with symptoms, such as cough, hemoptysis, or chest pain. There was also a broad range of sizes-from 1.7 to 10 cm at greatest dimension-but size was not necessarily a reliable prognostic indicator. At least 2 lesions less than 3 cm, which were histologically high grade, proved fatal within 1 year. Grossly, all of the lesions were described as well circumscribed, grayish white, firm, and rubbery. In high-grade lesions, areas of hemorrhage and necrosis were readily identified.

The histologic diagnosis of leimoyosarcoma is prompted by the recognition of a spindle cell proliferation that is characterized by broad fascicles of tumor cells that intersect at right angles. The tumor cells typically have scant fibrillary eosinophilic cytoplasm and elongated, bluntended nuclei (Figure 8). All of these features are more readily recognizable in lower-grade lesions. Moran et al42 subdivided these tumors into low grade, intermediate grade, and high grade. Low-grade lesions showed only mild cytologic atypia and occasional mitoses (average, 1-3 per 10 high-power fields [HPFs]). Cellular pleomorphism and areas of necrosis or hemorrhage were absent. Intermediate-grade lesions retained a fascicular growth pattern, but the tumors were more cellular, and the mitotic rate increased slightly (average, 3-8 per 10 HPFs). Cellular pleomorphism was rare, and areas of hemorrhage or necrosis were not apparent. In the high-grade lesions, epithelioid morphology and a fascicular configuration were focal with more solid areas of spindle cell proliferation. Storiform and hemangiopericytoma-like patterns were also identified. The tumor cells showed marked cellular pleomorphism with frequent mitotic figures (average, 8-12 mitoses per 10 HPFs). In their series,42 15 patients had follow-up. Six patients with low- grade or intermediate-grade lesions were alive and free of disease with 2 to 12 years of follow-up. Eight patients with high-grade lesions died of disease within 24 months of diagnosis. Highgrade histology, however, was not invariably predictive of a poor prognosis. One patient with a high-grade, 7-cm mass in the right upper lobe and bronchus was alive at 12 years follow-up without evidence of metastases.

The histologic impression of smooth muscle differentiation can be confirmed by a panel of immunohistochemical markers, such as desmin and smooth muscle actin. Confirmation of diagnosis is considerably less complicated in low-grade or intermediate-grade lesions. There is a tendency, however, for these stains to be more focal and weak in higher-grade lesions. Although there are other markers of smooth muscle differentiation available (HHF35, calponin), none of these markers are significantly more sensitive in higher-grade lesions. An additional pitfall may be the presence of scattered, keratin- positive, atypical cells. The differential diagnosis in higher- grade lesions includes a malignant solitary fibrous tumor, a malignant peripheral nerve sheath tumor, synovial sarcoma, sarcomatoid carcinoma, and malignant fibrous histiocytoma (if one accepts malignant fibrous histiocytoma as a distinct entity in the lung). There are some variations in histologic growth patterns and cytologic features, which might help to suggest an alternative diagnosis. Narrower fascicular bundles and a herringbone pattern are more typical of tumors formerly considered to be fibrosarcomas. There is a general tendency for primary neurogenic sarcomas to show wavy nuclei rather than blunt-ended nuclei, but overlaps in alternating fascicular growth pattern with cellular pleomorphism may be seen in both lesions. Primary synovial sarcomas may also show an alternating fascicular growth pattern and closely resemble a high- grade leiomyosarcoma. High-grade leiomyosarcomas can have areas with storiform growth patterns similar to a malignant fibrous histiocytoma. In those instances, the absence of reactivity for smooth muscle markers, plus an affirmative marker, such as CD34, S100, or multiple cytokeratins, may help to confirm an alternative diagnosis. The diagnosis of malignant fibrous histiocytoma requires the complete absence of any differentiation markers. It is less likely that a high-grade leiomyosarcoma will be confused with a sarcomatoid carcinoma if the lesion is well sampled and multiple cytokeratin antibodies are used.

PRIMARY PULMONARY SYNOVIAL SARCOMA

As defined by the 2004 WHO classification,3 pulmonary synovial sarcoma is a mesenchymal spindle cell tumor, which variably displays areas of cellular differentiation. Zeren et al43 were the first to report on a large series of 25 primary pulmonary synovial sarcomas, which were otherwise histologically indistinguishable from those monophasic synovial sarcomas of the soft tissues. Following this initial description, several additional series followed, and the recognition of the entity was further facilitated by the availability of molecular testing for the characteristic t(X;18) chromosomal translocation, which allows for diagnostic confirmation in more than 90% of cases.44-48 There remains a smaller subset of tumors that are more difficult to recognize when histological features unusual to synovial sarcomas, but common in other tumors, are focally present. This diagnostic dilemma was recently addressed in a large clinicopathologic study,47 which included 34 cases of pulmonary synovial sarcoma, as well as 5 mediastinal and 10 pleural synovial sarcomas. The common presenting symptoms (dyspnea, cough, chest pain, hemoptysis, or incidental radiographic finding) do not significantly differ from other lung tumors and are site-specific. In the 5 series that included primary pulmonary sarcomas, there was no gender bias, and there was a wide variation in age range with an overall median of about 40 years.43-47 Most pulmonary tumors are peripheral with occasional cases forming an endobronchial mass. At least 75% of the reported cases to date have been unencapsulated solid tumors with well-demarcated margins, but diffuse infiltration into the pleura/chest wall or mediastinum also has been described.44,46 The term pleuropulmonary synovial sarcoma may be reasonably applied in instances where it is not possible to precisely localize the tumor. Tumor size has been between 0.6 and 17 cm (with means in the 5-8-cm range). On cut surface, tumors are typically soft, tan masses, with foci of necrosis, hemorrhage, and cystic change (Figure 9). The monophasic subtype that consists solely of a spindle cell component is the most common subtype. Caution should be exercised to avoid misinterpreting entrapped pneumocytes as an epithelial component, but it is clear that there are pulmonary tumors with biphasic histology. A substantial minority of pulmonary tumors are poorly differentiated. The generally aggressive clinical behavior of pulmonary synovial sarcomas, from which most patients are dead of disease at 5 years, has been attributed to the percentage of tumors with poor differentiation, as well as the comparatively later presentation and the difficulty in obtaining a wide surgical margin when compared with its soft tissue counterpart. Tumors tend to recur locally with extension into the chest wall, pericardium, paraspinal soft tissue, diaphragm, and abdomen.

The monophasic subtype consists of densely packed, elongated spindle cells, arranged in interweaving fascicles. A prominent hemangiopericytoma-like vascular pattern is quite common as are other typical features of synovial sarcoma, such as dense hyalinized or eosinophilic stroma and focal myxoid change (Figures 10 through 12). Calcification is present in about 15% of cases. Mast cell infiltration may not be readily identified on hematoxylin-eosin (H&E) stains but can be highlighted by CD117 staining.47 In biphasic tumors, the epithelial component consists of cleftlike glandular spaces with scattered tubulopapillary differentiation. Poorly differentiated tumors can be classified according to Federation Nationale des Centres de Lutte Contre le Cancer grading, which incorporates tumor differentiation, mitotic count, and tumor necrosis. Unusual histologic features in pulmonary synovial sarcomas include Verocay body-like formations, vague rosettes, wellformed papillary structures, adenomatoid change, and rhabdoid morphology.47 The major differential diagnosis of synovial sarcoma arising in the lung includes sarcomatoid carcinoma, the biphasic or sarcomatoid subtype of pleural diffuse malignant mesothelioma, leiomyosarcoma, malignant solitary fibrous tumor or fibrosarcoma, and malignant peripheral nerve sheath tumor. It is also critical to consider metastasis from an occult extrathoracic primary because, paradoxically, metastatic disease from an extrathoracic synovial sarcoma may have a more indolent course. Almost all biphasic synovial sarcomas are positive for cytokeratin markers and EMA in the epithelial component. Positive cytokeratin and EMA staining in monophasic synovial sarcomas is still quite high and in the general range of 50% to 70% but the staining is often less intense than in the epithelial component. Cytokeratins 7 and 19 may be particularly helpful because these cytokeratins are often negative in other spindle cell sarcomas.49,50 A certain number of synovial sarcomas will be positive for S100, and this may make differentiation from a malignant peripheral nerve sheath tumor problematic.51 Synovial sarcomas are strongly and diffusely positive for Bcl-2, but that is of limited utility in distinguishing synovial sarcoma from other sarcomas. CD99, which is frequently positive in synovial sarcoma, is a potential diagnostic pitfall given the morphologic overlap with some cases of primitive neuroectodermal tumors.51 A high percentage of calretinin positivity is similarly problematic given the morphologic overlap with diffuse malignant mesothelioma.52 D2-40 positivity has also been reported in epithelioid component of synovial sarcomas.36 Some synovial sarcomas are positive for smooth muscle actin, but they should be negative for desmin. TLE1 has recently been proposed53 as another marker with high sensitivity for synovial sarcomas, although moderate staining was seen in a significant number of solitary fibrous tumors and hemangiopericytomas. When a combination of molecular approaches to detect the SS18-SSX fusion transcripts is used and interpreted along with clinical and immunohistochemical data, a very high degree of sensitivity and specificity for the diagnosis of synovial sarcoma can be achieved.48

MALIGNANT PERIPHERAL NERVE SHEATH TUMOR

Malignant peripheral nerve sheath tumors (MPNSTs) are defined as any malignant tumor arising from a peripheral nerve or showing nerve sheath differentiation, with the exception of tumors originating from the epineurium or the peripheral nerve vasculature.54 It is unlikely that diagnostic difficulties will occur in the clinical setting of a patient with known type I neurofibromatosis, but sporadic cases do occur with some frequency in the thorax, and there is a known association in sites of previous radiation. 54 There are instances when the site of origin is not clearly localized to the chest wall or to the mediastinum and when definitive diagnosis may be difficult in a tumor with infiltrative borders. If the sampling is large enough, observing tumor growth in relationship to adjacent nerves may help to support the diagnosis. Histologically, highgrade peripheral nerve sheath tumors might easily be confused with leiomyosarcoma, monophasic synovial sarcoma, sarcomatoid diffuse malignant mesothelioma, malignant solitary fibrous tumor, or fibrosarcoma. The most common pattern of MPNST is fibrosarcoma- like, where the tumor is composed of hyperchromatic spindle cells that are arranged in a fascicular pattern (Figures 13 and 14). Alternating areas of hypocellurity and hypercellurity are seen, in addition to foci of necrosis and increased mitoses. Focal benign epithelial or malignant mesenchymal differentiation has been well documented. Rhabdomyosarcomatous differentiation is most commonly seen, but osseous and chondromatous differentiation can also occur. 55 In addition to the complexities introduced by divergent differentiation, there is variability in S100 staining, such that only 50% to 70% of MPNSTs will show scattered tumor cells that are S100 positive.56 The significant phenotypic and immunophenotypic overlap between MPNSTs and synovial sarcoma extends to molecular analysis, where it has been demonstrated that the t(X;18) is not entirely specific to synovial sarcoma.57 At the current time, there is a small subset of thoracic tumors in which it is simply not possible to conclusively exclude either possibility.

MALIGNANT SOLITARY FIBROUS TUMOR

It is now well accepted that solitary fibrous tumor is a distinctive mesenchymal tumor of probable fibroblastic origin with a range of appearances that can vary from a fibrous variant to a more cellular variant to a tumor with a prominent hemangiopericytoma- like growth pattern. The tumor commonly involves the pleura and occasionally arises within the lung or mediastinum, as well as within a number of extrathoracic sites. Following the study by van de Rijn et al in 1994,58 which documented CD34 expression by solitary fibrous tumors of the pleura, mediastinum, and lung, the diagnosis of primary pulmonary hemangiopericytoma has virtually disappeared from the pathology literature.59-61 Solitary fibrous tumors classically show a patternless architecture with both hypocellular and hypercellular areas separated by fibrous stroma having hemangiopericytoma-like, branching blood vessels. The hypercellular areas show bland spindle cells arranged in short intersecting fascicles, creating herringbone or storiform arrays (Figures 15 and 16).59 The hypocellular areas may be densely collagenized or show myxoid change. As in better-differentiated leiomyosarcomas, it is seldom difficult to confirm the diagnosis of an intrapulmonary solitary fibrous tumor, which is largely fibrous, by positive CD34 and Bcl-2 staining along with reciprocal negative staining for cytokeratin. The diagnosis becomes more problematic in more cellular or frankly malignant lesions. A hemangiopericytoma- like pattern of branching vessels is typically seen in solitary fibrous tumors. However, a hemangiopericytomatous pattern can also be seen in synovial sarcomas, malignant peripheral nerve sheath tumors, leiomyosarcomas, diffuse malignantmesotheliomas, malignant melanomas, sarcomatoid carcinomas, metastatic endometrial stromal sarcomas, and thymomas-to name other tumors likely to be encountered in the thorax. Low-grade, exclusively intraparenchymal, solitary, fibrous tumors have been reported in the lung, but the criteria predictive of malignancy have been based on pleuralbased tumors and must be extrapolated to tumors that might appear to be primarily parenchymal. These criteria include greater cellularity with an infiltrative growth pattern, moderate to marked cytologic atypia, and a high mitotic rate (>4 mitoses per 10 HPFs).62 In instances of a malignant sarcomatoid tumor that is suspected to be a malignant solitary fibrous tumor but appears to be CD34 negative, extensive sectioning may yield areas that are better differentiated and more likely to be CD34 positive (Figures 17 through 20). Otherwise, the diagnosis may rest on the workup and exclusion of other entities, such as synovial sarcoma.

PULMONARY EPITHELIOID HEMANGIOENDOTHELIOMA

Epithelioid hemangioendothelioma is a low-grade to intermediate- grade vascular tumor with a distinctive histologic appearance, which has been described in the lung as well as in numerous other sites including the liver, soft tissue, bone, mediastinum, and pleura.63 The tumor is distinctive in histologic appearance with short cords and nests of epithelioid cells associated with a myxohyaline matrix (Figure 21). In the lung, the tumor has been reported most frequently in whites, and most often in white women (80%).64-66 Most patients have been younger than 40 years but with a wider age range from 12 to 61 years. About half of patients are asymptomatic, with the remaining half presenting with cough, dyspnea, or chest pain. The radiographic presentation is typically that of multiple bilateral nodules of varying size (in the general range of 1-2 cm), with occasional calcification. Solitary lung masses have also been described. The presence of multiple lesions always raises the issue of metastasis from another site, and these findings should prompt a careful radiographic evaluation. Cases with multifocal and bilateral disease, in the absence of a documented extrathoracic primary, have been reported. Grossly, the tumor is usually circumscribed with a gray-white or gray-tan appearance. The cut surface has a cartilaginous consistency, and there may be central calcification. Of the malignant tumors in the lung, the entity that epithelioid hemangioendothelioma would be most likely confused with is chondrosarcoma. This differential diagnosis is easily sorted out by immunohistochemical stains for CD31, CD34, friend leukemia integration 1 (Fli1), and S100.67 Cytokeratin stains are not reliable discriminators because 20% to 30% of cases will show focal cytokeratin positivity.63

PRIMARY PULMONARY ANGIOSARCOMA

Primary pulmonary angiosarcomas are exceeding rare, even within the select group of primary pulmonary sarcomas or otherwise rare tumors. Patients typically present with late-stage disease, and in many instances, it is difficult to actually establish that the lung is the primary site. As a practical point, angiosarcoma in the lung is far more likely to represent metastatic disease.68 Whether primary or metastatic, epithelioid angiosarcoma can mimic a carcinoma and show cytokeratin positivity.69 The diagnosis of angiosarcoma should be considered in the immunohistochemical workup of any poorly differentiated tumor within the lung, particularly if associated with excessive hemorrhage (Figure 22). These stains should include CD31 and CD34. KAPOSI SARCOMA

For completeness’ sake, Kaposi sarcoma is included in this discussion of vascular spindle cell lesions in the lung. Unless there is a complete absence of relevant history, radiographic information, and bronchoscopic findings, it is not likely that Kaposi sarcoma will be mistaken for other sarcomatoid tumors in the lung. Kaposi sarcoma typically presents as purple-red, raised nodules along the tracheobronchial tree or as diffuse bronchial wall thickening. The most common patterns of lung involvement are nodular and interstitial infiltrates, in addition to pleural effusion, rather than forming a single large mass as is characteristic of many of the other sarcomatoid lesions. The disease is uniformly associated with human herpesvirus 8 infection. 70 The spindled cells are positive for CD31 and CD34 but not factor VIII (Figure 23).

INFLAMMATORY MYOFIBROBLASTIC TUMOR

As defined by the 2004 WHO classification, inflammatory myofibroblastic tumor is a subgroup in the broad category of inflammatory pseudotumors.71 The lesion is composed of a variable mixture of collagen, inflammatory cells, and usually, cytologically bland spindle cells that show myofibroblastic differentiation. Whether this lesion is a reactive inflammatory condition or a low- grade mesenchymal malignancy remains controversial. Regardless of etiology, this lesion’s clinical, radiographic, and gross presentation overlap with other pulmonary sarcomas. Inflammatory myofibroblastic tumors can occur at any age, although most occur in patients younger than 40 years old, and this tumor is the most common endobronchial mesenchymal lesion reported in childhood. Inflammatory myofibroblastic tumors occur in both endobronchial and peripheral locations. Presenting symptoms reflect the lesion’s location. Patients with endobronchial lesions present with cough, wheezing, and hemoptysis as well as postobstructive pneumonia and atelectasis. Peripheral lesions may be asymptomatic, but some do invade the chest wall and cause pain. Grossly, the lesions are usually solitary, round, rubbery masses, with a wide variation in size range reported from 1 to 36 cm (average size, 3 cm). The variability in yellow to gray discoloration reflects the histiocytic component of the inflammatory infiltrate. Like other sarcomas, the lesions do not appear encapsulated, and local invasion into hilar soft tissue, pleura, or chest wall can be seen.

The identification of this lesion and its separation from other spindle cell tumors may be particularly challenging on an endobronchial biopsy or closed needle biopsy. Like other sarcomas, the spindle cells are arrayed in fascicles or may have storiform architecture. Upon closer examination (and in most cases), the spindle cells should not have obvious cytologic atypia, and mitoses should be rare. The spindle cells typically have oval nuclei, fine chromatin, inconspicuous nucleoli, and abundant lightly eosinophilic cytoplasm (Figure 24). Further consideration of this entity may be prompted by the recognition of a prominent inflammatory infiltrate that includes lymphocytes, plasma cells, and histiocytes as well as Toutonlike giant cells. Foamy histiocytes, in particular, can be quite numerous. The spindle cells show evidence of fibroblastic and myofibroblastic differentiation with expression of vimentin and smooth muscle actin. Desmin immunoreactivity is rare. The spindle cells should be negative for myogenin, myoglobin, CD117 (c-Kit), and S100. Focal cytokeratin reactivity has been reported, but it is not clear whether that represents entrapped alveolar cells. Expression of ALK-1 and p80 has been reported in about 40% of cases, but these stains are not routinely used for diagnosis. With complete excision, the prognosis for this lesion is excellent. Recurrence usually occurs with incomplete excision. About 5% of these lesions may be locally aggressive, recur, or metastasize. Poor prognostic histologic features include focal invasion, vascular invasion, high cellularity, nuclear pleomorphism with bizarre giant cells, a high mitotic rate, and necrosis.

OTHER EXCEEDINGLY RARE SARCOMAS

As with the other rare types of pulmonary sarcoma discussed, it is important to consider the possibility of metastasis from another primary site or more common diagnoses. such as carcinosarcoma, in this group of tumors.

Primary pulmonary rhabdomyosarcomas are extremely rare but have been reported in both children and adults. The widespread use of immunohistochemistry and molecular analysis has increased the recognition of rhabdomyosarcoma in sites throughout the body and has confirmed the lung as an uncommon site. Endobronchial, intraparenchymal, and pulmonary trunk sites have all been reported. The literature has been summarized in several reviews, but it is difficult to determine the reliability of the older reports.72-75 The histologic findings of malignant cells with deeply eosinophilic cytoplasm and cross-striations may suggest the diagnosis, but these are generally difficult to find.72 Immunohistochemical stains, such as desmin and myoglobin, are useful, but staining can be focal.

Primary Chondrosarcoma of the Lung

Nearly all the older and current literature on primary chondrosarcomas of the lung consist of single-case reports with review of the literature.72,76-78 Both endobronchial and peripheral locations have been described. The central tumors tend to be discovered at an earlier stage and appear to have a relatively good prognosis until tumor size precludes complete resection.

Primary Pulmonary Osteosarcoma

There are fewer than 20 cases of primary pulmonary osteosarcoma reported in the literature.72,79,80 One of the more recent case reports during the past decade included a molecular analysis that demonstrated several specific genetic aberrations in common with other extraskeletal osteosarcomas. 80 As with other rare types of pulmonary sarcoma, it is important to consider an alternative diagnosis and this seems to be particularly true of osteosarcomatous foci. Tumors that were initially thought to be primary lung osteosarcomas proved to be carcinosarcomas upon additional sampling.79 The limited number of cases of pulmonary osteosarcoma precludes any meaningful statement on prognosis.

Primary Liposarcoma

Primary pulmonary liposarcoma is another tumor with fewer than 20 cases reported in the literature.72,81 The more common occurrence of liposarcoma metastatic to the lung can be diagnostically challenging. The diversity in histologic appearance that may be encountered when liposarcoma metastasizes to lung has been recently reviewed.82

Primary Pulmonary Fibrosarcoma, Malignant Fibrous Histiocytoma, and Hemangiopericytoma

And what of primary pulmonary fibrosarcoma, malignant fibrous histiocytoma, and hemangiopericytoma-entities that used to be well enough represented in series of lung sarcomas?83-87 Suffice it to say that, in the recent pathology literature, to my knowledge, there have been no new reported cases.

Other Metastatic Tumors With Spindle Cell Features That May Closely Mimic Primary Pulmonary Sarcomas

Although not intended as an exhaustive list, there are several other metastatic tumors that deserve mention. Most melanomas are not entirely spindled in appearance, but metastatic melanoma may be spindled enough to mimic sarcoma in the lung. An adequate clinical history and consideration of the entity, in addition to the routine use of S100 in the workup of a spindled cell lesion in the lung, is helpful in avoiding this diagnostic pitfall (Figures 25 through 27). Similarly, an adequate clinical history and consideration of a temporally remote primary, along with use of cytokeratin stains, such as CAM 5.2, should avoid misinterpretation of a metastatic sarcomatoid renal cell carcinoma (Figures 28 and 29). Metastatic endometrial stromal sarcoma can be an overlooked consideration in the workup of a primitive-appearing mesenchymal tumor in the lung. In this instance, the more-likely uterine primary will not be radiographically obvious or clinically apparent without a thorough physical examination and an appropriate history.

CONCLUSION

This review of sarcomatous pulmonary tumors has provided an overview of primary pulmonary sarcomas as well as other thoracic lesions that may mimic them. For the most part, the clinical, radiographic, and gross presentation of these rare and extremely rare tumors does not differ significantly from the more common tumors of the lung. As a general principle, complete excision of these malignant tumors is recommended if the patient is an operative candidate but the relative infrequency of these tumors makes it difficult to predict clinical behavior in many individual circumstances. Appropriate classification ultimately requires complete sampling and a thorough microscopic evaluation. The general availability of ancillary diagnostic techniques, such as immunohistochemistry and molecular analysis, has refined and, no doubt, will continue to refine tumor identification and classification.

References

1. Huo L, Moran CA, Fuller GN, Gladish G, Suster S. Pulmonary artery sarcoma: a clinicopathologic and immunohistochemical study of 12 cases. Am J Clin Pathol. 2006;125:419-424.

2. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, Sobin LH. Histological Typing of Lung and Pleural Tumours. 3rd ed. Berlin, Germany: Springer-Verlag; 1999.

3. Corrin B, Chang YL, Rossi G, et al. Sarcomatoid carcinoma. In: Travis WD, Brambilla E, Mu ller-Hermelink HK, Harris CC, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004: 53-58. World Health Organization Classification of Tumours; vol 10. 4. Koss MN, Hochholzer L, Frommelt RA. Carcinosarcomas of the lung: a clinicopathologic study of 66 patients. Am J Surg Pathol. 1999;23:1514-1526.

5. Manivel JC, Priest JR, Watterson J, et al. Pleuropulmonary blastoma: the socalled pulmonary blastoma of childhood. Cancer. 1986;62:1516-1526.

6. Spencer H. Pulmonary blastoma. J Pathol Bacteriol. 1961;82:161- 165.

7. Francis D, Jacobsen M. Pulmonary blastoma. Curr Top Pathol. 1983;73:265-294.

8. Davis MP, Eagan RT,Weiland LH, Pairolero PC. Carcinosarcoma of the lung: Mayo Clinic experience and response to chemotherapy. Mayo Clin Proc. 1984; 59:598-603.

9. Cabarcos A, Gomez Dorronsoro M, Beristain JL. Pulmonary carcinosarcoma: a case study and review of the literature. Br J Dis Chest. 1985;79:83-94.

10. Humphrey PA, Scroggs MW, Roggli VL, Shelburne JD. Pulmonary carcinomas with a sarcomatoid element: an immunocytochemical and ultrastructural analysis. Hum Pathol. 1988;19:155-165.

11. Ishida T, Tateishi M, Kaneko S, et al. Carcinosarcoma and spindle cell carcinoma of the lung: clinicopathologic and immunohistochemical studies. J Thorac Cardiovasc Surg. 1990;100:844- 852.

12. Yousem SA, Wick MR, Randhawa P, Manivel JC. Pulmonary blastoma: an immunohistochemical analysis with comparison with fetal lung in its pseudoglandular stage. Am J Clin Pathol. 1990;93:167- 175.

13. Matsui K, Kitagawa M. Spindle cell carcinoma of the lung: a clinicopathologic study of three cases. Cancer. 1991;67:2361-2367.

14. Moore TC. Carcinosarcoma of the lung. Surgery. 1991;50:886- 893.

15. Chejfec G, Candel A, Jansson DS, et al. Immunohistochemical features of giant cell carcinoma of the lung: patterns of expression of cytokeratins, vimentin, and the mucinous glycoprotein recognized by monoclonal antibody A-80. Ultrastruct Pathol. 1991;15:131-138.

16. Koss MN, Hochholzer L, O’Leary T. Pulmonary blastomas. Cancer. 1991; 67:2368-2381.

17. Ro JY, Chen JL, Lee JS, Sahin AA, Ordonez NG, Ayala AG. Immunohistochemical and ultrastructural studies of 14 cases. Cancer. 1992;69:376-386.

18. Eng J, Sabanathan S. Carcinosarcoma of the lung with gastrointestinal metastasis: case report. Scand J Thorac Cardiovasc Surg. 1992;26:161-162.

19. Fishback NF, Travis WD, Moran CA, Guinee DG Jr, McCarthy WF, Koss MN. Pleomorphic (spindle/giant cell) carcinoma of the lung: a clinicopathologic correlation of 78 cases. Cancer. 1994;73:2936- 2945.

20. Nappi O, Glasner SD, Swanson PE, Wick MR. Biphasic and monophasic sarcomatoid carcinoma of the lung: a reappraisal of “carcinosarcomas” and “spindle-cell carcinomas.” Am J Clin Pathol. 1994;102:331-340.

21. Rainosek DE, Ro JY, Ordonez NG, Kulaga AD, Ayala AG. Sarcomatoid carcinoma of the lung: a case with atypical carcinoid and rhabdomyosarcomatous components. Am J Clin Pathol. 1994;102:360- 364.

22. Terzi A, Gorla A, Piubello Q, Tomezzoli A, Furlan G. Biphasic sarcomatoid carcinoma of the lung: report of 5 cases and review of the literature. Eur J Surg Oncol. 1997;23:457.

23. Wick MR, Ritter JH, Humphrey PA. Sarcomatoid carcinomas of the lung: a clinicopathologic review. Am J Clin Pathol. 1997;108:40- 53.

24. Nakajima M, Kasai T, Hashimoto H, Iwata Y, Manabe H. Sarcomatoid carcinoma of the lung: a clinicopathologic study of 37 cases. Cancer. 1999;86:608-616.

25. Chang YL, Lee YC, Shih JY, Wu CT. Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary nonsmall cell carcinoma. Lung Cancer. 2001;34:97-91.

26. Robert J, Pache JC, Seium Y, de Perrot M, Spiliopoulos A. Pulmonary blastoma: report of five cases and identification of clinical features suggestive of the disease. Eur J Cardiothorac Surg. 2002;22:708-711.

27. Nishida K, Kobayashi Y, Ishikawa Y, et al. Sarcomatoid adenocarcinoma of the lung: clinicopathological, immunohistochemical and molecular analyses. Anticancer Res. 2002;22:3477-3483.

28. Pelosi G, Fraggetta F, Nappi O, et al. Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol. 2003;27:1203-1215.

29. Rossi G, Cavazza A, Sturm N, et al. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic study of 75 cases. Am J Surg Pathol. 2003;27:311- 324.

30. Raveglia F, Mezzetti M, Panigalli T, et al. Personal experience in surgical management of pulmonary pleomorphic carcinoma. Ann Thorac Surg. 2004;78: 1742-1747.

31. Adluri RKP, Boddu SR, Martin-Ucar A, Duffy JP, Beggs FD, Morgan WE. Pulmonary blastoma-a rare tumor with variable presentation. Eur J Cardiothorac Surg. 2006;29:236-239.

32. Martin LW, Correa AM, Ordonez NG, et al. Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg. 2007;84:973-981.

33. Churg A, Cagle PT, Roggli BL. Tumors of the Serosal Membranes. Washington, DC: Armed Forces Institute of Pathology; 2006. Atlas of Tumor Pathology; 4th series, fascicle 10.

34. Mayall FG, Goddard H, Gibbs AR. The diagnostic implications of variable cytokeratin expression in mesotheliomas. J Pathol. 1993;170:165-168.

35. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2- 40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18:105-110.

36. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive markers of epithelioid malignant mesothelioma. Hum Pathol. 2005;36:372-380.

37. Hinterberger M, Reineke T, Storz M, Weder W, Vogt P, Moch H. D2-40 and calretinin-a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol. 2007;20:248-255.

38. Kung IT, Thallus V, Spencer EJ, Wilson SM. Expression of muscle actins in diffuse mesothelioma. Hum Pathol. 1995;26:565-570.

39. Trupiano JK, Geisinger KR, Willingham MC, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol. 2004; 17:476-481.

40. Attanoos RL, Dojcinov SD, Webb R, Gibbs AR. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology. 2000;37:224-231.

41. Lucas DR, Pass HI, Madan SK, Adsay NV, Wali A, Tabaczka P, Lonardo F. Sarcomatoid mesothelioma and its histologic mimics: a comparative immunohistochemical study. Histopathology. 2003;42:270- 279.

42. Moran CA, Suster S, Abbondanzo SL, Koss MN. Primary leiomyosarcomas of the lung: a clinicopathologic and immunohistochemical study of 18 cases. Mod Pathol. 1997;10:121-128.

43. Zeren H, Moran CA, Suster S, Fishback NF, Koss MN. Primary pulmonary sarcomas with features of monophasic synovial sarcoma: a clinicopathological, immunohistochemical, and ultrastructural study of 25 cases. Hum Pathol. 1995; 26:474-480.

44. Essary LR, Vargas SO, Fletcher CD. Primary pleuropulmonary synovial sarcoma: reappraisal of a recently described anatomic subset. Cancer. 2002;94:459-469.

45. Okamoto S, Hisaoka M, Daa T, Hatakeyama K, Iwamasa T, Hashimoto H. Primary pulmonary synovial sarcoma: a clinicopathologic, immunohistochemical and molecular study of 11 cases. Hum Pathol. 2004;35:850-856.

46. Begueret H, Galateau-Salle F, Guillou L, et al. Primary intrathoracic synovial sarcoma: a clinicopathologic study of 40 t(X;18)-positive cases from the French Sarcoma Group and the Mesopath Group. Am J Surg Pathol. 29:339-346.

47. Hartel PH, Fanburg-Smith JC, Frazier AA, et al. Primary pulmonary and mediastinal synovial sarcoma: a clinicopathologic study of 60 cases and comparison with five prior series. Mod Pathol. 2007;20:760-769.

48. Amary MF, Berisha F, Bernardi Fdel C, Herbert A, et al. Detection of SS18-SSX fusion transcripts in formalin-fixed embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. Mod Pathol. 2007;20:482-96.

49. Miettinen M. Keratin subsets in spindle cell sarcomas: keratins are widespread but synovial sarcoma contains a distinctive keratin polypeptide pattern and desmoplakins. Am J Pathol. 1991;138:505-513.

50. Smith TA, Machen SK, Fisher C, et al. Usefulness of cytokeratin subsets for distinguishing monophasic synovial sarcoma from peripheral malignant nerve sheath tumor. Am J Clin Pathol. 1999;112:411-414.

51. Folpe AL, Schmidt RA, Chapman D, Gown A. Poorly differentiated synovial Arch Pathol Lab Med-Vol 132, July 2008 Pulmonary Sarcomatous Tumors-Litzky 1117 sarcoma: immunohistochemical distinction from primitive neuroectodermal tumors and high-grade malignant peripheral nerve sheath tumors. Am J Surg Pathol. 1998;22:673-682.

52. Miettinen M, Limon J, Niezabitowski A, Lasota J. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol. 2001;25:610-617.

53. Terry J, Saito T, Subramanian S, et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol. 2007;31:240-246.

54. Woodruff JM, Kourea HP, Louis DN, Sheithauer BW. Malignant peripheral nerve sheath tumor (MPNST). In: Kleihues P, Cavanee WK, eds. Pathology and Genetics of Tumors of the Nervous System. Lyon, France: IARC Press; 2000:172-174. World Health Organization Classification of Tumours; vol 7.

55. Stasik CJ, Tawfik O. Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor). Arch Pathol Lab Med. 2006;130:1878-1881.

56. Weiss SM, Langloss JM, Enzinger FM. Value of S-100 protein in the diagnosis of soft tissue tumors with particular reference to benign and malignant Schwann cell tumors. Lab Invest. 1983;49:299- 308.

57. O’Sullivan MJ, Kyriakos M, Zhu X, et al. Malignant peripheral nerve sheath tumors with t(X;18): a pathologic and molecular genetic study. Mod Pathol. 2000; 13:1336-1346. 58. van de Rijn M, Lombard CM, Rouse RV. Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum, and lung. Am J Surg Pathol. 1994;18: 814-820.

59. Travis WD, Churg A, Aubry MC, et al. Solitary fibrous tumour. In: Travis WD, Brambilla E, Mu ller-Hermelink HK, Harris CC, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004:142-143. World Health Organization Classification of Tumours; vol 10.

60. Nappi O, Ritter JH, Pettinato G, Wick MR. Hemangiopericytoma: histopathological pattern or clinicopathologic entity? Semin Diagn Pathol. 1995;12: 221-232.

61. Gengler C, Guillou L. Solitary fibrous tumor and haemangiopericytoma: evolution of a concept. Histopathology. 2006;48:63-74.

62. England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura: a clinicopathologic review of 223 cases. Am J Surg Pathol. 1989;13:887-899.

63. Travis WD, Tazelaar HD, Miettinen M. Epithelioid haemangioendothelioma/angiosarcoma. In: Travis WD, Brambilla E, Mu ller-Hermelink HK, Harris CC, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004:97-98. World Health Organization Classification of Tumours; vol 10.

64. Dail DH, Liebow AA, Gmelich JT, et al. Intravascular, bronchiolar, and alveolar tumor of the lung (IVBAT): an analysis of twenty cases of a peculiar sclerosing endothelial tumor. Cancer. 1983;51:452-464.

65. Eggleston JC. The intravascular bronchioloalveolar tumor and the sclerosing hemangioma of the lung: misnomers of pulmonary neoplasia. Semin Diagn Pathol. 1985;270-280.

66. Weiss SW, Ishak KG, Dail DGH, et al. Epithelioid hemangioendothelioma and related lesions. Semin Diagn Pathol. 1986;3:259-287.

67. Folpe AL, Chand EM, Goldblum JR, Weiss SW. Expression of Fli- 1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol. 2001;25:1061-1066.

68. Patel AM, Ryu JH. Angiosarcoma in the lung. Chest. 1993;103:1531-5.

69. Sheppard MN, Hansell DM, Du Bois RM, Nicholson AG. Primary epithelioid angiosarcoma of the lung presenting as pulmonary hemorrhage. Hum Pathol 1997;28:383-385.

70. Lamovec J, Knuutila S. Kaposi sarcoma. In: Fletcher CDM, Unni KK, Martens F, eds. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002:170-172. World Health Organization Classification of Tumours; vol 5.

71. Yousem SA, Tazelaar HD, Manabe T, Dehner LP. Inflammatory myofibroblastic tumour. In: Travis WD, Brambilla E, Mu ller- Hermelink HK, Harris CC, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004:105-106. World Health Organization Classification of Tumours; vol 10.

72. Suster S. Primary sarcomas of the lung. Semin Diagn Pathol. 1995;12:140-157.

73. Przygodzki RM, Moran CA, Suster S. Koss MN. Primary pulmonary rhabdomyosarcoma: a clinicopathologic and immunohistochemical study of three cases. Mod Pathol. 1995;8:658-661.

74. Comin CE, Santucci M, Novelli L, Dini S. Primary pulmonary rhabdomyosarcoma: report of a case in an adult and review of the literature. Ultrastruct Pathol. 2001;25:269-273.

75. Gupta A, Sharma MC, Kochupillai V. Primary pulmonary rhabdomyosarcoma in adults: case report and review of literature. Clin Lung Cancer. 2007;8: 389-391.

76. Hayashi T, Tsuda N, Iseki M, Kishikawa M, Shinozaki T, Hasumoto M. Primary chondrosarcoma of the lung: a clinicopathologic study. Cancer. 1993; 72:67-74.

77. Shukla K, Jetly D, Parikh B. Primary chondrosarcoma of lung: case report and review of literature. Indian J Pathol Microbiol. 2006;49:570-573.

78. Steurer S, Huber M, Lintner F. Dedifferentiated chondrosarcoma of the lung: case report and review of the literature. Clin Lung Cancer. 2007;8:439-442.

79. Colby TV, Bilbao JE, Battifora H, Unni KK. Primary osteosarcoma of the lung: a reappraisal following immunohistologic study. Arch Pathol Lab Med. 1989;113:1147-1150.

80. Chapman AD, Pritchard SC, Yap WW, et al. Primary pulmonary osteosarcoma: case report and molecular analysis. Cancer. 2001;91:779-784.

81. Krygier G, Amado A, Salisbury S, Fernandez I, Maedo N, Vazquez T. Primary lung liposarcoma. Lung Cancer. 1997;17:271-275.

82. Nicholas M, Moran CA, Suster S. Pulmonary metastasis from liposarcoma: a clinicopathologic and immunohistochemical study of 24 cases. Am J Clin Pathol. 2005;123:265-275.

83. Attanoos RL, Appleton MA, Gibbs AR. Primary sarcomas of the lung: a clinicopathological and immunohistochemical study of 14 cases. Histopathology. 1996;29:29-36.

84. Bacha EA, Wright CD, Grill HC, et al. Surgical treatment of primary pulmonary sarcomas. Eur J Cardiothorac Surg. 1999;15:456- 460.

85. Keel SB, Bacha E, Mark EJ, Nielsen GP, Rosenberg AE. Primary pulmonary sarcoma; a clinicopathologic study of 26 cases. Mod Pathol. 1999;12:1124-1131.

86. Etienne-Mastroianni B, Falchero L, Chalabreysse L, et al. Primary sarcomas of the lung: a clinicopathologic study of 12 cases. Lung Cancer. 2002;38:283-289.

87. Petrov DB, Vlassov VI, Kalaydjiev GT, et al. Primary pulmonary sarcomas and carcinosarcomas-postoperative results and comparative survival analysis. Eur J Cardiothorac Surg. 2003;23:461- 466.

Leslie A. Litzky, MD

Accepted for publication January 11, 2008.

From the Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia.

The author has no relevant financial interest in the products or companies described in this article.

Reprints: Leslie A. Litzky, MD, Department of Pathology and Laboratory Medicine, 6 Founders Bldg, University of Pennsylvania Medical Center, 3400 Spruce St, Philadelphia, PA 19104-4283 (e- mail: [email protected].

Pulmonary Neoplasia

By Allen, Timothy Craig

The diagnosis of pulmonary malignant neoplasia generally portends a poor prognosis. The facts are stark. Worldwide, lung cancer is expected to increase in prevalence during the 21st century.1 Lung cancer is the leading cause of cancer death in both men and women in the United States. One in 10 cigarette smokers will develop lung cancer during his or her lifetime, with a decades-static overall 5- year survival rate for lung cancer in the United States of approximately 15%.1-3 More people die of lung cancer than prostate, colon, and breast cancers combined. 4,5 Earlier detection of lung cancer is being promoted, and therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib has been identified in a limited number of adenocarcinomas, generally in nonsmoking Asian women.6-9 However, although molecular therapies show promise for the future, presently molecular therapy does not affect overall lung cancer prognosis.10- 12 Although rare, pleural diffuse malignant mesothelioma has increased in incidence worldwide during the last several decades and is rapidly increasing in incidence throughout Western Europe.13-15 It is generally refractory to treatment, and overall survival is dismal, with a median of less than 12 months postdiagnosis.13,16

Differentiating benign and malignant pulmonary neoplasms, preneoplastic lesions, and tumor mimics, with their often markedly different therapies and prognoses, remains of the utmost importance. The surgical pathologist’s task of diagnosing malignant and benign pulmonary neoplasms, and their mimics, is not going to get easier in the near future. Indeed, to apply various molecular diagnostic and therapeutic tumor regimens that are anticipated to be available in the future, accurate histologic diagnosis is imperative. An understanding of the pathology of the common as well as uncommon malignant and benign lung and pleural neoplasms, tumor mimics, and preneoplastic lesions is necessary for accurate diagnosis of pulmonary tumors, and the goal of this special issue on pulmonary neoplasia is to assist the practicing pathologist in that endeavor.

In the 9 articles within this special issue, the authors cover a broad spectrum of topics relevant to the accurate diagnosis of pulmonary neoplasms. Radiologic correlation is an important adjunct to proper diagnosis in pulmonary disease, and the concept of neuroendocrine neoplasia in the lung is evolving. Drs Teri Franks and Jeff Galvin examine the radiologic-pathologic correlation of neuroendocrine lung neoplasms. Dr Mary Beth Beasley discusses the current state of immunohistochemistry as it relates to pulmonary neoplasia. Dr Sanja Dacic reviews the increasingly important subject of pulmonary preneoplasia. Drs Megan Dishop and Supriya Kuruvilla present a thorough and valuable examination of pediatric neoplasms and pseudotumors. Dr Leslie Litzky discusses the often-confusing sarcomatous pulmonary neoplasms. Dr Kelly Butnor presents a constructive article on avoiding overdiagnosis, underdiagnosis, and misdiagnosis in pulmonary neoplasia. Dr Alain Borczuk reviews a variety of benign lung neoplasms and pseudotumors. The literature contains many useful articles regarding the histologic and immunohistochemical features of pleural diffuse malignant mesothelioma (a few are referenced)17-24 so Dr Don Guinee and I offer a review of the pathology of primary pleural neoplasms other than diffuse malignant mesothelioma. Finally, because pulmonary histiocytic lesions, especially pulmonary Langerhans cell histiocytosis, may occasionally mimic neoplasms, a review of pulmonary histiocytoses is presented.

It is my privilege to present these articles written by a number of experts rich in experience in the pathology of pulmonary neoplasia. It is our hope that these articles will assist the general pathologist in making accurate diagnoses of lung and pleural neoplasms, premalignant lesions, and tumor mimics, whether they occur commonly or uncommonly. In closing, I offer my sincere appreciation and thanks to Dr Philip T. Cagle for the opportunity to put forth this special issue.

References

1. Siegfried JM. Lung cancer screening in high-risk populations. Clin Lung Cancer. 1999;1:100-106.

2. Franklin WA. Pathology of lung cancer. J Thorac Imaging. 2000;15:3-12.

3. Hirsch FR, Brambilla E, Gray N, et al. Prevention and early detection of lung cancer-clinical aspects. Lung Cancer. 1977;17:163- 174.

4. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. Ca Cancer J Clin. 2004;54:8-29.

5. McWilliams A, Lam S. Lung cancer screening. Curr Opin Pulm Med. 2005; 11:272-277.

6. Tsao AS, Tang XM, Sabloff B, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006;1:231-239.

7. Kimura H, Suminoe M, Kasahara K, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer. 2007;97:778-784.

8. Pugh TJ, Bebb G, Barclay L, et al. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. BMC Cancer. 2007;7:128.

9. Field JK, Brambilla C, Caporaso N, et al. Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Int J Oncol. 2002;21:369-373.

10. Rosell R, Cobo M, Isla D, et al. Applications of genomics in NSCLC. Lung Cancer. 2005;50(suppl):S33-S40.

11. Alvarez M, Roman E, Santos ES, Raez LE. New targets for non- small-cell lung cancer therapy. Expert Rev Anticancer Ther. 2007;7:1423-1437.

12. Felip E, Santarpia M, Rosell R. Emerging drugs for on-small- cell lung cancer. Expert Opin Emerg Drugs. 2007;12:449-460.

13. Borasio P, Berruti A, Bille A, et al. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg. 2008;33:307-313.

14. Pelucchi C, Malvezzi M, La Vecchia C, et al. The mesothelioma epidemic in Western Europe: an update. Br J Cancer. 2004;90:1022- 1024.

15. Chapman A, Mulrennan S, Ladd B, Muers MF. Population-based epidemiology and prognosis of mesothelioma in Leeds, United Kingdom [published online ahead of print January 17, 2008]. Thorax. doi:10.1136/thx.2007.081430.

16. Baas P. Optimizing survival in malignant mesothelioma. Lung Cancer. 2007;57(suppl):S24-S29.

17. Wick MR, Moran CA, Mills SE, Suster S. Immunohistochemical differential diagnosis of pleural effusions, with emphasis on malignant mesothelioma. Curr Opin Pulm Med. 2001;7:187-192.

18. Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopathology. 1997;30:403-418.

19. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24:1183-1200.

20. Allen TC. Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies. Arch Pathol Lab Med. 2005;129:1415-1420.

21. Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med. 2005;1421-1427.

22. Hammar SP. Macroscopic, histologic, histochemical, immunohistochemical, and ultrastructural features of mesothelioma. Ultrastruc Pathol. 2006;30:3-17.

23. English JC, Leslie KO. Pathology of the pleura. Clin Chest Med. 2006;27: 157-180.

24. Mark EJ, Kradin RL. Pathological recognition of diffuse malignant mesothelioma of the pleura: the significance of the historical perspective as regards this signal tumor. Semin Diagn Pathol. 2006;23:25-34.

Timothy Craig Allen, MD, JD

Accepted for publication February 14, 2008.

From the Department of Pathology, The University of Texas Health Science Center at Tyler.

The author has no relevant financial interest in the products or companies described in this article.

Reprints: Timothy Craig Allen, MD, JD, Department of Pathology, The University of Texas Health Science Center at Tyler, 11937 US Hwy 271, Tyler, TX 75708 (e-mail: [email protected]).

Timothy Craig Allen, MD, JD, obtained his medical degree from Baylor College of Medicine in 1984. He completed his residency in anatomic pathology and clinical pathology and subsequently served on the faculty of Baylor College of Medicine until 1995. He then attended the University of Chicago Law School where he obtained the degree of Doctor of Law with honors in 1998. He subsequently practiced litigation and health care law. Dr Allen completed a 2- year fellowship in pulmonary pathology under the direction of Philip T. Cagle, MD, at the Texas Medical Center in Houston in 2004. He is currently chair of the Department of Pathology at the University of Texas Health Science Center at Tyler. Dr Allen is certified by the American Board of Pathology in anatomic and clinical pathology, with added qualification in cytopathology. He was a contributing editor to the 2000 edition of Product Liability Desk Reference, a book summarizing United States product liability laws. He has authored and coauthored a variety of articles and book chapters on lung and pleural pathology. Dr Allen was an associate editor of the first and second editions of Color Atlas and Text of Pulmonary Pathology, coeditor of the second edition of Diagnostic Pulmonary Pathology, and coeditor-in-chief of Transbronchial and Endobronchial Biopsies. Dr Allen is the current chair of the Program Committee of the Pulmonary Pathology Society. He is an associate editor of the Archives of Pathology & Laboratory Medicine.

Copyright College of American Pathologists Jul 2008

(c) 2008 Archives of Pathology & Laboratory Medicine. Provided by ProQuest Information and Learning. All rights Reserved.

When $1 Million Isn’t Enough Insurance

Mary Wusterbarth thought her toddler was struggling with an ear infection when she seemed sluggish. Instead, a virus had attacked the little girl’s heart, damaging it beyond repair. Brea needed a transplant.

Within three weeks of a 2007 doctor visit, the 20-month-old had exhausted the $1 million lifetime maximum on her health insurance. Her parents have scrambled ever since for ways to cover thousands of dollars in monthly medical costs.

“We have no idea what kind of financial future we have,” said Wusterbarth, of Wake Forest, N.C. “The medical bills come almost daily. There’s never an end.”

Insurers set lifetime limits to keep rates low on some policies, but holders are learning that individual caps that seemed large quickly max out as health care costs soar. Several patient advocacy groups are prodding insurers to raise the caps, which generally don’t adjust for inflation. Congress also is considering two bills that would do that.

Only 1 percent of employer-offered group plans – the largest health insurance segment – had caps as low as $1 million last year, according to a survey by The Henry J. Kaiser Family Foundation. But 22 percent had caps of less than $2 million, and some want to see all these relatively low maximums eliminated.

Insurers, however, say most health coverage already offers either a comfortable maximum of several million dollars or unlimited coverage. They note that more government regulation could lead to higher coverage costs, and low lifetime caps help them offer a greater variety of coverages.

Kelly and Tom Treinen used to think the $1 million individual cap that came with the insurance they had for seven years offered plenty of protection. In fact, they chose that plan, which Mrs. Treinen received through her job as an elementary school principal, over a higher-priced option through Mr. Treinen’s business. That one offered a $5 million cap.

Then doctors diagnosed their teenage son, Michael, with an aggressive form of leukemia in May 2007. His treatment called for 10 doses of a chemotherapy drug that cost $10,000 per dose. A 56- day stay in an intensive care unit cost about $400,000.

Michael reached his $1 million lifetime maximum in less than a year. The Noblesville, Ind., family had to issue a public plea for help after a hospital told them it needed either $600,000 in certified insurance or a $500,000 deposit to continue preparing for a critical bone marrow transplant.

The Treinens raised $865,000 in six days. Money came from all over the United States and as far away as Germany. But Michael’s cancer had stopped responding to chemotherapy, and he died May 25 before he could receive the transplant.

The family had no idea how fast costs were piling up. Some initial bills didn’t arrive until months after treatment started. Then they would receive multiple mailings for each treatment, each listing a different amount – the hospital cost, the insurance discount, the amount they owed.

“When you’re dealing with constant care of your child, you’re not going home with a calculator and adding up to see where you’re at,” Mrs. Treinen said.

Insurance can shield patients from the true cost of health care, said Jerry Flanagan, health care policy director for California- based Consumer Watchdog. He noted that most people have no idea how quickly $1 million “can evaporate,” unless they’ve been seriously ill before.

Low lifetime maximums are found more often in small-employer group plans, Mr. Flanagan said, noting that those businesses generally have less insurance buying power. He said employers often give their workers a choice on plans or premiums but not on lifetime maximums.

The Kaiser Family Foundation study says a greater percentage of employer-offered group plans are providing lifetime caps of at least $2 million, and the percentage that offers caps below $2 million has declined slightly.

But medical costs for employer-sponsored health plans should increase 9.9 percent and 9.6 percent this year and next, according to PricewaterhouseCoopers Health Research Institute.

“The nature of caps is that over time it becomes easier and easier to hit (them) because the cost of health care services keeps going up,” said Mike Thompson, a health care and employee benefits expert with the firm.

A coverage cap of $1 million in the 1970s would have had to grow to more than $10 million today to keep pace with rising costs, said Glenn Mones of the National Hemophilia Foundation.

The foundation’s vice president for public policy says he’s seen more patients approach their lifetime caps in recent years. People with hemophilia can spend more than $200,000 a year just on drugs that prevent internal bleeding.

His foundation renewed a lobbying push in Congress this year for higher lifetime caps because it sees a better political climate for one.

Originally published by Tom Murphy Associated Press.

(c) 2008 Augusta Chronicle, The. Provided by ProQuest Information and Learning. All rights Reserved.

Primary Pleural Neoplasia

By Guinee, Donald G Allen, Timothy Craig
* Context.-Overwhelmingly, the most common neoplasm involving the pleura is metastatic carcinoma. In contrast, diffuse malignant mesothelioma occurs relatively rarely; however, it is nonetheless the most common neoplasm primary to the pleura. Metastatic carcinoma and diffuse malignant mesothelioma each have their own prognostic and therapeutic characteristics. Other primary pleural neoplasms occur uncommonly or rarely, with their own prognostic and therapeutic characteristics. Objective.-To review primary pleural neoplasms other than diffuse malignant mesothelioma, to better ensure correct diagnosis and optimal assessment of prognosis and treatment.
Data Sources.-Literature review and primary material from the authors’ institutions.
Conclusions.-A nonexhaustive group of uncommon to rare benign and malignant primary pleural neoplasms-other than diffuse malignant mesothelioma-are presented, of which one must be aware in order to maintain an appropriate index of suspicion to include them in the differential diagnosis of a pleural tumor.
(Arch Pathol Lab Med. 2008;132:1149-1170)
By far the most common neoplasm involving the pleura is metastatic carcinoma, causing approximately 200 000 pleural effusions each year in the United States.1 Diffuse malignant mesothelioma (DMM), which in contrast is relatively rare, accounting for approximately 1500 malignant pleural effusions in the United States each year, is nonetheless the most common neoplasm primary to the pleura.2 Differentiation between metastatic carcinoma and other neoplasms involving the pleura, with their variable prognoses and therapeutic options, and pleural DMM, with its prognosis, limited therapeutic options, and frequent relationship to asbestos exposure, is extremely important both medically and legally and has been the subject of numerous articles during many years, a few of which are referenced.3-12 Aside from metastases and DMM, other primary pleural neoplasms, with their individual prognostic and therapeutic characteristics, occasionally are encountered. An understanding of the pathologic features of these uncommon or rare neoplasms is necessary to ensure optimal treatment and prognosis. The following is a nonexhaustive group of the primary pleural neoplasms of which one must be aware in order to maintain an appropriate index of suspicion of them.
BENIGN PRIMARY PLEURAL NEOPLASMS
Solitary Fibrous Tumor
Solitary fibrous tumor (SFT), also termed localized fibrous tumor, is the most common benign primary pleural neoplasm. 13 It may on occasion present with more than 1 tumor mass, and as such, the term localized fibrous tumor may be more descriptively accurate; however, the term SFT is so engrained in the literature that it probably should be retained, especially as pleural SFT already has a history of confusing terminology.
The first report of SFT has been attributed to Wagner in 1870,14 and in 1931 Klemperer and Rabin15 provided the first accurate pathologic description of pleural SFT, dividing primary pleural tumors into diffuse mesotheliomas and localized mesotheliomas. In 1942, Stout and Murray16 introduced the term localized fibrous mesothelioma and proposed a mesothelial cell origin for SFT based on their cell culture findings of tumor growing in mesothelial-like sheets. Three decades later, other authors proposed a mesenchymal origin for SFT.17-21 Currently, these tumors are considered to arise from mesenchymal cells-submesothelial cells or soft tissue fibroblasts.22,23 Their mesenchymal cell origin is supported by immunohistochemical findings including general vimentin positivity and CD34 positivity. 24-26 Because of the controversy regarding histogenesis, SFT was in the past given a variety of different names, including benign fibrous mesothelioma, solitary fibrous mesothelioma, localized fibrous mesothelioma, pleural fibroma, benign mesothelioma, and submesothelial fibroma. As SFTs are believed to arise from submesothelial cells, all of these terms should be avoided. The diagnostically inaccurate terms localized mesothelioma and fibrous mesothelioma should not be used in order to avoid confusion with localized malignant mesothelioma (LMM) and sarcomatous DMM, respectively.
Besides their pleural location, SFTs have been recognized in a wide variety of extrapleural sites, including head and neck and nasal cavity, retroperitoneum, soft tissues, orbit, liver, thyroid, salivary glands, kidney, and breast, among others.27-37 Approximately 800 cases of pleural SFT have been reported, and a few series of cases have been published, including those of Briselli et al in 1981, documenting 360 cases from the literature and another 8 of their own, and England et al in 1989, reporting 223 cases.21,24,38-40 Even though SFT is the second most common primary pleural neoplasm, after DMM, it makes up less than 5% of all pleural neoplasms.41,42
Clinically, SFTs occur in people ranging in age from childhood to the eighth decade, with the majority occurring in middle-aged and older adults, with men and women generally equally affected.13,39,43 Most patients with benign SFTs are asymptomatic and found incidentally to have a well-circumscribed, pleural-based mass on radiologic studies.13,43 Symptoms such as cough, chest pain, and dyspnea are suggestive of malignancy.13,22,39,43 Approximately 10% to 20% of patients with SFT exhibit digital clubbing and hypertrophic pulmonary osteoarthropathy-Pierre-Marie-Bamberg syndrome; however, these features generally resolve within 2 to 5 months after surgical resection. 22 The syndrome has been hypothesized to occur due to abnormal hepatocyte growth factor production or tumoral release of hyaluronic acid.22 Less than 5% of SFT patients develop Doege-Potter syndrome-refractory hypoglycemia due to secretion of insulin-like growth factor. Blood glucose levels typically return to normal within 2 or 3 days after surgical resection.44-46 Solitary fibrous tumor is not associated with asbestos exposure.13,43 Approximately three fourths of SFTs are attached to the visceral pleura, with the remaining tumors attached to the parietal pleura, the fissural pleura, or the diaphragm. Most tumors are about 5 to 10 cm in greatest dimension, but rare tumors ranging up to about 40 cm have been reported.13,43,47 Grossly, SFTs are off-white to light grey or light tan and may have a whorled appearance on cut section (Figure 1, A). Although small foci of hemorrhage may be present in benign SFTs, extensive hemorrhage or necrosis suggests malignancy. About half are sessile and half pedunculated, often with a fibrous stalk (Figure 1, B). Most SFTs are benign; malignant SFTs are discussed below. If SFT is suspected, multiple sections from the lesion are necessary to facilitate proper diagnosis.
The microscopic features of benign SFT include a variety of histologic patterns, one or all of which may be present in an individual tumor.43 The “patternless pattern of Stout” is characterized by relatively hypocellular areas composed of thick, ropey collagen with associated slitlike spaces and bland, sometimes inconspicuous spindle cells13,39,43 (Figure 1, C and D). A hemangiopericytoma-like pattern may also be identified, with variable cellularity and characteristic “staghorn” vascular structures13,43 (Figure 1, E and F). Also, a cellular pattern may be present, with spindle cells forming loose sheets, fascicles, or storiform or “herringbone” arrangements13,39 (Figure 1, G and H). Focal areas of myxoid change and focal calcification may occur13,39 (Figure 1, I). Any or all patterns may be found in a SFT, and the patterns may blend gradually with each other or may have an abrupt transition (Figure 1, J). Cytologic atypia and mitotic figures are absent or minimal; and increased cellularity, hemorrhage, and necrosis are absent or very focal in benign SFT.13,43 Benign SFTs that are sessile, frequently attached to the visceral pleura, generally have a pushing pattern of growth, which may include a peglike pattern of growth that should not be confused with invasive tumor43 (Figure 1, K and L). Inclusions of benign pulmonary epithelial cells may be found adjacent to the peglike growing edge and should not be confused with epithelial malignancy (Figure 1, M). Epithelial-like areas that are immunohistochemically not truly epithelial and are not prognostically important may occasionally be found within SFTs; these areas must not be confused with the true pulmonary epithelial cell inclusions described above.43
Studies have shown that between 80% and 100% of SFTs stain positively with CD34.13,41,43,48-52 Tumor cells generally stain positively with vimentin, Bcl-2, and CD99 as well. Solitary fibrous tumors are typically immunonegative with keratin, factor VIII, smooth muscle actin, muscle-specific actin, desmin, CD31, and S100.41,48-52 CD34 immunopositivity is not a specific feature of SFTs and may be found in other tumors such as neurofibromas, smooth muscle tumors, and schwannomas.41,49,52 Immunostains are of benefit in differentiating SFT from various other differential diagnoses. Sarcomatous DMMs are, in contrast to SFT, generally immunopositive with actin and pankeratin, and immunonegative with Bcl-2 and CD34. Pleuropulmonary synovial sarcomas are generally immunonegative with CD34 and immunopositive with AE1 and collagen IV. Smooth muscle tumors are typically immunonegative with CD34 and immunopositive with actin, desmin, and h-caldesmon. Undifferentiated carcinomas are generally immunopositive with pankeratin, AE1/AE3, and epithelial membrane antigen (EMA) and immunonegative with CD99. Adenomatoid Tumor
Adenomatoid tumors are rare benign neoplasms of mesothelial differentiation. Although these tumors occur most often in the male or female genital tract, 3 cases have been described in the pleura. The tumors described have consisted of 0.5- to 3.0-cm pleural nodules identified at the time of thoracic surgery for other processes.53-55
Histologically, adenomatoid tumors within the pleura are similar to adenomatoid tumors within the genital tract. They consist of nodular expansile proliferations of plump to flattened vacuolated epithelioid cells often arranged as tubular or glandlike spaces within a fibromuscular stroma sometimes containing smooth muscle (Figure 2, A and B). Vacuolated epithelioid cells may appear similar to signet rings. However, special stains for mucin (mucicarmine and periodic acid-Schiff with diastase) are negative. The epithelioid cells within adenomatoid tumors stain positively with markers of mesothelial origin including calretinin, HBME-1, and cytokeratin and lack expression of vascular markers or pulmonary adenocarcinoma including carcinoembryonic antigen, BER-EP4, B72.3, and CD15. The cells lack staining for vascular markers such as CD34, factor VIII, or Qbend.53,54
The differential diagnosis of pleural adenomatoid tumors includes reactive mesothelial hyperplasia, DMM, metastatic adenocarcinoma, and vascular neoplasms. The distinct nodular proliferation of cells and unremarkable underlying pulmonary parenchyma helps to separate adenomatoid tumor from a reactive process, whereas the solitary nature of the tumor, overall circumscription, and absence of invasion distinguishes it from DMM. Adenomatoid tumors may prompt consideration of metastatic signet ring cell adenocarcinomas. However, the cells lack mucin on special stains (mucicarmine or periodic acid-Schiff with diastase), stain positively with mesothelial markers (eg, calretinin), and do not express markers identified preferentially in pulmonary adenocarcinomas such as carcinoembryonic antigen, B72.3, BER-EP4, or CD15. Likewise, epithelioid hemangioendothelioma or other vascular neoplasms can be excluded by the lack of staining for vascular markers such as CD34, factor VIII, or Qbend.53
Calcifying Fibrous Pseudotumor
Calcifying fibrous pseudotumor is a rare, distinct soft tissue lesion most commonly found in the extremities, trunk, scrotum, groin, or axilla. Rare cases of calcifying fibrous pseudotumor have been described within the pleura.56,57 The reported cases have usually been found incidentally during investigation of other disorders. Imaging studies show single to multiple lobular pleural- based masses with areas of calcification.56-58
Resected specimens have consisted of one to several well- demarcated but unencapsulated white to tan masses ranging from 1.5 to 12.5 cm (Figure 3, A). These usually have a gritty cut surface. Histologically, the masses are well circumscribed and consist of hyalinized connective tissue admixed with benign-appearing spindle cells (Figure 3, B). A distinctive feature is the presence of scattered psammomatous microcalcifications (Figure 3, C). Some areas of dystrophic calcification may also be present. There is a sparse perivascular chronic inflammatory infiltrate consisting of lymphocytes, histiocytes, and plasma cells.58 Follow-up of these lesions so far indicates they are benign. Local excision appears to be adequate therapy.56-58
The differential diagnosis includes SFT, old calcified granulomas, pleural plaques, inflammatory pseudotumor, and hyalinizing granuloma. These can be distinguished based on their clinical and histologic features. The presence of a “patternless pattern” and absence of calcification and inflammatory infiltrate help to distinguish SFT from calcifying fibrous pseudotumor. In contrast to calcifying fibrous pseudotumor, hyalinizing granuloma and inflammatory pseudotumor usually occur within pulmonary parenchyma. Hyalinizing granuloma may contain areas of dystrophic calcification but lacks psammomatous calcification typical of this disorder. Inflammatory pseudotumor is more cellular than calcifying fibrous pseudotumor and lacks any kind of calcification.58
Miscellaneous Benign Mesenchymal Neoplasms
Lipomas and schwannomas may occasionally present within the pleura. Their gross and histologic features are similar to those reported in soft tissue59-61 (Figure 4, A through C).
Reactive Eosinophilic Pleuritis
Although a reactive process, reactive eosinophilic pleuritis may mimic other forms of pleural neoplasia. Reactive eosinophilic pleuritis refers to a nonneoplastic nodular to diffuse proliferation of eosinophils, histiocytes, giant cells, and other inflammatory cells62,63 (Figure 5, A and B). This reaction occurs commonly along the visceral pleura as a reaction to spontaneous pneumothorax. Its chief importance lies in its distinction from pleural involvement by pulmonary Langerhans cell histiocytosis. The distinction can be facilitated by consideration of the clinical setting (pneumothorax in the absence of radiographic features of pulmonary Langerhans cell histiocytosis as well as the absence of collections of Langerhans cells on immunohistochemical stains for S100 and CD1a.62,63
MALIGNANT PLEURAL NEOPLASMS OTHER THAN DMM OCCURRING PRINCIPALLY IN THE PLEURA
Localized Malignant Mesothelioma
By definition, DMM of the pleura grows widely over the pleural surface with a pattern of diffuse spread that is a key feature for both the radiologist and the pathologist to appreciate in order to make a correct diagnosis.64,65 Early DMMs exhibit nodular studding of the pleura (Figure 6, A and B), and with time tumor encases the lung and may extend to surrounding areas such as the mediastinum and may metastasize to distant sites, with most patients dead generally within 2 years of diagnosis. However, a small number of localized tumors with histopathologic, histochemical, immunohistochemical, and ultrastructural features identical to those of DMM, termed localized malignant mesothelioma, have been described in the pleura and other serosal membranes such as pericardium and peritoneum. 64,65 In 1994, Crotty et al64 described a series of 6 LMMs, and in 2005 the United States-Canadian Mesothelioma Reference Panel reported on 23 cases collected by the panel.65 Other LMMs have been reported in the English language literature, primarily as case reports.21,39,64-79 Most tumors are identified incidentally, and some patients present with nonspecific symptoms. The median age of patients is 62 years, and almost all are older than 40 years of age.65 The male-female ratio is approximately 3:2, in contrast to DMM, in which the vast majority of cases occur in men.64 No defined role of occupational asbestos exposure has been identified in the causation of LMM.
Grossly, pleural LMMs are solitary, well-circumscribed, pedunculated or sessile, nodular tumors, attached to the visceral or parietal pleura.65 Tumor size averages about 6 cm, but size does not correlate with prognosis. As noted above, a defining characteristic of LMM is that it is histologically, immunohistochemically, and ultrastructurally identical to DMM.64,65 All 3 subtypes-epithelial, biphasic, and sarcomatous-occur, with the epithelial subtype predominating64,65; however, histologic subtype does not correlate with survival, as opposed to DMMs where epithelial forms have a better prognosis65 (Figure 6, C through F).
Localized malignant mesothelioma must be differentiated from DMM. Diffuse malignant mesotheliomas are generally grossly widespread along the pleural surface, often as a rind surrounding the lung or as multiple individual tumor nodules; but in some cases microscopically widespread tumor along the pleural surface is identified histologically. Occasionally, DMM may present with a single, dominant nodule, and this circumstance must be distinguished from LMM, as “even microscopic evidence of tumor away from the main lesion automatically removes the cases from the category of LMM.” 65 Tumor recurrence and metastases may occur, ultimately causing patient death; however, diffuse pleural spread of tumor in the manner of DMM does not occur.65
Although many patients diagnosed with LMM ultimately succumb to their disease, “the crucial feature of localized malignant mesothelioma is that many cases can, apparently, be cured by surgical excision.” 65 Of the patients studied by the United States- Canadian Mesothelioma Reference Panel in 2005, approximately half of the patients who had follow-up information available were alive, many for several years, in stark contrast to the usual clinical course of DMM patients.65
Well-Differentiated Papillary Mesothelioma
Unlike DMM, a cancer with an almost uniformly poor prognosis generally occurring in the pleura of men in their seventh and eighth decades, well-differentiated papillary mesothelioma (WDPM) is a rare tumor typically considered to be of low malignant potential, usually involving the peritoneum in women of an average age younger than that of the age seen among DMM in men.80-97 While most DMMs arise in the pleura and cause patient death within months of diagnosis, with almost all patients dead of disease within 2 years of diagnosis, WDPMs may arise in a variety of locations in both women and men and are traditionally associated with completely benign behavior.80,81,83,86,90 Typically, patients survive several years even in cases of tumor recurrence. 80-83,86,90-93,97 Occupational exposure to asbestos has been suggested but has not been confirmed to be a causative agent in the pathogenesis of WDPMs.80,81,83,88- 93,97,98 Well-differentiated papillary mesotheliomas are frequently identified incidentally, often during surgery; however, patients may be symptomatic and present with pleural effusion, ascites, pneumothorax, or abdominal or chest pain.80,81,90 Well- differentiated papillary mesothelioma does occur in men and may arise from various sites besides the peritoneum, including the pleura, pericardium, and tunica vaginalis testis.80- 97Welldifferentiated papillary mesotheliomas usually occur as diffuse, multifocal lesions, but a WDPM may occasionally arise as a solitary, localized lesion. Grossly, WDPM is most often diffusely nodular, with small pleural nodules measuring from millimeters to a few centimeters in greatest dimension, giving the serosal surface a velvet-like appearance.80,81,90 A central scar may occur, usually in the solitary form of WDPM.80,81 The primary histologic pattern of WDPM is papillae with broad fibrovascular cores covered by a single layer of bland, flattened to cuboidal mesothelial cells, without necrosis, large nucleoli, or mitoses80,81,83,86,88,90 (Figure 7, A through C). The papillary cores may have a myxoid appearance, and areas of tubular or solid tumor may also occur80,81,90 (Figure 7, D). Psammoma bodies may be present. Covering cells may contain basal vacuoles.80,90 Although invasion is not a characteristic feature of WDPM, some cases show limited invasion80,81,83,85,90,97 (Figure 7, E). Immunohistochemical stains in WDPM are similar to those of epithelial DMM.80
Well-differentiated papillary mesothelioma must be distinguished histologically from DMM with a papillary pattern, which has relatively thin fibrovascular cores containing prominent, usually centrally placed blood vessels, and lining mesothelial cells characterized by round, atypical nuclei, frequent prominent nucleoli, and variable numbers of mitotic figures (Figure 7, F). Occasionally, tumors initially diagnosed as WDPM eventually prove fatal80,82,85,86; and at least some if not most of these cases represent actual DMMs for which material from a limited biopsy showed only a WDPM-like pattern. As such, care must be used in interpreting small biopsy specimens in this context. 80,81
Malignant Solitary Fibrous Tumor
Although SFTs, described above, are usually slow-growing tumors with a generally good prognosis, malignant SFTs are not infrequent and have been described in several published series.1 Malignant SFTs have been reported to make up from 7% to 60% of SFTs of the pleura, with most reports approximating one third of cases.23,24,39,52,100,102 Compared with patients with benign SFTs, patients with malignant SFTs are generally symptomatic, with cough, chest pain, and dypnea.22,39 Pleural effusion is much more common with malignant SFT than benign tumor.43 As with its benign counterpart, approximately 10% to 20% of patients with malignant SFTs exhibit digital clubbing and hypertrophic pulmonary osteoarthropathy-Pierre-Marie-Bamberg syndrome.
Grossly, malignant SFTs generally present as large masses. Malignant SFTs are often larger that 10 cm, and tumors attached to the mediastinum or parietal pleura, inverted into lung parenchyma, are more likely to be malignant. 22,43 Like benign SFTs, malignant tumors are usually firm, smooth, lobulated, pedunculated or sessile masses22 (Figure 8, A); however, hemorrhagic and necrotic areas may be present in relatively wide areas and may predominate the gross presentation in malignant tumors, probably due to their larger size and subsequent vascular compromise. 22 Malignant SFTs frequently recur locally and in some cases metastasize; however, these tumors do not spread over the pleural surface.43
Criteria for diagnosing malignancy in SFTs were developed by England et al in 1989.103 The criteria include (1) high mitotic activity (>4 mitoses per 10 high-power fields), (2) high cellularity with crowding and overlapping of nuclei, (3) the presence of necrosis, and (4) pleomorphism103 (Figure 8, B through E). Tumors are considered malignant if at least 1 criterion is present. Absence of the 4 criteria for malignancy is necessary to consider a tumor benign; however, the absence of malignant criteria may be difficult to establish due to heterogeneity of tumors or the subjectiveness of criteria.103 While these criteria are “established and are widely accepted,” the histologic distinction between benign and malignant SFTs is often difficult; and although the above criteria exist, “there are no unifying histological criteria” for malignant SFTs.103 Occasional large bizarre cells or focal areas of high cellularity, without cellular atypia or mitoses, are generally insufficient to categorize the tumors as malignant.22
In some cases, malignant SFTs arise from otherwise histologically benign SFTs and have the same basic histopathology of benign SFTs but with areas containing cytologic pleomorphism, hemorrhage, tumor necrosis, or more than 4 mitoses per 10 high-power fields102 (Figure 8, F and G). In other cases, malignant SFTs have high-grade, frankly sarcomatous areas within otherwise histologically benign SFTs (Figure 8, H). Other malignant SFTs arise de novo, without obvious areas of histologically benign SFT present adjacent to histologically malignant areas.102 The criteria for malignancy established by England et al103 remain sound and, along with the gross finding of sessile tumor, have been shown to predict recurrence. In 2000, Cardillo et al22 found that recurrent tumors occurred in 63% of patients with malignant sessile and histologically malignant tumors, 14% of patients with histologically malignant pedunculated tumors, 8% or less of patients with sessile SFTs with histologically benign features, and 2% or less of patients with histologically benign pedunculated tumors.
Malignant SFTs typically show the same immunostaining pattern as benign tumors; however, CD34, while typically showing 80% to 100% immunopositivity in benign tumors, has been shown in some studies to exhibit reduced expression in malignant SFTs.41,43,104,105 Overexpression of p53 and CD31 and high levels of Ki-67 expression have also been shown in malignant SFTs.41,52,104 Caution must be used when attempting to diagnose SFT in cases with atypical features or small biopsy specimens, as the tissue may not be representative of the lesion. Differential diagnosis includes sarcomatous DMM, sarcomatous LMM, synovial sarcoma, and leiomyosarcoma, among others. Immunostains may be helpful in differentiating among these tumors.
As with benign SFTs, resectability of the malignant tumor is considered the single most important prognostic indicator. Wide surgical excision is necessary in these patients because most can be cured by compete resection if done prior to metastasis or extensive local invasion.23,39 Tumors with benign histology that recur may represent inadequate sampling of a malignant SFT; therefore, the pathologist must widely sample all SFTs. Close follow-up of all patients is necessary to allow for early detection and treatment of any recurrences.102
Pleuropulmonary Blastoma
Pleuropulmonary blastoma (PPB) is a rare aggressive malignant tumor that almost always occurs in children under the age of 6 years. The neoplasm commonly presents within the lung but may also occur within the mediastinum or pleura.106-108
Presenting symptoms of affected patients are nonspecific and include cough, respiratory distress, fever, chest or abdominal pain, anorexia, and malaise.106-108 Radiographic studies show a parenchymal or pleural-based mass. On computed tomography (CT), the mass may be extensively multicystic, resembling a congenital cystic adenomatoid malformation. Alternatively, it may be entirely solid or contain solid enhancing nodules within cyst cavities. Pleural effusion is common.109,110
Pathologically, PPB has been subdivided into 3 types based on the degree and extent of cystic change. Type I is predominantly cystic, type II is cystic and solid, and type III is entirely solid. Histologic features vary according to the subtype.108
Type I PPB consists of multiloculated cysts lined by a ciliated columnar epithelium. Within septa there is a variably continuous zone of condensed immature round to spindle-shaped cells with a “cambium layer-like” appearance (Figure 9, A and B). This zone may be focal in some cases. Accompanying these areas, scattered rhabdomyoblasts are often present.108
Solid areas in types II and III PPB have admixtures of cellular islands of blastematous cells with fewer cellular areas of a spindle cell sarcoma. Mitoses are numerous within areas of blastema. Foci of skeletal muscle (eg, rhabdomyoblasts) or cartilaginous differentiation may be present within the sarcomatous areas (Figure 9, C through E). Focal cellular anaplasia with giant, bizarre pleomorphic cells may occur in types II and III PPB. Cystic areas in type II PPB are lined by a ciliated columnar epithelium similar to that observed in type I PPB. True cysts, by definition, do not occur in type III PPB. However, areas of necrosis may cause “cystic degeneration” which, unlike the true cystic areas in types II and III PPB, lacks a ciliated columnar epithelial lining.108
Immunohistochemical studies are not particularly helpful. Cytokeratin stains the overlying ciliated columnar epithelial component but is not expressed in the sarcomatous or blastemal areas. Muscle-specific actin and desmin label areas of skeletal muscle differentiation and may be positive, to a lesser extent, in areas of blastema. S100 stains areas of cartilaginous differentiation.108
Type I PPBs overlap histologically with type IV congenital cystic adenomatoid malformations, and distinction between the entities may be difficult on histologic grounds alone. However, the presence of any area of stromal hypercellularity in a type IV congenital cystic adenomatoid malformation should engender consideration of PPB.111 In this regard, careful sampling of any cystic mass submitted from a child is necessary. Sections from any thickened or plaquelike area may show blastematous or sarcomatous foci and thereby facilitate the diagnosis of this tumor.108 Patients with type I PPB tend to have a better prognosis than patients with types II or III PPB.108 However, recurrences tend to show progression to types II or III over time.108,112-114 Survival varies according to type, but PPB is an aggressive neoplasm. Metastases may occur within the central nervous system (brain and spinal cord), bone, liver, and soft tissue. The overall 5-year survival rate is 45%. Treatment consists of surgical resection, when possible, accompanied by chemotherapy and radiation therapy.108
PRIMARY PLEURAL PRESENTATION OF MALIGNANT TUMORS MORE COMMON IN OTHER LOCATIONS
Synovial Sarcoma
Synovial sarcoma is a rare, aggressive sarcoma that most commonly arises in periarticular soft tissues. It most commonly occurs in young adults between ages 20 and 40 years but may occur at any age. Synovial sarcoma within the pleura most often represents a metastasis from a soft-tissue primary. However, primary pleural presentation has increasingly been recognized since 1996, when Gaertner et al described a series of 5 biphasic synovial sarcomas originating within the pleural cavity.115,116
Clinically, primary pleural synovial sarcoma occurs in a wide age range of patients. In a study by Begueret et al117 of 40 patients with intrathoracic synovial sarcoma, the median age was 47 years with a range of 16 to 79 years. Men and women appear affected approximately equally.118 Patients usually present with variable combinations of chest pain, dyspnea, fever, dysphagia, cough, or spontaneous pneumothorax.115,118,119 Chest x-ray films show a well- circumscribed, uniform-appearing mass based in the pleura. Computed tomographic and magnetic resonance imaging scans show a heterogeneously enhancing wellcircumscribed mass within the pleural space (or lung if primary pulmonary or with pulmonary involvement).118
Grossly, most tumors are solitary and well circumscribed although they may rarely be multifocal. Their cut surface is often variegated with zones of necrosis, hemorrhage, and solid tumor.118 Histologically, most pleural synovial sarcomas are either monophasic or poorly differentiated. 117 Occasional cases are biphasic. Monophasic tumors are composed entirely of dense but bland spindled cells in intertwining fascicles. Poorly differentiated synovial sarcomas are of higher grade and contain areas of pleomorphic cells distinct from the bland spindled cells of the monophasic variety. They vary from tumors composed of large epithelioid cells, tumors composed of small blue cells resembling peripheral neuroectodermal tumors, and tumors with spindle cells growing in a “herringbone” pattern. 120 Biphasic tumors show variable degrees of epithelial differentiation ranging from poorly defined nests to wellformed glands.115,121 All types of tumors may show areas of necrosis, hemorrhage, and frequent mitoses115-117,121,122 (Figure 10, A and B).
Most synovial sarcomas (90%) are at least focally positive for one or more epithelial markers, although the degree and distribution of staining vary somewhat according to the type (monophasic, poorly differentiated, or biphasic). Epithelial membrane antigen is most consistently present in all 3 tumor types: present in 90%, 85%, and 100% of monophasic, poorly differentiated, and biphasic synovial sarcomas, respectively.115-117 Broad-spectrum cytokeratins are present less often (100%, 60%, and 58% of biphasic, monophasic, and poorly differentiated synovial sarcomas, respectively).115,123 BER- EP4 and CK7 are expressed more often in biphasic synovial sarcomas (76%, 90%, and 100%, respectively) than in monophasic or poorly differentiated synovial sarcomas (7%, 78%, and 6%, 50%, respectively, for monophasic and poorly differentiated synovial sarcoma123). In biphasic tumors, periodic acid-Schiff-positive, diastase-resistant material may be present within glandular spaces (Figure 10, C). In addition, staining for epithelial markers is more diffusely present and stronger in the epithelial component.115,118
Synovial sarcomas frequently stain positively for some markers also preferentially expressed in DMMs. In a study of soft tissue synovial sarcomas, Miettinen et al123 identified calretinin expression (both nuclear and cytoplasmic) in 71%, 52%, and 56% of biphasic, monophasic, and poorly differentiated synovial sarcomas, respectively. Begueret et al117 reported a somewhat lower expression of calretinin in synovial sarcomas limited to the thorax (12.8% of monophasic and poorly differentiated synovial sarcomas, combined). Expression of calretinin in synovial sarcomas, when present, varies from focal to diffuse. CK5/6 is present in most biphasic synovial sarcomas (76%) but is less often expressed in monophasic or poorly differentiated tumors (30% and 18%, respectively). In contrast, expression of WT1 is not identified in any of the subtypes of synovial sarcoma.123
Expression of other antigens may be helpful in the diagnosis of synovial sarcoma. Both Bcl-2 and CD99 are expressed by most synovial sarcomas. CD34 and CD117 are only rarely expressed.117
Molecular diagnostic techniques have greatly enhanced the diagnosis of synovial sarcoma. Greater than 90% to 95% of synovial sarcomas harbor the t(X;18) translocation (SYT-SSX). This translocation leads to the fusion of SYT (at 18q11) with SSX1 or, less commonly, SSX2 or SSX4 (all at Xp11), resulting in fusion protein products thought, through their effect on cell cycle regulation, to be integral to the pathogenesis of this tumor.124,125 Identification of the SYT-SSX translocation through reverse transcriptase polymerase chain reaction (PCR), fluorescence in situ hybridization or conventional cytogenetics is currently regarded as the most sensitive and specific method of diagnosis. 122,126-128 This translocation is not found in sarcomatoid DMMs129 or other types of malignancies.130,131
The differential diagnosis of synovial sarcoma in the pleura consists of metastatic synovial sarcoma, sarcomatoid and biphasic variants of DMM, benign and malignant SFTs, metastatic sarcomatoid carcinomas, and metastases or pleural involvement from other types of sarcomas. These entities can usually be distinguished on the basis of their clinical, gross, and histopathologic features.121
Soft tissue synovial sarcomas may commonly metastasize to the lung and pleura. Accordingly, an extrapleural primary should be rigorously excluded clinically before accepting a pleural origin.115 In contrast to synovial sarcoma, DMMs usually present with diffuse pleural thickening in older individuals with a history of asbestos exposure. 115,132 Although the immunohistochemical profiles of synovial sarcoma and DMM overlap,132 DMMs tend to express cytokeratin more diffusely and intensely than synovial sarcomas do.121,133 Expression of the mesothelial markers calretinin and CK5/ 6 is not useful as they may be seen in both DMM and synovial sarcoma.123,132 Benign and malignant SFTs can usually be distinguished by their histologic and immunohistochemical features. Immunohistochemical staining for CD34 is useful as it has been reported only rarely in synovial sarcoma but is usually present in both benign and malignant SFTs.117,133 Likewise, immunohistochemical staining for epithelial markers such as EMA and cytokeratin is negative in SFTs but positive in most synovial sarcomas.117,133 Positive staining for the epithelioid markers EMA and cytokeratin in synovial sarcoma tends to exclude pleural involvement or metastases from other types of sarcomas. In addition, synovial sarcomas lack staining for neural (S100) and smooth muscle (desmin, smooth muscle actin) markers.123,134 Metastatic sarcomatoid carcinomas can usually be distinguished by consideration of the clinical history as well as differing histopathologic and immunohistochemical features. In all of these cases, assessment of the SYT-SSX translocation by reverse transcriptase PCR, fluorescence in situ hybridization, or cytogenetics is very helpful in confirming or excluding synovial sarcoma.122,126-131
The prognosis of primary pleural synovial sarcoma is poor. In the series published by Gaertner et al,115 4 of 5 patients died within 3 years of initial surgery. Given the rare nature of this presentation, treatment is not standardized but usually consists of surgical resection occasionally accompanied by preoperative or postoperative radiation and chemotherapy.118
Angiosarcoma
Angiosarcoma may rarely present in the pleura and often mimics DMM (“pseudomesotheliomatous angiosarcoma”).135-139 Patients range in age from 22 to 79 years (mean, 57 years) with a male to female ratio of 9:1.139 Tumors present most commonly with diffuse pleural thickening and effusion,135,139 although occasional cases are localized. 140-142 Clinical symptoms include chest discomfort or pain, cough, hemoptysis, and dyspnea on exertion.136,143
The majority of cases have an epithelioid morphology histologically with variable degrees of vascular differentiation. Biopsy specimens show ragged infiltration by sheets or nests of large spindled and polygonal epithelioid cells interspersed with occasional ill-defined, variably sized vascular spaces. Within these spaces there may be micropapillary projections of tumor cells. The cells are cytologically malignant with large, pleomorphic, vesicular nuclei and prominent nucleoli. Mitotic figures are often frequent (Figure 11, A through C). As in angiosarcomas of other areas, cells may contain small intracytoplasmic vacuoles containing intact or degenerating erythrocytes. 135,139
The differential diagnosis includes DMM, metastatic carcinoma, and epithelioid hemangioendothelioma. These entities can be distinguished based on a combination of histopathologic features and expression of epithelial, mesothelial, and vascular immunohistochemical markers.
Unlike DMM and metastatic carcinoma, angiosarcoma lacks expression of calretinin and CK5/6, markers of mesothelial differentiation.143,144 Epithelioid angiosarcoma often shows some staining for broad spectrum cytokeratin. If present, however, this staining is usually weaker and more focal than typically seen in DMM. Angiosarcoma should stain for one or more vascular markers including CD34, CD31, or factor VIII.135,139 Staining for these markers is not observed in DMM.138 Although not formally studied in this setting, D2-40, a newly described mesothelial marker, does not appear to be useful, as it is also a lymphatic endothelial marker and stains a subset of angiosarcomas. 145-147 Epithelioid hemangioendothelioma is distinguished from angiosarcoma by its generally lower grade histologic appearance. Compared with angiosarcomas, epithelioid hemangioendotheliomas show milder degrees of nuclear atypia, fewer mitoses, and less necrosis. Zhang et al,139 however, suggest that this distinction may not be prognostically important as the prognoses of both epithelioid hemangioendothelioma and angiosarcoma are similar.
Putative etiologic factors of pleural angiosarcoma are diverse. In Japan, pleural angiosarcoma has been strongly linked to chronic pyothorax. A history of prior radiation or asbestos exposure has been noted in a few cases from Western Europe.139
Some authors have postulated that angiosarcoma may represent a divergent pathway of differentiation in DMMs. In this view, angiosarcoma would be analogous to the reports of DMMs showing areas of liposarcomatous, osseous, and cartilaginous differentiation.148,149 However, this theory is not currently supported, as DMMs showing areas of angiosarcomatous differentiation have not been described. Moreover, Attanoos et al138 found no evidence of endothelial differentiation in a study of 92 cases of DMM studied by immunochemistry for CD31, CD34, or vonWillebrand factor.
The prognosis of angiosarcoma is generally poor. In the study by Zhang et al,139 most patients were dead within 6 months despite aggressive surgery including pneumonectomy and pleurectomy. Localized cases have occasionally fared better with long-term survival in a few.139,140
Epithelioid Hemangioendothelioma
Epithelioid hemangioendothelioma in the lung was first described by Dail et al,150 who initially termed it intravascular bronchioloalveolar cell tumor. Aside from the lung, the tumor also commonly presents in the soft tissue, liver, and bone. Rare cases of epithelioid hemangioendothelioma have also been reported within the pleura.135,151,152
The clinical characteristics of epithelioid hemangioendothelioma are similar to those of angiosarcoma. Most patients are male and present with chest pain or discomfort and dyspnea. Chest CT scans show smooth to nodular, localized to diffuse pleural thickening.135,151
Gross findings on pneumonectomy or pleurectomy mirror those in imaging studies, showing localized to diffuse thickening of the pleura, which can extend along interlobar fissures in a “pseudomesotheliomatous” growth pattern. Histologically, biopsy and resection specimens show cords, strands, or nests of epithelioid cells within a myxoid or hyaline stroma. Epithelioid cells often have intracytoplasmic lumina, which may contain variably degenerated erythrocytes. Nuclear features are generally bland, and mitotic figures are scarce139,151 (Figure 12, A through C).
The immunohistochemical profile of epithelioid hemangioendothelioma is similar to that of angiosarcoma. The neoplastic cells stain weakly and/or focally for cytokeratin135 and also stain for one or more of the vascular markers CD31, CD34, and factor VIII.135,138 To our knowledge, expression of the mesothelial markers calretinin and CK5/6 has not been studied in this setting.
The differential diagnosis of epithelioid hemangioendothelioma consists of DMM, metastatic carcinoma, metastases from other sites of origin, and angiosarcoma. Diffuse malignant mesotheliomas and metastatic carcinomas generally show diffuse strong immunohistochemical staining for cytokeratin in contrast to the weak and/or focal staining in epithelioid hemangioendotheliomas. Moreover, expression of vascular markers CD31, CD34 and/or factor VIII is present in epithelioid hemangioendothelioma but not observed in DMM138 or metastatic carcinoma. 135 Metastases from another soft tissue or visceral origin are generally excluded by appropriate clinical workup.
Epithelioid hemangioendothelioma is distinguished from angiosarcoma by its generally lower grade histologic appearance including blander nuclear cytology, lower frequency of mitoses, and lesser degree of necrosis. Nonetheless, as Lin et al135 recognized, the boundary between higher grades of epithelioid hemangioendothelioma and well-differentiated angiosarcoma is not clearly defined and can, in occasional cases, be somewhat arbitrary. In this regard, Zhang et al139 argue that because of their invariably fatal outcome all epithelioid vascular tumors of the pleura should be regarded as highly malignant regardless of their distinction as angiosarcoma or epithelioid hemangioendothelioma.
Primary Effusion Lymphoma
Primary effusion lymphoma comprises a subset of large B-cell non- Hodgkin lymphomas recognized in the 1990s due to their unique presentation as pleural, pericardial, or peritoneal lymphomatous effusions in patients with acquired immunodeficiency syndrome. A remarkable finding in these cases was the absence of an associated mass lesion. Subsequent studies showed that the majority of these lymphomas are associated with coinfection by Epstein-Barr virus (EBV) and human herpesvirus 8 (HHV-8).153-156
In recent years, the clinical and pathologic spectrum of this disorder has expanded. Cases of primary effusion lymphoma have been reported in patients without acquired immunodeficiency syndrome,157 and some cases have lacked infection by HHV-8, EBV, or both.158-164 Reports have also recognized HHV-8-associated solid extracavitary lymphomas with cytologic features of primary effusion lymphoma either with or without associated serous effusions.165-169 Although most cases were originally thought to have a B-cell origin, rare cases with a T-cell phenotype have been described.170,171
Given the absence of an associated mass in most cases, diagnosis of primary effusion lymphoma is usually made on examination of cytologic preparations accompanied by immunohistochemical, flow cytometric, and molecular diagnostic studies. On Wright-Giemsa- stained and Papanicolaou-stained cytospin preparations, cells show highly atypical intermediate to large lymphoid cells with irregular nuclei and one to several prominent nucleoli (Figure 13, A and B). The overall cytologic features are consistent with a large cell lymphoma.153-156,170 Flow cytometric and immunohistochemical studies usually show positive staining of the cells for CD45 as well as activation markers such as CD30, CD38, and CD138. In most cases, cells usually have a null cell phenotype and do not express lineageassociated B-cell- or T-cell-associated antigens (eg, CD20, CD79a, CD3).154-156 Occasional cases, however, may show a B-cell or T-cell phenotype. The cells express the HHV-8/KSHV-associated latent protein by immunohistochemistry169,170,172 Despite the association with EBV, however, staining for EBV LMP 1 is negative.173 Clonal rearrangement of the immunoglobulin genes can be identified in most cases either through Southern blot analysis or by PCR.154-156 Rare cases have also been reported with rearrangement of the T-cell receptor genes.170,171 Southern blot or PCR analysis shows HHV-8 present in all cases.153-156 Epstein-Barr virus can also be detected in most cases on Epstein-Barr virus-encoded RNA in situ hybridization.
The prognosis of primary effusion lymphoma is poor, with a median survival of 6 months. Treatment usually consists of a combination of chemotherapy (CHOP-cyclophosphamide, doxorubicin, vincristine, and prednisone) combined with antiretroviral therapy (if the patient is human immunodeficiency virus positive).174
Pyothorax-Associated Lymphoma
Pyothorax-associated lymphoma refers to the development of a pleural EBV-associated diffuse large B-cell lymphoma in patients with longstanding chronic pyothorax. Pyothorax-associated lymphoma was initially described in 1987 in 3 patients who had developed chronic pyothorax after artificial pneumothorax for tuberculosis.175- 177 Since this original description, many additional cases have been reported.
Pyothorax-associated lymphoma occurs predominantly in elderly men (mean age in the seventh decade with marked male predominance).175,178 Most patients have a history of chronic pyothorax subsequent to artificial pneumothorax performed in the management of tuberculosis. However, pyothorax-associated lymphoma or similar EBVassociated pleural lymphomas have rarely been reported in other conditions associated with chronic pleural inflammation such as prior exposure to asbestos or following pneumonectomy.179,180
The duration of chronic pyothorax preceding diagnosis ranges from 20 to 64 years (median, 37 years).181-183 Patients present most commonly with chest and/or back pain sometimes accompanied by a chest wall mass. Chest x-ray films identify a pleural-based mass in approximately half of patients, although CT scan is more sensitive (85%). The mass is usually 10 cm or larger and may involve the lung or chest wall. Ancillary studies may demonstrate extrapleural dissemination to lymph nodes, liver, bone, bone marrow, and other organs.183
Biopsy specimens show a diffuse proliferation of large cytologically atypical lymphoid cells associated with a background of chronic fibrous pleuritis. The lymphoid cells often have immunoblastic features consisting of round nuclei with prominent and sometimes multiple nucleoli (Figure 14, A). Many cases show plasmacytoid differentiation. Mitoses are frequent and often associated with apoptotic bodies.175,181,182 On immunohistochemistry, most cases are of B-cell phenotype and express CD20 and/or CD79a, sometimes associated with expression of CD138 (Figure 14, B). The neoplastic cells generally lack expression of CD10 and Bcl-6 but are positive for MUM1, consistent with derivation from late germinal center/post-germinal center B cells. In some cases, there may be dual or aberrant expression of T-cell markers (CD2, CD3, and CD4).175,181 Rare cases stain only with T-cell markers, although it is unclear whether these represent pyothorax associated peripheral T-cell lymphomas or loss of B-cell antigens with aberrant T-cell antigen expression. Rare cases express no lineage specific antigens.175,181-183 In situ or PCR studies for EBV are positive in the majority of cases. Petitjean et al181 found that most cases show expression of EBV LMP 1 and EBNA-2 consistent with a type III latency profile. Immunohistochemical or in situ studies for HHV-8 are negative.181,184 Of the cases studied, most show light- chain restriction on immunohistochemistry or clonal rearrangements of the immunoglobulin heavy chain gene by PCR.184
Prognosis of patients with pyothorax associated lymphoma is poor. In a clinicopathologic review of 98 patients, Narimatsu et al183 reported a 35% 5-year survival rate. Treatment consists of adjuvant radiation, chemotherapy, or chemoradiotherapy with response rates of 56%, 71%, and 83%, respectively. Pleuropneumonectomy has been reported as successful in some cases.185
Malignant Small Cell Tumor of Thoracopulmonary Region (Primitive Neuroectodermal Tumor or “Askin Tumor”)
In 1979, Askin et al186 described a rare malignant neoplasm composed of undifferentiated small cells involving the chest wall, lung, and/or pleura of children (Askin tumor). This tumor appeared distinct from Ewing sarcoma, malignant lymphoma, embryonal rhabdomyosarcoma, and neuroblastoma. Based on the presence of occasional rosettelike structures on light microscopy combined with ultrastructural observations of rare neurosecretory-like granules, they postulated a primitive neuroectodermal origin.186
Since the original description by Askin et al,186 the application of immunophenotypic and molecular genetic techniques has shown that these tumors, along with Ewing sarcoma and primitive neuroectodermal tumors of soft tissue are a common neoplastic entity collectively termed Ewing sarcoma family of tumors (ESFT).187-189 All of these tumors are defined by a chromosomal translocation that leads to the fusion of the Ewing sarcoma gene (EWS) with one of the ETS family of transcription factors (including FLI1, ERG, E1AF, FEV, and ZSG). The most common translocation, t(11;22)(q24;q12), leads to in-frame fusion of EWS to FLI1, which results in an oncoprotein consisting of the N-terminal domain of EWS and the DNA-binding domain of FLI- 1.188,190,191
In the original article by Askin et al,186 patients were generally younger than 20 years old (range, 4 months to 20 years; median, 11 years) and most commonly presented with a mass (either solitary or multiple nodules) involving the chest wall, lung, or pleura. Other clinical symptoms included dyspnea or fever.
Pathologically, round, ovoid, multinodular gray-white masses are present in the chest wall or bulging through the parietal pleura. Histologically, the tumors consist of homogeneous cells with small round to oval nuclei and only a small amount of cytoplasm. The cells are arranged in sheets or in a vaguely lobular pattern. There is variable neural differentiation manifest as Homer-Wright rosettes or pseudorosettes186,188,189 (Figure 15, A). Variable amounts of glycogen are present in a minority of tumors on periodic acid- Schiff stain with diastase.
On immunohistochemistry, CD99 (the protein product of the MIC2 gene) is expressed by nearly all ESFTs.192-195 Strong and diffuse staining for this marker is characteristic of this entity such that the diagnosis of ESFT in a tumor lacking expression of CD99 should only be accepted if the characteristic translocation can be documented with molecular techniques. CD99 expression, however, is not specific as it may be present in lymphoblastic lymphoma, rhabdomyosarcoma, neuroblastoma, and others. Thus a panel of markers including terminal deoxynucleotidyl transferase, myogenin, myo-D1, and synaptophysin should be applied to any tumor suspected of ESFT to exclude these other entities.188,196,197 More recently, Folpe and others have shown that FLI-1 protein can be detected in most ESFTs and may also be helpful in characterizing these tumors.198,199
In addition to immunohistochemistry, molecular techniques are helpful in confirming the diagnosis of ESFT. Translocations involving EWS may be detected by reverse transcriptase PCR or fluorescence in situ hybridization techniques.188,196,200-204
Up to one third of patients with ESFT have metastases at presentation, and their prognosis is poor (5-year survival rate of 35%). Common metastatic sites include lung, bone, and bone marrow. The prognosis of patients with localized disease is better (5-year survival rate of 73%).188
Desmoplastic Small Round Cell Tumor
Desmoplastic small round cell tumor (DSRCT) is a recently described aggressive malignancy of adolescent and young adult males. Although it was originally reported in a predominantly or exclusively intra-abdominal location, 205 more recent studies have noted that it may rarely occur in the pleura, lung, and other extraabdominal locations. 206-212 At a molecular level, DSRCT is defined by a unique chromosomal translocation, t(11;22)(p13;q12), which results in a fusion protein combining the EWS gene with the DNA binding area of WT1 (EWS/WT1).213-216
Within the abdomen, a DSRCT usually consists of a large intra- abdominal mass accompanied by widespread peritoneal and omental implants and without a clear visceral origin.205,211,217 Tumors occurring within the pleura have a similar presentation and may grossly mimic DMMs.209
Histologically, DSRCTs are characterized by irregular, angulated nests of small cells embedded within a cellular fibromyxoid stroma (Figure 16, A). Necrosis is variably present within the centers of nests (Figure 16, B). The small cells within nests are generally uniform, with scanty, eosinophilic cytoplasm (Figure 16, C). In some areas, cells may have a “rhabdoid” appearance with a deeply eosinophilic inclusion-like cytoplasm which indents the nucleus. Mitotic figures are numerous.205,211
Since its original description, additional studies have expanded the clinical and histologic spectrum of this disorder. Less classic histologic features are present in a minority (approximately one third) of cases. Cells may have more irregular or pleomorphic nuclei with a greater amount of cytoplasm, and cells may have rhabdoid features. Some cases have areas of spindled or signet ring cells, which may occasionally be a prominent feature.211
Desmoplastic small round cell tumors have a complex, but distinctive, immunohistochemical profile with coexpression of epithelial, muscle, and neural markers. This immunohistochemical profile helps to distinguish them from other small round blue cell tumors of childhood. Desmin is perhaps the most useful marker, as it is expressed in most cases (81% to 100%). Expression is usually strong and diffuse, in many cases (75%) with a “globoid” or “dotlike” pattern of reactivity.205,210,217 In contrast, other muscle specific markers such as muscle specific actin or alpha smooth muscle actin are expressed less often (16% and 19%, respectively). Cytokeratin (AE1/AE3, CAM 5.2) can be found in most cases (95%), although it may rarely be absent. Most cases also stain positively for other epithelial markers including EMA (96%), MOC-31 (90%), and BEREP4 (71%). Expression of neural markers including neuron-specific enolase, CD57 (Leu-7), and synaptophysin is more variable (72%, 67%, and 16%, respectively). Approximately one third of tumors stain positively with CD99.210,217 Recently, WT1 has been reported as helpful in the diagnosis of DSRCT. Nuclear staining for WT1 is present in almost all cases, but is not expressed in ESFT or neuroblastomas.210,218-220
Molecular techniques may also be helpful in the diagnosis of DSRCT, particularly in cases with atypical features. The chimeric EWS/WT1 gene fusion transcript may be detected by reverse transcriptase PCR.221-223 Fluorescence in situ hybridization techniques have also been used.224
The prognosis of patients with pleural presentation of DSRCT is poor, similar to that of patients with an abdominal presentation. In the study by Parkash et al,209 there was an incomplete response to chemotherapy in all patients, and 2 of 3 patients died within 2 years.
Pleural Liposarcoma
Liposarcomas may rarely present within the pleura. Histologic types are similar to those found in soft tissue including well- differentiated/sclerosing, myxoid, and round cell. Radiographically, the tumors present with pleural-based masses. Histologic features are similar to those in soft tissue. Well-differentiated/sclerosing liposarcoma consists of mature adipose tissue with scattered atypical more hyperchromatic cells, some with the appearance of lipoblasts. There are variable amounts of intervening sclerotic/ fibrous tissue (Figure 17, A through C). Myxoid/round cell types are more cellular with elongated spindled to round cells with hyperchromatic nuclei within a myxoid stroma containing a delicate capillary network.225-227
Pleural Presentation of Thymoma
Thymomas typically involve the pleura by direct extension from the mediastinum. Rarely, however, they may present as pleural-based masses. The described cases have occurred across a broad age range from 38 to 75 years. Affected patients are either asymptomatic or have nonspecific respiratory complaints. Radiographic studies typically show diffuse, often nodular pleural thickening, sometimes accompanied by encasement of the associated lung.228 Histologically, the thymomas reported show a similar histologic spectrum as present in mediastinal lymphomas (types A, B, and C by World Health Organization criteria). They consist of lobules separated by dense fibrous bands (Figure 18). The lobules contain small round lymphocytes admixed with variable numbers of scattered larger epithelial cells. Mitotic activity is not prominent. Hassall corpuscles are rare.228,229 The epithelial cells can be highlighted on immunohistochemical stains for cytokeratin CK5/6 and p63. Background lymphocytes are positive for terminal deoxynucleotidyl transferase, CD99, and CD1a.229-231
The differential diagnosis of pleural thymoma consists chiefly of pleural involvement by a mediastinal thymoma, malignant lymphoma, and DMM. Pleural extension of a mediastinal thymoma should be excluded with appropriate radiographic studies. In contrast to thymoma, lymphoma does not contain admixed epithelial cells. Pleural thymoma may mimic DMM clinically and radiographically. 232,233 However, on histologic examination DMM usually shows areas of tubular and papillary growth and does not show the typical lobulation and fibrous bands of thymoma. Diffuse malignant mesothelioma also usually lacks the conspicuous lymphoid infiltrate present in most thymomas. 228,229 Immunohistochemical stains for mesothelial markers such as calretinin and CK5/6 are generally not helpful, as they may stain the epithelial cells in both thymoma and DMM. The prognosis of pleural thymoma is unclear from the limited data available. In the study of 8 patients by Moran et al,228 1 died, 1 recurred, 4 were lost to follow-up, and 2 patients were free of disease at 2 and 10 years after diagnosis.
Pleural Desmoid Tumor
Desmoid tumors (fibromatosis) may also rarely present within the pleura.235-237 Clinical and radiographic presentations are similar to SFTs, although the tumors can usually be distinguished histologically (Figure 19, A). Desmoid tumors within the pleura are similar to their counterparts in soft tissue, consisting of slender cytologically bland spindle cells in a collagenous background (Figure 19, B and C). In general, they lack the heterogeneity of patterns (patternless pattern) found in SFTs. On immunohistochemical stains, the tumors stain negatively for CD34 and positively for smooth muscle actin. This pattern of reactivity aids in their distinction from SFTs, which are positive for CD34 and negative for smooth muscle actin. Pleural desmoid tumors stain positively for beta catenin, although expression of this marker is not diagnostically useful in this context as it is also observed in SFT.235-237
Pleural Presentation of Rosai-Dorfman Disease
Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy) is a rare disease of uncertain histogenesis. It most commonly presents as lymphadenopathy due to effacement of affected nodes by a proliferation of large, pale, histiocytic- appearing cells admixed with neutrophils, lymphocytes, and plasma cells, with a background of variable fibrosis. The large pale histiocytes with associated emperipolesis of other inflammatory cells are a distinctive feature of this disease.238-240 Positive immunohistochemical staining of these cells for S100 helps to facilitate their distinction from more typical reactive histiocytes. However, the cells lack staining for CD1a and are thus also distinct from Langerhans cells.241-243
Although this disorder usually presents with lymphadenopathy, extranodal presentation may rarely occur. Pulmonary parenchymal involvement occurs in 3% of extranodal cases. Ohori et al reported a single case: an 81-year-old man who presented primarily with pleural involvement with a pleural effusion associated with parietal pleural thickening.244 The histologic features in this case were typical of Rosai-Dorfman disease at other extranodal sites (Figure 20, A and B).
CONCLUSION
Compared with metastatic malignancy to the pleura, DMM is uncommon; nonetheless it is the most common malignant primary pleural neoplasm. Relatively uncommon in relation to DMM are a variety of benign and malignant pleural neoplasms. The pathologist needs to maintain an appropriate index of suspicion of these uncommon to rare primary pleural neoplasms in order to render an optimal diagnosis.
References
1. Laucirica R. Pleural metastases. In: Cagle PT, Allen TC, Barrios R, et al, eds. Color Atlas and Text of Pulmonary Pathology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:163-164.
2. Light RW. Clinical diagnosis of pleural diseases. In: Cagle PT, ed. Diagnostic Pulmonary Pathology. 1st ed. New York, NY: Marcel Dekker; 2000:571-581.
3. Attanoos RL, Gibbs AR. “Pseudomesotheliomatous” carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff. Histopathology. 2003;43:444-452.
4. Burns TR, Greenberg SD, Mace ML, Johnson EH. Ultrastructural diagnosis of epithelial malignant mesothelioma. Cancer. 1985;56:2036- 2040.
5. Butnor KJ. My approach to the diagnosis of mesothelial lesions. J Clin Pathol. 2006;59:564-574.
6. Corson JM. Pathology of diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997;9:347-355.
7. Gumurdulu D, Zeren EH, Cagle PT, et al. Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages. Pathol Oncol Res. 2002;8:188-193.
8. Kawai T, Greenberg SD, Truong LD, Mattioli CA, Klima M, Titus JL. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung. Am J Pathol. 1988;130:401-410.
9. Khoor A, Whitsett JA, Stahlman MT, Olson SJ, Cagle PT. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from mal

KCI’s V.A.C.(R) Therapy Remains Available for Medicare Patients in the Home

Kinetic Concepts, Inc. (NYSE: KCI) today announced that V.A.C.(R) Therapy will remain available for Medicare patients in the home as a result of the Medicare Improvements for Patients and Providers Act of 2008, which was enacted into law by Congress on July 15, 2008. The Act delays and significantly modifies the Competitive Bidding Program of the Centers for Medicare and Medicaid Services (CMS). Key provisions of the Act affecting KCI include:

— Exemption of Negative Pressure Wound Therapy (NPWT) from the first round of Competitive Bidding.

— Termination of all durable medical equipment supplier contracts previously awarded by CMS in the first round of Competitive Bidding.

— Delay of implementation of the first round of Competitive Bidding until January 2010.

— Delay of implementation of the second round of Competitive Bidding until January 2011.

— Imposed reduction of NPWT pricing by 9.5% for Medicare Part B placements, effective January 2009.

The law effectively delays competitive bidding for NPWT for at least thirty (30) months until January of 2011. As a result of this delay, KCI’s V.A.C. Therapy is immediately available to all Medicare Part B patients in all of the first round competitive bidding areas (CBAs).

“Passage of this legislation is good news for patients, caregivers and the healthcare delivery system. It means that all Medicare patients in the home will continue to have access to V.A.C. Therapy,” said Catherine M. Burzik, President and Chief Executive Officer of KCI. “We believe this is vitally important given the overwhelming evidence of the clinical and economic effectiveness of KCI’s V.A.C. Therapy System and the lack of comparable or effective alternatives.”

About KCI

Kinetic Concepts, Inc. (NYSE: KCI) is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, tissue regeneration and therapeutic support system markets. Headquartered in San Antonio, Texas, KCI’s success spans more than three decades and can be traced to a history deeply rooted in innovation and a passion for significantly improving the healing – and the lives – of patients around the world.

KCI’s three primary businesses include:

Advanced Wound Care – Includes KCI’s proprietary Vacuum Assisted Closure(R), or V.A.C.(R) Therapy System, which has been clinically demonstrated to promote wound healing through unique mechanisms of action while reducing the overall cost of treating patients with complex wounds.

Tissue Regeneration – Represented by KCI’s LifeCell business and includes tissue-based products for use in reconstructive, orthopedic and urogynecologic surgical procedures to repair soft tissue defects.

Therapeutic Support Systems – Includes specialty hospital beds, mattress replacement systems and overlays designed to address pulmonary complications associated with immobility, to reduce skin breakdown and assist caregivers in the safe and dignified handling of patients of size.

The company employs 7,000 people and markets its products in more than 20 countries. For more information about KCI, and how its products are changing the practice of medicine, visit www.KCI1.com.

Forward-Looking Statements

This press release may contain forward-looking statements regarding the expected performance of the company. Forward-looking statements may contain words such as believes, expects, anticipates, estimates, projects, intends, should, seeks, future, continue, or the negative of such terms, or other comparable terminology. Forward-looking statements are subject to risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from those expressed in or indicated by them. Additional risks and factors are identified in KCI’s filings with the U.S. Securities Exchange Commission (the SEC), including its Annual Report on Form 10-K for the fiscal year ending December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, which are available on the SEC’s Web site at http://www.sec.gov. KCI undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Span-America Named Best Value Supplier By Cardinal Health for Therapeutic Support Surfaces

Span-America Medical Systems, Inc. (NASDAQ: SPAN) today announced that it was named as a Best Value(TM) provider for therapeutic support surfaces by Cardinal Health, Inc. (NYSE: CAH), one of the nation’s largest healthcare distributors.

The Best Value program provides Cardinal’s customers with a select list of products that meet strict criteria for excellence in the areas of performance, economics and service. Span-America has enjoyed Best Value status for its overlay and patient positioner products since 1996. The new agreements with Cardinal are effective through June 2009 and cover Span-America’s overlays, patient positioners and therapeutic support surfaces, including the company’s Geo-Mattress(R) line of therapeutic foam prevention mattresses and PressureGuard(R) series of specialty air therapy treatment surfaces.

“We are pleased that Cardinal has recognized the value and efficacy of our therapeutic support surfaces with their Best Value program,” stated James D. Ferguson, president and chief executive officer of Span-America. “Cardinal is recognized as one of the leading distributors for medical equipment and the addition of our proprietary specialty mattress products is expected to create new sales opportunities for Span-America in the prevention and treatment segments of the market.

“We expect overall market demand for therapeutic support surfaces to gain momentum due to forthcoming changes in Medicare rules. Beginning in October 2008, Medicare will hold hospitals financially accountable for the cost of care associated with facility-acquired pressure ulcers. As a result, we expect hospitals to focus more resources on prevention measures, including increased use of therapeutic support surfaces like our Geo-Mattress and PressureGuard lines of specialty mattresses,” concluded Mr. Ferguson.

About Span-America Medical Systems, Inc.

Span-America manufactures and markets a comprehensive selection of pressure management products for the medical market, including Geo-Matt(R), PressureGuard(R), Geo-Mattress(R), Span+Aids(R), Isch-Dish(R), and Selan(R) products. The Company also supplies custom foam and packaging products to the consumer and industrial markets. Span-America’s stock is traded on The NASDAQ Global Market under the symbol “SPAN.” For more information, visit www.spanamerica.com.

About Cardinal Health, Inc.

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an $87 billion, global company serving the health care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at www.cardinal.com.

Elderly Sex Abuser Preyed on Young Girls

By ROB KENNEDY

A CHILD sex predator who systematically abused two young girls has been jailed for 13 and a half years.

Edward Trotter raped, indecently assaulted and photographed the children when they were aged between nine and 13.

Newcastle Crown Court heard the 71-year-old had only begun offending at the age of 64, having retired from his job as a plasterer.

Having carried out the abuse he took indecent pictures of the girls and threatened to show them round their schools if they reported him to the police. Jailing him, Judge Beatrice Bolton said: “You pleaded guilty to a catalogue of offences against very young girls.

“You have become a man who is a danger to young girls if you can get yourself in a position of trust with them and you are capable of the worst kind of exploitation.

“Despite your age, this requires a substantial custodial sentence.”

Trotter, of Greens Place, South Shields, admitted more than 20 offences against the two youngsters, including rape and indecent assault.

After the hearing DC Lynne Colledge, of Northumbria Police, said: “We are pleased on behalf of the victims that this is over.

“It was obviously a very harrowing time for them and their families and it will be a relief to know the man who attacked them has finally accepted responsibility for what he has done. Hopefully the victims can now move on with their lives.

“Unfortunately far too many sexual offences go unreported. We would encourage all victims of rape or indecent assault to report such cases, which will be handled in confidence and with great sensitivity.”

(c) 2008 Evening Chronicle – Newcastle-upon-Tyne. Provided by ProQuest Information and Learning. All rights Reserved.

The Palm Beach Post, Fla., The Source Column

By Alexandra Clough, The Palm Beach Post, Fla.

Jul. 13–CLEVELAND CLINIC TO OPEN NEW DIGS IN OCTOBER: An all-star roster of doctors and medical services is coming to West Palm Beach in the fall, courtesy of the Cleveland Clinic Florida. October is the target opening month of the famed academic medical center’s opening at CityPlace Tower, West Palm Beach’s newest office building. Cleveland Clinic is taking the entire 14th floor of the 18-story tower, plus space on the ground floor for an imaging center.

With construction proceeding rapidly on the clinic space, the pace of hiring also is picking up, said Dr. Bernie Fernandez, chief executive of Cleveland Clinic Florida in Weston.

In the past couple of weeks, the clinic has made a couple of key hires, including Dr. Lester Rosen, a respected colorectal surgeon from Pennsylvania and a past president of the American Society of Colon and Rectal Surgeons. Other physicians who will be staffing the new offices include a urologist, gynecologist, and an internist. About seven physicians will be part of Phase I of the clinic’s opening.

More will come aboard later when the clinic starts performing outpatient procedures such as endoscopies, Fernandez added. Recruitment of nurses also is under way.

Initially, the local Cleveland Clinic will employ 30 to 35 people, but by the third year that figure should rise to 60.

Interest in the clinic’s upcoming opening is strong: People are saying, ‘Let us know when you open the new place so we can start making appointments,’ Fernandez said.

And what’s the hot field of medicine among patients?

Internal medicine is in the greatest demand, but if we look at our services, colorectal surgery has been extremely busy, Fernandez said. There’s also cardiology, and orthopedic sports medicine. Fernandez says he’s still on the prowl for one more speciality at the new West Palm Beach office, and that’s an endocrinologist.

Diabetes is an epidemic, Fernandez said. In Weston, we have five endocrinologists and they’re completely booked. We’re trying to identify one more for West Palm Beach. The Cleveland Clinic has been seeing patients at an interim facility at the Northbridge Center in West Palm Beach. But the clinic’s range of services will dramatically expand once it moves into its new space next to the CityPlace shopping and dining complex on Okeechobee Boulevard.

Cleveland Clinic’s target audience: Wealthy patients and benefactors in nearby Palm Beach and in surrounding areas. Already, some 50 percent of Cleveland Clinic’s Weston patients are from outside its immediate zip codes. Now those patients coming from Palm Beach County and points north will be able to visit clinic doctors in a luxurious, convenient setting.

The vistas from the 14th floor are stunning, Fernandez said. We’ll be providing first-class medical care.

CITYPLACE TOWER FILLING UP: Space in CityPlace Tower is filling up fast and more deals are in the works.

One possible deal involves the venerable Casey, Ciklin law firm in West Palm Beach.

Alan Ciklin, the firm’s managing partner, acknowledged the firm was considering a move to CityPlace Tower from its longtime perch at Northbridge, aka the Darth Vader building (in honor of the structure’s imposing black glass facade).

Casey, Ciklin leaving Northbridge would be a seismic shift in the commercial landscape, akin to Santa Claus relocating from the North Pole.

But perhaps the firm’s sentimental ties to the building aren’t the same since its founding partner, William R. Boose III, left the firm.

Boose was a part of the investor group that developed Northbridge, which is located on North Flagler Drive. Now Boose is serving a two-year prison sentence in rural North Carolina for his part in a corruption scheme.

Ciklin said the firm’s move to CityPlace Tower could make sense, if the numbers add up. At CityPlace Tower, the firm will probably take about 5,000 square feet less than its current 30,000 square feet at Northbridge. A more efficient configuration on one floor would work much better than the current arrangement on two floors at Northbridge, Ciklin said.

He also likes the tower’s hurricane-resistant construction, including the impact-resistant windows, plus the generator that will keep power running even if a storm cuts power to the area.

Still, the rents at CityPlace Tower are considerably higher, starting in the $30-plus range for space, and that doesn’t include taxes and maintenance. Ciklin said base rents at Northbridge are in the mid-$20s.

Ultimately, the decision will be based on — what else — money.

The less overhead you have, the better, and the more money you make, Ciklin said.

Ciklin said the firm’s lease is up in two years at Northbridge, but he hopes to make a decision soon. It’s a gorgeous building, Ciklin said of CityPlace Tower. But on the other hand, we’d hate to move.

All in all, about 80 percent of the CityPlace Tower is leased, a tower spokeswoman said. Talks are ongoing with more potential tenants, including Casey Ciklin, another law firm and a financial services firm.

The Source is a weekly online column about business and real estate in Palm Beach County and the Treasure Coast. You can read more of Alexandra Clough on Mondays in the Inside Local Business section.

—–

To see more of The Palm Beach Post — including its homes, jobs, cars and other classified listings — or to subscribe to the newspaper, go to http://www.palmbeachpost.com.

Copyright (c) 2008, The Palm Beach Post, Fla.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

North Mississippi Medical Center Expands Affiliation With Premier Healthcare Alliance to Include Infection Tracking Tool

The Premier healthcare alliance today announced that it is expanding its relationship with North Mississippi Medical Center (NMMC). The Tupelo, Miss.-based healthcare system, which in 2006 was named a Malcolm Baldrige National Quality Award recipient along with Premier Inc., will deploy both the infection control and pharmacy modules of Premier’s SafetySurveillor(TM).

The third largest rural healthcare system in the nation will use SafetySurveillor to track and prevent healthcare-associated infections (HAIs) and to optimize antibiotic use, thereby increasing patient safety and reducing costs.

NMMC also joins QUEST: High Performing Hospitals, a Premier program designed to help hospitals and healthcare systems drive healthcare to new levels of performance. QUEST will develop next-generation quality, safety and cost metrics with a level of consistency and standardization that does not exist today.

The diversified not-for-profit healthcare system serving 22 counties in north Mississippi and northwest Alabama has used Quality Manager for more than seven years to collect, aggregate, and analyze Joint Commission/CMS Core Measure data, identify areas for clinical outcomes improvement, and implement process changes that directly impact patient care.

NMMC Chief Quality Officer Dr. Michael L. O’Dell said, “Safety and control of spread of infections are top priorities for NMMC – Tupelo and our affiliated community hospitals. A patient with an infection presents us with two mandates: a mandate to discover that infection rapidly and successfully treat the patient and a mandate to protect other patients, staff, and visitors from inadvertently being exposed to that same infection. HAIs are particularly important to us in that these illnesses are often more difficult than most to treat once acquired. SafetySurveillor offers us a better means to meet our mandates.”

NMMC will deploy SafetySurveillor at the 650-bed North Mississippi Medical Center, the system’s flagship hospital, and NMMC Women’s Hospital, both in Tupelo, as well as community hospitals in Eupora, Iuka, Pontotoc and West Point, Miss., and Hamilton, Ala.

More than 200 hospitals nationwide have chosen the Web-based application, making SafetySurveillor the most widely adopted infection control solution in the past 12 months. It helps hospitals meet state-mandated public reporting of certain HAIs, including screening for methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile, some of the most common and harmful infections found in hospitals today. With SafetySurveillor hospitals can automatically detect HAIs and alert staff, facilitating timely intervention to reduce and prevent infections.

Premier’s SafetySurveillor is one of the HAI surveillance system software vendors participating in a Centers for Disease Control and Prevention project to develop a standards-based solution for transmission of HAI data from hospitals using existing commercial software systems to the agency’s National Healthcare Safety network.

North Mississippi Health Services

North Mississippi Health Services is a diversified regional healthcare organization, which serves 22 counties in north Mississippi and northwest Alabama from headquarters in Tupelo. The NMHS organization covers a broad range of acute diagnostic and therapeutic services, offered through North Mississippi Medical Center in Tupelo; a community hospital system with locations in Eupora, Iuka, Pontotoc, and West Point in Mississippi and Hamilton in Alabama; and North Mississippi Medical Clinics, a regional network of more than 30 primary and specialty clinics; and nursing homes. NMHS offers a comprehensive portfolio of managed care plans. Educational programs and early intervention are important aspects of our services, but our main focus is to provide convenient access to quality health care. NMHS works to achieve its corporate mission to improve the health of the people of this region by providing conveniently accessible, cost-effective healthcare of the highest quality.

About Premier Inc., 2006 Malcolm Baldrige National Quality Award recipient

Serving more than 2,000 U.S. hospitals and 53,000-plus other healthcare sites, the Premier healthcare alliance and its members are transforming healthcare together. Owned by not-for-profit hospitals, Premier operates one of the leading healthcare purchasing networks and the nation’s most comprehensive repository of hospital clinical and financial information. A subsidiary operates one of the nation’s largest policy-holder owned, hospital professional liability risk-retention groups. A world leader in helping healthcare providers deliver dramatic improvements in care, Premier is working with the United Kingdom’s National Health Service North West and the Centers for Medicare & Medicaid Services to improve hospital performance. Headquartered in San Diego, Premier has offices in Charlotte, N.C., Philadelphia and Washington. For more information, visit www.premierinc.com.

Delcath Systems’ Targeted Drug Delivery System for Liver Cancer Treatment to Be Featured on FOX Business News

Delcath Systems, Inc. (NASDAQ: DCTH) today announced that CEO Richard L. Taney will appear on FOX Business Network (FBN) to discuss the Company’s proprietary Percutaneous Hepatic Perfusion (PHP) System, which is designed to deliver targeted high doses of therapeutic and chemotherapeutic agents. The PHP System is currently being tested in Phase III and II clinical trials for the treatment of hepatocellular carcinoma and metastatic tumors in the liver. Also appearing on this segment will be Dr. James Pingpank of the National Cancer Institute in Bethesda, Maryland. Dr. Pingpank is the Principal Investigator for the Company’s ongoing pivotal Phase III trial of metastatic melanoma in the liver. Mr. Taney will discuss the health industry’s efforts towards treating cancer on a regionalized basis and provide an update on current approaches to the treatment of liver cancer, including Delcath’s PHP System. Mr. Taney will be featured on the “Money for Breakfast” segment on Wednesday, July 16, 2008 to be broadcast at 7:30 AM/ET.

In making this announcement, Mr. Taney commented, “The appearance on FOX Business News is an important step in our ongoing effort to increase public awareness of the Company’s targeted drug delivery system for the treatment of liver cancers. We are pleased to have the opportunity to present our technology and the promise that it holds for patients suffering from this terrible disease.”

FOX Business Network (FBN) is a financial news channel delivering real-time information across all platforms that impact both Main Street and Wall Street. FBN is headquartered in New York, the business capital of the world. Launched in October 2007, the Network is available in more than 35 million homes in major markets across the United States. Owned by News Corp., the Network has bureaus in Chicago, Los Angeles, Silicon Valley, Washington, DC and London. (www.foxbusiness.com).

About Delcath Systems, Inc.

Delcath Systems is a technology-based therapeutic company specializing in cancer treatment. The Company is working to complete its first Phase III clinical trial for its Percutaneous Hepatic Perfusion System (“PHP”) for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The PHP System is currently being tested in Phase III and Phase II clinical trials for the treatment of hepatocellular carcinoma and metastatic tumors in the liver, including melanomas, neuroendocrine tumors and adenocarcinomas. The Company’s intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company’s website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

 Delcath Systems, Inc. Contact: Mr. Richard Taney President & Chief Executive Officer T: (212) 489-2100 E: Email Contact  Investor Relations Contact: Mr. Richard Cooper Chairman Mr. Cass Almendral Vice President Strategic Growth International, Inc. T: 212-838-1444 E: Email Contact

SOURCE: Delcath Systems, Inc.

Law Grants a Piece of Life to Families of Stillborns Parents Can Now Get a Certificate of Birth to Help Them With Grief.

By JAKE ARMSTRONG

ATLANTA-Life was rolling along for Allie Brokhoff.

She and her husband Andrew had just settled into their Richmond Hill home, and a trip to the doctor’s office in mid-August 2007 confirmed she was three weeks away from adding a third healthy boy to their brood – Ethan Isaac Shark Brokhoff, a name their two sons helped choose.

Days later, she noticed the unborn baby wasn’t moving much. She ate a bowl of Cocoa Krispies, which usually elicited a flurry of activity from the boy, but still felt nothing.

Brokhoff’s slowly growing worry dissipated some on a return visit to her doctor’s office, where an ultrasound picked up a heartbeat.

Then came the bad news: That heartbeat was her own.

Ethan Brokhoff became one of the roughly 1,000 babies stillborn in Georgia each year. His grieving mother was later told she was not entitled to a record showing that he entered the world, only a certificate showing he died as a fetus.

“When you carry a child, you have all kinds of expectations and hopes and dreams – and they just end,” Brokhoff said recently. “And for some people to not recognize your child as a child is just an added insult.”

A new law seeks to alleviate the psychological pain of stillbirth. The No Heartbeat Act took effect July 1 and allows parents of stillborn children to obtain a certificate of birth resulting in stillbirth, a vital record proponents say will help console parents and aid researchers studying the phenomenon.

A stillbirth occurs when a fetus dies after 20 weeks. Though 25,000 babies are stillborn each year in the United States, the cause of death is unknown in about half of all cases, according to the U.S. Centers for Disease Control and Prevention.

Doctors were unable to determine why Ethan died, Brokhoff said.

Joanne Cacciatore-Garard, a doctor who researches stillbirths at Arizona State University and founder of a nationwide stillbirth- support group, the MISS Foundation, said infant deaths have been reduced in the past 20 years, largely because of increased monitoring.

Yet the number of stillbirths remains unchanged year to year because the deaths are not being recorded as such in many states, stymieing efforts to address the causes, Cacciatore-Garard said.

“This is a real public health problem and we have been systematically ignoring it,” she said.

The issue caught the attention of Marcia McGinnis, who runs a grieving-parents support group, and she and a handful of group members got Sen. Dan Weber, R-Dunwoody, to carry a bill through the General Assembly.

“It became clear to me as we were walking through all this we need to find answers as to why babies die,” McGinnis said.

Georgia became the 23rd state to enact a law allowing parents to obtain the certificate.

The Department of Human Resources previously tracked stillbirths along with the roughly 10,000 fetal deaths recorded in the state each year.

In some states, the push to recognize stillbirths has drawn opposition from pro-choice advocates who fear it is an attempt to whittle away at abortion rights by establishing fetal personhood. That proved no obstacle in Georgia, and the No Heartbeat Act sailed through the General Assembly with only three votes against it.

Like many parents who experience stillbirth, Brokhoff and her husband keep a memory box that holds a picture, a lock of hair, footprints and ultrasound images of Ethan.

She expects her son’s certificate to arrive soon from the state Vital Records Office, and hopes the law helps other mothers recognize their stillborn children.

So far, about 20 requests have come in to the Vital Records Office, which processes requests, but officials expect to receive more as the law gains notoriety.

“It’s going to make it so much easier for women in the future,” Brokhoff said.

For more information about certificates of birth resulting in stillbirth, call the Vital Records Call Center at (404) 679- [email protected], (404) 589-8424

(c) 2008 Florida Times Union. Provided by ProQuest Information and Learning. All rights Reserved.

Record ‘Door-to-Balloon’ Time at Presbyterian Hospital of Dallas

DALLAS, July 15 /PRNewswire-USNewswire/ — A man suffering a heart attack recently arrived at the Presbyterian Hospital of Dallas ER and was eventually treated with an angioplasty procedure in the hospital’s cardiac catheterization lab in 28 minutes. The procedure, performed by Dr. Kenneth Saland, an interventional cardiologist at Presbyterian, involved using a tiny balloon to open a blocked coronary artery and illustrates the importance of providing treatments in a safe, rapid way to those suffering heart attacks.

“Research shows that the quicker a heart attack is treated the less potential damage there is to the heart muscle,” Dr. Saland said. “Preserving more heart muscle helps the patient survive the heart attack and improves the long-term survival and quality of life for patients.”

The time it takes to treat a heart attack patient when he or she arrives in a hospital’s ER to the moment a balloon is deployed to open their blocked artery is called “door-to-balloon” time. Major clinical studies, endorsed by the American Heart Association, have shown that treating heart attack patients within 90 minutes of arrival significantly reduces damage to the heart muscle.

“Not only is this the best time ever for our hospital, it ranks among the best times regionally and nationally,” said Jon Gardner, Presbyterian’s director of the Heart & Vascular Service Line. “But the record isn’t what’s important. The importance of this is that it’s another example of the commitment by physicians on the hospital’s medical staff, the EMS personnel, and our emergency room and cardiovascular staff at Presbyterian to provide evidence-based health care in an efficient, quality way.”

Recently, a separate door-to-balloon time at Presbyterian reached the 31-minute mark. During spring 2008, 14 consecutive emergency angioplasty procedures were performed within the 90-minute door-to-balloon timeframe.

The emergency room also plays a critical role in the process, since that’s where heart-attack patients typically arrive. “That’s the ‘front door’ of the hospital, so providing rapid cardiac assessments and efficiently communicating with the cath lab is critical to achieving our goal,” Gardner said.

Coronary angioplasty is a procedure in which a balloon is used to open a blockage in a coronary artery narrowed by plaque buildup on the inner walls of the arteries. Annually, more than 1 million people undergo angioplasty in the U.S., the National Heart, Lung and Blood Institute reports.

Texas Health Resources

CONTACT: Stephen O’Brien of Texas Health Resources, +1-214-345-4960,[email protected]

Web Site: http://www.texashealth.org/

Tenet Pays $2 Million Over Delay in Stroke Treatment

By Phil Galewitz, The Palm Beach Post, Fla.

Jul. 15–Tenet Healthcare Corp. has paid nearly $2 million to settle a malpractice lawsuit filed by the family of a Boca Raton woman who died in 2004 after two of its hospitals failed to find a neurosurgeon to treat her stroke.

The lawsuit was settled in late April, though the payment was not disclosed to the state Office of Insurance Regulation until last month.

According to the lawsuit filed in Palm Beach County Circuit Court, the four-hour delay in treating Barbara Masterson contributed to her death.

Masterson, 52, awoke on Feb. 22, 2004, with slurred speech and weakness on her right side, according to the lawsuit and attorney Gary Cohen.

The woman was bleeding in her brain when she arrived at Tenet’s West Boca Medical Center emergency room. The hospital tried calling four neurosurgeons, all of whom refused to come in to treat Masterson.

West Boca had a transfer agreement with Delray Medical Center, also Tenet-owned, but a doctor there also refused to come in to treat her.

By the time Masterson was transferred to Holy Cross Hospital in Fort Lauderdale, she was unresponsive and paralyzed on her right side. She underwent surgery but died March 2.

Masterson, a former ER nurse, is survived by her husband, James, disabled with multiple sclerosis, and three adult children.

“You expect when you get to the front door of a hospital, you will see a doctor to treat you right away,” James Masterson said. “To not be able to find a doctor is incomprehensible.” Over the past four years in Palm Beach County, showing up at a hospital ER has been a little like playing Russian roulette because of the shortage of specialists. The problem has persisted among several specialties, including neurosurgery.

Since 2004, stroke care in the county has improved as several hospitals, including Delray Medical, have become state-designated stroke centers with the ability to handle emergency stroke patients 24 hours a day.

Tenet Healthcare (NYSE: THC, $5.51), which owns five Palm Beach County hospitals, would not comment, citing a confidentiality agreement.

“However, we have made great strides in our stroke care over the last several years,” said spokesman David Matthews.

—–

To see more of The Palm Beach Post — including its homes, jobs, cars and other classified listings — or to subscribe to the newspaper, go to http://www.palmbeachpost.com.

Copyright (c) 2008, The Palm Beach Post, Fla.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

THC,

Crossroads Holds Rummage Sale Benefiting Sarah’s Kids

By Kandace McCoy, Mt. Vernon Register-News, Ill.

Jul. 15–MT. VERNON — In an effort to help the children of a woman killed by a house fire, the Crossroads Community Hospital Business Office is holding a benefit rummage sale.

The Rummage Sale for Sarah’s Kids will be held Friday at the CCH Business Office and Sleep Lab (inside), 4 Doctors Park Road in Mt. Vernon beginning at 8 a.m. All proceeds will go to the children of Sarah Rollinson, a former CCH employee, who died in a house fire on July 3. The grandmother of the children is CCH Registered Nurse Sandi Rollinson.

“We’re taking all sorts of donations and whatever money raised will be given to the children to spend for their needs,” said CCH business office director Rhonda Hudnall. “They lost their money and also lost all their stuff in the fire.”

“We sincerely appreciate the support of the community for all the contributions for the children. Words cannot describe the trauma these kids are going through with Aaron and Cassidy losing their mom and Garrett losing his dad. We know no amount of money can take away their pain but we don’t want these kids to have to want for anything that can be provided for them right now. They lost their toys, bedding, CDs, DVDs, video games — anything other average kids have they probably had and we want them to have that stuff again. And more importantly, we want them to know they are not alone. We empathize with their pain and want to show them we care about them,” stated Angela Schrum, volunteer coordinator at Crossroads. “Sandi [Rollinson] is a valuable asset to our hospital and one of the benefits of being a smaller facility is you know pretty much everyone and their family, we all kind of become one family and this part of our family has a need: mostly prayers and definitely funds to take care of what is needed.”

Hudnall said items are being accepted through the end of Thursday, and may be dropped off at the business office. Suggestions for the rummage sale include CDs, DVDs, VCR tapes, cassette tapes, books, magazines, jewelry, makeup and toiletries, household and kitchen items, linens, electronics, decorating items, sporting and fishing goods, yard, garden, and garage items, tools, toys and games, clothing, plants and bulbs, craft items and supplies, furniture and appliances, and birdhouses. No donation will be refused.

The CCH case management department and the emergency room department are also accepting age-specific clothing for Sarah’s children, Aaron, age 10, and Cassidy, age 8, Hudnall noted. Boys size 12 husky in pants and shorts, shirt size 12-14 and shoe size 6 1/2 to 7 are being accepted for Aaron; girls size 8-10 in pants and shorts, shirt size 10-12 and size 2 shoes are being accepted for Cassidy.

A previous fundraiser, a bake sale hosted by the CCH Auxiliary, brought in $1,328 for the children, according to Hudnall. Several employees, hospital volunteers and community members dropped off cash donations and Comfort Inn and Suites donated two one-night stays that were auctioned off in addition to numerous baked goods donations. An additional fundraiser — a pasta dinner — is being planned by the dietary department at Crossroads with details to be announced later.

The business office is open Monday through Friday from 8 a.m.. to 5 p.m., but Hudnall said she will remain after hours for those who wish to drop off donations.

For more information contact Hudnall at 241-8515.

—–

To see more of Mt. Vernon Register-News or to subscribe to the newspaper, go to http://www.register-news.com/.

Copyright (c) 2008, Mt. Vernon Register-News, Ill.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Acupuncture Added to Crystal’s Wellness Options

LOS ANGELES, July 15 /PRNewswire/ — Enriching its portfolio of wellness opportunities, Crystal Cruises is introducing onboard acupuncture, along with a menu of Chinese herbs revered for restoring and enhancing health, beauty and longevity. A menu of optional acupuncture treatments, launching this month on Crystal Serenity, focuses on weight loss, pain management, stress reduction, detoxification, smoking cessation, facial rejuvenation and even sea sickness.

“For many, a vacation offers the freedom to try something new,” says Thomas Mazloum, senior vice president, hotel operations. “Whether one is just curious or one wants to pursue new treatments, acupuncture complements Crystal’s myriad of onboard wellness activities, which have transformed guests into devotees of disciplines like yoga or reflexology or Spinning(R).”

Acupuncture is a technique of inserting and manipulating fine needles into specific points on the body to ease pain and for other therapeutic purposes. According to the World Health Organization and other reputable entities, acupuncture helps relieve aches and pains; stimulate weight loss; alleviate stress; detoxify the body; smoking cessation; seasickness; and anti-aging.

The Crystal acupuncture program includes:

— Onboard acupuncturist – Nancy Kerastas, Crystal Serenity’s licensed acupuncture physician, has been practicing the art since 2002;

— Menus of Chinese herbs – Includes remedies that reactivate the body’s fat-burning process; stabilize blood sugar metabolism; and relieve swollen or immobile joints; and

— Shipboard seminars – Three to five classes will be held per cruise, discussing acupuncture, Chinese herbal medicine and Feng Shui practices and benefits.

Guests receive pre-session consultations to discuss their conditions and medical histories. Cost is $150 for a 60-minute session and can be booked through Crystal’s Feng Shui-designed spa.

Crystal also offers complimentary yoga, Pilates and newly introduced “Tour de Spin” cycling classes, and an exclusive Walk on Water(R) program utilizing weighted vests to increase resistance. The line continues its partnership with the esteemed Cleveland Clinic to feature onboard lectures and seminars with leading medical experts.

In December 2008, and in 2009 both Crystal Symphony and Crystal Serenity host Mind, Body & Spirit theme cruises, focusing on general wellness through classes and discussions with guest instructors in Tai Chi, yoga, Pilates and general fitness.

For additional information and Crystal reservations, please contact a travel agent or call 888-799-4625. Visit the luxury line’s website, crystalcruises.com.

CONTACT: Mimi Weisband 310-203-4302

[email protected]

Crystal Cruises

CONTACT: Mimi Weisband of Crystal Cruises, +1-310-203-4302,[email protected]

Web site: http://www.crystalcruises.com/

Nerve Problem Causes Stabbing Face Pain

DEAR DR. DONOHUE: I wrote to you about six months ago about trigeminal neuralgia but haven’t seen a reply. I have it, and take Tegretol, which helps with the pain. Before I was correctly diagnosed, I went through hell. An ear, nose and throat doctor finally made the diagnosis. Thank God for him. Nobody knows the pain of this unless you go through it. The pain hit the left side of my face. Please tell me about it. – J.S.

ANSWER: Being stabbed in the cheek with an ice pick gives people a slight idea of the pain of trigeminal neuralgia. The pain is relatively brief, but can recur several to a dozen or more times in any 24-hour period, and during the pain-free time, patients are in high anxiety waiting for the next attack. Chewing, washing the face, shaving or even a light breeze blowing on the cheek can set off another paroxysm of pain.

The probable explanation is that an artery encircles the trigeminal nerve, the nerve that brings sensations from the face to the brain. It’s from this nerve that the name of the condition comes. Pulsations of the artery irritate the nerve and render it sensitive to harmless signals that would not be interpreted as pain by people with a healthy trigeminal nerve.

Tegretol, a seizure medicine, controls the pain for many. Neurontin and baclofen are two other medicines for this condition. Should medicines not control pain, focusing gamma rays on a short section of the nerve often can eliminate the problem. This procedure is called gamma knife treatment, but no knife is used. Another highly successful method of dealing with trigeminal neuralgia is to place a spongelike material between the nerve and the encircling artery to dampen its pulsations.

The Trigeminal Neuralgia Association can provide you with a wealth of information. Contact them at www.tna-support.org. The Trigeminal Neuralgia Association of Canada is found at www.tnac.org. It, too, is a wonderful source of up-to-date information.

DEAR DR. DONOHUE: I have a daughter, 44 years old, who has a problem with boils under her arms and in the groin area. She gets boils on top of boils, clusters of them. She has taken antibiotics for them, but they come back just as bad. Doctors want to remove her sweat glands. She does not do well with surgery. What do you say? – B.S.

ANSWER: Ask your daughter if her doctors ever used the words “hidradenitis (HID-rat-uh-NITE-is) suppurativa (SUE-purr-uh-TEA- vuh).” It’s recurring outbreaks of tender, red bumps under the arms and in the groin. The bumps look like boils. At first, they’re solid, but they become soft, fluid-filled and painful. Like boils, they drain. Eventually, scars form. Crop after crop of these bumps keep coming back. Special sweat glands in those areas – called apocrine glands – become inflamed, as do the pores through which hairs emerge.

Daily cleaning with antibacterial soaps, the application of antibiotic lotions and salves, and oral antibiotics sometimes can control outbreaks. In situations like your daughter’s, doctors often judge that removal of infected, irritated skin and sweat glands is the best way to resolve the problem. Surgery might be your daughter’s only way to win the battle over this distressing condition.

DEAR DR. DONOHUE: My husband died of advanced lung cancer on Jan. 3, 2008. The cancer had spread to his spine, ribs and diaphragm. In early October 2007, he began to complain of right-sided abdominal pain. Although gallbladder tests were negative, doctors removed the gallbladder and declared him cured because it was enlarged and diseased. Ten days later, after much pain and weight loss, a chest scan was done and the correct diagnosis was made. I can’t understand why an easy and inexpensive chest X-ray wasn’t ordered. – J.S.

ANSWER: I am at a loss for any words that would make you feel better. It seems like a chest X-ray would be a mandatory screening test for everyone; it isn’t. The chest X-ray doesn’t pick up early lung cancer. Even at the beginning of his pain, your husband had widespread dissemination of the cancer. Making the diagnosis two months earlier would not have saved him. It would have spared him an operation; I cannot argue about that. Your story is most unfortunate. You have my sincerest sympathy.

DEAR DR. DONOHUE: I have two questions. After looking at my CT scan, my urologist told me I have some small cysts in my left kidney. He said that, at my age (91), I have nothing to worry about. Is this true?

After breaking a bone in my foot, my doctor suggested I start taking Centrum Silver. Could this medication cause constipation? – F.M.

ANSWER: You can trust your urologist with as much faith as you would trust Honest Abe Lincoln. Those small cysts are not going to bother you one bit. They’re not going to make you sick or shorten your life. They’re “incidentilomas” – incidental findings that have no bearing on health.

Centrum Silver really isn’t a medication. It’s a multivitamin, one that contains all the important vitamins as well as many minerals, including zinc and calcium. It has vitamin D, which is so essential for calcium absorption. Perhaps your bone break came about from osteoporosis and your doctor made the suggestion to take this preparation to stop osteoporosis from worsening. The pill shouldn’t constipate you.

Dr. Donohue regrets that he is unable to answer individual letters, but he will incorporate them in his column whenever possible. Readers may write him or request an order form of available health newsletters at P.O. Box 536475, Orlando, FL 32853- 6475. Readers may also order health newsletters from www.rbmamall.com

(c) 2008 Sun-Journal Lewiston, Me.. Provided by ProQuest Information and Learning. All rights Reserved.

Starbucks Adds Fruit Smoothies To Their Menu

Not so long ago, everyone sought to imitate Starbucks (SBUX), home of the hip, WiFi-enabled cafes and cool baristas whipping up fancy coffee. These days, many coffee fiends prefer the premium coffees from Dunkin’ Donuts and fast-food giant McDonald’s (MCD) — they also cost a lot less. [McDonald’s coffee even beat out Starbucks in a 2007 taste test conducted by Consumer Reports.]

The beverage tide has clearly turned. Now, Starbucks is joining the battle of the fruit smoothies, becoming somewhat of a Dunkin’ Donuts wannabe. Starbucks’ smoothie, dubbed Vivanno, will include banana, milk, and an orange-mango-blend juice, along with whey protein and fiber powder. McDonald’s is contemplating a national launch of its own smoothies, which are being tested in several markets says McDonald’s spokeswoman Danya Proud. Those smoothies, being tested in California and Michigan, include berries, bananas, and fruit syrup, and are being sold in three sizes, ranging from $2.79 to $3.99.

The 16-ounce Starbucks smoothie will cost $3.75 nationwide [$3.95 in New York], more expensive than the one at Dunkin’ Donuts for $3.39. Whether Americans will shell out a little more for Starbucks’ extra ingredients remains a key question.

Calories for Sweetness

While smoothies are almost always made with fresh fruit, they are often sweetened with syrup and other sweeteners, which can drive the calorie count higher. For instance, Dunkin’ Donuts’ small, 16-oz. strawberry-banana smoothie contains yogurt, sugar, strawberry and banana puree, and high fructose corn syrup among other things — and 350 calories. Starbucks, however, says it formulated its new drinks “with a strong nutritional goal in mind,” with no more than 270 calories and less than five grams of fat per drink.

“By getting into smoothies, Starbucks is just doing what everybody else is doing. It does nothing to revitalize the brand,” says Robert Passikoff, chief executive of Brand Keys, a brand consulting firm in New York. In 2008, Starbucks dropped to the third spot in Brand Keys’ annual customer loyalty index, below Dunkin’ Donuts and McDonald’s. Before 2007, Starbucks had held the top spot for four years.

A cool, healthy drink certainly sounds like a good fit for a summer introduction for a beverage joint like Starbucks. “We have been testing these beverages in our stores, and we have received very positive response from our customers,” CEO Howard Schultz said Apr. 30 on the company’s second-quarter earnings conference call. Schultz recently came back to head the company after an eight-year hiatus from the top job, hoping to revive flagging sales. “In our research, more than 60% of customers surveyed said they would come to Starbucks to buy healthy, nutritious beverages, and we are confident we have found the perfect answer to their needs.”

Health Trend

Overall, sales of smoothies are hot. In a recent report, researcher Mintel International Group, with U.S. offices in Chicago, found that sales of smoothies in the U.S. topped $2.45 billion, a 139% increase from 2002, and it expects sales to rise a further 68% in the next five years. Dunkin Donuts, Subway and Applebee’s have all introduced smoothies in the past two years. “It synchronizes with the current trend of consumers wanting to eat and drink healthy,” says Garima Goel Lal, a senior analyst at Mintel.

Goel Lal says, however, that price will play a crucial role in the success of the smoothie introduction, especially given that consumers have shut their wallets in the current economic downturn. “Launching smoothies at the right price is very important,” she says. Indeed, Seattle-based Starbucks has seen its customer base erode as many people shifted to cheaper premium coffee from McDonald’s, which saw a 22% increase in coffee sales in 2007. And in the first quarter ended Mar. 31, sales at McDonald’s restaurants open a year or more increased 7.4%, with coffee helping lift sales in its breakfast division. In the same period, Starbucks’ fiscal second quarter that ended Mar. 30, comparable store sales dropped mid-single digits. Starbucks has stopped providing specific numbers.

In the past couple of years, as the growth in coffee sales started declining, Starbucks started relying on food for sales growth, introducing warm breakfast sandwiches. When Schultz returned, however, the breakfast sandwiches were the first thing he decided to get rid of. The company is also closing 600 stores.

The challenge for Schultz now is to grow by attracting new customers while getting existing customers to come back for more. But with the smoothies, analysts worry that Starbucks may not necessarily attract new customers, and could see existing customers merely switch from coffee to smoothie purchases. “It won’t help sales much if their existing customers just switched beverages,” says Goel Lal. Of course, Starbucks is aiming higher. It hopes to not just lure a new customer who is health-conscious, but also to steal market share from the Dunkin’ Donuts and Subways of the world.

On the Net:

www.starbucks.com

Physicians Practice and Nevada Cancer Institute Partner to Improve Patient Care

BALTIMORE, July 15 /PRNewswire/ — Physicians and patients of community-based medical practices in Nevada and SW Utah will benefit from a new partnership between Physicians Practice(R), America’s Leading Practice Management Journal and Nevada Cancer Institute (NVCI). The new partnership will provide resources to help local physicians manage their practices more efficiently, thereby improving patient care.

Under this partnership, Physicians Practice will be mailed monthly, beginning this month, to approximately 5,100 physicians from multiple specialties in Nevada and SW Utah, with articles pertinent to the daily business issues faced by area physicians and their staff. Additionally, the journal will serve as a resource for physicians who are caring for patients with cancer. Physicians can read about clinical trials and scientific research being conducted at NVCI in a feature section of the journal sponsored and written by NVCI.

“Physicians Practice is a unique opportunity to share the resources and oncology care available at Nevada Cancer Institute with community clinicians and their patients,” said Nicholas J. Vogelzang, M.D., NVCI director. “We hope the special section, Pathways, will open doors to further collaborations throughout our region that will bring us all closer to developing a cure and offering new hope to cancer patients.”

In this month’s issue, physicians can read how genetic research being conducted by two internationally renowned geneticists, Drs. Hong Sun, M.D., Ph.D and Hui Zhang, Ph.D, who are working to target cancer cells at their core and help scientists discover ways to eliminate them.

“We’re extremely pleased to be able to partner with NVCI to not only deliver practice management information, but to also provide Nevada and SW Utah physicians with a resource to stay abreast with the clinical trials and research occurring at NVCI,” said Kenneth Karpay, vice-president and publisher of Physicians Practice.

For more information on the benefits of partnering with Physicians Practice to improve patient care, visit http://www.physicianspractice.com/, and select For Hospitals.

About Physicians Practice

For more than 15 years, health care executives have turned to Physicians Practice to help them cultivate physician relationships. Physicians Practice journal maintains nearly 60 hospital partnerships and is distributed to more than 265,000 practicing physicians. We create award-winning content and multimedia services to help community-based doctors in the United States and Canada strengthen their practice operations, which ultimately improves patient care. Physicians Practice is owned by CMP Healthcare Media, a division of United Business Media. Visit http://www.physicianspractice.com/ for additional information about our acclaimed healthcare business education solutions.

About Nevada Cancer Institute

Nevada Cancer Institute (NVCI) is the official cancer institute for the State of Nevada. A nonprofit organization, NVCI is committed to reducing the burden of cancer by pursuing the development of a comprehensive cancer research institute, as defined by the National Cancer Institute. Through the knowledge and expertise of the finest scientists, clinicians, educators and caregivers, the Institute provides hope to communities in Nevada, the southwest and beyond through research, education, early detection, prevention and high quality patient care. NVCI is striving for a future without cancer that is achieved through initiated and collaborative research in basic, clinical and population science. For more information, please visit http://www.nevadacancerinstitute.org/ or call (702) 822-LIFE.

    Hospital Program Contact:     Steve Gottshall    Associate Publisher    847-242-9552    [email protected]     Media Contact:     For Physicians Practice:     Monique Griffin    Senior Marketing Manager    443-543-5134    [email protected]     For Nevada Cancer Institute:     Jennifer McDonnell    Marketing and Public Relations Director, NVCI    (702) 821-0082    [email protected]  

Physicians Practice

CONTACT: Hospital Program: Steve Gottshall, Associate Publisher,+1-847-242-9552, [email protected]; or Media: For PhysiciansPractice, Monique Griffin, Senior Marketing Manager, +1-443-543-5134,[email protected]; or For Nevada Cancer Institute, JenniferMcDonnell, Marketing and Public Relations Director, NVCI, +1-702-821-0082,[email protected]

Web site: http://www.physicianspractice.com/http://www.nevadacancerinstitute.org/

David J. Mulvaney, M.D. Joins Ultroid(R) Technologies Inc. And Vascular Technologies Inc. As New Medical Affairs Director

Ultroid(R) Technologies Inc. and Vascular Technologies, Inc., announce today that David J. Mulvaney, M.D. has joined the Company as Medical Affairs Director. Dr. Mulvaney will be responsible for overseeing medical research, data acquisition, and the medical publication process, in addition to facilitating training and education of our doctor network and key distributor partners.

Dr. Mulvaney is a graduate of the University Of Alabama School Of Medicine in Birmingham, Alabama. He trained in general surgery in Macon, Georgia and thoracic surgery in Miami, Florida. He was board certified in general surgery in 1997 and in thoracic surgery in 2000. He has practiced general and thoracic surgery as well as emergency medicine in Florida since 2003. Dr. Mulvaney was involved in immunobiology research at the U.A. B. School of Medicine and Institute Pasteur in Paris, France for a total of 4 years. He published a sentinel article on B cell development in Nature in 1986 after his work in Paris.

“Ultroid(R) and Vascular Technologies are very pleased to bring Dr. Mulvaney on board. He will facilitate delivering on our promise to bring superior patient care and to help family practitioners and other doctors understand `how to’ and `how easy it is to’ administer the Ultroid(R) procedure,” commented Brent Willis, CEO, who recently joined following stints at Cott Corporation (COT), InBev (INB.BR), and the Coca-Cola Company (KO). “With Dr. Mulvaney’s extensive medical experience we will be able to accelerate the learning curve of both physicians and patients with broader scale communication on Ultroid(R) becoming the “standard of care” for the painless treatment of hemorrhoids and potentially other varicose veins.

About Vascular Technologies and Ultroid Technologies

Vascular Technologies, Inc. is one of the fastest growing medical device companies in the United States. Its principal product is the breakthrough Ultroid(R) Medical System, a less expensive and more effective treatment than current procedures for the treatment of hemorrhoids with new applications for other varicose and spider veins. Ultroid(R) is a painless, non-invasive outpatient treatment with an over 90% effective rate that replaces ineffective over-the-counter creams and painful surgeries that can be accompanied by infection and prolonged recovery. The Ultroid(R) procedure can be performed by any physician, regardless of specialty, in their office, in approximately 10-15 minutes. Patients are able to resume their normal daily activities immediately, versus the several month recovery often associated with current laser and other surgical treatments. Ultroid(R) is FDA-cleared and accepted by most insurers and Medicare.

The Company’s website is www.Ultroid.com. The brand names referenced in this press release are trademarks of Vascular Technologies, Inc. and Ultroid(R) Technologies, Inc., its affiliated companies, customers, or other third parties. The Company manages web video-enabled training clinics and markets and manufactures the Ultroid(R) Medical Devices.

Safe Harbor Statements

This press release may contain forward-looking statements reflecting management’s current expectations regarding future results of operations, economic performance, financial condition and achievements of the Company. The forward-looking statements are based on the assumption that operating performance will continue to exponentially grow in line with recent trends and consistent with distribution expansion. Management believes these assumptions to be reasonable but there is no assurance that they will prove to be accurate. Forward-looking statements, specifically those concerning future performance are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company’s filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

QuadraMed Signs $10.6 Million QCPR Contract With Saudi Arabia NFHA

QuadraMed, a developer of IT solutions for healthcare industry, has announced that the Saudi Arabia National Guard Health Affairs has signed a contract for QuadraMed CPR service expansion, migration to InterSystem’s Cache database and interface licenses that represent sales bookings of approximately $8.8 million, with a total contract value of approximately $10.6 million.

This agreement covers the rollout of the QuadraMed CPR (QCPR) product to the National Guard Health Affairs (NGHA) facilities throughout the Kingdom of Saudi Arabia.

Currently installed at one hospital and four primary healthcare centers in the central region of Riyadh, QuadraMed will install QCPR at three additional hospitals and twelve primary healthcare centers: two primary healthcare centers in the eastern region, eight in the western region and two in the central region of Saudi Arabia.

The Saudi Arabia NGHA provides modern medical care to National Guard employees and their dependents, as well as to Saudi Nationals with tertiary health problems. Under the umbrella of NGHA, there are four hospitals and sixty primary and secondary health centers around the Kingdom. Supplying the only Level I trauma center in the Kingdom, NGHA has achieved the lowest mortality and morbidity rates among the patient population.

Richland Man Still Has Hope He Can Beat Rare Cancer

By Laura Kate Zaichkin, Tri-City Herald, Kennewick, Wash.

Jul. 15–The scar in the shape of a plus sign that stretches in both directions across Lonnie Cook’s abdomen isn’t just a souvenir from a complicated surgery he had in Miami last month.

It’s a sign of victory after his frustrating battle with his health insurance company, as well as a renewed hope that he can beat his rare cancer.

The 44-year-old Richland man has gone through 10 rounds of chemotherapy in the last year to treat his Leiomyosarcoma, which affects one in 4 million people.

He was ready to give up the treatment that was slowing the progression of his terminal cancer when he and his wife, Lori, learned of a surgery done twice before that has stopped his form of cancer.

But his insurance company refused three times to pay for the nearly $1 million surgery. In fact, the company refused to cover the procedure up until just days before his June 27 surgery at Miami’s Jackson Memorial Hospital.

“You definitely have to be your own advocate,” Lori Cook said. “You can’t take ‘no’ for an answer.”

But their victory was short lived.

The surgery was supposed to completely remove the tumor lodged deep in Lonnie’s abdomen.

“We both were convinced that we would leave Miami and be cancer free,” Lori Cook said.

But once inside Lonnie’s abdomen the three surgeons realized the tumor was connected to too many organs to be removed safely. He would need a liver, pancreas, stomach and intestine transplant if it was taken out.

However, the Cooks are hopeful. Since the surgeons were able to pinpoint certain parts of the tumor, radiation should be a more effective treatment option.

“Now with it marked they can get to it,” Lori said. “The doctor told Lonnie, ‘At this point, I think the transplant is a worst-case scenario.’ He said, ‘Radiation’s going to be your best bet at this point.’ If it doesn’t shrink it will at least keep it from growing.”

The Cooks say this new treatment option gives them hope that Lonnie can beat his cancer. And Lonnie said he’s glad treatment no longer is limited to chemotherapy.

“It’ll be a lot less painful,” he said.

The family is waiting to hear from doctors about when he can begin radiation.

w Laura Kate Zaichkin: 582-1521; lzaichkin@tricity herald.com

—–

To see more of the Tri-City Herald, or to subscribe to the newspaper, go to http://www.tri-cityherald.com.

Copyright (c) 2008, Tri-City Herald, Kennewick, Wash.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

North Miami Beach Hosts Miss Florida Asia Pageant

By Carli Teproff and Judith Hudson, The Miami Herald

Jul. 15–May Shir Igawa had just sat down on the stool ready for her “up do” when the warning came.

First it was in Cantonese, a dialect the Japanese-Israeli-American teenager did not recognize.

Then the announcement came again — this time in English.

“It’s time to go,” said some of May’s new friends.

In about two minutes, the nervous 17-year-old’s long, thick, dark-brown locks were transformed into a twist that sat on top of her head adorned with flowers. A cloud of hair spray helped to keep the handiwork in place.

Nothing at that moment could tell May she would soon be crowned Miss Florida Asia out seven other girls at North Miami Beach’s Julius Littman Performing Arts Theater on Saturday night.

And when the moment came, the soon-to-be senior at Doral’s John Ferguson High School tried to hold back tears. Kayla Chin Luke, 22 was named second princess and Tia Bao-Tran Vo, 20, was named first princess. “I am just happy to be a part of this,” May said. “It keeps me in touch with my Asian roots.” It is the second year North Miami Beach’s theater played host to the pageant that draws contestants from across South Florida. The girls compete for $1,500 in cash and the crown of Miss Florida Asia.

“North Miami Beach is not only centrally located,” said the pageant’s producer Winnie Tang, “over the years it as become the center of Asian culture.”

Tang said the pageant also draws Asians to the community, which could further an effort to establish a China Town along Northeast 163rd Street in the city.

Several months ago Tang started recruiting young, talented Asian girls representing countries east of Turkey, including Japan, Iran, China, Vietnam and the Philippines. In its second year, Tang said referrals came easily.

“I think many people are proud of their culture and want to share it,” she said.

The pageant, which started with the pulsating sound coming from Japanese drummers, included competitions in which the girls could showcase their countries.

During the talent portion, 18-year-old Mimi Goon, who lives in Plantation and is originally from China, performed a Chinese ballet. During the national costume portion, three girls representing China wore Qipaos — traditional dresses. May, representing Japan, wore a Kimono.

Before the eight girls were set to take the stage for the evening gown competition, May was feeling the pressure.

“I have to go,” she said as she hurried to the left side of the stage. “I am the last one.”

The tall, thin beauty-pageant novice was then ushered onto the stage following the other girls who were decked out in sparkly long gowns.

One by one, the girls strutted across stage to the sounds of screams and applause from the crowd.

Vo, a student at Florida Atlantic University who was representing Vietnam, said even though she came in second it did not matter. She agrees with May that friendship and cultural awareness is much more important. She encourages girls to enter the pageant.

“The pageant is not only about beauty, but intelligence also plays a part,” Vo said.

—–

To see more of The Miami Herald or to subscribe to the newspaper, go to http://www.herald.com.

Copyright (c) 2008, The Miami Herald

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.